WO2016011381A1 - Reducing cxcr4 expression and/or function to enhance engraftment of hematopoietic stem cells - Google Patents
Reducing cxcr4 expression and/or function to enhance engraftment of hematopoietic stem cells Download PDFInfo
- Publication number
- WO2016011381A1 WO2016011381A1 PCT/US2015/040954 US2015040954W WO2016011381A1 WO 2016011381 A1 WO2016011381 A1 WO 2016011381A1 US 2015040954 W US2015040954 W US 2015040954W WO 2016011381 A1 WO2016011381 A1 WO 2016011381A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cxcr4
- hsc
- cells
- hscs
- expression
- Prior art date
Links
- 210000003958 hematopoietic stem cell Anatomy 0.000 title claims abstract description 517
- 230000014509 gene expression Effects 0.000 title claims abstract description 142
- 101100441540 Xenopus laevis cxcr4-a gene Proteins 0.000 title 1
- 101100441541 Xenopus laevis cxcr4-b gene Proteins 0.000 title 1
- 102000012000 CXCR4 Receptors Human genes 0.000 claims abstract description 360
- 108010061299 CXCR4 Receptors Proteins 0.000 claims abstract description 360
- 238000000034 method Methods 0.000 claims abstract description 264
- 230000000694 effects Effects 0.000 claims abstract description 76
- 238000010362 genome editing Methods 0.000 claims abstract description 28
- 230000003750 conditioning effect Effects 0.000 claims abstract description 15
- 238000002512 chemotherapy Methods 0.000 claims abstract description 11
- 108090000623 proteins and genes Proteins 0.000 claims description 197
- 230000035772 mutation Effects 0.000 claims description 109
- 210000004369 blood Anatomy 0.000 claims description 103
- 239000008280 blood Substances 0.000 claims description 103
- 230000009368 gene silencing by RNA Effects 0.000 claims description 69
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 65
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 51
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 51
- 201000010099 disease Diseases 0.000 claims description 49
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 claims description 41
- 230000001965 increasing effect Effects 0.000 claims description 39
- 230000008901 benefit Effects 0.000 claims description 31
- 108700028369 Alleles Proteins 0.000 claims description 29
- 230000009395 genetic defect Effects 0.000 claims description 24
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 19
- 201000005787 hematologic cancer Diseases 0.000 claims description 19
- 208000010115 WHIM syndrome Diseases 0.000 claims description 18
- 150000001413 amino acids Chemical class 0.000 claims description 16
- 230000003828 downregulation Effects 0.000 claims description 16
- 230000008707 rearrangement Effects 0.000 claims description 16
- 238000003780 insertion Methods 0.000 claims description 15
- 230000037431 insertion Effects 0.000 claims description 15
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 14
- 208000007056 sickle cell anemia Diseases 0.000 claims description 14
- 206010025323 Lymphomas Diseases 0.000 claims description 13
- 230000002829 reductive effect Effects 0.000 claims description 13
- 230000003827 upregulation Effects 0.000 claims description 13
- 208000026350 Inborn Genetic disease Diseases 0.000 claims description 12
- 208000016361 genetic disease Diseases 0.000 claims description 12
- 208000028529 primary immunodeficiency disease Diseases 0.000 claims description 12
- 206010020608 Hypercoagulation Diseases 0.000 claims description 9
- 239000011230 binding agent Substances 0.000 claims description 9
- 201000005665 thrombophilia Diseases 0.000 claims description 9
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 8
- 230000009870 specific binding Effects 0.000 claims description 8
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims description 7
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims description 7
- 108010054147 Hemoglobins Proteins 0.000 claims description 7
- 208000009292 Hemophilia A Diseases 0.000 claims description 7
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims description 7
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 7
- 239000003114 blood coagulation factor Substances 0.000 claims description 7
- 102100022641 Coagulation factor IX Human genes 0.000 claims description 6
- 102100026735 Coagulation factor VIII Human genes 0.000 claims description 6
- 206010053138 Congenital aplastic anaemia Diseases 0.000 claims description 6
- 201000003542 Factor VIII deficiency Diseases 0.000 claims description 6
- 201000004939 Fanconi anemia Diseases 0.000 claims description 6
- 102000001554 Hemoglobins Human genes 0.000 claims description 6
- 108010094028 Prothrombin Proteins 0.000 claims description 6
- 208000009429 hemophilia B Diseases 0.000 claims description 6
- 208000033065 inborn errors of immunity Diseases 0.000 claims description 6
- 208000032839 leukemia Diseases 0.000 claims description 6
- 102100021519 Hemoglobin subunit beta Human genes 0.000 claims description 5
- 108091005904 Hemoglobin subunit beta Proteins 0.000 claims description 5
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 5
- 206010043561 Thrombocytopenic purpura Diseases 0.000 claims description 5
- 108010056708 bcr-abl Fusion Proteins Proteins 0.000 claims description 5
- 208000031845 Pernicious anaemia Diseases 0.000 claims description 4
- 102100027378 Prothrombin Human genes 0.000 claims description 4
- 201000006288 alpha thalassemia Diseases 0.000 claims description 4
- 208000005980 beta thalassemia Diseases 0.000 claims description 4
- 208000006602 delta-Thalassemia Diseases 0.000 claims description 4
- 108010091897 factor V Leiden Proteins 0.000 claims description 4
- 238000012224 gene deletion Methods 0.000 claims description 4
- 229940039716 prothrombin Drugs 0.000 claims description 4
- 108091005670 ADAMTS13 Proteins 0.000 claims description 3
- 102000043853 ADAMTS13 Human genes 0.000 claims description 3
- 208000027276 Von Willebrand disease Diseases 0.000 claims description 3
- 229960004222 factor ix Drugs 0.000 claims description 3
- 229960000301 factor viii Drugs 0.000 claims description 3
- 238000003306 harvesting Methods 0.000 claims description 3
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 3
- 208000012137 von Willebrand disease (hereditary or acquired) Diseases 0.000 claims description 3
- 210000003995 blood forming stem cell Anatomy 0.000 claims 3
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 claims 1
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 claims 1
- 101150023944 CXCR5 gene Proteins 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 241
- 101150066398 CXCR4 gene Proteins 0.000 abstract description 122
- 238000010322 bone marrow transplantation Methods 0.000 abstract description 26
- 238000002054 transplantation Methods 0.000 abstract description 26
- 238000001415 gene therapy Methods 0.000 abstract description 9
- 230000002708 enhancing effect Effects 0.000 abstract description 7
- 238000001959 radiotherapy Methods 0.000 abstract description 4
- 230000001400 myeloablative effect Effects 0.000 abstract description 3
- 230000005855 radiation Effects 0.000 abstract description 2
- 238000003197 gene knockdown Methods 0.000 description 120
- 210000001185 bone marrow Anatomy 0.000 description 99
- 238000001802 infusion Methods 0.000 description 75
- 108020004414 DNA Proteins 0.000 description 74
- 150000007523 nucleic acids Chemical class 0.000 description 68
- 238000002617 apheresis Methods 0.000 description 66
- 230000007423 decrease Effects 0.000 description 66
- 239000011575 calcium Substances 0.000 description 65
- 229960005069 calcium Drugs 0.000 description 65
- 229910052791 calcium Inorganic materials 0.000 description 65
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 64
- 238000001228 spectrum Methods 0.000 description 61
- 210000000349 chromosome Anatomy 0.000 description 57
- 102000039446 nucleic acids Human genes 0.000 description 55
- 108020004707 nucleic acids Proteins 0.000 description 55
- 102000004169 proteins and genes Human genes 0.000 description 54
- 241000699670 Mus sp. Species 0.000 description 53
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 46
- 238000010459 TALEN Methods 0.000 description 45
- 239000000047 product Substances 0.000 description 44
- 239000013598 vector Substances 0.000 description 43
- 241000699666 Mus <mouse, genus> Species 0.000 description 36
- 210000002798 bone marrow cell Anatomy 0.000 description 34
- 108091033409 CRISPR Proteins 0.000 description 31
- 230000037430 deletion Effects 0.000 description 30
- 238000012217 deletion Methods 0.000 description 30
- 238000003556 assay Methods 0.000 description 28
- 230000002068 genetic effect Effects 0.000 description 28
- 208000036225 Chromothripsis Diseases 0.000 description 27
- 108091030071 RNAI Proteins 0.000 description 27
- 210000001744 T-lymphocyte Anatomy 0.000 description 26
- 238000002474 experimental method Methods 0.000 description 26
- 210000005087 mononuclear cell Anatomy 0.000 description 26
- 238000004458 analytical method Methods 0.000 description 25
- 230000008859 change Effects 0.000 description 25
- 239000013612 plasmid Substances 0.000 description 25
- 101710163270 Nuclease Proteins 0.000 description 24
- 210000000265 leukocyte Anatomy 0.000 description 24
- 239000002773 nucleotide Substances 0.000 description 24
- 125000003729 nucleotide group Chemical group 0.000 description 24
- 208000024891 symptom Diseases 0.000 description 24
- 239000012530 fluid Substances 0.000 description 23
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 22
- 210000000440 neutrophil Anatomy 0.000 description 21
- 238000012360 testing method Methods 0.000 description 21
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 20
- 108010017070 Zinc Finger Nucleases Proteins 0.000 description 19
- 238000005516 engineering process Methods 0.000 description 19
- 210000000130 stem cell Anatomy 0.000 description 19
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 18
- 206010028980 Neoplasm Diseases 0.000 description 18
- 210000003719 b-lymphocyte Anatomy 0.000 description 18
- 210000003743 erythrocyte Anatomy 0.000 description 17
- 210000001616 monocyte Anatomy 0.000 description 17
- 230000008569 process Effects 0.000 description 17
- 230000009467 reduction Effects 0.000 description 17
- 239000000243 solution Substances 0.000 description 17
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 16
- 108020005004 Guide RNA Proteins 0.000 description 16
- 208000035475 disorder Diseases 0.000 description 16
- 208000015181 infectious disease Diseases 0.000 description 16
- 108020004999 messenger RNA Proteins 0.000 description 16
- 238000001890 transfection Methods 0.000 description 16
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 15
- 108090000994 Catalytic RNA Proteins 0.000 description 15
- 102000053642 Catalytic RNA Human genes 0.000 description 15
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 15
- 239000003795 chemical substances by application Substances 0.000 description 15
- 238000000684 flow cytometry Methods 0.000 description 15
- 239000002679 microRNA Substances 0.000 description 15
- 108091092562 ribozyme Proteins 0.000 description 15
- 108091028043 Nucleic acid sequence Proteins 0.000 description 14
- 108020004459 Small interfering RNA Proteins 0.000 description 14
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 14
- 230000000069 prophylactic effect Effects 0.000 description 14
- 239000011780 sodium chloride Substances 0.000 description 14
- 238000010561 standard procedure Methods 0.000 description 14
- 230000035897 transcription Effects 0.000 description 14
- 238000013518 transcription Methods 0.000 description 14
- 230000002159 abnormal effect Effects 0.000 description 13
- 210000000601 blood cell Anatomy 0.000 description 13
- 230000002860 competitive effect Effects 0.000 description 13
- 230000006870 function Effects 0.000 description 13
- 238000012070 whole genome sequencing analysis Methods 0.000 description 13
- 241000701806 Human papillomavirus Species 0.000 description 12
- 238000003776 cleavage reaction Methods 0.000 description 12
- 210000000987 immune system Anatomy 0.000 description 12
- 238000002493 microarray Methods 0.000 description 12
- 230000007017 scission Effects 0.000 description 12
- 102000004127 Cytokines Human genes 0.000 description 11
- 108090000695 Cytokines Proteins 0.000 description 11
- 108700011259 MicroRNAs Proteins 0.000 description 11
- 230000002559 cytogenic effect Effects 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 229960002169 plerixafor Drugs 0.000 description 11
- YIQPUIGJQJDJOS-UHFFFAOYSA-N plerixafor Chemical compound C=1C=C(CN2CCNCCCNCCNCCC2)C=CC=1CN1CCCNCCNCCCNCC1 YIQPUIGJQJDJOS-UHFFFAOYSA-N 0.000 description 11
- 239000002243 precursor Substances 0.000 description 11
- 230000008439 repair process Effects 0.000 description 11
- 238000012546 transfer Methods 0.000 description 11
- 230000004568 DNA-binding Effects 0.000 description 10
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 10
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 10
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 10
- 230000000735 allogeneic effect Effects 0.000 description 10
- 230000027455 binding Effects 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 239000000306 component Substances 0.000 description 10
- 230000003247 decreasing effect Effects 0.000 description 10
- 230000004069 differentiation Effects 0.000 description 10
- 230000005782 double-strand break Effects 0.000 description 10
- 230000003394 haemopoietic effect Effects 0.000 description 10
- 238000005534 hematocrit Methods 0.000 description 10
- 238000000338 in vitro Methods 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- 239000004055 small Interfering RNA Substances 0.000 description 10
- 238000001712 DNA sequencing Methods 0.000 description 9
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 9
- 241000725303 Human immunodeficiency virus Species 0.000 description 9
- 208000029462 Immunodeficiency disease Diseases 0.000 description 9
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 9
- 241000700605 Viruses Species 0.000 description 9
- 210000001772 blood platelet Anatomy 0.000 description 9
- 230000034431 double-strand break repair via homologous recombination Effects 0.000 description 9
- 230000004927 fusion Effects 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 210000005259 peripheral blood Anatomy 0.000 description 9
- 239000011886 peripheral blood Substances 0.000 description 9
- 230000001105 regulatory effect Effects 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 8
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 description 8
- 101710168331 ALK tyrosine kinase receptor Proteins 0.000 description 8
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 8
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 8
- 206010061598 Immunodeficiency Diseases 0.000 description 8
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 8
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 8
- 208000007502 anemia Diseases 0.000 description 8
- 230000002222 downregulating effect Effects 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 8
- 238000012239 gene modification Methods 0.000 description 8
- 230000005017 genetic modification Effects 0.000 description 8
- 235000013617 genetically modified food Nutrition 0.000 description 8
- 229960002897 heparin Drugs 0.000 description 8
- 229920000669 heparin Polymers 0.000 description 8
- 230000007813 immunodeficiency Effects 0.000 description 8
- 238000001990 intravenous administration Methods 0.000 description 8
- 230000005291 magnetic effect Effects 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 210000003643 myeloid progenitor cell Anatomy 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- 230000014616 translation Effects 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 230000003612 virological effect Effects 0.000 description 8
- 239000011701 zinc Substances 0.000 description 8
- 229910052725 zinc Inorganic materials 0.000 description 8
- 210000003967 CLP Anatomy 0.000 description 7
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 description 7
- 102000015696 Interleukins Human genes 0.000 description 7
- 108010063738 Interleukins Proteins 0.000 description 7
- 108091005461 Nucleic proteins Chemical group 0.000 description 7
- 108091034117 Oligonucleotide Proteins 0.000 description 7
- 230000000692 anti-sense effect Effects 0.000 description 7
- 230000017531 blood circulation Effects 0.000 description 7
- 230000000295 complement effect Effects 0.000 description 7
- 238000013461 design Methods 0.000 description 7
- 231100000118 genetic alteration Toxicity 0.000 description 7
- 230000004077 genetic alteration Effects 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 238000010172 mouse model Methods 0.000 description 7
- 208000004235 neutropenia Diseases 0.000 description 7
- 230000006780 non-homologous end joining Effects 0.000 description 7
- 230000035755 proliferation Effects 0.000 description 7
- 238000013519 translation Methods 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 6
- 206010052234 Citrate toxicity Diseases 0.000 description 6
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 6
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 6
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 6
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 description 6
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 6
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 6
- 239000000074 antisense oligonucleotide Substances 0.000 description 6
- 238000012230 antisense oligonucleotides Methods 0.000 description 6
- 239000011324 bead Substances 0.000 description 6
- 238000004364 calculation method Methods 0.000 description 6
- 238000002659 cell therapy Methods 0.000 description 6
- 230000002759 chromosomal effect Effects 0.000 description 6
- 238000013401 experimental design Methods 0.000 description 6
- 210000002950 fibroblast Anatomy 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 230000010354 integration Effects 0.000 description 6
- 238000005304 joining Methods 0.000 description 6
- 230000014759 maintenance of location Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 230000007170 pathology Effects 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 238000012545 processing Methods 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 238000012552 review Methods 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 230000005945 translocation Effects 0.000 description 6
- 239000013603 viral vector Substances 0.000 description 6
- 239000002699 waste material Substances 0.000 description 6
- 108091023037 Aptamer Proteins 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 5
- 230000007018 DNA scission Effects 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 5
- 238000012300 Sequence Analysis Methods 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 230000004075 alteration Effects 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 239000003146 anticoagulant agent Substances 0.000 description 5
- 229940127219 anticoagulant drug Drugs 0.000 description 5
- 239000010836 blood and blood product Substances 0.000 description 5
- 229940125691 blood product Drugs 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 238000012258 culturing Methods 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 238000010353 genetic engineering Methods 0.000 description 5
- 210000003714 granulocyte Anatomy 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 238000002372 labelling Methods 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 238000012423 maintenance Methods 0.000 description 5
- 230000036210 malignancy Effects 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 108700024542 myc Genes Proteins 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 210000004940 nucleus Anatomy 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 102000040430 polynucleotide Human genes 0.000 description 5
- 108091033319 polynucleotide Proteins 0.000 description 5
- 239000002157 polynucleotide Substances 0.000 description 5
- 230000002062 proliferating effect Effects 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 230000011664 signaling Effects 0.000 description 5
- 150000003384 small molecules Chemical class 0.000 description 5
- 238000010911 splenectomy Methods 0.000 description 5
- 210000003954 umbilical cord Anatomy 0.000 description 5
- 241001430294 unidentified retrovirus Species 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 208000008190 Agammaglobulinemia Diseases 0.000 description 4
- 201000007155 CD40 ligand deficiency Diseases 0.000 description 4
- 238000010356 CRISPR-Cas9 genome editing Methods 0.000 description 4
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 4
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 4
- 102000009410 Chemokine receptor Human genes 0.000 description 4
- 108050000299 Chemokine receptor Proteins 0.000 description 4
- 102000019034 Chemokines Human genes 0.000 description 4
- 108010012236 Chemokines Proteins 0.000 description 4
- 206010068051 Chimerism Diseases 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 208000031886 HIV Infections Diseases 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 4
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 4
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 4
- 206010020983 Hypogammaglobulinaemia Diseases 0.000 description 4
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 238000001574 biopsy Methods 0.000 description 4
- 238000004820 blood count Methods 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 239000001110 calcium chloride Substances 0.000 description 4
- 229910001628 calcium chloride Inorganic materials 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 108091092356 cellular DNA Proteins 0.000 description 4
- 230000008711 chromosomal rearrangement Effects 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 238000012937 correction Methods 0.000 description 4
- 229940121384 cxc chemokine receptor type 4 (cxcr4) antagonist Drugs 0.000 description 4
- 230000007547 defect Effects 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 210000000777 hematopoietic system Anatomy 0.000 description 4
- 102000053523 human CXCR4 Human genes 0.000 description 4
- 238000010348 incorporation Methods 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 239000011777 magnesium Substances 0.000 description 4
- 229910052749 magnesium Inorganic materials 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- 235000019341 magnesium sulphate Nutrition 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 108091070501 miRNA Proteins 0.000 description 4
- 239000011325 microbead Substances 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 3
- 102100027211 Albumin Human genes 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 3
- 102100035248 Alpha-(1,3)-fucosyltransferase 4 Human genes 0.000 description 3
- 108091093088 Amplicon Proteins 0.000 description 3
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 3
- 108020005544 Antisense RNA Proteins 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 3
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 description 3
- 102100036008 CD48 antigen Human genes 0.000 description 3
- 238000010354 CRISPR gene editing Methods 0.000 description 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 238000007400 DNA extraction Methods 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 3
- 102000004533 Endonucleases Human genes 0.000 description 3
- 108010042407 Endonucleases Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010066476 Haematological malignancy Diseases 0.000 description 3
- 101001022185 Homo sapiens Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 description 3
- 101100220044 Homo sapiens CD34 gene Proteins 0.000 description 3
- 101000716130 Homo sapiens CD48 antigen Proteins 0.000 description 3
- 101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 description 3
- 102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 description 3
- 108091092878 Microsatellite Proteins 0.000 description 3
- 206010068052 Mosaicism Diseases 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- 108010066816 Polypeptide N-acetylgalactosaminyltransferase Proteins 0.000 description 3
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 3
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 3
- 102100038052 Retinol dehydrogenase 14 Human genes 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- 102000009618 Transforming Growth Factors Human genes 0.000 description 3
- 108010009583 Transforming Growth Factors Proteins 0.000 description 3
- 101710185494 Zinc finger protein Proteins 0.000 description 3
- 102100023597 Zinc finger protein 816 Human genes 0.000 description 3
- 101150063416 add gene Proteins 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 230000001745 anti-biotin effect Effects 0.000 description 3
- 230000010100 anticoagulation Effects 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 208000022362 bacterial infectious disease Diseases 0.000 description 3
- 210000002960 bfu-e Anatomy 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 239000012503 blood component Substances 0.000 description 3
- 229910001424 calcium ion Inorganic materials 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 210000002230 centromere Anatomy 0.000 description 3
- 239000002576 chemokine receptor CXCR4 antagonist Substances 0.000 description 3
- 239000003184 complementary RNA Substances 0.000 description 3
- 230000001351 cycling effect Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000002489 hematologic effect Effects 0.000 description 3
- 230000011132 hemopoiesis Effects 0.000 description 3
- 238000002744 homologous recombination Methods 0.000 description 3
- 230000006801 homologous recombination Effects 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 230000000415 inactivating effect Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 229940047122 interleukins Drugs 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 231100000518 lethal Toxicity 0.000 description 3
- 230000001665 lethal effect Effects 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 210000003071 memory t lymphocyte Anatomy 0.000 description 3
- 210000000822 natural killer cell Anatomy 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 210000002568 pbsc Anatomy 0.000 description 3
- 238000000053 physical method Methods 0.000 description 3
- 239000013600 plasmid vector Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- -1 rRNA Proteins 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 3
- 238000010187 selection method Methods 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 230000005783 single-strand break Effects 0.000 description 3
- 230000000392 somatic effect Effects 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 230000005026 transcription initiation Effects 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 102100027831 14-3-3 protein theta Human genes 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 206010069754 Acquired gene mutation Diseases 0.000 description 2
- 102100034135 Activin receptor type-1C Human genes 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 102100039659 Adenylate cyclase type 3 Human genes 0.000 description 2
- 241000710929 Alphavirus Species 0.000 description 2
- 108010049777 Ankyrins Proteins 0.000 description 2
- 102000008102 Ankyrins Human genes 0.000 description 2
- 240000002022 Anthriscus cerefolium Species 0.000 description 2
- 102100040202 Apolipoprotein B-100 Human genes 0.000 description 2
- 102100028820 Aspartate-tRNA ligase, cytoplasmic Human genes 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 102000001902 CC Chemokines Human genes 0.000 description 2
- 108010040471 CC Chemokines Proteins 0.000 description 2
- 102100027207 CD27 antigen Human genes 0.000 description 2
- 102100025238 CD302 antigen Human genes 0.000 description 2
- 108010029697 CD40 Ligand Proteins 0.000 description 2
- 238000010453 CRISPR/Cas method Methods 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 102100031221 Centromere protein O Human genes 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 108010008951 Chemokine CXCL12 Proteins 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 102100035229 Coiled-coil domain-containing protein 148 Human genes 0.000 description 2
- 208000024678 Complex chromosomal rearrangement Diseases 0.000 description 2
- 108010051219 Cre recombinase Proteins 0.000 description 2
- 102100024112 Cyclin-T2 Human genes 0.000 description 2
- 102100025802 Cystin-1 Human genes 0.000 description 2
- 102100028183 Cytohesin-interacting protein Human genes 0.000 description 2
- 102100035855 Cytosolic 5'-nucleotidase 1B Human genes 0.000 description 2
- 102100038590 Death-associated protein-like 1 Human genes 0.000 description 2
- 241000702421 Dependoparvovirus Species 0.000 description 2
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 2
- 102100024105 DnaJ homolog subfamily C member 27 Human genes 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 102100030376 Ermin Human genes 0.000 description 2
- 102000009095 Fanconi Anemia Complementation Group A protein Human genes 0.000 description 2
- 102000018825 Fanconi Anemia Complementation Group C protein Human genes 0.000 description 2
- 102000007122 Fanconi Anemia Complementation Group G protein Human genes 0.000 description 2
- 102100034553 Fanconi anemia group J protein Human genes 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 102100037010 Fidgetin Human genes 0.000 description 2
- 108010029961 Filgrastim Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 102100038644 Four and a half LIM domains protein 2 Human genes 0.000 description 2
- 102100030280 G-protein coupled receptor 39 Human genes 0.000 description 2
- 102100035716 Glycophorin-A Human genes 0.000 description 2
- 102100035363 Growth/differentiation factor 7 Human genes 0.000 description 2
- 108010042283 HSP40 Heat-Shock Proteins Proteins 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 102100027685 Hemoglobin subunit alpha Human genes 0.000 description 2
- 101000799193 Homo sapiens Activin receptor type-1C Proteins 0.000 description 2
- 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 description 2
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 2
- 101000934351 Homo sapiens CD302 antigen Proteins 0.000 description 2
- 101000737238 Homo sapiens Coiled-coil domain-containing protein 148 Proteins 0.000 description 2
- 101000916686 Homo sapiens Cytohesin-interacting protein Proteins 0.000 description 2
- 101000802746 Homo sapiens Cytosolic 5'-nucleotidase 1B Proteins 0.000 description 2
- 101001054007 Homo sapiens DnaJ homolog subfamily C member 27 Proteins 0.000 description 2
- 101001063322 Homo sapiens Ermin Proteins 0.000 description 2
- 101001031714 Homo sapiens Four and a half LIM domains protein 2 Proteins 0.000 description 2
- 101001009007 Homo sapiens Hemoglobin subunit alpha Proteins 0.000 description 2
- 101001038505 Homo sapiens Ly6/PLAUR domain-containing protein 1 Proteins 0.000 description 2
- 101001005556 Homo sapiens Mitogen-activated protein kinase kinase kinase 19 Proteins 0.000 description 2
- 101000589316 Homo sapiens N-cym protein Proteins 0.000 description 2
- 101000591388 Homo sapiens Neurotensin receptor type 2 Proteins 0.000 description 2
- 101000572989 Homo sapiens POU domain, class 3, transcription factor 3 Proteins 0.000 description 2
- 101000871096 Homo sapiens Probable G-protein coupled receptor 45 Proteins 0.000 description 2
- 101001090669 Homo sapiens Profilin-4 Proteins 0.000 description 2
- 101001082138 Homo sapiens Pumilio homolog 2 Proteins 0.000 description 2
- 101000743768 Homo sapiens R3H domain-containing protein 1 Proteins 0.000 description 2
- 101000742934 Homo sapiens Retinol dehydrogenase 14 Proteins 0.000 description 2
- 101000575639 Homo sapiens Ribonucleoside-diphosphate reductase subunit M2 Proteins 0.000 description 2
- 101001126009 Homo sapiens Secretory phospholipase A2 receptor Proteins 0.000 description 2
- 101000595526 Homo sapiens T-box brain protein 1 Proteins 0.000 description 2
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 description 2
- 101000777156 Homo sapiens UBX domain-containing protein 4 Proteins 0.000 description 2
- 101000743195 Homo sapiens WD repeat-containing protein 35 Proteins 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 2
- 206010062016 Immunosuppression Diseases 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 102000013691 Interleukin-17 Human genes 0.000 description 2
- 108050003558 Interleukin-17 Proteins 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 102100026236 Interleukin-8 Human genes 0.000 description 2
- 239000007760 Iscove's Modified Dulbecco's Medium Substances 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 102100040284 Ly6/PLAUR domain-containing protein 1 Human genes 0.000 description 2
- 102100033486 Lymphocyte antigen 75 Human genes 0.000 description 2
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 108050004064 Major facilitator superfamily Proteins 0.000 description 2
- 102000015841 Major facilitator superfamily Human genes 0.000 description 2
- 108010072582 Matrilin Proteins Proteins 0.000 description 2
- 102100033670 Matrilin-3 Human genes 0.000 description 2
- 102100034148 Mesogenin-1 Human genes 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 102100025217 Mitogen-activated protein kinase kinase kinase 19 Human genes 0.000 description 2
- 206010027906 Monocytosis Diseases 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 101100497626 Mus musculus Cxcr4 gene Proteins 0.000 description 2
- 102100032847 N-cym protein Human genes 0.000 description 2
- 102100036946 Nck-associated protein 5 Human genes 0.000 description 2
- 208000009869 Neu-Laxova syndrome Diseases 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 206010029379 Neutrophilia Diseases 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- 102220580210 Non-receptor tyrosine-protein kinase TYK2_D10A_mutation Human genes 0.000 description 2
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 2
- 102100037223 Nuclear receptor coactivator 1 Human genes 0.000 description 2
- 102100038456 Nucleolar protein 10 Human genes 0.000 description 2
- 208000001388 Opportunistic Infections Diseases 0.000 description 2
- 102100021079 Ornithine decarboxylase Human genes 0.000 description 2
- 238000002944 PCR assay Methods 0.000 description 2
- 102100026456 POU domain, class 3, transcription factor 3 Human genes 0.000 description 2
- 208000009608 Papillomavirus Infections Diseases 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 241000009328 Perro Species 0.000 description 2
- 102100025731 Phosphatidate phosphatase LPIN1 Human genes 0.000 description 2
- 102100030365 Plakophilin-4 Human genes 0.000 description 2
- 229920002873 Polyethylenimine Polymers 0.000 description 2
- 102100023209 Polypeptide N-acetylgalactosaminyltransferase 13 Human genes 0.000 description 2
- 102100039697 Polypeptide N-acetylgalactosaminyltransferase 5 Human genes 0.000 description 2
- 108010069820 Pro-Opiomelanocortin Proteins 0.000 description 2
- 102100027467 Pro-opiomelanocortin Human genes 0.000 description 2
- 102100033048 Probable G-protein coupled receptor 45 Human genes 0.000 description 2
- 102100034730 Profilin-4 Human genes 0.000 description 2
- 102100027352 Pumilio homolog 2 Human genes 0.000 description 2
- 102100038382 R3H domain-containing protein 1 Human genes 0.000 description 2
- 102100031536 RAD51-associated protein 2 Human genes 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 108010091086 Recombinases Proteins 0.000 description 2
- 102000018120 Recombinases Human genes 0.000 description 2
- 108091028664 Ribonucleotide Proteins 0.000 description 2
- 108091006647 SLC9A1 Proteins 0.000 description 2
- 102100029392 Secretory phospholipase A2 receptor Human genes 0.000 description 2
- 108020003224 Small Nucleolar RNA Proteins 0.000 description 2
- 102000042773 Small Nucleolar RNA Human genes 0.000 description 2
- 102100035256 Solute carrier family 66 member 3 Human genes 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 102100035721 Syndecan-1 Human genes 0.000 description 2
- 102100036083 T-box brain protein 1 Human genes 0.000 description 2
- 102000006467 TATA-Box Binding Protein Human genes 0.000 description 2
- 108010044281 TATA-Box Binding Protein Proteins 0.000 description 2
- 102000036693 Thrombopoietin Human genes 0.000 description 2
- 108010041111 Thrombopoietin Proteins 0.000 description 2
- 108010073062 Transcription Activator-Like Effectors Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 108700019146 Transgenes Proteins 0.000 description 2
- 102100025764 Transmembrane protein 163 Human genes 0.000 description 2
- 102100024323 Transmembrane protein 182 Human genes 0.000 description 2
- 108010020764 Transposases Proteins 0.000 description 2
- 102000008579 Transposases Human genes 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 102100031308 UBX domain-containing protein 4 Human genes 0.000 description 2
- LFTYTUAZOPRMMI-NESSUJCYSA-N UDP-N-acetyl-alpha-D-galactosamine Chemical compound O1[C@H](CO)[C@H](O)[C@H](O)[C@@H](NC(=O)C)[C@H]1O[P@](O)(=O)O[P@](O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(NC(=O)C=C2)=O)O1 LFTYTUAZOPRMMI-NESSUJCYSA-N 0.000 description 2
- LFTYTUAZOPRMMI-UHFFFAOYSA-N UNPD164450 Natural products O1C(CO)C(O)C(O)C(NC(=O)C)C1OP(O)(=O)OP(O)(=O)OCC1C(O)C(O)C(N2C(NC(=O)C=C2)=O)O1 LFTYTUAZOPRMMI-UHFFFAOYSA-N 0.000 description 2
- 102100020891 Uridine phosphorylase 2 Human genes 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 102100038287 Visinin-like protein 1 Human genes 0.000 description 2
- 102100038158 WD repeat-containing protein 35 Human genes 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 238000011316 allogeneic transplantation Methods 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- 238000002869 basic local alignment search tool Methods 0.000 description 2
- 102000004441 bcr-abl Fusion Proteins Human genes 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 229960004755 ceftriaxone Drugs 0.000 description 2
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 2
- 230000011712 cell development Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 238000013479 data entry Methods 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 229940096118 ella Drugs 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 230000000925 erythroid effect Effects 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
- 229960005420 etoposide Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000004720 fertilization Effects 0.000 description 2
- 210000004700 fetal blood Anatomy 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 108700014844 flt3 ligand Proteins 0.000 description 2
- 229960000390 fludarabine Drugs 0.000 description 2
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 2
- 238000001917 fluorescence detection Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000002055 immunohistochemical effect Effects 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 238000001638 lipofection Methods 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 210000003738 lymphoid progenitor cell Anatomy 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 238000012243 multiplex automated genomic engineering Methods 0.000 description 2
- CWJJHESJXJQCJA-UHFFFAOYSA-N n-(pyridin-2-ylmethyl)-1-[4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methanamine Chemical compound C=1C=C(CN2CCNCCCNCCNCCC2)C=CC=1CNCC1=CC=CC=N1 CWJJHESJXJQCJA-UHFFFAOYSA-N 0.000 description 2
- 210000004976 peripheral blood cell Anatomy 0.000 description 2
- 210000004180 plasmocyte Anatomy 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 230000032361 posttranscriptional gene silencing Effects 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 229940076372 protein antagonist Drugs 0.000 description 2
- 108020001580 protein domains Proteins 0.000 description 2
- 229950010131 puromycin Drugs 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 239000002336 ribonucleotide Substances 0.000 description 2
- 125000002652 ribonucleotide group Chemical group 0.000 description 2
- 102220235660 rs1131691993 Human genes 0.000 description 2
- 239000004017 serum-free culture medium Substances 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 238000007390 skin biopsy Methods 0.000 description 2
- 210000001626 skin fibroblast Anatomy 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 230000037439 somatic mutation Effects 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000004960 subcellular localization Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 108091035539 telomere Proteins 0.000 description 2
- 102000055501 telomere Human genes 0.000 description 2
- 210000003411 telomere Anatomy 0.000 description 2
- 230000005029 transcription elongation Effects 0.000 description 2
- 230000037426 transcriptional repression Effects 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- 230000014621 translational initiation Effects 0.000 description 2
- OOLLAFOLCSJHRE-ZHAKMVSLSA-N ulipristal acetate Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(OC(C)=O)C(C)=O)[C@]2(C)C1 OOLLAFOLCSJHRE-ZHAKMVSLSA-N 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 230000007502 viral entry Effects 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- ZRTOMVALFCAFJW-OWOJBTEDSA-N (3E)-2-aminobuta-1,3-diene-1,1,4-tricarboxylic acid Chemical compound NC(=C(C(=O)O)C(=O)O)\C=C\C(=O)O ZRTOMVALFCAFJW-OWOJBTEDSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 102100030990 2-amino-3-carboxymuconate-6-semialdehyde decarboxylase Human genes 0.000 description 1
- 102100032282 26S proteasome non-ATPase regulatory subunit 14 Human genes 0.000 description 1
- 102100027283 28S ribosomal protein S9, mitochondrial Human genes 0.000 description 1
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- 108091022885 ADAM Proteins 0.000 description 1
- 102000029791 ADAM Human genes 0.000 description 1
- 108091007505 ADAM17 Proteins 0.000 description 1
- 101150023956 ALK gene Proteins 0.000 description 1
- WVLHHLRVNDMIAR-IBGZPJMESA-N AMD 070 Chemical compound C1CCC2=CC=CN=C2[C@H]1N(CCCCN)CC1=NC2=CC=CC=C2N1 WVLHHLRVNDMIAR-IBGZPJMESA-N 0.000 description 1
- 102100021405 ATP-dependent RNA helicase DDX1 Human genes 0.000 description 1
- 108091006112 ATPases Proteins 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 206010000871 Acute monocytic leukaemia Diseases 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- 239000012117 Alexa Fluor 700 Substances 0.000 description 1
- 102100037982 Alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase A Human genes 0.000 description 1
- 101710145634 Antigen 1 Proteins 0.000 description 1
- 101710095342 Apolipoprotein B Proteins 0.000 description 1
- 241000203069 Archaea Species 0.000 description 1
- 102100030732 Ashwin Human genes 0.000 description 1
- 108010065272 Aspartate-tRNA ligase Proteins 0.000 description 1
- 102000017917 Atypical chemokine receptor Human genes 0.000 description 1
- 108060003357 Atypical chemokine receptor Proteins 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 206010005940 Bone and joint infections Diseases 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102100021574 Bromodomain adjacent to zinc finger domain protein 2B Human genes 0.000 description 1
- 108050009021 Bromodomains Proteins 0.000 description 1
- 102000001805 Bromodomains Human genes 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 101710085500 C-X-C motif chemokine 9 Proteins 0.000 description 1
- 108091008927 CC chemokine receptors Proteins 0.000 description 1
- 102000005674 CCR Receptors Human genes 0.000 description 1
- 102100022002 CD59 glycoprotein Human genes 0.000 description 1
- 108050006947 CXC Chemokine Proteins 0.000 description 1
- 102000019388 CXC chemokine Human genes 0.000 description 1
- 108091008928 CXC chemokine receptors Proteins 0.000 description 1
- 102100026860 CYFIP-related Rac1 interactor A Human genes 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 1
- 102000004031 Carboxy-Lyases Human genes 0.000 description 1
- 108090000489 Carboxy-Lyases Proteins 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 102100029855 Caspase-3 Human genes 0.000 description 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
- 101710084075 Centromere protein O Proteins 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 208000025212 Constitutional neutropenia Diseases 0.000 description 1
- 108010068106 Cyclin T Proteins 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 101710106195 Cystin-1 Proteins 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 102100026234 Cytokine receptor common subunit gamma Human genes 0.000 description 1
- 101710189311 Cytokine receptor common subunit gamma Proteins 0.000 description 1
- 102100027819 Cytosolic beta-glucosidase Human genes 0.000 description 1
- 102100024812 DNA (cytosine-5)-methyltransferase 3A Human genes 0.000 description 1
- 108010024491 DNA Methyltransferase 3A Proteins 0.000 description 1
- 230000005971 DNA damage repair Effects 0.000 description 1
- 230000008265 DNA repair mechanism Effects 0.000 description 1
- 102100033720 DNA replication licensing factor MCM6 Human genes 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 108700020911 DNA-Binding Proteins Proteins 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 101710202004 Death-associated protein-like 1 Proteins 0.000 description 1
- 206010051055 Deep vein thrombosis Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 description 1
- 102100031111 Disintegrin and metalloproteinase domain-containing protein 17 Human genes 0.000 description 1
- 102100029721 DnaJ homolog subfamily B member 1 Human genes 0.000 description 1
- 101000785401 Drosophila melanogaster Polycomb protein Asx Proteins 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 102100024071 Dystrobrevin beta Human genes 0.000 description 1
- 108010031068 E2F6 Transcription Factor Proteins 0.000 description 1
- 102000005718 E2F6 Transcription Factor Human genes 0.000 description 1
- 102100023147 E3 ubiquitin-protein ligase MARCHF7 Human genes 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 206010014522 Embolism venous Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102100027847 Endonuclease ZRANB3 Human genes 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 108091092566 Extrachromosomal DNA Proteins 0.000 description 1
- 101150036441 F5 gene Proteins 0.000 description 1
- 206010058279 Factor V Leiden mutation Diseases 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 101710116377 Fidgetin Proteins 0.000 description 1
- 102100024058 Flap endonuclease GEN homolog 1 Human genes 0.000 description 1
- 101710108858 G-protein coupled receptor 39 Proteins 0.000 description 1
- 108050004787 GREB1 Proteins 0.000 description 1
- 102000016251 GREB1 Human genes 0.000 description 1
- 102000018898 GTPase-Activating Proteins Human genes 0.000 description 1
- 108091006094 GTPase-accelerating proteins Proteins 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 102400000321 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010053240 Glycogen storage disease type VI Diseases 0.000 description 1
- 108091005250 Glycophorins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102100022083 Grancalcin Human genes 0.000 description 1
- 101710124985 Grancalcin Proteins 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 102100034221 Growth-regulated alpha protein Human genes 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- 101710173757 H/ACA ribonucleoprotein complex subunit 3 Proteins 0.000 description 1
- 101710105673 H/ACA ribonucleoprotein complex subunit 3-like protein Proteins 0.000 description 1
- 101710195321 H/ACA ribonucleoprotein complex subunit NOP10 Proteins 0.000 description 1
- 208000003577 HIV wasting syndrome Diseases 0.000 description 1
- 102000004447 HSP40 Heat-Shock Proteins Human genes 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 108090001102 Hammerhead ribozyme Proteins 0.000 description 1
- 102100039894 Hemoglobin subunit delta Human genes 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000723543 Homo sapiens 14-3-3 protein theta Proteins 0.000 description 1
- 101000773667 Homo sapiens 2-amino-3-carboxymuconate-6-semialdehyde decarboxylase Proteins 0.000 description 1
- 101000590281 Homo sapiens 26S proteasome non-ATPase regulatory subunit 14 Proteins 0.000 description 1
- 101000694240 Homo sapiens 28S ribosomal protein S9, mitochondrial Proteins 0.000 description 1
- 101001041697 Homo sapiens ATP-dependent RNA helicase DDX1 Proteins 0.000 description 1
- 101000959328 Homo sapiens Adenylate cyclase type 3 Proteins 0.000 description 1
- 101000775481 Homo sapiens Adenylate cyclase type 8 Proteins 0.000 description 1
- 101000951392 Homo sapiens Alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase A Proteins 0.000 description 1
- 101000889953 Homo sapiens Apolipoprotein B-100 Proteins 0.000 description 1
- 101000703100 Homo sapiens Ashwin Proteins 0.000 description 1
- 101000696909 Homo sapiens Aspartate-tRNA ligase, cytoplasmic Proteins 0.000 description 1
- 101000971143 Homo sapiens Bromodomain adjacent to zinc finger domain protein 2B Proteins 0.000 description 1
- 101000897400 Homo sapiens CD59 glycoprotein Proteins 0.000 description 1
- 101000912003 Homo sapiens CYFIP-related Rac1 interactor A Proteins 0.000 description 1
- 101000980898 Homo sapiens Cell division cycle-associated protein 4 Proteins 0.000 description 1
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 1
- 101000776468 Homo sapiens Centromere protein O Proteins 0.000 description 1
- 101000910484 Homo sapiens Cyclin-T2 Proteins 0.000 description 1
- 101000855767 Homo sapiens Cystin-1 Proteins 0.000 description 1
- 101000859692 Homo sapiens Cytosolic beta-glucosidase Proteins 0.000 description 1
- 101001018484 Homo sapiens DNA replication licensing factor MCM6 Proteins 0.000 description 1
- 101000956090 Homo sapiens Death-associated protein-like 1 Proteins 0.000 description 1
- 101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 description 1
- 101001053693 Homo sapiens Dystrobrevin beta Proteins 0.000 description 1
- 101000978673 Homo sapiens E3 ubiquitin-protein ligase MARCHF7 Proteins 0.000 description 1
- 101000723417 Homo sapiens Endonuclease ZRANB3 Proteins 0.000 description 1
- 101000878296 Homo sapiens Fidgetin Proteins 0.000 description 1
- 101000833646 Homo sapiens Flap endonuclease GEN homolog 1 Proteins 0.000 description 1
- 101001009541 Homo sapiens G-protein coupled receptor 39 Proteins 0.000 description 1
- 101001074244 Homo sapiens Glycophorin-A Proteins 0.000 description 1
- 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 description 1
- 101001023968 Homo sapiens Growth/differentiation factor 7 Proteins 0.000 description 1
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 description 1
- 101001055222 Homo sapiens Interleukin-8 Proteins 0.000 description 1
- 101001130192 Homo sapiens Lipid droplet-associated hydrolase Proteins 0.000 description 1
- 101001018034 Homo sapiens Lymphocyte antigen 75 Proteins 0.000 description 1
- 101000997662 Homo sapiens Lysosomal acid glucosylceramidase Proteins 0.000 description 1
- 101001012613 Homo sapiens Major facilitator superfamily domain-containing protein 2B Proteins 0.000 description 1
- 101000575457 Homo sapiens Major facilitator superfamily domain-containing protein 9 Proteins 0.000 description 1
- 101001133999 Homo sapiens Mesogenin-1 Proteins 0.000 description 1
- 101000587058 Homo sapiens Methylenetetrahydrofolate reductase Proteins 0.000 description 1
- 101000585693 Homo sapiens Mitochondrial 2-oxodicarboxylate carrier Proteins 0.000 description 1
- 101001059984 Homo sapiens Mitogen-activated protein kinase kinase kinase kinase 4 Proteins 0.000 description 1
- 101000962088 Homo sapiens NBAS subunit of NRZ tethering complex Proteins 0.000 description 1
- 101001024703 Homo sapiens Nck-associated protein 5 Proteins 0.000 description 1
- 101000602926 Homo sapiens Nuclear receptor coactivator 1 Proteins 0.000 description 1
- 101000604135 Homo sapiens Nucleolar protein 10 Proteins 0.000 description 1
- 101001041245 Homo sapiens Ornithine decarboxylase Proteins 0.000 description 1
- 101000598781 Homo sapiens Oxidative stress-responsive serine-rich protein 1 Proteins 0.000 description 1
- 101001060736 Homo sapiens Peptidyl-prolyl cis-trans isomerase FKBP1B Proteins 0.000 description 1
- 101000983854 Homo sapiens Phosphatidate phosphatase LPIN1 Proteins 0.000 description 1
- 101000583189 Homo sapiens Plakophilin-4 Proteins 0.000 description 1
- 101000829541 Homo sapiens Polypeptide N-acetylgalactosaminyltransferase 13 Proteins 0.000 description 1
- 101000886222 Homo sapiens Polypeptide N-acetylgalactosaminyltransferase 5 Proteins 0.000 description 1
- 101000925087 Homo sapiens Protein EFR3 homolog B Proteins 0.000 description 1
- 101000937704 Homo sapiens Protein FAM228A Proteins 0.000 description 1
- 101001065830 Homo sapiens Protein LRATD1 Proteins 0.000 description 1
- 101000657325 Homo sapiens Protein TANC1 Proteins 0.000 description 1
- 101001098769 Homo sapiens Protein disulfide-isomerase A6 Proteins 0.000 description 1
- 101000613717 Homo sapiens Protein odd-skipped-related 1 Proteins 0.000 description 1
- 101000728107 Homo sapiens Putative Polycomb group protein ASXL2 Proteins 0.000 description 1
- 101000964068 Homo sapiens Putative ankyrin repeat domain-containing protein 30B-like Proteins 0.000 description 1
- 101000834257 Homo sapiens Putative beta-actin-like protein 3 Proteins 0.000 description 1
- 101001135635 Homo sapiens Putative peptidyl-tRNA hydrolase PTRHD1 Proteins 0.000 description 1
- 101000983605 Homo sapiens Putative uncharacterized protein CDRT15P3 Proteins 0.000 description 1
- 101000713813 Homo sapiens Quinone oxidoreductase PIG3 Proteins 0.000 description 1
- 101001130240 Homo sapiens RAD51-associated protein 2 Proteins 0.000 description 1
- 101000668165 Homo sapiens RNA-binding motif, single-stranded-interacting protein 1 Proteins 0.000 description 1
- 101001061915 Homo sapiens Rab3 GTPase-activating protein catalytic subunit Proteins 0.000 description 1
- 101100203078 Homo sapiens SF3B6 gene Proteins 0.000 description 1
- 101001098464 Homo sapiens Serine/threonine-protein kinase OSR1 Proteins 0.000 description 1
- 101000713310 Homo sapiens Sodium bicarbonate cotransporter 3 Proteins 0.000 description 1
- 101001094105 Homo sapiens Solute carrier family 66 member 3 Proteins 0.000 description 1
- 101000702566 Homo sapiens Structural maintenance of chromosomes protein 6 Proteins 0.000 description 1
- 101000874179 Homo sapiens Syndecan-1 Proteins 0.000 description 1
- 101000837903 Homo sapiens TATA box-binding protein-associated factor RNA polymerase I subunit B Proteins 0.000 description 1
- 101000612743 Homo sapiens Tetratricopeptide repeat protein 32 Proteins 0.000 description 1
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 1
- 101000866340 Homo sapiens Transcription factor E2F6 Proteins 0.000 description 1
- 101000655536 Homo sapiens Transforming growth factor-beta receptor-associated protein 1 Proteins 0.000 description 1
- 101000645402 Homo sapiens Transmembrane protein 163 Proteins 0.000 description 1
- 101000831491 Homo sapiens Transmembrane protein 182 Proteins 0.000 description 1
- 101000766349 Homo sapiens Tribbles homolog 2 Proteins 0.000 description 1
- 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 description 1
- 101000983603 Homo sapiens Uncharacterized protein C2orf27A Proteins 0.000 description 1
- 101000793957 Homo sapiens Uncharacterized protein C2orf50 Proteins 0.000 description 1
- 101000644171 Homo sapiens Uridine phosphorylase 2 Proteins 0.000 description 1
- 101001061851 Homo sapiens V(D)J recombination-activating protein 2 Proteins 0.000 description 1
- 101000775702 Homo sapiens V-type proton ATPase subunit C 2 Proteins 0.000 description 1
- 101000666874 Homo sapiens Visinin-like protein 1 Proteins 0.000 description 1
- 101000771640 Homo sapiens WD repeat and coiled-coil-containing protein Proteins 0.000 description 1
- 101000650167 Homo sapiens WD repeat, SAM and U-box domain-containing protein 1 Proteins 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- 208000013038 Hypocalcemia Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- 206010021450 Immunodeficiency congenital Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 206010052210 Infantile genetic agranulocytosis Diseases 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 102000042838 JAK family Human genes 0.000 description 1
- 108091082332 JAK family Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 102100031360 Lipid droplet-associated hydrolase Human genes 0.000 description 1
- 101710157884 Lymphocyte antigen 75 Proteins 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 206010025280 Lymphocytosis Diseases 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 101150022024 MYCN gene Proteins 0.000 description 1
- 102100029810 Major facilitator superfamily domain-containing protein 2B Human genes 0.000 description 1
- 102100025611 Major facilitator superfamily domain-containing protein 9 Human genes 0.000 description 1
- 241001327631 Meara Species 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 101710111259 Mesogenin-1 Proteins 0.000 description 1
- 102100029684 Methylenetetrahydrofolate reductase Human genes 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 102000016397 Methyltransferase Human genes 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- 102100028194 Mitogen-activated protein kinase kinase kinase kinase 4 Human genes 0.000 description 1
- 208000035489 Monocytic Acute Leukemia Diseases 0.000 description 1
- 206010027905 Monocytopenia Diseases 0.000 description 1
- 101001065556 Mus musculus Lymphocyte antigen 6G Proteins 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 239000012580 N-2 Supplement Substances 0.000 description 1
- 102100039210 NBAS subunit of NRZ tethering complex Human genes 0.000 description 1
- 102000017938 NTSR2 Human genes 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 101710134624 Nck-associated protein 5 Proteins 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 108010077960 Neurocalcin Proteins 0.000 description 1
- 102100034002 Neurotensin receptor type 2 Human genes 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 108020004485 Nonsense Codon Proteins 0.000 description 1
- 108090001146 Nuclear Receptor Coactivator 1 Proteins 0.000 description 1
- 101710127813 Nucleolar protein 10 Proteins 0.000 description 1
- 206010030154 Oesophageal candidiasis Diseases 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 101710120430 Ornithine decarboxylase 1 Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 102100037780 Oxidative stress-responsive serine-rich protein 1 Human genes 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 206010033661 Pancytopenia Diseases 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 102100027914 Peptidyl-prolyl cis-trans isomerase FKBP1B Human genes 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 108050005456 Phosphatidate phosphatase LPIN1 Proteins 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 108050004723 Plakophilin-4 Proteins 0.000 description 1
- 241000589579 Planomicrobium okeanokoites Species 0.000 description 1
- 208000005384 Pneumocystis Pneumonia Diseases 0.000 description 1
- 206010073755 Pneumocystis jirovecii pneumonia Diseases 0.000 description 1
- 229920012196 Polyoxymethylene Copolymer Polymers 0.000 description 1
- 101710189229 Polypeptide N-acetylgalactosaminyltransferase 13 Proteins 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 239000000683 Pro-Opiomelanocortin Substances 0.000 description 1
- 102000006010 Protein Disulfide-Isomerase Human genes 0.000 description 1
- 102100033970 Protein EFR3 homolog B Human genes 0.000 description 1
- 102100027301 Protein FAM228A Human genes 0.000 description 1
- 102100036828 Protein GREB1 Human genes 0.000 description 1
- 101710112198 Protein GREB1 Proteins 0.000 description 1
- 102100032095 Protein LRATD1 Human genes 0.000 description 1
- 102100034764 Protein TANC1 Human genes 0.000 description 1
- 102100037061 Protein disulfide-isomerase A6 Human genes 0.000 description 1
- 101710092489 Protein kinase 2 Proteins 0.000 description 1
- 102000015176 Proton-Translocating ATPases Human genes 0.000 description 1
- 108010039518 Proton-Translocating ATPases Proteins 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 241001672981 Purpura Species 0.000 description 1
- 102100029750 Putative Polycomb group protein ASXL2 Human genes 0.000 description 1
- 102100040380 Putative ankyrin repeat domain-containing protein 30B-like Human genes 0.000 description 1
- 102100026659 Putative beta-actin-like protein 3 Human genes 0.000 description 1
- 102100033217 Putative peptidyl-tRNA hydrolase PTRHD1 Human genes 0.000 description 1
- 102100029919 Putative uncharacterized protein C2orf48 Human genes 0.000 description 1
- 102100026631 Putative uncharacterized protein CDRT15P3 Human genes 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 101710122445 Pyrimidine/purine nucleoside phosphorylase 2 Proteins 0.000 description 1
- 102100036522 Quinone oxidoreductase PIG3 Human genes 0.000 description 1
- 101710182818 RAD51-associated protein 2 Proteins 0.000 description 1
- 102000001183 RAG-1 Human genes 0.000 description 1
- 108060006897 RAG1 Proteins 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 102100039692 RNA-binding motif, single-stranded-interacting protein 1 Human genes 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102000011070 Rab3 Human genes 0.000 description 1
- 102100029548 Rab3 GTPase-activating protein catalytic subunit Human genes 0.000 description 1
- 108700001248 Ran binding domains Proteins 0.000 description 1
- 102000057707 Ran binding domains Human genes 0.000 description 1
- 208000035977 Rare disease Diseases 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 101710178611 Retinol dehydrogenase 14 Proteins 0.000 description 1
- 102100027611 Rho-related GTP-binding protein RhoB Human genes 0.000 description 1
- 101150054980 Rhob gene Proteins 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 102100026006 Ribonucleoside-diphosphate reductase subunit M2 Human genes 0.000 description 1
- 102000002278 Ribosomal Proteins Human genes 0.000 description 1
- 108010000605 Ribosomal Proteins Proteins 0.000 description 1
- 108091006207 SLC-Transporter Proteins 0.000 description 1
- 102000037054 SLC-Transporter Human genes 0.000 description 1
- 108091006265 SLC4A10 Proteins 0.000 description 1
- 108091006650 SLC9A2 Proteins 0.000 description 1
- 108091006655 SLC9A4 Proteins 0.000 description 1
- 102100030571 STE20-like serine/threonine-protein kinase Human genes 0.000 description 1
- 101710157230 STE20-like serine/threonine-protein kinase Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010040642 Sickle cell anaemia with crisis Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 102100036911 Sodium bicarbonate cotransporter 3 Human genes 0.000 description 1
- 102000006633 Sodium-Bicarbonate Symporters Human genes 0.000 description 1
- 102100030382 Sodium/hydrogen exchanger 2 Human genes 0.000 description 1
- 102100030707 Sodium/hydrogen exchanger 4 Human genes 0.000 description 1
- 206010062255 Soft tissue infection Diseases 0.000 description 1
- 101710187580 Solute carrier family 66 member 3 Proteins 0.000 description 1
- 206010041660 Splenomegaly Diseases 0.000 description 1
- 102100021817 Splicing factor 3B subunit 6 Human genes 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 101710088580 Stromal cell-derived factor 1 Proteins 0.000 description 1
- 102100031030 Structural maintenance of chromosomes protein 6 Human genes 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 108090000058 Syndecan-1 Proteins 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 208000030928 T-B+ severe combined immunodeficiency Diseases 0.000 description 1
- 208000022175 T-B- severe combined immunodeficiency Diseases 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 108010045306 T134 peptide Proteins 0.000 description 1
- 108010025037 T140 peptide Proteins 0.000 description 1
- 102100028546 TATA box-binding protein-associated factor RNA polymerase I subunit B Human genes 0.000 description 1
- 101150080074 TP53 gene Proteins 0.000 description 1
- 108010027179 Tacrolimus Binding Proteins Proteins 0.000 description 1
- 102000018679 Tacrolimus Binding Proteins Human genes 0.000 description 1
- 241001365914 Taira Species 0.000 description 1
- 102100040945 Tetratricopeptide repeat protein 32 Human genes 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- 208000005485 Thrombocytosis Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 1
- 108091028113 Trans-activating crRNA Proteins 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 102100031631 Transcription factor E2F6 Human genes 0.000 description 1
- 102100032349 Transforming growth factor-beta receptor-associated protein 1 Human genes 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 101710191786 Transmembrane protein 163 Proteins 0.000 description 1
- 101710191745 Transmembrane protein 182 Proteins 0.000 description 1
- 102100026394 Tribbles homolog 2 Human genes 0.000 description 1
- 102000004271 Tryptophan 5-monooxygenases Human genes 0.000 description 1
- 108090000885 Tryptophan 5-monooxygenases Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 1
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 1
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 1
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 description 1
- 108050006631 U-box domains Proteins 0.000 description 1
- 102000019229 U-box domains Human genes 0.000 description 1
- 102100026633 Uncharacterized protein C2orf27A Human genes 0.000 description 1
- 102100029913 Uncharacterized protein C2orf50 Human genes 0.000 description 1
- 101710116598 Uridine phosphorylase 2 Proteins 0.000 description 1
- 102100029591 V(D)J recombination-activating protein 2 Human genes 0.000 description 1
- 102100032185 V-type proton ATPase subunit C 2 Human genes 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 101710101493 Viral myc transforming protein Proteins 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 102100029476 WD repeat and coiled-coil-containing protein Human genes 0.000 description 1
- 102100027553 WD repeat, SAM and U-box domain-containing protein 1 Human genes 0.000 description 1
- 208000033355 WHIM syndrome 1 Diseases 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 241000589634 Xanthomonas Species 0.000 description 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
- WCDYMMVGBZNUGB-ORPFKJIMSA-N [(2r,3r,4s,5r,6r)-6-[[(1r,3r,4r,5r,6r)-4,5-dihydroxy-2,7-dioxabicyclo[4.2.0]octan-3-yl]oxy]-3,4,5-trihydroxyoxan-2-yl]methyl 3-hydroxy-2-tetradecyloctadecanoate Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](COC(=O)C(CCCCCCCCCCCCCC)C(O)CCCCCCCCCCCCCCC)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H]2OC[C@H]2O1 WCDYMMVGBZNUGB-ORPFKJIMSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 108010023082 activin A Proteins 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 108010023456 adenylate cyclase 3 Proteins 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 238000007818 agglutination assay Methods 0.000 description 1
- 150000001408 amides Chemical group 0.000 description 1
- 108010073901 aminoacyl-tRNA hydrolase Proteins 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000003855 balanced salt solution Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 239000000227 bioadhesive Substances 0.000 description 1
- 238000003766 bioinformatics method Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000004970 cd4 cell Anatomy 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 230000012820 cell cycle checkpoint Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 238000011072 cell harvest Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- WGGSNNMSSGLKHI-HLICZWCASA-N chembl525205 Polymers C([C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H]2C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CC=3C=CC=CC=3)C(=O)N[C@H](C(N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CSSC2)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)=O)CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CCCNC(N)=N)=O)C(C)C)C1=CC=CC=C1 WGGSNNMSSGLKHI-HLICZWCASA-N 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 239000012829 chemotherapy agent Substances 0.000 description 1
- 238000009104 chemotherapy regimen Methods 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 201000010902 chronic myelomonocytic leukemia Diseases 0.000 description 1
- 238000011509 clonal analysis Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 229940105778 coagulation factor viii Drugs 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- KJQOYUHYAZGPIZ-PIJHVLQJSA-N conotoxin vc1.1 Chemical compound C([C@H]1C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H]2NC(=O)[C@@H](NC(=O)CN)CSSC[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC2=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CC(O)=O)C(=O)N1)C(N)=O)=O)[C@@H](C)CC)C1=CN=CN1 KJQOYUHYAZGPIZ-PIJHVLQJSA-N 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007821 culture assay Methods 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 230000037437 driver mutation Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000012407 engineering method Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 230000010502 episomal replication Effects 0.000 description 1
- 201000005655 esophageal candidiasis Diseases 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011124 ex vivo culture Methods 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000005294 ferromagnetic effect Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 229960004177 filgrastim Drugs 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000002509 fluorescent in situ hybridization Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 231100000221 frame shift mutation induction Toxicity 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 230000009760 functional impairment Effects 0.000 description 1
- 238000012246 gene addition Methods 0.000 description 1
- 238000003192 gene knockdown by RNA interference Methods 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 238000010363 gene targeting Methods 0.000 description 1
- 231100000722 genetic damage Toxicity 0.000 description 1
- 102000054766 genetic haplotypes Human genes 0.000 description 1
- 230000007614 genetic variation Effects 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 210000002360 granulocyte-macrophage progenitor cell Anatomy 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 108010070827 growth differentiation factor 7 Proteins 0.000 description 1
- 108090001052 hairpin ribozyme Proteins 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 108010049074 hemoglobin B Proteins 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 102000044493 human CDCA4 Human genes 0.000 description 1
- 208000021145 human papilloma virus infection Diseases 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 201000004108 hypersplenism Diseases 0.000 description 1
- 230000000705 hypocalcaemia Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 229960002751 imiquimod Drugs 0.000 description 1
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 1
- 210000003297 immature b lymphocyte Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000000951 immunodiffusion Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940027941 immunoglobulin g Drugs 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000003017 in situ immunoassay Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 229940096397 interleukin-8 Drugs 0.000 description 1
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000007885 magnetic separation Methods 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 210000001806 memory b lymphocyte Anatomy 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000031864 metaphase Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 108091073241 miR-1301 stem-loop Proteins 0.000 description 1
- 108091077997 miR-3125 stem-loop Proteins 0.000 description 1
- 108091063862 miR-3679 stem-loop Proteins 0.000 description 1
- 108091047611 miR-4261 stem-loop Proteins 0.000 description 1
- 108091039988 miR-4262 stem-loop Proteins 0.000 description 1
- 108091038302 miR-4429 stem-loop Proteins 0.000 description 1
- 108091030589 miR-4757 stem-loop Proteins 0.000 description 1
- 108091028842 miR-4772 stem-loop Proteins 0.000 description 1
- 108091037434 miR-4785 stem-loop Proteins 0.000 description 1
- 108091056912 miR-663b stem-loop Proteins 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 229940029345 neupogen Drugs 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- 229940043515 other immunoglobulins in atc Drugs 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 108700025694 p53 Genes Proteins 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 201000000317 pneumocystosis Diseases 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 108020003519 protein disulfide isomerase Proteins 0.000 description 1
- 230000002488 pyknotic effect Effects 0.000 description 1
- 108010065559 rab3 GTP-Binding Proteins Proteins 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002629 repopulating effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 108010047866 ribonucleotide reductase M2 Proteins 0.000 description 1
- 102220004287 rs104886459 Human genes 0.000 description 1
- 102220194524 rs1057516430 Human genes 0.000 description 1
- 102220002564 rs121434425 Human genes 0.000 description 1
- 102220001837 rs137852986 Human genes 0.000 description 1
- 102220002569 rs587776640 Human genes 0.000 description 1
- 102200087780 rs77375493 Human genes 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007480 sanger sequencing Methods 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000009394 selective breeding Methods 0.000 description 1
- 230000007651 self-proliferation Effects 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 230000003007 single stranded DNA break Effects 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- PVGBHEUCHKGFQP-UHFFFAOYSA-N sodium;n-[5-amino-2-(4-aminophenyl)sulfonylphenyl]sulfonylacetamide Chemical compound [Na+].CC(=O)NS(=O)(=O)C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 PVGBHEUCHKGFQP-UHFFFAOYSA-N 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 210000000603 stem cell niche Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000026676 system process Effects 0.000 description 1
- IMOHHNXUCDZLKM-ADZSTZGASA-N t140 Chemical compound C([C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](CCCCN)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CC=1C=C2C=CC=CC2=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)=O)CCCCN)C1=CC=C(O)C=C1 IMOHHNXUCDZLKM-ADZSTZGASA-N 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960001196 thiotepa Drugs 0.000 description 1
- 230000003582 thrombocytopenic effect Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- 101150115463 trg gene Proteins 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 230000009452 underexpressoin Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 108090000883 varkud satellite ribozyme Proteins 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000004043 venous thromboembolism Diseases 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 108010047303 von Willebrand Factor Proteins 0.000 description 1
- 102100036537 von Willebrand factor Human genes 0.000 description 1
- 229960001134 von willebrand factor Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/54—Control of apparatus or devices for radiation diagnosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
Definitions
- This application relates to methods of enhancing engraftment of donor hematopoietic stem cells (HSCs), for example increasing the efficiency and durability of donor HSC repopulation, by reducing expression or activity of CXCR4 in HSCs. In some examples such methods are used in combination with gene therapy.
- HSCs donor hematopoietic stem cells
- WHIM syndrome warts, hypogammaglobulinemia, infections, and myelokathexis syndrome
- WHIM syndrome is an autosomal dominant immunodeficiency that can be caused by multiple
- hypogammaglobulinemia, Infections, and Myelokathexis (Wetzler et al., 1990). Warts are the manifestation of chronic human papillomavirus (HPV) infection of the skin or oral or genital mucosa and are a severe and chronic problem in these patients (Beaulich Cohen et al., 2012; Dotta et al., 2011; Kawai and Malech, 2009). Hypogammaglobulinemia (low immunoglobulin G) is typically mild but variable and can predispose to frequent sinopulmonary infections and poor vaccine responses. The patients also suffer from oral, skin/soft tissue and bone and joint infections that arise because of severe blood neutropenia.
- HPV chronic human papillomavirus
- CXCR4 is a chemokine receptor expressed on the surface of most leukocytes whose human ligand is CXCL12 (also known as stromal cell derived factor-1 or SDF-1) (Bachelerie et al., 2014).
- CXCR4 was originally discovered as a fusion co-factor (with CD4) for HIV viral entry and is particularly important in late stage HIV disease (Berger et al., 1999; Feng et al., 1996); while CXCL12 is constitutively expressed in the bone marrow stroma and is known to play a vital role in hematopoietic stem cell (HSC) retention in the marrow (Bleul et al., 1996; Broxmeyer et al., 2005).
- HSC hematopoietic stem cell
- plerixafor A small molecule CXCR4 antagonist, plerixafor (formerly known as AMD3100), is FDA approved to facilitate the collection of HSC by apheresis for autologous bone marrow transplantation in certain malignancies. Plerixafor has also been successful at reversing the panleukopenia and treating WHIM syndrome in small studies (Dale et al., 2011; McDermott et al., 2011; McDermott et al., 2014).
- Human hematopoiesis is a complex, hierarchical differentiation of a variety of progenitor cells that form all the terminally differentiated elements of the blood including red blood cells, platelets, lymphocytes, monocytes, and granulocytes (Seita and Weissman, 2010). All of these lineages can be traced back to a group of true pluripotent HSC that are capable of life-long self- renewal. These HSC undergo regulated differentiation to maintain homeostasis and markedly increased proliferation during injury or infection (emergency hematopoiesis) and have been identified by the expression of unique combinations of cell surface markers as well as in vitro and in vivo functional assays.
- CXCR4 signaling promotes HSC quiescence and homeostasis and can also play a role in HSC differentiation into committed myeloid progenitors such as the common myeloid progenitor (CMP) (Broxmeyer et al., 2003a; Broxmeyer et al., 2003b; Nie et al., 2008; Sugiyama et al., 2006).
- CMP common myeloid progenitor
- the phenomenon was recently discovered when new genetic techniques of whole genome sequencing, single nucleotide polymorphism microarray, and bioinformatics analysis were applied to malignant tumor DNA. It represents a new paradigm for oncogenesis where a sudden catastrophic event can create multiple clustered genetic rearrangements and deletions rather than the sequential genetic changes that result in most tumorigenesis (Stephens et al., 2011).
- Criteria developed to allow the inference of chromothripsis include clustering of breakpoints in limited areas of one or several chromosomes with large intervening regions of normal sequence, copy number states that suddenly oscillate between areas of normal heterozygosity and loss of heterozygosity, rearrangements affecting a single haplotype and with multiple fragments rearranged in random orientation and order (Korbel and Campbell, 2013).
- the methods include reducing expression or function of CXC chemokine receptor 4 (CXCR4) in a donor HSC, thereby generating a CXCR4 knockdown HSC.
- CXCR4 CXC chemokine receptor 4
- expression and/or activity of CXCR4 can be reduced by at least 20%, at least 30%, at least 40%, at least 50% or at least 75% (but not 100%) in the CXCR4 knockdown HSC as compared to expression of CXCR4 in the donor HSC prior to reducing CXCR4 expression and/or activity.
- this is done ex vivo, for example after obtaining HSCs from a donor.
- donor HSCs are obtained from the recipient subject, while in other examples donor HSCs are obtained from a subject different from the recipient subject.
- the method can further include harvesting HSC from a donor subject.
- the disclosure is not limited to specific methods of editing gene expression or activity in a cell, but in some examples gene editing or RNA interference (RNAi) methods are used to manipulate a CXCR4 gene or other CXCR4 nucleic acid in the HSC.
- RNAi RNA interference
- the CXCR4 protein is targeted, for example with CXCR4 protein antagonists, such as small molecules, antibodies, or aptamers.
- the resulting CXCR4 knockdown HSCs are then administered or transplanted into a recipient subject in therapeutically effective amounts, thereby increasing HSC engraftment in the recipient subject.
- at least 1 x 10 6 , at least 1 x 10 7 , or at least 1 x 10 8 CXCR4 knockdown HSCs are administered to the subject. Any method of administration can be used that allows proper function of the HSCs in vivo (for example allows the CXCR4 knockdown HSCs to reach the bone marrow), such as by injection of the CXCR4 knockdown HSCs into the subject, such as by intravenous administration.
- the recipient subject has not received conditioning prior to administering the CXCR4 knockdown HSCs to the recipient subject, such as chemotherapy and/or total body irradiation.
- the methods further include manipulating one or more other genes (such as correcting a mutation and/or altering its expression) in the CXCR4 knockdown HSCs, which can then be used to treat a disease or disorder in the subject related to the gene that is manipulated.
- manipulating one or more other genes such as correcting a mutation and/or altering its expression
- manipulating one or more other genes in the donor HSC can include one or more of correcting a genetic defect in the HSC, wherein the genetic defect causes a disease in the recipient subject; reducing expression of a first target gene in the HSC, wherein reducing expression of the first target gene treats a disease caused by upregulation of the first target gene in the recipient subject or treats a disease that benefits from reducing expression of the first target gene in the recipient subject; and increasing expression of a second target gene in the HSC, wherein increasing expression of the second target gene treats a disease caused by downregulation of the second target gene in the recipient subject or treats a disease that benefits from increasing expression of the second target gene in the recipient subject.
- manipulation of CXCR4 expression in the HSC and manipulation of one or more other genes is performed at the same time, such as by using gene editing methods or RNAi methods.
- the donor HSC is first manipulated to decrease CXCR4
- a CXCR4 knockdown HSC can include other genetic alterations.
- the method is a method of treating a disease or disorder in the subject.
- CXCR4 knockdown HSCs which may include other genetic manipulations, can be used to treat a hematologic malignancy (such as chronic myelogenous leukemia wherein a BCR- ABL fusion gene is silenced or removed from the donor HSC), HIV-1 (wherein expression of the viral coreceptor and CC chemokine receptor CCR5 is reduced in the donor HSC), anemia, and a genetic disease of the blood, such as any of sickle cell anemia, hemophilia A, hemophilia B, alpha- thalassemia, beta-thalassemia, delta-thalassemia, von Willebrand Disease, pernicious anemia, Fanconi anemia, thrombocytopenic purpura, thrombophilia, and all primary immunodeficiency diseases.
- a hematologic malignancy such as chronic myelogenous leukemia wherein a BCR- ABL fusion gene is silence
- FIGS. 1A-1C DNA sequencing of a family with WHIM syndrome revealed genetic mosaicism of the index patient.
- A Family Pedigree, males (squares); females (circles); shaded (history of or current evidence of clinical WHIM); arrow (index patient); WT (wild- type CXCR4 genotype); R334X (CXCR4 R334X heterozygous genotype).
- B DNA sequencing of the family. Shown are representative Sanger sequencing results from blood DNA for the 3 patients of the family at the site of the CXCR4 R334X mutation (nucleotide position 1000).
- C DNA sequencing from different tissues of the index patient at position 1000. Shown are the discrepant results from blood versus cheek versus skin fibroblast DNA.
- FIGS. 2A-2B Loss of the WHIM allele in myeloid derived cells from the index patient.
- PCR-RFLP polymerase chain reaction- restriction fragment length polymorphism
- PCR- amplification in the absence of target DNA serving as a negative control
- HD healthy donor
- PBMC peripheral blood mononuclear cells
- uncut not subjected to restriction enzyme digestion
- cut cut with BstXJI restriction enzyme
- LCL lymphoblastoid cell line derived from PBMC
- CD4 + purified CD4 + T cells
- CD8 + purified CD8 + T cells
- CD19 + purified CD19 + B cells
- CD56 + purified CD56 + natural killer cells
- CD14 + purified CD14 + monocytes
- CD34 + purified CD34 + hematopoietic stem cells
- CD3 + purified CD3 + T cells
- CD15 + purified CD15 + neutrophils
- cultured CD34 + purified CD34 + hematopoietic stem cells grown ex vivo.
- FIG. 3 Blood counts by age in the index patient.
- WBC white blood count
- ANC absolute neutrophil count
- AMC absolute monocyte count
- ALC absolute lymphocyte count.
- FIGS. 4A-4C Bone marrow pathology.
- a representative hematoxylin and eosin stain of the bone marrow is shown for an unrelated adult female WHIM patient (WHIM-03, A) and the index patient (WHIM-09) at age 9 (B, taken from Zuelzer, 1964) and at age 59 (C).
- Bone marrow characteristics of myelokathexis seen in WHIM-03 at age 30 and in WHIM-09 at age 9 such as an increased myeloid to erythroid ratio, increased late myeloid precursors, and hypersegmented, pyknotic appearing mature neutrophils with dense nuclear lobes connected by long, thin
- intranuclear strands and intracytoplasmic vacuolization are no longer present in WHIM-09 at age 59.
- FIGS. 5A-5C Cytogenetics and Hybridization. Bone marrow aspirate was cultured and metaphase cells were lysed and stained with Giemsa. An analysis of the chromosomal banding pattern revealed that some of the patient cells were lacking part of one copy of chromosome 2 and that there was evidence of partial translocation of the centromere (A) while other chromosomes were normal. Fluorescence in situ hybridization (FISH) was performed on these cells for ALK (B), multicolor stain revealed translocation from 2p to 2q arm) and for MYCN (green) and the centromere (red) (C). The latter revealed a deletion of MYCN with a partial centromeric translocation. When this FISH test was applied to cells with polymorphic nuclei nearly all were positive, but roughly 40% of the cells with round nuclei were negative (data not shown).
- FISH Fluorescence in situ hybridization
- FIGS. 6A-6B Microarray Results. Bone marrow cellular DNA was amplified and hybridized to a clinical microarray designed for investigation of chromosome abnormalities (Affymetrix Cytoscan HD array). Analysis of the copy number state and single nucleotide polymorphism variation using the Chromosome Analysis suite software revealed 7 distinct areas of chromosome 2 that were deleted (red boxes in screenshot (A)). A closer inspection of the 4th and 5th deleted regions reveals that CXCR4 is in the 5th deleted region (B).
- Affymetrix Cytoscan HD array Analysis of the copy number state and single nucleotide polymorphism variation using the Chromosome Analysis suite software revealed 7 distinct areas of chromosome 2 that were deleted (red boxes in screenshot (A)). A closer inspection of the 4th and 5th deleted regions reveals that CXCR4 is in the 5th deleted region (B).
- FIGS. 7A-7B Whole Genome Sequencing of the Index Patient. Purified neutrophil DNA was isolated and subjected to whole genome sequencing with paired end analysis. Depicted in (A) is a circular plot from the program Circos of chromosome 2 and its Giemsa cytogenetic banding pattern labeled from the p arm telomere (0) to the q arm telomere (-240) in megabases. Large pieces of chromosome 2 were missing (deletions marked by brackets) and 18 remaining pieces were arranged in random order. Connections between these pieces and their orientation are depicted by the colored lines. Note that 2 connections were poorly defined because of the involvement of repetitive centromeric sequence.
- the inner circular trace is the copy number variation data derived from the microarray.
- the sites of connections derived from the paired end sequencing analysis closely matches the sites where copy number variation abruptly falls from 2 to 1.
- 8 larger piece locations are labeled in bold around the outside of the circle. The arrangement of these 8 larger pieces is given in cartoon form below the plot.
- (B, left side) shows a cartoon of the Giemsa cytogenetic banding pattern and the order and orientation of the 18 pieces with the deletions called by microarray shaded in yellow.
- the resultant remaining chromosome 2 banding pattern predicted by whole genome sequencing closely matches that seen by cytogenetic analysis (see Figure 5).
- FIGS. 8A-8B Hematopoietic Differentiation Precursor Markers and Chromothripsis
- HSC hematopoietic stem cell
- MPP multipotent precursor
- CMP common myeloid precursor
- MEP megakaryocyte-erythroid precursor
- GFP granulocyte-monocyte precursor
- CLP common lymphoid precursor
- Red + symbol indicates precursors and final elements found to have evidence of chromothripsis and green - symbol indicates those that retain the CXCR4 R334X allele.
- CD cluster of differentiation.
- FIG. B shows the results of DNA from the purified bone marrow precursors after PCR- RFLP to detect the CXCR4 R334X mutation (left side gel) and amplification using primers specific for one of the 18 chromothripsis rearrangements (right side gel).
- CLP demonstrate continued presence of the CXCR4 R334X heterozygous mutation and lack amplification for the derivative chromosome that resulted from chromothripsis.
- BM CD16+ indicate purified CD16+ neutrophils given as a positive control
- HD PBMC indicates healthy donor peripheral blood mononuclear cell DNA as a negative control.
- PCR- indicates amplification in the absence of input DNA as a negative control.
- FIG. 9 Serum Cytokines. Frozen serum from the index patient, 5 healthy donors and 5 WHIM patients was sent for measurement of 26 cytokines. Shown are selected results in picograms / milliliter (pg/ml) where each value for an individual is a dot with circles representing healthy donors (HD), squares representing WHIM patients, and W9 representing the index patient (WHIM-09). The lines represent the mean + the standard error of the mean. See Table 3 for a complete list.
- FIGS. 10A-10B Cxcr4 Haploinsufficiency Enhances Bone Marrow Engraftment in WHIM Syndrome Mouse Model.
- A Competitive bone marrow transplantation experiment in irradiated recipients: Cxcr4 +/o versus Cxcr4 +/S338X (mouse model of WHIM syndrome),
- i
- Bone marrow cells from donors with a Cxcr4 +/o genotype on a CD45.2 homozygous and Cxcr4 +/S338x on a CD45.1/45.2 heterozygous background were mixed equally and then 5 million bone marrow cells were injected intravenously into each CD45.1 recipient mouse that had been lethally irradiated 8 hours prior.
- Donor-derived blood cell frequency data for the leukocyte subsets indicated at the top of each panel, presented as the mean + SEM percentage ( ) of total cells for each subset (n 5 mice per data point).
- Red circles blood cells from Cxcr4 +/o donors
- blue triangles blood cells from Cxcr4 +/S338x donors
- black triangles blood cells from
- FIGS. 11A-11B Cxcr4 Haploinsufficiency Enhances Bone Marrow Engraftment.
- A Competitive bone marrow transplantation experiment in irradiated recipients: Cxcr4 +/o versus Cxcr4 +/+ .
- i Experimental design: Bone marrow cells from donors with a Cxcr4 +/o genotype on a CD45.2 homozygous and a Cxcr4 +/+ genotype on a CD45.1/45.2 heterozygous background were mixed equally and then 5 million mixed bone marrow cells were injected intravenously into each CD45.1 recipient mouse that had been lethally irradiated 8 hours prior.
- FIGS. 12A-12B Cxcr4 Haploinsufficiency Enhances Bone Marrow Engraftment in mice in a Hematopoietic Stem Cell (HSC) Intrinsic Manner.
- HSC Hematopoietic Stem Cell
- Bone marrow cells from donors with a Cxcr4 +/o genotype on a CD45.2 homozygous and from donors with a Cxcr4 +/S338x genotype on a CD45.1/45.2 heterozygous background were mixed equally.
- the mixed BM cells were lineage-depleted by negative selection with Lineage Cell Depletion Kit (Miltenyi Biotech Inc) and then HSC cells (lineage " Scal + c- Kit + CD48 " CD34 " CD150 + ) were sorted with a flow cytometer. 2000 isolated HSC cells were injected intravenously into each CD45.1 recipient mouse that had been lethally irradiated 8 hours prior.
- FIGS. 13A-13B Cxcr4 haploinsufficiency enhances HSC engraftment in a mouse bone marrow transplantation model.
- A Haploinsufficiency of Cxcr4 promotes enhanced proliferation of HSCs. Bone marrow cells from donors with a Cxcr4 +/o genotype on a CD45.2 homozygous and from donors with a Cxcr4 genotype on a CD45.1/45.2 heterozygous background were mixed (47:53) and then 5 million mixed bone marrow cells were injected intravenously into each CD45.1 recipient mouse that had been lethally irradiated 8 hours prior.
- mice were euthanized for hematopoietic progenitor population analysis 303 days after bone marrow transplantation.
- One experiment was performed with five CD45.1 and five CD45.2 male recipient mice and the results were combined in the figure because they were identical, (i) Gating scheme for the long term HSC (LT-HSC: CD34 " Flt3 " Lin " Scal + c-Kit + ), short term HSC (ST-HSC: CD34 + Flt3 " Lin " Scal + c-Kit + ), multipotent progenitors (MPP: CD34 + Flt3 + Lin " Scal + c-Kit + ), and common lymphoid progenitors (CLP: IL7ra + Lin " Scal low c-Kit low ).
- LT-HSC CD34 " Flt3 " Lin " Scal + c-Kit +
- ST-HSC CD34 + Flt3 " Lin " Scal + c-Kit +
- MPP CD34 + Flt3 + Lin " Scal +
- FIG. 14 Bone marrow Testing for ALK activity. Two representative photomicrographs from a WHIM-09 bone marrow biopsy are shown. On the left is a typical hematoxylin and eosin stain and on the right is an immunohistochemical stain for anaplastic lymphoma receptor tyrosine kinase (ALK) activity. Lack of brown color indicates that although the ALK gene is translocated there is no detectable increased enzymatic activity.
- ALK lymphoma receptor tyrosine kinase
- FIGS. 15A and 15B Bone Marrow Progenitor In vitro Culture Assay and PCR.
- A Representative example of the in vitro culture and differentiation of a healthy blood donor (HD) and WHIM-09's (W9) CD34 + HSC cultured to create burst forming unit-erythroid (BFU-E) colonies. DNA isolated from these colonies was then used in the PCR-RFLP assay for the CXCR4 R334X allele.
- BFU-E Demonstrates that BFU-E colonies lack the WHIM allele.
- FIGS. 16A-16D Complete TALEN system creates deletions in CXCR4 resulting in loss of CXCR4 expression.
- A Genomic DNA sequence of human CXCR4. TALEN sequences are underlined. (SEQ ID NO: 11 top, SEQ ID NO: 12 bottom)
- B FACS analysis of HeLa cells 2 days after transfection with maxGFP as a transfection control, CXCR4-copGFP-CXCR4 donor, incomplete TALEN (LI) with CXCR4-copGFP-CXCR4 donor, or complete TALEN (L1+R2) system with CXCR4-copGFP-CXCR4 donor;
- C HeLa cells that were transfected with the complete TALEN system were sorted by FACS (top), cultured for 7 days and analyzed by FACS analysis 7 days later (bottom);
- D Sequence analysis of the GFP negative cell population from (B).
- Sequences corresponding to LI and R2 TALENs are highlighted in green. Red box highlights sequences (sequences from top SEQ ID NOS: 13, 15, 13, 13, 16, 13, 13, 17, 13, 13, 13, and 13) from cells that express low levels of CXCR4 (CXCR4 Lo) population. SEQ ID NOS: 13, 13, 13, 14, 13, 13, 15, 13, 13, 16, 13, 13, 17, 13, 13, 13, 13 and 13 from top to bottom.
- FIGS. 17A-17E CRISPR-Cas9 system creates deletions in CXCR4 to generate cells with one copy of CXCR4.
- A Genomic DNA sequence of human CXCR4. CRISPR guide sequences are underlined, PAM motif is in italics; (SEQ ID NO: 18 top, SEQ ID NO: 19 bottom)
- B FACS analysis 6 days after HeLa cells were transfected with 2 ⁇ g maxGFP (transfection efficiency control), 2 ⁇ g CRISPR-cas9 D10A Nickase or 1 ⁇ g Nickase with 0.5 ⁇ g of each guide;
- C HeLa cells that were transfected with the complete Nickase system were sorted by FACS (top), after which surveyor assay was carried out to detect mutations in the sorted populations.
- CXCR4 Lo cells were cultured for 4 days and analyzed by FACS analysis (bottom);
- D Sequence analysis of populations of cells that expressed high (CXCR4 Hi; SEQ ID NOS: 20, 21, 20, 20, 20, 20, 20, 20, 20, 20, 20, 20, 20, 20, 20, 22, 20, 20, 20 and 20 from top to bottom), medium (CXCR4 Mid SEQ ID NOS: 20, 20, 23, 24, 20, 20, 20, 25, and 20 from top to bottom), and low (CXCR4 Lo SEQ ID NOS: 26, 20, 20, 27, 20, 20, 20, 20, 28, 20, 20, 20, 20, 20, 20, 20, 20, 20, 20, 20, 20, 29, 30, 31, 31, 31, 20, 20, 20, 20, 20, 20, 20, 20, 20, 32, 31, 31, 31, 31, and 31 from top to bottom) levels of CXCR4 and a consensus sequence is shown at the bottom (SEQ ID NO: 20);
- E Sequence analysis from 5 single cell clones. Each clone has at least 2 sequence reads. Sequences corresponding to guides are highlighted in green. SEQ ID NOS: 33, 33, 33, 34, 34, 34, 33, 34, 35, 34, 33
- nucleic and amino acid sequences listed in the accompanying sequence listing are shown using standard letter abbreviations for nucleotide bases, and three letter code for amino acids, as defined in 37 C.F.R. 1.822. Only one strand of each nucleic acid sequence is shown, but the complementary strand is understood as included by any reference to the displayed strand.
- SEQ ID NOS: 1-4 are PCR primers for amplification of CXCR4.
- SEQ ID NOS: 5 and 6 are exemplary human CXCR4 coding and protein sequences.
- nt 1-2643 is the promoter, 2603-2607 TATA signal, 2632-6409 the gene, with nt 2721..2735 joined to 4844..5911 to form the coding sequence.
- SEQ ID NOS: 7-8 are PCR primers for genomic DNA amplification of CXCR4 for indel analysis.
- SEQ ID NOS: 9-10 are PCR primers for genomic DNA amplification of CXCR4 for single cell clonal analysis.
- SEQ ID NOS: 11-12 are human CXCR4 genomic DNA sequence targeted by TALENs.
- SEQ ID NOS: 13-17 are resulting mutated human CXCR4 genomic DNA sequences using the TALEN system. A consensus sequence is shown in SEQ ID NO: 13.
- SEQ ID NOS: 18-19 are human CXCR4 genomic DNA sequence containing CRISPR guide sequences and PAM sequences.
- SEQ ID NOS: 20-32 are resulting mutated human CXCR4 genomic DNA sequences using the nickase system.
- SEQ ID NOS: 20 and 22 are sequences from cells that expressed high (CXCR4 Hi) levels of CXCR4;
- SEQ ID NOS: 20, 23, 24 and 25 are sequences from cells that expressed medium (CXCR4 Mid) levels of CXCR4, and
- SEQ ID NOS: 20, 26, 27, 28, 29, 30, 31 and 32 are sequences from cells that expressed low (CXCR4 Lo) levels of CXCR4.
- SEQ ID NOS: 33-35 are normal (SEQ ID NO: 33) and resulting mutated human CXCR4 genomic DNA sequences (SEQ ID NOS: 34-35) using the nickase system from 5 single cell clones.
- SEQ ID NOS: 36-50 are exemplary sequences that can be used to knock-down CXCR4 expression using CRISPR or TALEN.
- nucleic acid molecule means “including a nucleic acid molecule” without excluding other elements. It is further to be understood that any and all base sizes given for nucleic acids are approximate, and are provided for descriptive purposes, unless otherwise indicated. Although many methods and materials similar or equivalent to those described herein can be used, particular suitable methods and materials are described below. In case of conflict, the present specification, including explanations of terms, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting. All references, including patent applications and patents, and sequences associated with the GenBank® Accession Numbers listed (as of July 18, 2014) are herein incorporated by reference.
- exemplary routes of administration include, but are not limited to, injection (such as subcutaneous, intramuscular, intradermal, intraperitoneal, and intravenous), transdermal, intranasal, and inhalation routes.
- Double- stranded DNA has two strands, a 5' -> 3' strand, referred to as the plus strand, and a 3' -> 5' strand (the reverse complement), referred to as the minus strand.
- dsDNA Double- stranded DNA
- the plus strand a 5' -> 3' strand
- the minus strand the reverse complement
- the minus strand the minus strand of the DNA serves as the template for the RNA during transcription.
- the RNA formed will have a sequence complementary to the minus strand and identical to the plus strand (except that U is substituted for T).
- CD34 A cell surface antigen formerly known as hematopoietic progenitor cell antigen 1, and MY10, which is a marker of human hematopoietic stem cells. For example, CD34 is expressed selectively on human hematopoietic progenitor cells. CD34 is an adhesion molecule. The human CD34 gene, which maps to chromosome lq32, spans 26 kb and has 8 exons. CD34 is a 67 kDa transmembrane glycoprotein.
- CD34 sequences are publically available, for example from the GenBank® sequence database (e.g., Accession Nos. NP_001020280.1 (precursor) and AAB25223.1 provide exemplary human CD34 protein sequences; while Accession Nos. M81104.1 and BC039146.1 provide exemplary human CD34 nucleic acid sequences).
- CD34 variants e.g., sequences having at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98% or at least 99% sequence identity to the sequence of any Accession number listed).
- Cell Culture Cells grown under controlled conditions.
- a primary cell culture is a culture of cells, tissues or organs taken directly from an organism (such as a human or other mammal).
- Cells are expanded in culture when they are placed in a growth medium under conditions that facilitate cell growth and/or division, resulting in a larger population of the cells.
- the rate of cell proliferation is typically measured by the amount of time required for the cells to double in number, otherwise known as the doubling time.
- donor HSCs are grown in culture prior to introduction into a recipient.
- HSCs grown in culture can be manipulated to downregulate CXCR4 expression or activity.
- CXC chemokine receptor 4 OMIM 162643.
- fusin or CD 184, is a gene that encodes for the CXCR4 protein, an alpha-chemokine receptor found on most leukocytes that is specific for stromal cell-derived-factor- 1 (CXCL12), a molecule that has chemo tactic activity for both lymphocytes and phagocytes.
- CXCR4 gene is found on chromosome 2 (2q22.1), and in mice it is found on chromosome 1.
- CXCR4 sequences are publically available, for example from the GenBank® sequence database (e.g., Accession Nos. NP_001008540 and CAA12166.1 provide exemplary human
- CXCR4 protein sequences NP_034041.2 and AAH31665.1 provide exemplary mouse CXCR4 protein sequences, while Accession Nos. NG_011587.1 and AJ224869.1 provide exemplary human CXCR4 nucleic acid sequences and Accession Nos. NM_009911.3 and BC098322.1 provide exemplary mouse CXCR4 nucleic acid sequences).
- CXCR4 nucleic acid and protein sequences including CXCR4 variants (e.g., sequences having at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98% or at least 99% sequence identity to the sequence of any Accession number listed, or to SEQ ID NO: 5 or 6).
- CXCR4 variants e.g., sequences having at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98% or at least 99% sequence identity to the sequence of any Accession number listed, or to SEQ ID NO: 5 or 6).
- Downregulated or knocked down When used in reference to the expression of a molecule, such as a (e.g., CXCR4) gene or a protein, refers to any process which results in a decrease in production of a gene product, but in some examples not complete elimination of the gene product or gene function.
- a gene product can be RNA (such as mRNA, rRNA, tRNA, and structural RNA) or protein. Therefore, downregulation or knock down includes processes that decrease transcription of a gene or translation of mRNA and thus decrease the presence of proteins or nucleic acids, such as a CXCR4 protein or nucleic acid molecule.
- processes that decrease transcription include those that facilitate degradation of a transcription initiation complex, those that decrease transcription initiation rate, those that decrease transcription elongation rate, those that decrease processivity of transcription and those that increase transcriptional repression.
- Gene downregulation can include reduction of expression above an existing level.
- processes that decrease translation include those that decrease translational initiation, those that decrease translational elongation and those that decrease mRNA stability.
- a gene editing method, inhibitory RNA, antibody, or other specific binding agent is used to decrease or knock down expression, such as expression or activity of CXCR4.
- Downregulation or knock down includes any detectable decrease in the production of a gene product, such as a CXCR4 protein.
- detectable target protein or nucleic acid expression in a cell decreases by at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% (such as a decrease of 40% to 90%, 40% to 80% or 50% to 95%) as compared to a control (such an amount of protein or nucleic acid expression detected in a corresponding normal cell or sample).
- a control is a relative amount of expression in a normal HSC (e.g., a non-recombinant HSC or an HSC from a healthy or normal subject).
- downregulation or knock down does not result in complete elimination of detectable expression or activity (such as expression or activity of CXCR4).
- Expression The process by which the coded information of a nucleic acid molecule, such as a CXCR4 nucleic acid molecule (e.g., Cxcr4 gene) is converted into an operational, non- operational, or structural part of a cell, such as the synthesis of a protein (e.g., CXCR4 protein).
- a gene can be regulated anywhere in the pathway from DNA to RNA to protein. Regulation can include controls on transcription, translation, RNA transport and processing, degradation of intermediary molecules such as mRNA, or through activation, inactivation, compartmentalization or degradation of specific protein molecules after they are produced.
- nucleic acid molecule or protein can be altered relative to a normal (wild type) nucleic acid molecule or protein (such as in a normal non- recombinant HSC).
- Alterations in gene expression, such as differential expression include but are not limited to: (1) overexpression (e.g., upregulation); (2) underexpression (e.g., downregulation); or (3) suppression of expression.
- Alternations in the expression of a nucleic acid molecule can be associated with, and in fact cause, a change in expression of the corresponding protein.
- Protein expression can also be altered in some manner to be different from the expression of the protein in a normal (wild type) situation. This includes but is not necessarily limited to: (1) a mutation in the protein such that one or more of the amino acid residues is different; (2) a short deletion or addition of one or a few (such as no more than 10-20) amino acid residues to the sequence of the protein; (3) a longer deletion or addition of amino acid residues (such as at least 20 residues), such that an entire protein domain or sub-domain is removed or added; (4) expression of an increased amount of the protein compared to a control or standard amount (e.g., upregulation); (5) expression of a decreased amount of the protein compared to a control or standard amount (e.g., downregulation); (6) alteration of the subcellular localization or targeting of the protein; (7) alteration of the temporally regulated expression of the protein (such that the protein is expressed when it normally would not be, or alternatively is not expressed when it normally would be); (8) alteration in stability of a protein through increased longevity
- Controls or standards for comparison to a sample, for the determination of differential expression include samples believed to be normal (in that they are not altered for the desired characteristic, for example a HSC from a normal subject) as well as laboratory values, even though possibly arbitrarily set, keeping in mind that such values can vary from laboratory to laboratory.
- Laboratory standards and values may be set based on a known or determined population value and can be supplied in the format of a graph or table that permits comparison of measured,
- Fokl nuclease A nonspecific DNA nuclease that occurs naturally in Flavobacterium okeanokoites.
- the term includes fragments of the Fokl nuclease protein that retain nuclease activity that are, or may be, fused to a DNA-binding polypeptide. Also includes variants of a wild-type Fokl sequence.
- Functional deletion A mutation, partial or complete deletion, insertion, or other variation made to a gene sequence that reduces or can even inhibit production of the gene product or renders the gene product non-functional.
- a functional deletion of a single CXCR4 allele in a HSC results in a cell that cannot produce CXCR4 protein from that allele (but can produce CXCR4 from the other allele), which results in the HSC having an increased engraftment and repopulation abilities.
- Genomic insertion site A site of the genome that is targeted for, or has undergone, insertion of an exogenous polynucleotide.
- HSC Hematopoietic stem cell
- HSCs have the ability to durably generate all blood lineages in vivo. They are present in the umbilical cord, blood, and bone marrow (BM). In some examples, HSCs express CD34. In some examples, HSCs express the following markers:
- CXCR4 knock down HSC is a recombinant HSC having reduced, but not eliminated, CXCR4 expression and activity, such as a reduction of at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% (such as a decrease of 40% to 60%, 40% to 90%, 40% to 80%, 50% to 90%, or 50% to 95%) as compared to a control (such as a non-recombinant HSC with normal or wild- type CXCR4 expression).
- HIV Human Immunodeficiency Virus
- AIDS acquired immunodeficiency syndrome
- This immunosuppression results from a progressive depletion and functional impairment of T lymphocytes expressing the CD4 cell surface glycoprotein.
- the loss of CD4 helper/inducer T cell function may underlie the loss of cellular and humoral immunity leading to the opportunistic infections and malignancies seen in AIDS.
- HIV subtypes can be identified by particular number, such as HIV-1 and HIV-2.
- Increase or Decrease A statistically significant positive or negative change, respectively, in quantity from a control value.
- An increase is a positive change, such as an increase at least 50%, at least 100%, at least 200%, at least 300%, at least 400% or at least 500% as compared to the control value.
- a decrease is a negative change, such as a decrease of at least 20%, at least 25%, at least 50%, at least 75%, at least 80%, at least 90%, at least 95%, at least 98%, at least 99%, or at least 100% decrease as compared to a control value. In some examples the decrease is less than 100%, such as a decrease of no more than 90%, no more than 95% or no more than 99%.
- Isolated An "isolated" biological component (such as an HSC cell, nucleic acid or protein) has been substantially separated, produced apart from, or purified away from other biological components in the cell or tissue of the organism in which the component naturally occurs, such as other cells, chromosomal and extrachromosomal DNA and RNA, and proteins.
- Nucleic acids and proteins which have been "isolated” include nucleic acids and proteins purified by standard purification methods. The term also embraces nucleic acids and proteins prepared by recombinant expression in a host cell as well as chemically synthesized nucleic acids and proteins.
- Isolated HSCs in some examples are at least 50% pure, such as at least 75%, at least 80%, at least 90%, at least 95%, at least 98%, or at least 100% pure (that is free from other cell types in the blood or bone marrow).
- Mammal This term includes both human and non-human mammals. Similarly, the term “subject” includes both human and veterinary subjects. Modulate: A change in the content of genomic DNA gene. Modulation can include, but is not limited to, gene activation (e.g., upregulation), gene repression (e.g., downregulation), gene deletion, polynucleotide insertion, and/or polynucleotide excision.
- gene activation e.g., upregulation
- gene repression e.g., downregulation
- gene deletion e.g., polynucleotide insertion, and/or polynucleotide excision.
- a first nucleic acid sequence is operably linked with a second nucleic acid sequence when the first nucleic acid sequence is placed in a functional relationship with the second nucleic acid sequence.
- a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence.
- operably linked DNA sequences are contiguous and, where necessary to join two protein-coding regions, in the same reading frame.
- compositions and formulations suitable for pharmaceutical delivery of a CXCR4 knock down HSC are conventional. Remington's Pharmaceutical Sciences, by E. W. Martin, Mack Publishing Co., Easton, PA, 15th Edition (1975), describes compositions and formulations suitable for pharmaceutical delivery of a CXCR4 knock down HSC.
- parenteral formulations usually comprise injectable fluids that include pharmaceutically and physiologically acceptable fluids such as water, physiological saline, balanced salt solutions, aqueous dextrose, glycerol or the like as a vehicle.
- pharmaceutical compositions to be administered can contain minor amounts of non-toxic auxiliary substances, such as wetting or emulsifying agents, preservatives, and pH buffering agents and the like, for example sodium acetate or sorbitan monolaurate.
- a promoter is an array of nucleic acid control sequences which direct transcription of a nucleic acid.
- a promoter includes necessary nucleic acid sequences near the start site of transcription.
- a promoter also optionally includes distal enhancer or repressor elements.
- a "constitutive promoter” is a promoter that is continuously active and is not subject to regulation by external signals or molecules. In contrast, the activity of an "inducible promoter” is regulated by an external signal or molecule (for example, a transcription factor).
- the promoter is a U6 promoter or a CMV promoter.
- Recombinant or host cell A cell that has been genetically altered, or is capable of being genetically altered by introduction of an exogenous polynucleotide, such as a recombinant plasmid or vector.
- a host cell is a cell in which a vector can be propagated and its DNA expressed.
- the cell is an HSC.
- the term also includes any progeny of the subject host cell. It is understood that all progeny may not be identical to the parental cell since there may be mutations that occur during replication. However, such progeny are included when the term "host cell” is used.
- RNA molecules into cells (such as double stranded RNA), results in binding of the RNA molecules to other specific messenger RNA (mRNA) molecules and can either increase or decrease their activity, for example by preventing an mRNA from producing a protein.
- inhibitory RNA molecules include small interfering RNA (siRNA), micro RNA (miRNA), ribozymes (such as a hammerhead ribozyme, VS ribozyme, or hairpin ribozyme), and antisense molecules.
- siRNA small interfering RNA
- miRNA micro RNA
- ribozymes such as a hammerhead ribozyme, VS ribozyme, or hairpin ribozyme
- antisense molecules antisense molecules.
- an RNAi molecule is directed against a target gene, such as CXCR4 in an HSC, and is used to increase engraftment of the resulting recombinant
- an RNAi molecule is at least about 19 nucleotides (nt), such as at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 26, or at least 27 nt in length.
- Selectable marker A gene introduced into a cell, such as HSCs in culture, which confers a trait suitable for artificial selection from HSCs that do not possess the gene.
- Sequence identity/similarity The similarity between amino acid (or nucleotide) sequences is expressed in terms of the similarity between the sequences, otherwise referred to as sequence identity. Sequence identity is frequently measured in terms of percentage identity (or similarity or homology); the higher the percentage, the more similar the two sequences are.
- BLAST Basic Local Alignment Search Tool
- NCBI National Center for Biotechnology Information
- blastp blastn
- blastx blastx
- tblastn tblastx
- Homologs and variants of protein and nucleic acid sequences known in the art and disclosed herein are typically characterized by possession of at least about 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity counted over the full length alignment with the amino acid sequence using the NCBI Blast 2.0, gapped blastp set to default parameters.
- the Blast 2 sequences function is employed using the default BLOSUM62 matrix set to default parameters, (gap existence cost of 11, and a per residue gap cost of 1).
- sequence identity When aligning short peptides (fewer than around 30 amino acids), the alignment should be performed using the Blast 2 sequences function, employing the PAM30 matrix set to default parameters (open gap 9, extension gap 1 penalties). Proteins with even greater similarity to the reference sequences will show increasing percentage identities when assessed by this method, such as at least 95%, at least 98%, or at least 99% sequence identity.
- homologs and variants When less than the entire sequence is being compared for sequence identity, homologs and variants will typically possess at least 80% sequence identity over short windows of 10-20 amino acids, and may possess sequence identities of at least 85% or at least 90% or at least 95% depending on their similarity to the reference sequence. Methods for determining sequence identity over such short windows are available at the NCBI website on the internet. One of skill in the art will appreciate that these sequence identity ranges are provided for guidance only; it is entirely possible that strongly significant homologs could be obtained that fall outside of the ranges provided.
- a CXCR4 protein can have at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to any of GenBank® Accession Nos. NP_001008540, CAA12166.1, NP_034041.2 and AAH31665.1.
- exemplary CXCR4 nucleic acid sequences in some examples have at least 70%, at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 98%, or at least 99% sequence identity to any of GenBank® Accession Nos. NG_011587.1, AJ224869.1, NM_009911.3 and BC098322.1.
- Subject Any subject that has a vascular system and has hematopoietic cells in the wild- type organism.
- the subject is a non-human mammalian subject, such as a monkey or other primate, mouse, rat, rabbit, pig, goat, sheep, dog, cat, horse, or cow.
- the subject is a human subject.
- the subject has a genetic disease of the blood (e.g. sickle cell disease, primary immunodeficiency diseases), HIV (such as HIV-1), anemia, or a hematologic malignancy or cancer, such as one of those listed in Table 1.
- Therapeutically effective amount The amount of agent, such as CXCR4 knock down HSCs (which may include one or more other repaired genetic mutations as discussed herein), that is sufficient to prevent, treat, reduce and/or ameliorate the symptoms and/or underlying causes of a disorder or disease.
- agent such as CXCR4 knock down HSCs (which may include one or more other repaired genetic mutations as discussed herein)
- it can be an amount of CXCR4 knock down HSCs sufficient to reconstitute hematopoiesis in a subject receiving the CXCR4 knock down HSCs, such as a subject having genetic disease of the blood (e.g. sickle cell disease, primary immunodeficiency diseases), ⁇ (such as HIV-1), or a hematologic malignancy or cancer, such as one of those listed in Table 1.
- an effective amount of CXCR4 knock down HSCs can be determined by various methods, including generating an empirical dose-response curve, predicting potency and efficacy by using modeling, and other methods used in the art.
- a therapeutically effective amount of CXCR4 knock down HSCs is at least 10,000, at least 20,000, at least 30,000, at least 40,000, at least 50,000, at least 100,000, at least 500,000, at least 1,000,000, at least 2,000,000, at least 3,000,000, at least 4,000,000, at least 5,000,000, at least 10,000,000, at least 20,000,000, at least 25,000,000, or at least 50,000,000 CXCR4 knockdown HSCs. Specific assays for
- donor HSC engraftment e.g., by measuring HSC repopulation
- HSC repopulation can be measured in the recipient subject.
- an "effective amount" of CXCR4 knockdown HSCs is an amount sufficient to reduce symptoms of a genetic disease of the blood, such as a primary
- immunodeficiency disease for example by at least 10%, at least 20%, at least 50%, at least 70%, or at least 90% (as compared to no administration of the CXCR4 knockdown HSCs).
- an "effective amount" of CXCR4 knockdown HSCs is an amount sufficient to reduce symptoms of anemia for example by at least 10%, at least 20%, at least 50%, at least 70%, or at least 90% (as compared to no administration of the CXCR4 knockdown HSCs).
- a therapeutically effective amount of CXCR4 knockdown HSCs is an amount of CXCR4 knockdown HSCs sufficient to increase the number of red blood cells in an anemic recipient, wherein such cells are generated from the CXCR4 knockdown HSCs.
- the anemia is Fanconi anemia
- the CXCR4 HSCs include a repaired Fanconi anemia gene(s).
- an "effective amount" of CXCR4 knockdown HSCs is an amount sufficient to increase the number of CD4+ T cells in an HIV-infected subject. In one example, an "effective amount" of CXCR4 knockdown HSCs is an amount sufficient to reduce symptoms of HIV-l infection, for example by at least 10%, at least 20%, at least 50%, at least 70%, or at least 90% (as compared to no administration of the CXCR4 knockdown HSCs).
- an "effective amount" of CXCR4 knockdown HSCs is an amount sufficient to reduce the number of abnormal white blood cells in a subject with a hematological malignancy, such as a leukemia. In one embodiment, an "effective amount" of CXCR4 knockdown HSCs is an amount sufficient to reduce the number of abnormal plasma cells in a subject with multiple myeloma. In one example, an "effective amount" of CXCR4 knockdown HSCs is an amount used to treat or reduce the undesirable effects of a lymphoma, such as reduce the size of the lymphoma, volume of the lymphoma, rate of growth of the lymphoma, and/or metastasis of the lymphoma.
- Such reduction can be at least 10%, at least 20%, at least 50%, at least 70%, or at least 90% (as compared to no administration of the CXCR4 knock down HSCs).
- an "effective amount" is an amount of CXCR4 knockdown HSCs sufficient to reduce symptoms of a hematological malignancy, for example by at least 10%, at least 20%, at least 50%, at least 70%, or at least 90% (as compared to no administration of the CXCR4 knockdown HSCs).
- the therapeutically effective amount of cells can be dependent on the subject being treated (e.g., the species or size of the subject), the severity of the disease in the recipient subject.
- a therapeutically effective amount of CXCR4 knockdown HSCs is an amount of CXCR4 knockdown HSCs sufficient to increase the number of B cells, T cells, monocytes and/or macrophages in the peripheral blood of a recipient, wherein such cells are generated from the CXCR4 knockdown HSCs.
- a virus or vector "transduces" a cell when it transfers nucleic acid molecules into a cell, such as an HSC.
- a cell is "transformed” or
- transfected by a nucleic acid transduced into the cell (such as an HSC) when the nucleic acid becomes stably replicated by the cell, either by incorporation of the nucleic acid into the cellular genome, or by episomal replication.
- nucleic acid molecule can be introduced into such a cell, including transfection with viral vectors, transformation with plasmid vectors, and introduction of naked DNA by electroporation, lipofection, particle gun acceleration and other methods in the art.
- the method is a chemical method (e.g., calcium- phosphate transfection), physical method (e.g., electroporation, microinjection, particle
- fusion e.g., liposomes
- receptor-mediated endocytosis e.g., DNA-protein complexes, viral envelope/capsid-DNA complexes
- biological infection by viruses such as recombinant viruses (Wolff, J. A., ed, Gene Therapeutics, Birkhauser, Boston, USA, 1994).
- retroviruses the infecting retrovirus particles are absorbed by the target cells, resulting in reverse transcription of the retroviral RNA genome and integration of the resulting pro virus into the cellular DNA.
- Methods for the introduction of genes into cells are known (e.g., see U.S. Patent No. 6,110,743). These methods can be used to transduce a HSC to manipulate its genome.
- Genetic modification of the target cell is an indicium of successful transfection.
- Genetically modified cells refers to cells whose genotypes have been altered as a result of cellular uptakes of exogenous nucleotide sequence by transfection, transduction, or transformation.
- a reference to a transfected cell or a genetically modified cell includes both the particular cell into which a vector or polynucleotide is introduced and progeny of that cell.
- Transgene An exogenous gene.
- Transplantation The transfer of a tissue or an organ, or cells (such as HSCs), from one body or part of the body to another body or part of the body.
- An "allogeneic transplantation” or a “heterologous transplantation” is transplantation from one individual to another, wherein the individuals have genes at one or more loci that are not identical in sequence in the two individuals.
- An allogeneic transplantation can occur between two individuals of the same species, who differ genetically, or between individuals of two different species.
- An “autologous transplantation” is a transplantation of a tissue or cells from one location to another in the same individual, or transplantation of a tissue or cells from one individual to another, wherein the two individuals are genetically identical.
- Treating, Treatment, and Therapy Any success or indicia of success in the attenuation or amelioration of an injury, pathology or condition, including any objective or subjective parameter such as abatement, remission, diminishing of symptoms or making the condition more tolerable to the patient, slowing in the rate of degeneration or decline, making the final point of degeneration less debilitating, improving a subject's physical or mental well-being, or prolonging the length of survival.
- the treatment may be assessed by objective or subjective parameters; including the results of a physical examination, blood and other clinical tests, and the like.
- Upregulated When used in reference to the expression of a molecule, such as a gene or a protein, refers to any process which results in an increase in production of a gene product.
- a gene product can be RNA (such as mRNA, rRNA, tRNA, and structural RNA) or protein. Therefore, upregulation includes processes that increase transcription of a gene or translation of mRNA and thus increase the presence of proteins or nucleic acids.
- Examples of processes that increase transcription include those that increase transcription initiation rate, those that increase transcription elongation rate, those that increase processivity of transcription and those that decrease transcriptional repression.
- Gene upregulation can include increasing expression above an existing level.
- Examples of processes that increase translation include those that increase translational initiation, those that increase translational elongation and those that increase mRNA stability.
- a gene editing method, antibody, or other specific binding agent is used to increase expression.
- Upregulation includes any detectable increase in the production of a gene product.
- detectable target protein or nucleic acid expression in a cell increases by at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 90%, at least 95%, at least 100%, at least 200%, at least 400%, or at least 500% as compared to a control (such an amount of protein or nucleic acid expression detected in a corresponding normal cell or sample).
- a control is a relative amount of expression in a normal HSC (e.g., a non-recombinant HSC or an HSC from a healthy or normal subject).
- a phrase that is used to describe any environment that permits a desired activity is introduction of a nucleic acid molecule into an HSC, for example to reduce expression and activity of CXCR4 in the HSC.
- a vector can include nucleic acid sequences that permit it to replicate in a host cell, such as an origin of replication.
- a vector can also include one or more selectable marker genes and other genetic elements known in the art.
- An integrating vector is capable of integrating itself into a host nucleic acid.
- An expression vector is a vector that contains the necessary regulatory sequences to allow transcription and translation of inserted gene or genes. Vectors include plasmid vectors and viral vectors.
- the vector is a plasmid vector engineered to target CXCR4 by expressing single guide RNA (sgRNA) under the control of the U6 promoter and contain selection markers of puromycin resistance (e.g., from Genecopoeia, Rockville, MD).
- sgRNA sequences target the Cas9 nuclease enzyme or the D10A mutant of the Cas9 nuclease enzyme known as 'nickase' encoded on a second plasmid to the wild-type or WHIM CXCR4 gene to create a double strand break (DSB) or single strand break (SSB) in the gene, respectively.
- DSB double strand break
- SSB single strand break
- Donor sequence encoding markers to interrupt CXCR4 can also be incorporated such that a fluorescent molecule such as GFP is inserted into the CXCR4 gene inactivating it or sequences designed to result in the repair of the targeted gene such as the mutant CXCR4 WHIM allele or other genes listed in Table 1 can be accomplished at the same time.
- a TALEN encoding vector includes the promoter EF- 1 alpha and the selection marker puromycin (e.g., made by Sidansai Biotechnology, Shanghai, China).
- Methods to transfect HSC with plasmid DNA are available (e.g., Lonza nucleofector technology, WalkersviUe, MD).
- Other methods to transfect HSC include 3rd generation integration-deficient lenti viral vectors (for example Life Technologies, Gaithersburg, MD) and Adeno-Associated viral (AAV) vectors (for example Clontech, Moutain View, CA).
- Chromothripsis is a recently discovered phenomenon of multiple clustered genetic abnormalities occurring simultaneously. It is estimated to occur in at least 2% of all cancers and occurs with varying frequency in a wide variety of malignancies.
- This disclosure describes a patient who was born with a congenital immunodeficiency called WHIM syndrome due to a nonsense point mutation in the chemokine receptor CXCR4. As an adult she exhibits phenotypic and genetic evidence of reversion of her immunodeficiency syndrome and she is now a somatic mosaic within the hematopoietic system.
- chromothripsis may occasionally have beneficial effects and has implications for understanding hematopoietic stem cell development, bone marrow transplantation, and the immune system's control of human papillomavirus infection.
- a patient with WHIM syndrome described herein was found to have all the above features of chromothripsis confined to a single copy of chromosome 2 (the location of CXCR4) and associated with loss of the disease allele (and 163 other genes on one copy of chromosome 2) and durable resolution of the clinical manifestations of her disease.
- the chromothriptic event most probably occurred in a single HSC that engrafted and acquired a selective advantage enabling it to repopulate her bone marrow with cells lacking the disease allele, thus affecting cure. To the inventors' knowledge this is the first chromothripsis event to be described that has a positive medical outcome.
- HSC engraftment can be durably enhanced by silencing one copy of CXCR4.
- deletion of one Cxcr4 allele was sufficient to confer a selective advantage on donor cells when transplanted into a mouse model of WHIM syndrome, phenocopying the patient.
- Cxcr4 haploinsufficiency also enhanced engraftment of HSCs in wild-type mice.
- Methods can be used to reduce CXCR4 expression and activity, for example by using gene editing to specifically delete one copy of the CXCR4 gene in the donor HSCs before HSC transplantation into a recipient (e.g., prior to bone marrow transplantation), enhancing the efficiency and durability of donor HSC repopulation.
- This concept may also overcome a major hurdle limiting all gene therapy applications, namely that the corrected cell numbers wane with time.
- the disclosed methods in some examples include (1) reducing expression or activity of CXCR4 in a donor HSC, for example by inactivating one copy of CXCR4 in the donor HSC, and (2) introducing (e.g., infusing, administering, transplanting) the CXCR4 knockdown HSCs into a recipient subject (e.g., if the HSC was manipulated ex vivo).
- Such methods can be used to treat diseases which benefit from improved HSC engraftment.
- the disclosed methods can be used to improve bone marrow transplants (BMTs).
- BMTs bone marrow transplants
- subjects need not undergo conditioning traditionally used in BMTs, but engraftment still occurs, thus reducing major side effects.
- these methods can be used in combination with manipulating one or more other genes in the donor HSC, for example using genome editing techniques, for controlling HIV and in treating diseases that benefit from gene therapy.
- HSCs donor hematopoietic stem cells
- Subjects that can be treated with the disclosed methods include those with a hematopoietic system, such as a mammal, for example a non-human primate (such as an ape or monkey), veterinary subject (such as a cat, dog, mouse, rat, horse, cow, goat, sheep or pig), and humans.
- a hematopoietic system such as a mammal, for example a non-human primate (such as an ape or monkey), veterinary subject (such as a cat, dog, mouse, rat, horse, cow, goat, sheep or pig), and humans.
- engraftment is increased by at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 90%, at least 95%, at least 100%, at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 10-fold, at least 20-fold, or at least 30-fold, for example at 30 days, 60 days, 90 days, 120 days, 1 year or 2 years following the HSC transplant.
- enhanced engraftment is indicated by an increase in donor HSC repopulation in the recipient faster than donor HSC with normal CXCR4 expression or activity.
- the donor HSCs can repopulate at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 90%, at least 95%, at least 100%, at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 10-fold, at least 20-fold, or at least 30-fold, faster than donor HSCs with normal CXCR4 expression or activity (e.g., a wild-type HSC), for example at 30 days, 60 days, 90 days, 120 days, 1 year or 2 years following the HSC transplant.
- normal CXCR4 expression or activity e.g., a wild-type HSC
- enhanced engraftment is indicated by donor HSC lasting longer in the recipient than donor HSC with normal CXCR4 expression or activity.
- the donor HSCs can survive at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 90%, at least 95%, at least 100%, at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 10-fold, at least 20-fold, or at least 30-fold longer than donor HSCs with normal CXCR4 expression or activity (e.g., a wild-type HSC), for example at 30 days, 60 days, 90 days, 120 days, 1 year or 2 years following the HSC transplant.
- donor cells can be tracked by virtue of CD45.1 and CD45.2 variants.
- the donor chimerism can be tracked using specific common polymorphic genetic variations.
- correction of the genetic defect that is targeted can be determined (e.g., loss of the CXCR4 WHIM allele as occurred naturally in the patient).
- the methods include reducing expression of (e.g., downregulating) CXC chemokine receptor 4 (CXCR4) in a donor HSC, thereby generating a CXCR4 knockdown HSC.
- CXCR4 CXC chemokine receptor 4
- expression and/or activity (e.g., function) of CXCR4 can be reduced in the donor HSC by at least 20%, at least 30%, at least 40%, at least 50%, at least 75%, at least 80%, at least 90%, at least 95% or at least 98% (but not 100%, such a reduction of 20% to 50%, 40% to 50%, 20 to 75%, 40% to 60%, or 20% to 90%) in the HSC as compared to expression of CXCR4 in the donor HSC prior to reducing CXCR4 expression and/or activity.
- CXCR4 CXC chemokine receptor 4
- reducing expression of CXCR4 includes functionally deleting one copy of a CXCR4 allele in the donor HSC.
- HSCs having reduced CXCR4 activity are referred to herein as CXCR4 knockdown HSCs.
- this downregulation of CXCR4 is done ex vivo, for example after obtaining HSCs from a donor. In other examples, this is done in vivo.
- the method can further include harvesting or obtaining HSC from a donor subject.
- HSCs can be obtained from peripheral blood, bone marrow, and umbilical cord blood.
- donor HSCs are obtained from the recipient subject, and then reintroduced into the recipient subject after they are manipulated (e.g. , to downregulate CXCR4), while in other examples donor HSCs are obtained from a subject different from the recipient subject.
- the disclosure is not limited to specific methods of editing gene expression or activity in a cell, but in some examples gene editing or RNA interference (RNAi) methods are used to manipulate a CXCR4 gene or other CXCR4 nucleic acid in the HSC.
- RNAi RNA interference
- the CXCR4 protein is targeted, for example with CXCR4 protein antagonists, such as small molecules, antibodies, or aptamers.
- the resulting CXCR4 knockdown HSCs are administered or transplanted into a recipient subject in therapeutically effective amounts, thereby increasing HSC engraftment in the recipient subject.
- at least 1 x 10 6 , at least 1 x 10 7 , or at least 1 x 10 8 CXCR4 knockdown HSCs are administered to the subject. Any method of administration can be used that allows proper function of the HSCs in vivo (for example, allows the CXCR4 knockdown HSCs to reach the bone marrow), such as by injection of the CXCR4 knockdown HSCs into the subject, such as by intravenous administration.
- the recipient subject has not received conditioning prior to administering the CXCR4 knockdown HSCs to the recipient subject, such as chemotherapy and/or total body irradiation which is typically used prior to bone marrow transplantation.
- the methods further include manipulating one or more other genes (such as correcting a mutation and/or altering its expression) in the CXCR4 knockdown HSCs, wherein the resulting HSCs are used to treat a disease or disorder in the subject related to the gene that is manipulated.
- manipulating one or more other genes such as correcting a mutation and/or altering its expression
- manipulating one or more other genes in the donor HSC can include one or more of correcting a genetic defect in the HSC, wherein the genetic defect causes a disease in the recipient subject; reducing expression of a first target gene in the HSC, wherein reducing expression of the first target gene treats a disease caused by upregulation of the first target gene in the recipient subject or treats a disease that benefits from reducing expression of the first target gene in the recipient subject; and increasing expression of a second target gene in the HSC, wherein increasing expression of the second target gene treats a disease caused by downregulation of the second target gene in the recipient subject or treats a disease that benefits from increasing expression of the second target gene in the recipient subject.
- genetic defects that can be fixed or corrected in the HSC include one or more of nucleotide point mutations, nucleotide deletions, nucleotide insertions, gene rearrangements, gene deletions, and gene insertions.
- manipulation of CXCR4 expression in the HSC and manipulation of one or more other genes is performed at the same time, such as by using gene editing methods or RNAi methods.
- the donor HSC is first manipulated to decrease CXCR4
- a CXCR4 knockdown HSC can include other genetic alterations.
- the method is a method of treating a disease or disorder in the subject.
- CXCR4 knockdown HSCs such as allogeneic HSCs
- a hematologic malignancy such as a leukemia, lymphoma, or myeloma (including those listed in Table 1).
- administration of CXCR4 knockdown HSCs not only enhances HSC engraftment, but results in a graft vs. tumor effect, thereby treating the hematologic malignancy.
- CXCR4 knockdown HSCs include other genetic manipulations, which can be used to treat a disorder associated with a genetic mutation or a disorder that would benefit from upregulation a target gene or from downregulation of a target gene.
- the use of autologous HSCs can reduce or eliminate a graft vs. host disease effect.
- CXCR4 knockdown HSCs (such as autologous HSCs) that include other genetic manipulations can be used to treat a hematologic malignancy, such as one that results from a genetic mutation (e.g. , chronic myelogenous leukemia wherein a BCR-ABL fusion gene is repaired or silenced in the donor HSC), HIV- 1 (wherein expression of CCR5 is reduced in the donor HSC), anemia, and a genetic disease of the blood, such as any of sickle cell anemia, hemophilia A, hemophilia B, alpha-thalassemia, beta- thalassemia, delta-thalassemia, von
- the genetic defect that is repaired in the donor HSC is a Glu to Val mutation in amino acid 6 of a ⁇ -globin chain of hemoglobin.
- the genetic defect that is repaired in the donor HSC can be a mutation in clotting factor VIII.
- the genetic defect that is repaired in the donor HSC can be a mutation in clotting factor IX.
- the genetic defect that is repaired in the donor HSC can be a mutation in ADAMTS 13.
- the genetic defect that is repaired in the donor HSC can be a mutation in factor V Leiden or prothrombin.
- Other exemplary diseases and mutations are provided in Table 1 below.
- the disclosure is not limited to particular diseases or mutations, as one skilled in the art will appreciate that based on the teaching provided herein, any genetic disease of the blood or any primary immunodeficiency disease that is due to a particular genetic mutation, can be treated with the disclosed methods.
- HSCs can be harvested from the umbilical cord, blood, and/or bone marrow.
- the HSCs are obtained from the same subject to be treated (autologous, the donor and recipient are the same person).
- the HSCs are obtained from a subject different from the one to be treated (allogeneic, the donor and recipient are different individuals, or syngeneic, the donor and recipient are identical twins).
- hematopoietic progenitors present at a frequency of 0.05-0.2% among peripheral blood mononuclear cells (PBMCs), 0.1-0.5% among cord blood mononuclear cells (MNCs) or 0.5-3% among bone marrow MNCs.
- the resulting HSCs are used to generate CXCR4 knock down HSCs (which can include further genetic manipulations to treat a disease).
- the population of HSCs used to generate the CXCR4 knock down HSCs, and the CXCR4 knock down HSCs administered to a subject do not need to be 100% pure; lower amounts of purity are acceptable.
- a population of cells that contains at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 99% HSCs or CXCR4 knock down HSCs can be used.
- unpurified HSCs are used, such as by using the bone marrow (or PBMCs) directly from the donor, without isolating the HSCs from the bone marrow (or PBMCs).
- HSC can be obtained from the bone marrow (BM) of the pelvis or femur using a needle and syringe.
- BM contains other cells including stromal cells, stromal stem cells, blood progenitor cells, and mature and maturing white and red blood cells. The resulting BM sample can then be used to isolate HSCs.
- donor subjects are injected with a cytokine, such as granulocyte colony- stimulating factor (G-CSF), to induce cells to leave the bone marrow and circulate in the blood vessels.
- G-CSF granulocyte colony- stimulating factor
- the donor can be injected with G-CSF alone or in combination with a CXCR4 inhibitor (e.g., plerixafor) before the cell harvest.
- G-CSF e.g., 10 ⁇ g/kg
- a CXCR4 inhibitor e.g., plerixafor
- a CXCR4 inhibitor e.g., plerixafor
- 240 ⁇ g/kg is administered subcutaneously.
- a mobilized peripheral blood stem cell (PBSC) concentrate can then be collected by leukapheresis on day 5 twelve hours after the administration of plerixafor and 2 hours after the last dose of G-CSF.
- G-CSF e.g., 10 ⁇ g/kg
- the PBSCs express CD34 and/or CD 133.
- the method of Bloan et al. is used to obtain PBMCs (Br. J. Haematol. 120:801-7, 2003).
- PBSCs collected by apheresis without CD34 selection are used to isolate HSCs. 1. PBSCs collected by apheresis without CD34 selection
- Donor stem cell mobilization with G-CSF can be performed as follows. After medical evaluation and clearance for suitability as an autologous or allogeneic donor, donors undergo mobilization with G-CSF (e.g., filgrastim, Neupogen, Amgen).
- G-CSF e.g., filgrastim, Neupogen, Amgen
- the G-CSF can be administered in a dose of approximately 10- 12 ug/kg/day for 5-6 days, subcutaneously.
- the doses for days 1-4 may be given at any time of day, but the doses for day 5 and if necessary, day 6 is given early in the morning, at least one hour and preferably two hours prior to starting apheresis.
- G-CSF can be administered according to a vial-based algorithm to reduce wastage and increase the G-CSF dose given to lighter weight donors to improve CD34 yields as shown below:
- PBSC Peripheral blood stem cell
- An optimum CD34 + HSC dose to be collected by apheresis is >5 x 10 6 /kg.
- the minimum CD34 + HSC dose that is recovered in order to proceed with further therapy is ⁇ 3 x 10 6 /kg.
- Donors can receive prophylactic continuous intravenous calcium chloride infusions to prevent citrate toxicity during apheresis.
- the volume processed per apheresis procedure can be determined by medical staff on the day of apheresis, based on peak CD34 + HSC cell mobilization response to G-CSF, optimum and minimum CD34 + HSC cell dose needed, and kilogram weight of recipient.
- Volume of blood processed can range from 12 to 30 liters per procedure for 1 to 2 consecutive daily procedures, not to exceed a total of 60 liters over 2 days. In pediatric subjects, defined as less than 40 kg, a maximum of 8 blood volumes will be processed per procedure, for up to 2 consecutive daily procedures.
- a central venous double-lumen catheter can be used for apheresis. It may be necessary to "prime" the apheresis instrument with a unit of allogeneic red cells, due to the fact that the volume of blood in the device during apheresis will exceed the safe extracorporeal volume (SEV) allowed for the patient.
- SEV is generally about 15% of circulating blood volume or 10.5 ml/kg.
- SEV is generally about 15% of circulating blood volume or 10.5 ml/kg.
- systemic heparinization can be used during apheresis.
- GCSF is administered as described above, except at the following dosage:
- PBMC donors can receive prophylactic continuous intravenous calcium chloride infusions.
- the target (or "optimum") CD34 + HSC dose recovered after CD34 selection of the apheresis component is >5 x 10 6 /kg.
- volume processed per apheresis procedure will be determined by medical staff on the day of apheresis, based on peak CD34 + HSC cell mobilization response to G-CSF, optimum and minimum CD34 + HSC cell dose needed, and kilogram weight of recipient. Volume processed will range can 12 to 30 liters per procedure for 1 to 2 consecutive daily procedures, not to exceed a total of 60 liters over 2 days. In pediatric subjects (less than 40 kg), a maximum of 8 blood volumes will be processed per procedure, for up to 2 consecutive daily procedures. The same pediatric considerations discussed above apply.
- Safe extracorporeal volume is defined as less than or equal to 15% of intravascular volume.
- Intravascular volume is defined as: 80 mL/kg for children who weigh ⁇ 20 kg and 75 mL/kg for children who weigh > 20 to ⁇ 40 kg.
- Extracorporeal volume in the COBE® Spectra Apheresis System is 285 mL. This can vary further depending on the number of leukocytes targeted for collection and the subject's hemoglobin and WBC count. In general, safe extracorporeal volume is exceeded with use of Spectra when the weight is less than 20 kg. Since it is not acceptable to administer a red blood cell prime for research purposes, the NIH Department of Transfusion Medicine (DTM) does not collect cells for research use in children less than 20 kg.
- DTM NIH Department of Transfusion Medicine
- Citrate is the routine anticoagulant used in apheresis procedures. This method uses continuous intravenous calcium and magnesium replacement in all subjects less than 40 kg undergoing more than 2 blood volumes processed. No adverse events related to divalent cation replacement have occurred with use of the Alaris Guardrail Continuous IV Monitoring System. Citrate may safely be used as the sole anticoagulant in subjects as small as 18-20 kg; below this, the citrate mg/kg infusion rate exceeds a safe level. The acceptable range of citrate infusion rates in DTM is 1.2-3.5 mg/kg/min. Heparin is generally required in subjects less than 18-20 kg. For such patients, full systemic heparinization is used, in addition to a reduced amount of citrate. Since heparin causes systemic anticoagulation and carries additional risk, DTM does not collect cells for research in children less than 20 kg.
- the inlet whole blood flow rate (WBFR) for Spectra is defined as the: AC Pump Rate (mL/min) x (Inlet:AC Ratio).
- the default citrate infusion rate (CIR) is 2.5 mg/kg/min.
- the CIR may be increased up to 3.5 mg/kg/min.
- the default Inlet:AC ratio is 25: 1.
- the Inlet:AC ratio may be set at 20: 1, 25: 1, or 30: 1.
- Threshold CBC values are the same in children and in adults, and are based on worst case scenarios, such as machine malfunction with inability to return the blood in the machine to the donor.
- Minimum hematocrit is 28%, minimum platelet count 10,000/uL (50,000 for research procedures), and minimum WBC count 2000/uL.
- MNC is selected on the COBE® Spectra Apheresis System
- the program will set up with a specific separation factor that is a measure of the centrifugal force to which the blood is exposed.
- Gambro BCT recommends a MNC separation factor of 500 g-minutes for MNC collection. This is the product of the centrifugal force and the length of time a blood element entering the channels is subjected to this force.
- Disposable tubing set volume 285 mL
- the citrate infusion rate (CIR) in subjects > 20 kg may range from 2.5 to 3.5 mg/kg/min, per MD order.
- the maximum allowable CIR will determine the AC pump rate.
- the default citrate infusion rate is 2.5 mg/kg/min
- Loading Dose Heparin (50 U/kg) bolus IV push into return line, administer ordered dose immediately before attaching patient to the machine. If a red cell prime is used, the heparin should be given prior to the infusion of the red cell prime.
- Maintenance dose Heparin (20 U/kg) IV push into draw/access line; administer ordered dose every 60 minutes, starting exactly one hour after administration of the loading dose.
- Return line Attach a 4-way stop-cock to end of return line of Spectra tubing.
- Draw line Attach a 3- way stop-cock to the end of the draw line. Attach a Braun Extension Set to the proximal port of the 3-way stopcock and prime.
- Quick Start is an automated method to establish the interface in WBC procedures.
- the Plasma pump will automatically change to position the interface.
- An accurate patient/donor hematocrit is required to properly establish the interface.
- To exit Quick Start change the plasma pump flow rate or press the Manual button twice.
- the collect valve moves to the open position. Quick Start is completed after the system processes 200 mL of RBC.
- the WBC ColorgramTM assists in determining the hematocrit of the product in the collect line. Insert the ColorgramTM under the smallest clear collect line where it exits the centrifuge. Compare the colored rectangles on the ColorgramTM to the color of the collect line. The hematocrit in the collect line, when compared against the ColorgramTM chart, should be maintained at 1-4% (such as 2-4%) for an MNC collection. Collecting light (1-2%) results in more platelets in the product. Collecting dark (4-5%) results in more granulocytes and RBC in the product. Adjust the plasma pump flow rate to adjust the hematocrit. See section 7.7 in the COBE ⁇ Spectra Apheresis System Operator's Manual (Terumo BCT).for additional information. Collect Pump Flow Rate
- CFR Collect Flow Rate
- the CFR generally varies between 0.8 and 1.5 mL/min which is the CFR recommended by the manufacturer to minimize cross cellular contamination.
- the CFR will be adjusted depending on the WBC count.
- the CFR cannot be changed during Quick Start (See above for information on Quick Start). CBC results may be obtained from Cell Processing Laboratory on the pre-apheresis tube.
- the default AC infusion rate is 0.8 mL/min/L of TBV.
- the AC infusion rate may be increased to 1.2 mL/min/L of TBV without operator override.
- the presence of cloudy, clumped light colored cells in the collect line and in the line entering the product bag may indicate platelet clumping and the need to decrease the AC ratio.
- the intermittent loss of a stable optimal interface during the procedure may indicate platelet clumping and that a clump has pushed through the collect line. This may require a decrease in the AC ratio.
- Plasma may be collected during a WBC procedure in the automatic mode. Plasma collection will not begin until Quick Start has completed. To enter the desired amount of plasma to be collected, use the Target Plasma key to enter the volume. The plasma will be collected at the rate the Plasma pump has been set to minimize disruption of the interface, however, the manufacturer recommends collecting the plasma at the end of the procedure as plasma collection may cause temporary interface instability. The Plasma valve will automatically close when the desired amount has been collected. The plasma collection may be started at any time during the procedure. If no plasma is to be collected, close the plasma line of the WBC set before starting prime.
- the manufacturer's default end point for MNC procedures is 2.0 X TBV.
- the endpoint maybe configured to: Specific run time, Specific volume of blood (inlet volume) to process, multiple of the donor/patient total blood volume. See COBE ⁇ Spectra Apheresis System
- the centrifuge may not spin longer than 10 minutes. Allow the centrifuge to automatically stop after 10 minutes. While in Pause, if the centrifuge is allowed to continue to spin, there is potential for hemolysis to the cells. The centrifuge can remain off for a maximum of 60 minutes. If the centrifuge is restarted, drainage of the tubing is required as described below. Opening the normal saline from the draw and return lines drains only
- Access Devices, Care and Maintenance of Central or remove the antecubital IVs apply direct pressure until bleeding has stopped then apply a pressure dressing.
- Repeat and document vital signs including temperature, blood pressure and pulse in procedures where 5L or greater of volume is processed or as indicated. Record Final values from the operator interface screen on the Apheresis Procedure Record. Complete the product label if the collection will be used for transfusion. Remove the procedural kit in the reverse order used to set it up. Dispose of all blood contaminated waste in the MPW container. Clean any spills.
- Fluids IN Rinseback + Prime (optional) + Calcium infusion (optional) + Magnesium infusion (optional) + Fluid Bolus + AC
- Fluids OUT Product Removed (cells + plasma) + pre-apheresis tube samples Appendix
- SOP Blood Product Administration .
- Scan product's donation ID number upper left corner of the product's labeling system.
- Scan product Code lower left corner of the product's labeling system.
- the Carefusion system Upon attempt to transfuse a red cell unit, the Carefusion system will issue an alert if the red cell units are not started within 30 minutes of issue. Select override reason, "Other / DTM
- the Carefusion system will issue an alert if the red cell unit is not completed within 4 hours of issue. If this time has been exceeded, you must stop the transfusion and seek DTM Physician approval to continue the transfusion. If approval via DTM Physician given, select override reason, "Other / DTM Physician Authorized” and proceed.
- MNC Mononuclear Cell
- PBSC Peripheral Blood Stem Cell
- MNC is selected on the COBE® Spectra Apheresis System
- the program will set up with a specific separation factor that is a measure of the centrifugal force to which the blood is exposed.
- Terumo BCT recommends a MNC separation factor of 500 g-minutes for MNC collection. This is the product of the centrifugal force and the length of time a blood element entering the channels is subjected to this force.
- WBC Disposable Tubing Set Fluid Volumes are as in the section above.
- DTM SOP 2401 Prophylactic Calcium Infusion for set up and dosing of calcium. Attach a 4-way stop-cock to end of return line of Spectra tubing. Attach a Braun Extension Set to the proximal port of the 4-way stopcock (on return line) and prime. Connect the calcium IV line to the medial port of the 4-way stop-cock. Initiate calcium infusion after prime has been diverted.
- the WBC ColorgramTM is as in the section above. Collect Pump Flow Rate
- the Collect Flow Rate (CFR) is as in the section above, with this modification.
- the device defaults to an Inlet: AC ratio of 12: 1. If the pre-apheresis platelet count is greater than or equal to 250,000/uL, the initial Inlet:AC Ratio should be set at the device default of 12: 1, but should be changed to 13: 1 after the first 2-3 liters are processed. If the pre-apheresis platelet count is less than 250,000, the Inlet:AC ratio should be set at 13: 1 at the start of the procedure.
- the default AC infusion rate is 0.8 mL/min/L of TBV.
- the AC infusion rate may be increased to 1.1 mL/min/L of TBV without operator override. Increases in the AC infusion rate exceeding these manufacturer' s recommendations must have physician approval and prophylactic calcium infusions ordered. See the COBE® Spectra Cell Therapy Guide for guidance though the operator interface screen. See SOP 2401 Prophylactic Calcium Infusion for calcium infusion guidelines.
- the presence of cloudy, clumped light colored cells in the collect line and in the line entering the product bag may indicate platelet clumping and the need to decrease the AC ratio.
- the intermittent loss of a stable interface during the procedure may indicate platelet clumping and that a clump has pushed through the collect line. This may require a decrease in the AC ratio.
- Post procedure using aseptic technique add 15 ml of ACDA for every final product collected that contains 150 ml or greater. This is done to prevent clumping. If less than 150 ml product is collected, no ACDA is added to the product.
- Plasma may be collected during a WBC procedure in the automatic mode. Plasma collection will not begin until Quick Start has completed. To enter the desired amount of plasma to be collected, use the Target Plasma key to enter the volume. The plasma will be collected at the rate the Plasma pump has been set to minimize disruption of the interface, however, the
- the manufacturer recommends collecting the plasma at the end of the procedure as plasma collection may cause temporary interface instability.
- the Plasma valve will automatically close when the desired amount has been collected.
- the plasma collection may be started at any time during the procedure.
- the default end point for MNC procedures is 2.0 X TBV.
- the endpoint maybe configured to: specific run time, specific volume of blood (inlet volume) to process, multiple of the donor/patient total blood volume. See the COBE® Spectra Cell Therapy Guide for guidance in setting these endpoints though the operator interface screen.
- a blood prime may be done if ordered by the physician or if the system's extracorporeal blood volume exceeds 10-15% of the patient's TBV. See “Maintaining Hemodynamic Stability in Pediatric Apheresis Patients” in the COBE® Spectra Apheresis System Essentials Guide and see BSS SOP 2425 Pediatric Apheresis in Subjects less than 20 kg: MNC/PBSC on Spectra 5. Prophylactic Calcium Infusion during Large- Volume Apheresis
- Prophylactic infusion refers to administration of calcium at the beginning of apheresis, to prevent subsequent development of symptoms during the procedure.
- Prophylactic calcium infusions may also be administered during red blood cell exchanges and therapeutic plasma exchanges.
- donors/patients at risk for citrate toxicity include: donors/patients who have had a recent prior apheresis procedure as progressive depletion of calcium and albumin stores may occur; donors/patients with lighter body mass who are exposed to higher citrate infusion rates per kg of body weight; donors/patients who experience early onset of mild symptoms as mild symptoms are strongly predictive of the subsequent occurrence of more serious symptoms;
- Calcium infusions should not be administered to patients with known renal impairment unless they become symptomatic. Ceftriaxone and calcium solutions must not be administered simultaneously due to risk of ceftriaxone-calcium precipitation. Ceftriaxone should not be administered during an apheresis procedure.
- the rate of calcium administration is based on the rate of ACD-A administration or replacement fluid administration (red cell or plasma exchange).
- the ACD-A rate is, in turn, related to the WBFR and the type of procedure being performed. Therefore, calcium infusions maybe be adjusted according to either the ACD-A flow rate or the WBFR.
- IV calcium infusion rates are dosed to administer 0.6 calcium ion per 1 mL ACD-A.
- the initial dose of calcium may be increased by 10 to 15% in donors at high risk for citrate toxicity, and in all donors undergoing apheresis procedures at citrate infusion rates greater than 2.0 mg/kg/min.
- the maximum dose of calcium administration is set by the Alaris system, and will vary according to the weight of the donor. Changes in WBFR during the procedure are accompanied by changes in the calcium infusion rate.
- Fenwal Amicus The formula below starts with a WBFR that is measured in mL/min, and converts it to a calcium solution infusion rate that is measured in mL/hr.
- [WBFR/(AC Ratio+1) X 18] Calcium solution flow rate
- (AC ratio + 1) 13
- COBE SpectraTM The Spectra is configured such that the ACD-A flow rate can be read directly from instrument's digital display panel. In addition to LVL, the Spectra may be used to perform plasma exchange and red cell exchange. The formulas below start with an ACD-A infusion rate that is measured in mL/min, and converts it to a calcium infusion rate that is measured in mL/hr.
- Plasma or Red Cell Exchange using the COBE SpectraTM may cause citrate-related symptoms due to infusion of replacement fluids containing citrate (plasma and red cells) or decreased levels of calcium (albumin).
- the dose of calcium replacement is further modified because a large part of the administered ACD-A is removed with the waste product.
- the rate of citrate administered to the patient depends on the rate of replacement fluid administration. Therefore, calcium replacement is based on the WBFR (as for the Amicus).
- Thawed Plasma: (1.7) x (whole blood flow rate in mL/min) calcium solution IV rate (in mL/hr).
- Calcium infusion rates must be rounded to the nearest whole number (round up when the decimal is 0.5 or greater). Do not use decimal places. Enter the VTBI (volume to be infused). The Dose will be calculated and displayed on the LCD read-out on the front of the pump module. Press Start. Do not enter more than 280 mL. Do not hang more than one bag of calcium solution at a time. For further details regarding Alaris pump operation, see manufacturer's manual. Connecting the Infusion Set to the Apheresis Tubing Kit
- Fenwal Amicus Attach a 4 way stopcock to the end of the return line of the apheresis Attach the calcium solution IV tubing to the medial port of a 4 way stopcock. Divert the prime saline into the a waste bag (volume - 150 mL). Start the calcium solution IV drip at the end of the diversion of the saline prime (as the blood begins to return to the patient).
- COBE SpectraTM Attach a 4 way stopcock to the end of the return line of the apheresis kit. Attach the calcium solution IV tubing to the medial port of a 4 way stopcock. The Spectra automatically diverts the prime to a waste bag unless the operator changes the default setting. Start the calcium solution IV drip at the end of the diversion of the saline prime (as the blood begins to return to the patient).
- Calcium infusions of 2 mg/mL are used. Calcium infusions are given via an Alaris Medley II IV pump. Calcium infusions are monitored continuously during the apheresis procedure. Rates of calcium infusion are recorded on the Apheresis Procedure Record (BSS form 2400) at 30 minute intervals or at the time of adjustments in WBFR or IV solution flow rate. At any cessation of blood flow, including PAUSE immediately PAUSE the calcium infusion. Failure to do so may cause clotting in the return line. Discontinuation of Calcium Infusion
- HSCs Blood is retrieved from the umbilical cord following birth. HSCs can be isolated from this blood sample, for example using CD34 and/or CD 133 antibodies as described herein.
- the HSCs in the sample can be optionally isolated or purified. Any methods of separating or isolating the HSCs from such samples can be used. Negative and positive selection methods can be used. Negative selection methods take advantage of cell surface markers which are not expressed on HSCs. Positive selection methods take advantage of cell surface markers, such as CD34 and CD133, which are expressed on HSCs.
- methods are used that deplete non-HSCs from the sample, thereby permitting enrichment of the HSCs (that is, negative selection). For example, methods that substantially reduce the number of B cells, T cells, Natural Killer cells, dendritic cells, monocytes, granulocytes, and/or red blood cells can be used.
- labeled antibodies specific for the undesired cells can be incubated with the sample, allowing the labeled antibodies to bind to the undesired cells. Separation methods can then be used to remove those cells from the sample.
- the antibody label such as biotin
- the sample is applied to the column, such that undesired cells bind to the column, while the HSCs pass through the column and can be collected.
- the label is a fluorophore and flow cytometry can be used to remove the cells.
- kits can be used to deplete non-HSCs from the sample, such as those from Miltenyi Biotec (San Diego, CA) and StemCell Technologies (Vancouver, Canada). For example, if mouse samples are used, the mouse lineage depletion kit (Miltenyi Biotec catalog number 130-090-858) or the EasyStepTM Mouse Hematopoietic Cell Isolation Kit
- the BM cells are magnetically labeled with a cocktail of biotinylated antibodies against a panel of lineage antigens (CD 5, CD45R (B220), CDl lb, Gr-1 (Ly-6G/C), 7-4, and Ter- 119) and Anti-Biotin MicroBeads.
- the labeling procedure leaves lineage-negative cells (e.g., HSCs) untouched, allowing further magnetic separation of lineage-negative cells according to expression of markers such as CD 117 or Sca- 1.
- the human lineage depletion kit (Miltenyi Biotec catalog number 130-092-211) can be used.
- Cells are labeled with a cocktail of biotin-conjugated antibodies against lineage- specific antigens (CD2, CD3, CDl lb, CD14, CD15, CD16, CD19, CD56, CD123, and CD235a (Glycophorin A)). These cells are subsequently magnetically labeled with anti-biotin beads. Lineage-negative stem and progenitor cells are obtained by depletion of the magnetically labeled cells.
- methods are used that recover HSCs from the sample, thereby permitting enrichment of the HSCs (positive selection).
- labeled antibodies specific for HSCs can be incubated with the sample, allowing the labeled antibodies to bind to the HSCs, and subsequent recovery of the labeled HSCs.
- the sample is exposed or incubated with labeled CD34 or CD133 antibodies, thereby labeling the HSCs.
- the labeled HSCs can then be recovered, for example using flow cytometry (e.g., if the label is a fluorophore) or by use of a column (e.g., if the label is a magnetic label, such as magnetic beads containing CD34 and/or CD 133).
- CD 133+ cells can be isolated from the sample by positive selection with anti-CD 133 and magnetic microparticles.
- CD34+ cells can be isolated from the sample by positive selection with anti-CD34 and magnetic microparticles.
- the antibodies are labeled with biotin, and the HSCs subsequently magnetically labeled with anti-biotin beads, thereby allowing selection of the magnetically labeled HSCs.
- kits can be used to recover HSCs from the sample, such as those from Miltenyi Biotec (San Diego, CA).
- the CD34 MicroBead Kit is used (e.g., Miltenyi Biotec catalog numbers 130-100-453 or 130-046-702) is used.
- the human CD 133 MicroBead Kit is used (e.g., Miltenyi Biotec catalog number 130-050-801) is used.
- the resulting HSCs can be used immediately to generate CXCR4 knock down HSCs, or frozen for future use (for example frozen in growth media containing DMSO).
- Isolated HSCs can be cultured ex vivo, for example to expand the HSC population prior to knocking down CXCR4 expression (and in some examples additional genetic manipulations).
- the HSCs are grown in Iscove' s modified Dulbecco' s Medium (IMDM), or RPMI- 1640, plus animal or human serum, or in serum free media designed for HSC culture such as mTesSR 1 medium (Stem Cell Technologies, catalog number 05850), DMEM:F12 (Lonza catalog number 12-719F, Walkersville, MD) supplemented with 20% serum replacement (Invitrogen, catalog number 10828-028) and in some examples also with cytokines, amino acids, and other growth supplements.
- IMDM Iscove' s modified Dulbecco' s Medium
- RPMI- 1640 plus animal or human serum
- serum free media designed for HSC culture such as mTesSR 1 medium (Stem Cell Technologies, catalog number 05850), DMEM:F12 (L
- the grown medium includes one or more of stem cell factor (SCF), thrombopoietin (TPO), and FMS-like tyrosine kinase 3 ligand (Flt-3L).
- SCF stem cell factor
- TPO thrombopoietin
- FMS-like tyrosine kinase 3 ligand Flt-3L
- the HSCs are grown in HPGMTM hematopoietic progenitor growth medium from Lonza (, Walkersville, MD catalog PT-3926), Stemline® II Hematopoietic Stem Cell Expansion Medium (Sigma-Aldrich, catalog # S0192, St. Louis, MO) for mouse cells or Stemline® Hematopoietic Stem Cell Expansion Medium (Sigma-Aldrich, catalog # SO 189) for human cells.
- HSCs obtained from a donor can be manipulated to downregulate CXCR4.
- manipulation is done at the nucleic acid level, for example by mutating the genome (e.g., genetically inactivating one of the two CXCR4 alleles in the HSC), by mutating CXCR4 mRNA or cDNA (e.g., by using an RNAi molecule), or by interfering with the function of a produced CXCR4 protein (e.g. , by using a CXCR4 protein specific-binding agent).
- exemplary CXCR4 editing methods target the CXCR4 sequences shown in GenBank Accession No. NG_011587.1, AJ224869.1, NM_009911.3 or BC098322.1 (sequence available on July 18, 2014).
- manipulating CXCR4 at the nucleic acid level in an HSC allows the HSC progeny to retain the manipulated (e.g., downregulated) CXCR4.
- the disclosed methods include introducing an appropriate nucleic acid molecule (such as a marker designed to disrupt the gene) into an HSC that downregulates CXCR4 expression and/or activity.
- one or more other genes are manipulated, such as correction of a genetic mutation that results in disease, or increasing or decreasing expression of a target gene to treat a disease.
- the methods described herein for CXCR4 can be similarly used to manipulate any gene of interest, for example to upregulate the target, downregulate the target, or fix genetic mutations (e.g., point mutations, gene rearrangements, and the like).
- manipulations to CXCR4 are made at the same time as a manipulation is made to another target gene (e.g., those in Table 1).
- manipulations to CXCR4 are made before or after making a manipulation to another target gene (e.g., those in Table 1).
- the disclosed methods include introducing an appropriate nucleic acid molecule (such as a vector encoding a transcription factor) into an HSC that upregulates or downregulates expression and/or activity of a target gene, or that corrects a genetic defect in a target gene associated with disease.
- detectable markers or selection markers can be introduced into the genome, to help permit the identification of cells with the desired target mutation.
- markers can be introduced into an allele of the target gene to be downregulated (e.g.,
- Gene editing methods can be used to manipulate expression of CXCR4, for example in combination with altering a gene associated with disease, in HSCs.
- gene editing can be used to reduce or silence gene expression, enhance gene expression or change specific genes, for example by correcting a gene carrying a harmful mutation (e.g., see those in Table 1).
- Such methods enable a specific area of a genome to be modified, thereby increasing the precision of the correction or insertion.
- Genome editing is based on the use of engineered nucleases composed of sequence-specific DNA-binding domains fused to a non-specific DNA cleavage module.
- chimeric nucleases enable efficient and precise genetic modifications by inducing targeted DNA double-strand breaks (DSBs) that stimulate the cellular DNA repair mechanisms, including error- prone non-homologous end joining (NHEJ) and homology-directed repair (HDR).
- DLBs DNA double-strand breaks
- NHEJ error- prone non-homologous end joining
- HDR homology-directed repair
- Indels nucleotides
- CRISPR clustered regularly interspaced short palindromic repeat
- Zinc finger nucleases ZFNs
- TALENs Zinc finger nucleases
- Zinc-finger nucleases and transcription activator-like effector nucleases (TALENs) are chimeric nucleases composed of programmable, sequence- specific DNA-binding modules linked to a nonspecific DNA cleavage domain (such as Fokl nuclease). ZFNs and TALENs enable a broad range of genetic modifications by inducing DNA double- strand breaks that stimulate error- prone nonhomologous end joining or homology-directed repair at specific genomic locations (for review see Gaj et al., Trends Biotechnol. 31:397-405, 2013, herein incorporated by reference).
- Zinc-finger proteins and TALEs can be fused to enzymatic domains, such as site-specific nucleases, recombinases and transposases, that catalyze DNA integration, excision, and inversion. Because these enzymes can perform DNA cleavage and re-ligation autonomously, potentially toxic DNA double-strand breaks should not accumulate in the genome. Additionally, for applications that require targeted gene addition, recombinase and transposase activity is marked by the insertion of donor DNA into the genome, thereby enabling off-target effects to be monitored directly.
- zinc finger nuclease based engineering methods can edit a target sequence (such as CXCR4) by using zinc-finger nucleases to edit a target gene.
- the TALEN method can be used to edit a target sequence (such as CXCR4) by using transcription activator-like effector nucleases to edit a target gene.
- Fokl cleavage domain variants with mutations designed to improve cleavage specificity and/or cleavage activity can also be used (e.g., see Bitinaite et al. (1998) Proc. Natl. Acad. Set USA 95: 10570-5 and U.S. Published Patent Application No. 20110027235).
- a ZFN is used to cut genomic DNA at a desired location.
- Two ZFNs are used, with each containing two functional domains.
- the first is a DNA- binding domain comprised of a chain of at least two (such as 2, 3, 4, 5 or 6) zinc finger modules, each recognizing a unique hexamer (6 bp) sequence of DNA (such as a 6 bp sequence of CXCR4).
- Two-finger modules are stitched together to form a Zinc Finger Protein, each with specificity of > 24 bp.
- the second is a DNA-cleaving domain that includes a Fokl endonuclease (such as the catalytic domain).
- a highly-specific pair of 'genomic scissors' are created. This permits editing of the HSC genome, for example downregulation of CXCR4.
- the ZFN pair recognizes and heterodimerizes around the target site (e.g., a CXCR4 allele). The ZFN pair makes a double strand break and then dissociates from the target DNA.
- repair template can be designed to repair a mutated gene or upregulate gene expression or activity. If no corresponding repair template is co-transfected with the ZFN pair, this will result in disruption of the target gene (e.g., downregulation due to mutations introduced by nonhomologus end joining). Thus, such a method can be use to disrupt CXCR4.
- a zinc finger DNA binding domain is a protein domain that binds DNA in a sequence-specific manner through one or more zinc fingers, which are regions of amino acid sequence within the binding domain whose structure is stabilized through coordination of a zinc ion.
- Zinc finger binding domains for example the recognition helix of a zinc finger, can be "engineered” to bind to a predetermined nucleotide sequence (e.g. , engineer it to bind to CXCR4 or other target).
- Rational criteria for design of zinc finger binding domains include application of substitution rules and computerized algorithms for processing information in a database storing information of existing ZFN pair designs and binding data, see for example U.S. Patent No.
- kits can be used to design and develop vectors that include ZFNs specific for a target (e.g., CompoZR® targeted integration kits from Sigma- Aldrich).
- two different sets (pairs) of ZFNs are used, such that one set is specific for downregulating CXCR4, while the other set is specific for another genetic mutation that is to be corrected in the HSC (such as one listed in Table 1).
- more than two different sets of ZFNs can be used (e.g., at least 2, at least 3, at least 4, or at least 5 different sets, such as 2, 3, 4, 5, 6, 7, 8, 9, or 10 different sets), such that one set is specific for downregulating CXCR4, while another set is specific for a different genetic mutation that is to be corrected in the HSC.
- Such ZFN sets can be introduced into the HSC simultaneously, or at different times.
- TALEN-mediated gene targeting in human embryonic stem cells (hESCs) and iPSCs e.g., see Hockenmeyer et al., Nat Biotechnol 29: 731— 734) are known and can be applied to the present disclosure.
- Genomic editing with TALENs and ZFNs capitalizes on the cell's ability to undergo homology directed repair (HDR), following an induced and targeted double-stranded DNA break (DSB).
- a donor DNA template can be provided to the cell to insert new transgene or delete DNA sequences at the site of DSB (e.g., see Cheng et al., Genes Cells. 17(6):431-8, 2012).
- commercially available kits can be used to design and develop vectors that include TALENs specific for a target (e.g., Golden Gate TALEN and TAL Effector Kit from Addgene (Cambridge, MA), catalog #1000000024 and Joung Lab REAL Assembly TALEN kit, from Addgene, catalog #1000000017).
- the TALE DNA binding domains which can be designed to bind any desired DNA sequence (such as CXCR4 or those genes in Table 1), come from TAL effectors, DNA-binding proteins excreted by certain bacteria that infect plants (Xanthomonas). These are combined with a DNA cleavage domain.
- the DNA binding domain contains a repeated highly conserved 33-35 amino acid sequence with the exception of the 12th and 13th amino acids. These two locations are highly variable (Repeat Variable Diresidue, RVD) and have specific nucleotide recognition. This relationship between amino acid sequence and DNA recognition has allowed for the engineering of specific DNA binding domains by selecting a combination of repeat segments containing the appropriate RVDs.
- the non-specific DNA cleavage domain for example from the end of a Fokl endonuclease, can be used to construct hybrid nucleases.
- the Fokl domain functions as a dimer, so that using two constructs with unique DNA binding domains for sites in the target genome with proper orientation and spacing allows excellent specificity. Both the number of amino acid residues between the TALE DNA binding domain and the Fokl cleavage domain and the number of bases between the two individual TALEN binding sites can be varied.
- TALENs are used in a similar way to design zinc finger nucleases. TALE specificity is determined by two hypervariable amino acids known as the repeat-variable diresidues (RVDs). Like zinc-fingers, modular TALE repeats are linked together to recognize contiguous DNA sequences. However in contrast to zinc finger proteins, there is no re-engineering of the linkage between repeats necessary to construct long arrays of TALEs with the ability to address single sites in the genome.
- TALENs are used to downregulate expression and/or activity of CXCR4 in a donor HSC. In some examples, in addition to downregulating CXCR4 expression in the donor HSC, other genetic defects are corrected using TALENs.
- TALEN genes Once the TALEN genes have been assembled they can be inserted into plasmids or other vectors; which are used to transfect the donor HSC where the gene products are expressed and enter the nucleus to access the genome.
- TALENs are delivered to the donor HSC as mRNA, which removes the possibility of genomic integration of the TALEN protein-encoding DNA. It can also increase the level of homology directed repair (HDR) and the success of integration during gene editing.
- HDR homology directed repair
- two different sets (pairs) of TALENs are used, such that one set is specific for downregulating CXCR4, while the other set is specific for another genetic mutation that is to be corrected in the HSC (such as one listed in Table 1).
- more than two different sets of TALENs can be used (e.g. , at least 2, at least 3, at least 4, or at least 5 different sets, such as 2, 3, 4, 5, 6, 7, 8, 9, or 10 different sets), such that one set is specific for downregulating CXCR4, while each other set is specific for a different genetic mutation that is to be corrected in the HSC.
- Such TALENs sets can be introduced into the HSC simultaneously, or at different times.
- CRISPR Clustered regularly interspaced short palindromic repeat
- CRISPR Clustered regularly interspaced short palindromic repeat
- RNA-guided adaptive immune systems that protect bacteria and archaea from infection by viruses have been repurposed for genome engineering in a wide variety of cell types and multicellular organisms.
- CRISPRs are DNA loci containing short repetitions of base sequences. Each repetition is followed by short segments of spacer DNA from previous exposures to a virus.
- CRISPRs are often associated with Cas genes. By introducing plasmids containing a Cas gene and specifically constructed CRISPRs into eukaryotic cells, the eukaryotic genome can be cut at any desired position.
- the Cas9 nuclease for targeted genome editing can include fused nuclear localization signals (NLSs) to a codon- optimized version of the Cas9 gene.
- This Cas9 sequence can be co-expressed with plasmids expressing the tracrRNA and a crRNA-guide, or a single chimeric guide RNA (gRNA).
- the CRISPR/Cas system can be used for gene editing in mammalian cells, for example of donor HSCs (see for example Le Cong et al., Science. 339:819-23, 2013; Mali et al., Science. 339:823-6, 2013; Wilkinson and Wiedenfeft FlOOOPrime Reports 6:3, 2014; Hsu et al, Cell
- kits can be used to design and develop vectors that include CRISPR/Cas9 genome editing materials for manipulating a specific target (e.g., those from Origene, Rockville, MD, from Addgene,
- Gaithersburg, MD such as the Gene Art® CRISPR Nuclease Vector Kit.
- commercial services to engineer specific CRISPR/Cas9 genome editing materials are available from companies such as Genecopoeia, Rockville, MD.
- the CRISPR/Cas system includes two components: (1) Cas9 protein (such as a wt or modified Cas9 gene, such as one that is codon optimized and/or mutated for specific nuclease activity), whose expression can be driven by a promoter, such as CMV and (2) single guide RNA (sgRNA) which is operably linked downstream of a target sequence (e.g., CXCR4) and upstream of a promoter (such as the U6 promoter).
- a target sequence e.g., CXCR4
- a promoter such as the U6 promoter
- Non-homologous end joining (NHEJ) repair of this cut will result in small insertions and deletions (indels), so the technique can be used to knockout genes.
- the technique can also be used to insert this DNA into the cut site through HDR.
- DNA sequences within the endogenous genome and their functional outputs are easily edited or modulated, for example in a donor HSC.
- the sgRNA and Cas9 protein can also be delivered to the target cell in fixed amounts using encapsulation techniques such as gesicles (Clontech).
- a native or wild-type Cas9 sequence is used.
- double strand (ds) breaks are introduced at sequences homologous to co-expressed gRNA.
- a mutated Cas9 sequence is used.
- the Cas9 sequence is codon optimized for mammalian or human cells.
- a mutated "nickase" version of Cas9 is used, which generates a single-strand DNA break, instead of a ds break (for example to knock down CXCR4 expression).
- a catalytically inactive Cas9 (dCas9) is used to knockdown gene expression by interfering with transcription (for example to knock down CXCR4 expression).
- the dCas9 can be fused to an additional repressor peptide if desired,
- a catalytically inactive Cas9 (dCas9) fused to an activator peptide can activate or increase gene expression (for example to treat a genetic disorder in which upregulation of a target gene is desired).
- CRISPR RNA-guided Fokl nucleases are used (e.g., for downregulation of CXCR4 and in some examples editing of one or more other target genes) (e.g., see Tsai et al., Nature Biotechnol. 32:569-76, 2014).
- Dimeric RNA-guided Fokl nucleases can recognize extended sequences and edit endogenous genes with high efficiencies in human cells. RFN cleavage activity depends on the binding of two guide RNAs (gRNAs) to DNA with a defined spacing and orientation. Such a method can be used to express multiple gRNAs bearing any 5' end nucleotide.
- CRISPR is used to downregulate expression of CXCR4 in a donor HSC.
- multiple plasmids are used for the gene editing.
- the Cas9 or modified Cas9 (e.g., nickase) enzyme (or the Fokl nuclease) is provided, for example on one vector or plasmid, and the guide RNA (gRNA) on another plasmid.
- gRNA guide RNA
- One or more other plasmids or vectors can supply a sequence for (1) downregulating CXCR4, (2) correction of a mutation using homologous recombination or an oligonucleotide template can be used, (3) downregulation of a target gene, or (4) upregulation of a target gene.
- Multiple plasmids can be mixed and transfected into HSCs at the same time, for example using Lonza nucleofector technology for the simultaneous transfection of multiple plasmids at this time.
- Lonza nucleofector technology for the simultaneous transfection of multiple plasmids at this time.
- other methods can be used to introduce these sequences, such as viral transduction using lentiviral, adeno-associated virus (AAV), retrovirus, adenovirus, or alphavirus technology, or by using vesicles preloaded with sgRNA and Cas9 protein.
- AAV adeno-associated virus
- retrovirus retrovirus
- adenovirus or alphavirus technology
- vesicles preloaded with sgRNA and Cas9 protein vesicles preloaded with sgRNA and Cas9 protein.
- Another method that can be used is to generate induced pluripotent stem cells and then edit them and test them using DNA sequencing to find correctly edited cell clones. Then
- a single vector is used to both supply the Cas9 or modified Cas9 (e.g., nickase) enzyme (or the Fokl nuclease) and the guide RNA (gRNA) with the target sequence.
- the Cas9 or modified Cas9 e.g., nickase
- gRNA guide RNA
- a plurality of different gRNAs, one for each target, are present on a single plasmid.
- the pCas-Guide vector from Origene can be used.
- the pLenti-Cas Guide vector from Origene can be used.
- the method can include introducing an appropriate sequence.
- the CRISPR Nuclease OFP Reporter vector from Life Technologies can be similarly used.
- other genes are manipulated, for example using the pCas-Guide vector or the pLenti-Cas Guide vector from Origene but with an appropriate target sequence specific for the target gene and the modification desired.
- RNAi Inhibitory RNA
- RNAi methods can be used to downregulate expression of CXCR4, for example in combination with altering a gene associated with disease, in HSC cells.
- RNAi can be used to reduce or silence gene expression of an undesired gene, for example where upregulation of the gene causes or results in disease, or is undesirable (e.g., decreasing expression of CCR5 in a subject with HIV).
- RNAi molecule includes antisense molecules, siRNAs, miRNAs, and ribozymes specific for a target gene whose expression is to be downregulated (such as CXCR4 or CCR5), which reduce or prevent expression of the target, for example by at least 50%, at least 60%, at least 75%, or at least 90%.
- RNAi molecules are at least 12 nt in length, at least 15 nt, or at least 19 nt in length, such as about 19 to 30 or 15 to 200 nucleotides in length, such as at least 21 nucleotides, for example at least 23 nucleotides (for example 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides).
- the RNAi molecule interacts with the target nucleic acid and generates an RNAi response.
- RNAi RNA interference
- CXCR4 target gene
- such methods decrease CXCR4 expression at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% (such as a decrease of 40% to 90%, 40% to 80% or 50% to 95%) as compared to a control (such as a non-recombinant HSC with normal or wild- type CXCR4 expression).
- exemplary CXCR4 RNAi molecules target a CXCR4 sequence shown in GenBank Accession No. NG_011587.1, AJ224869.1, NM_009911.3 or BC098322.1.
- RNAis that can be used to interrupt or alter translation of a target nucleic acid molecule (such as CXCR4) include, but are not limited to, antisense RNA, miRNA, ribozymes, antisense molecules, or an siRNA, that bind specifically to the target nucleic acid molecule (such as CXCR4).
- nucleic acid molecules such as a vector containing the RNAi molecule
- HSCs can be introduced into HSCs by a variety of methods known to those of skill in the art, such as by transfection or transformation (e.g., by encapsulation in liposomes, by iontophoresis, by incorporation into viruses or vectors which are introduced into the cell, or by incorporation into other delivery vehicles, such as hydrogels, cyclodextrins, biodegradable nanocapsules, and bioadhesive microspheres.).
- RNAi molecules are expressed within an HSC from a eukaryotic promoter.
- the RNAi molecules are administered directly to a subject, for example by injection (i.v., i.p., i.m.), topical administration, oral administration, by inhalation; or other routes.
- expression vectors are used to express the RNAi molecule in an HSC.
- an expression vector can include a nucleic acid sequence encoding at least one RNAi molecule that recognizes a target nucleic acid molecule (such as CXCR4 or CCR5).
- the vector contains a sequence encoding both strands of an RNAi molecule comprising a duplex.
- the vector also contains a sequence encoding a single nucleic acid molecule that is self-complementary and thus forms an RNAi molecule.
- Non-limiting examples of such expression vectors are described in Paul et al., Nature Biotech. 19:505, 2002; Miyagishi and Taira, Nature Biotech. 19:497, 2002.
- RNAi molecules can be expressed from transcription units (see for example, Couture et al., 1996, TIG 12:510) inserted into DNA or RNA vectors.
- the recombinant vectors can be DNA plasmids or viral vectors.
- RNAi expressing viral vectors can be constructed based on, for example, but not limited to, adeno-associated virus, retrovirus, adenovirus, lentivirus or alphavirus.
- pol III based constructs are used to express RNAi molecules (see for example, U.S. Pat. Nos. 5,902,880 and 6,146,886).
- RNAi molecules capable of expressing the RNAi molecules can be delivered as described above, and persist in target cells.
- viral vectors can be used that provide for transient expression of RNAi molecules.
- an RNAi molecule is an siRNA.
- siRNAs are double- stranded RNAs that can induce sequence- specific post-transcriptional gene silencing, thereby decreasing or in some examples inhibiting gene expression.
- siRNA triggers the specific degradation of homologous RNA molecules, such as mRNAs, within the region of sequence identity between both the siRNA and the target RNA.
- siRNA molecules are about 19-27 nucleotides (nt) in length, such as 20-25 nt, or 20 to 27 nt, for example 19, 20, 21, 22, 23, 24, 25, 26 or 27 nt in length.
- siRNAs which specifically bind to a target nucleic acid sequence, such as CXCR4 or any gene whose expression needs to be decreased (such as CCR5 in an HIV-infected patient).
- kits such as siRNA synthesizing kits from Qiagen, Origene (Rockville, MD), Life Technologies (Grand Island, NY), and SuperArray Bioscience Corporation (Hamburg, Germany) can be used to synthesize siRNA molecules.
- siRNAs can be obtained from commercial sources, such as from Life Technologies (Grand Island, NY) and GE Dharmacon (Lafayette, CO).
- Exemplary CXCR4 siRNA molecules target the CXCR4 sequences shown in GenBank Accession No. NG_011587.1,
- an RNAi molecule is an antisense oligonucleotide.
- Antisense RNA prevents protein translation of a target mRNA by binding to it.
- an antisense molecule can hybridize to a portion of a target (such as CXCR4 or CCR5).
- antisense oligonucleotides are at least 19 nucleotides (nt) in length, such as at least 20, at least 30, at least 40, at least 50, at least 75, at least 100, or at least 200 nt in length.
- the antisense oligonucleotide can be modified at the base moiety, sugar moiety, or phosphate backbone, and can include other appending groups such as peptides, or agents facilitating transport across a cell membrane (e.g., see Letsinger et al, Proc. Natl Acad. Sci. USA 1989, 86:6553-6; Lemaifre et al, Proc. Natl. Acad. Sci. USA 1987, 84:648-52; WO 88/09810), hybridization triggered cleavage agents (Krol et al.,
- Antisense molecules can be synthesized by standard methods, for example by use of an automated DNA synthesizer.
- an antisense oligonucleotide includes catalytic RNA, or a ribozyme (see WO 90/11364, Sarver et al, Science 247: 1222-5, 1990).
- the antisense oligonucleotides can include a sequence complementary to at least a portion of an RNA transcript of target gene, such as CXCR4 or CCR5.
- RNA transcript of target gene such as CXCR4 or CCR5.
- Exemplary CXCR4 antisense oligonucleotides target the CXCR4 sequences shown in GenBank Accession No. NG_011587.1, AJ224869.1, NM_009911.3 or BC098322.1 (sequence available on July 18, 2014).
- an RNAi molecule is a ribozyme.
- Ribozymes are enzymatic RNA molecules capable of catalyzing the specific cleavage of RNA. Ribozymes can be synthesized and administered to the subject, or can be encoded on an expression vector, from which the ribozyme is synthesized in the targeted cell (e.g., see WO 9523225, and Beigelman et al., Nucl. Acids Res. 1995, 23:4434-42). Methods of using ribozymes to decrease or inhibit RNA expression are known in the art.
- RNA target specific ribozyme cleavage sites within an RNA target can be identified by scanning the target molecule for ribozyme cleavage sites that include the following sequence: GUA, GUU and GUC.
- short RNA sequences of about 15 ribonucleotides such as 15 to 30 or 15 to 25 ribonucleotides
- the suitability of candidate targets can also be evaluated by testing their accessibility to hybridization with complementary oligonucleotides, using ribonuclease protection assays.
- ribozymes and methods of their use is provided in Kashani-Sabet (J. Imvestig. Dermatol Symp. Pwc, 7:76-78, 2002). Methods describing endogenous and exogenous delivery are known (e.g., see Marschall et ah, Cell Mol. Neurobiol 14:523-38, 1994).
- a plasmid that contains a ribozyme directed against CXCR4 placed behind a promoter, can be transfected into donor HSCs. Expression of this plasmid in the HSC will decrease CXCR4 expression.
- Exemplary CXCR4 ribozymes target the CXCR4 sequences shown in
- GenBank Accession No. NG_011587.1, AJ224869.1, NM_009911.3 or BC098322.1 (sequence available on July 18, 2014), and thus can include one or more sequences complementary to a CXCR4 mRNA and can include the well-known catalytic sequence responsible for mRNA cleavage (see U.S. Pat. No. 5,093,246).
- Nucleic acids encoding the necessary elements for the gene editing methods and RNAi methods can be introduced into a donor HSC using routine methods.
- such nucleic acids are cloned into a vector or plasmid, which is then used to transfect or transform a cell.
- naked nucleic acid molecules are used.
- donor HSCs can be incubated in a culturing medium in a culture apparatus for a period of time or until the cells reach confluency before passing the cells to another culture apparatus.
- the culturing apparatus can be of any culture apparatus commonly used for culturing cells in vitro. In one example, the level of confluency of the cells is greater than 70% before passing the cells to another culture apparatus. More preferably, the level of confluency of the cells is greater than 90%.
- a period of time can be any time suitable for the culture of cells in vitro.
- the culturing medium may be replaced during the culture of the HSCs. HSCs are then harvested from the culture apparatus.
- the HSCs can be used immediately or they can be cryopreserved and stored for use at a later time.
- NANEX system Arteriocyte Inc., Cleveland, OH
- the NANEX system can be used to culture and expand HSC from blood and bone marrow.
- Standard culture media typically contains a variety of essential components required for cell viability, including inorganic salts, carbohydrates, hormones, essential amino acids, vitamins, and the like.
- DMEM or F-12 is used as a culture medium. Additional additives can be used, such as glutamine, heparin, sodium bicarbonate and/or N2 supplement (Life Technologies, Gaithersburg, Md.).
- the pH of the culture medium is typically between 6-8, such as about 7, for example about 7.4.
- Cells are typically cultured at a temperature between 30-40°C, such as between 35-38°C, such as between 35-37°C, for example at 37°C.
- Methods for introducing DNA into HSCs in culture include chemical and physical methods.
- Chemical methods include liposome-based gene transfer or lipofection, calcium phosphate- mediated gene transfer, DEAE-dextran transfection techniques, and polyethyleneimine (PEI)- mediated delivery.
- Physical methods include ballistic gene transfer (introduces particles coated with DNA into cells), microinjection, and nucleofection (e.g., from Lonzasuch as the Amaxa biosystem).
- nucleofection can be used to introduce the nucleic acids disclosed herein into HSCs.
- the nucleofection involves the use of a Nucleofector 4d apparatus.
- CXCR4 produced in an HSC can be contacted with agents that decrease its activity, such as a decrease of at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% (such as a decrease of 40% to 90%, 40% to 80% or 50% to 95%) as compared to a control (such as a non-recombinant HSC with normal or wild- type CXCR4 expression).
- agents that decrease its activity such as a decrease of at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% (such as a decrease of 40% to 90%, 40% to 80% or 50% to 95%) as compared to a control (such as a non-recombin
- the agent that reduces CXCR4 protein activity is a CXCR4 antagonist, such as a small molecule (e.g., AMD3100 (plerixafor), AMD3465, T22 ([Tyr 5 ' 12 , Lys 7 ]-polyphemusin II), T134 (des-[Cys 8>13 , Tyr 9 ' 12 ]-[d-Lys 10 , Pro 11 , l-citrulline 16 ]-T22 without C-terminal amide), T140 ⁇ [l-3-(2-naphthyl)alanine3]-T134 ⁇ , and AMD070 (for review see Debnath et al., Theranostics, 2013; 3(l):47-75, herein incorporated by reference).
- a small molecule e.g., AMD3100 (plerixafor), AMD3465, T22 ([Tyr 5 ' 12 , Lys 7 ]-polyphemusin II),
- a specific binding agent is an agent that binds substantially only to a defined target, such as a CXCR4 protein.
- a CXCR4 protein- specific binding agent binds substantially only to a CXCR4 protein (such as a protein provided in any of GenBank® Accession Nos.
- Specific binding agents include CXCR4 antibodies (including polyclonal or monoclonal antibodies and functional fragments thereof, as well as humanized and chimeric antibodies), CXCR4 aptamers, and other agents that bind substantially only to the CXCR4 protein.
- CXCR4 antibodies can be produced using standard procedures such as those described in
- Antibodies can be polyclonal or monoclonal antibodies, humanized antibodies, Fab fragments, F(ab')2 fragments, single chain antibodies, or chimeric antibodies.
- CXCR4 antibodies are commercially available such as those from Abeam, Cambridge, MA (e.g., ab2074, ab58176, or abl617) and Novus Biologicals, Littleton, CO (e.g., NB100-74396 or NB 100-77835).
- a CXCR4 antibody is a neutralizing antibody (such as one from a non-Hodgkin's lymphoma patient, or an antibody derived from such).
- the determination that a particular agent binds substantially only to the target protein readily can be made by using or adapting routine procedures. For example, Western blotting can be used to determine that a given protein binding agent, such as a CXCR4 antibody or aptamer, binds substantially only to the CXCR4 protein.
- a given protein binding agent such as a CXCR4 antibody or aptamer
- assays include, but are not limited to, competitive and non-competitive homogenous and heterogeneous enzyme-linked immunosorbent assays (ELISA) as symmetrical or asymmetrical direct or indirect detection formats; "sandwich” immunoassays; immunodiffusion assays; in situ immunoassays (for example, using colloidal gold, enzyme or radioisotope labels); agglutination assays; complement fixing assays; immunoelectrophoretic assays; enzyme-linked immunospot assays (ELISPOT); radioallergosorbent tests (RAST); fluorescent tests, such as used in fluorescent microscopy and flow cytometry; Western, grid, dot or tissue blots; dip- stick assays; halogen assays; or antibody arrays (for example, see O'Meara and Tovey, Clin.
- ELISA enzyme-linked immunosorbent assays
- an HSC is contacted in vivo or ex vivo (or both) with a
- therapeutically effective amount of one or more agents that decrease CXCR4 activity such as one or more of the agents listed above.
- CXCR4 knockdown HSCs which may include one or more other repaired genetic mutations as discussed herein, can be introduced, that is administered or transplanted, into a subject. Such subjects are referred to as recipient subjects.
- the CXCR4 knockdown HSCs can be generated from the recipient subject (autologous), or a different subject (allogeneic).
- the subject has a hematologic malignancy and the CXCR4 knockdown HSCs used are allogeneic, for example to have graft vs. tumor effect.
- the subject has a genetic hematologic disease and the CXCR4 knockdown HSCs used are autologous to reduce or eliminate risk of graft vs. host disease after transplant. Such methods can be used to enhance engraftment of HSCs.
- transplantation of the disclosed CXCR4 knockdown HSCs can be used to treat patients with hematological cancers and other disorders of the blood and immune systems.
- the CXCR4 knockdown HSCs include other undesirable mutations, such as those shown in Table 1.
- one or more other undesirable mutations can be repaired, for example to treat a disease.
- the donor HSCs include any gene that is undesirably up- or down-regulated, that too can be repaired in the HSC as described herein.
- therapeutically effective amounts of CXCR4 knockdown HSCs include at least 1 x 10 6 , at least 2 x 10 6 , at least 3 x 10 6 , at least 4 x 10 6 , at least 5 x 10 6 , at least 6 x 10 6 , at least 7 x 10 6 , at least 8 x 10 6 , at least 9 x 10 6 , at least 1 x 10 7 , at least 2.5 x 10 7 , at least 5 x 10 7 , at least 1 x 10 8 , at least 2.5 x 10 8 , or at least 5 x 10 8 CXCR4 knockdown HSCs.
- Such amounts can be introduced into the recipient subject, for example by injection, such as intravenously.
- administration of the CXCR4 knockdown HSCs increases engraftment of the CXCR4 knockdown HSCs by at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 90%, at least 95%, at least 100%, at least 2-fold, at least 3- fold, at least 4-fold, at least 5-fold, at least 10-fold, at least 20-fold, or at least 30-fold, for example at 30 days, 60 days, 90 days, 120 days, 1 year or 2 years following the HSC transplant, for example as compared to engraftment observed with HSCs without downregulated CXCR4.
- enhanced engraftment is indicated by an increase in donor HSC repopulation in the recipient faster than donor HSC with normal CXCR4 expression.
- the CXCR4 knockdown HSCs can repopulate at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 90%, at least 95%, at least 100%, at least 2- fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 10-fold, at least 20-fold, or at least 30- fold, faster than donor HSCs with normal CXCR4 expression (e.g., a wild-type HSC), for example at 30 days, 60 days, 90 days, 120 days, 1 year or 2 years following the HSC transplant.
- normal CXCR4 expression e.g., a wild-type HSC
- enhanced engraftment is indicated by CXCR4 knockdown HSCs lasting longer in the recipient than donor HSC with normal CXCR4 expression.
- the donor HSCs can survive at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 90%, at least 95%, at least 100%, at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 10-fold, at least 20-fold, or at least 30-fold, longer than donor HSCs with normal CXCR4 expression (e.g., a wild-type HSC), for example at 30 days, 60 days, 90 days, 120 days, 1 year or 2 years following the HSC transplant.
- normal CXCR4 expression e.g., a wild-type HSC
- the subject receiving the CXCR4 knockdown HSCs does not receive a conditioning regimen prior to administration of the CXCR4 knockdown HSCs.
- the subject does not receive chemotherapy or irradiation (such as total body irradiation) that is typically used to suppress the immune system and/or destroy the bone marrow.
- chemotherapy or irradiation such as total body irradiation
- the subject to receive the CXCR4 knockdown HSCs does not previously receive a myeloablative regimen, such as chemotherapy agents given at maximally tolerated doses expected to eradicate the hematopoietic cells in the bone marrow and resulting in profound pancytopenia within one to three weeks from the time of administration.
- the subject does not previously receive a non-myeloablative regimen, such as reduced doses of chemotherapy or whole body irradiation expected to partially ablate but not eliminate the recipient bone marrow.
- a non-myeloablative regimen such as reduced doses of chemotherapy or whole body irradiation expected to partially ablate but not eliminate the recipient bone marrow.
- the recipient subject does not receive a therapy that will deplete or ablate the recipient's immune system, such as T cells, prior to receiving the CXCR4 knockdown HSCs.
- the recipient subject to receive the CXCR4 knockdown HSCs provided herein does not receive any of these chemotherapies prior to administration of the CXCR4 knockdown HSCs.
- the recipient subject does not receive an induction chemotherapy regimen which includes a therapeutically effective amount of etoposide, doxorubicin, vincristine, cyclophosphamide, and prednisone (EPOCH) or cytarabine with daunorubicin or idarubicin (7+3 regimen) prior to administration of the CXCR4 knockdown HSCs.
- an induction chemotherapy regimen which includes a therapeutically effective amount of etoposide, doxorubicin, vincristine, cyclophosphamide, and prednisone (EPOCH) or cytarabine with daunorubicin or idarubicin (7+3 regimen) prior to administration of the CXCR4 knockdown HSCs.
- EPOCH prednisone
- the recipient subject does not receive fludarabine prior to
- the subject to be treated with the methods provided herein does not receive irradiation, such as does not receive 1200 to 1300 centigray over three to four days, for example prior to receiving the CXCR4 knockdown HSCs.
- Diseases that can be treated with the disclosed methods include any genetic disease of the blood (e.g. sickle cell disease, primary immunodeficiency diseases), HIV (such as HIV-1), and hematologic malignancies or cancers, as well as WHIM syndome.
- the subject who receives the CXCR4 knockdown HSCs has one of these diseases.
- Primary immunodeficiency diseases weaken the immune system, allowing repeated infections and other health problems to occur more easily.
- Examples of primary immunodeficiency diseases and their corresponding mutations include those listed in Al-Herz et ah, Frontiers in Immunology, volume 5, article 162, April 22, 2014, herein incorporated by reference. Specific examples are provided in Table 1.
- Hematologic malignancies or cancers are those tumors that affect blood, bone marrow, and lymph nodes.
- leukemia e.g., acute lymphoblastic leukemia, acute myelogenous leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, acute monocytic leukemia
- lymphoma e.g., Hodgkin's lymphoma and non-Hodgkin's lymphoma
- myeloma myeloma.
- a subject with a hematologic malignancy benefits from receiving CXCR4 knockdown HSCs (such as allogeneic HSCs) without the need for repair of other genetic mutations (e.g., the cancer is not caused by a genetic mutation).
- CXCR4 knockdown HSCs can be used to induce a graft versus tumor effect in the subject with the hematologic malignancy.
- a subject with a hematologic malignancy benefits from receiving CXCR4 knockdown HSCs (such as autologous HSCs) which further have a genetic mutation that causes the malignancy, which has been repaired prior to introduction of the donor HSCs into the recipient.
- receiving the repaired CXCR4 knockdown HSCs can be used to treat CML caused by a BCR-ABL fusion (which is repaired in the CXCR4 knockdown HSCs prior to administration to the recipient).
- hemophilia A clotting factor VIII large deletions, insertions,
- FANCD2 FANCG, (p.Phel263del);
- Thrombocytopenic ADAMTS 13 Missense and nonsense purpura mutations
- carboxy- terminus e.g., in the carboxy- terminus
- carboxy- terminus truncation e.g., 10-19 residues
- CXCR4 knockdown HSCs can be used to treat any of these disorders. Treatment does not require 100% removal of all characteristics of the disorder, but can be a reduction in such. Although specific examples are provided below, based on this teaching one will understand that symptoms of other disorders can be similarly affected.
- CXCR4 knockdown HSCs can be used to treat or reduce the undesirable effects of a genetic disease of the blood, such as a primary immunodeficiency disease.
- CXCR4 knockdown HSCs which can also include genetic alterations to correct a mutation in the ⁇ -globin chain of hemoglobin
- administration of CXCR4 knockdown HSCs can be used to treat or reduce the undesirable effects of sickle cell disease.
- the donor HSC includes a genetic modification to correct a mutation in the ⁇ -globin chain of hemoglobin that results in the sickle-cell disease.
- the disclosed methods reduce the symptoms of sickle-cell disease in the recipient subject (such as one or more of, presence of sickle cells in the blood, pain, ischemia, necrosis, anemia, vaso-occlusive crisis, aplastic crisis, splenic sequestration crisis, and haemolytic crisis) for example a reduction of at least 10%, at least 20%, at least 50%, at least 70%, or at least 90% (as compared to no administration of the CXCR4 knock down HSCs).
- the symptoms of sickle-cell disease in the recipient subject such as one or more of, presence of sickle cells in the blood, pain, ischemia, necrosis, anemia, vaso-occlusive crisis, aplastic crisis, splenic sequestration crisis, and haemolytic crisis
- the disclosed methods decrease the number of sickle cells in the recipient subject, for example a decrease of at least 10%, at least 20%, at least 50%, at least 70%, at least 90%, or at least 95% (as compared to no administration of the CXCR4 knock down HSCs).
- CXCR4 knockdown HSCs can be used to treat or reduce the undesirable effects of thrombophilia.
- the donor HSC includes a genetic modification to correct a mutation in the factor V Leiden or prothrombin gene that results in the thrombophilia.
- the disclosed methods reduce the symptoms of thrombophilia in the recipient subject (such as one or more of, thrombosis, such as deep vein thrombosis, pulmonary embolism, venous thromboembolism, swelling, chest pain, palpitations) for example a reduction of at least 10%, at least 20%, at least 50%, at least 70%, or at least 90% (as compared to no administration of the CXCR4 knock down HSCs).
- the disclosed methods decrease the activity of coagulation factors in the recipient subject, for example a decrease of at least 10%, at least 20%, at least 50%, at least 70%, at least 90%, or at least 95% (as compared to no
- administration of the CXCR4 knock down HSCs can be used to treat or reduce the undesirable effects of CD40 ligand deficiency.
- the donor HSC includes a genetic modification to correct a mutation in the CD40 ligand gene that results in the CD40 ligand deficiency.
- the disclosed methods reduce the symptoms of CD40 ligand deficiency in the recipient subject (such as one or more of, elevate serum IgM, low serum levels of other immunoglobulins, opportunistic infections, autoimmunity and malignancies) for example a reduction of at least 10%, at least 20%, at least 50%, at least 70%, or at least 90% (as compared to no administration of the CXCR4 knock down HSCs).
- the disclosed methods increase the amount or activity of CD40 ligand deficiency in the recipient subject, for example an increase of at least 10%, at least 20%, at least 50%, at least 70%, at least 90%, at least 100%, at least 200% or at least 500% (as compared to no administration of the CXCR4 knock down HSCs).
- CXCR4 knockdown HSCs can be used to treat or reduce the undesirable effects of HIV- 1 infection.
- the donor HSC includes a genetic modification to decrease CCR5 activity in the HSC, such as a decrease of at least 20%, at least 50%, at least 70% or at least 90%.
- the CCR5 is modified to include a 32-bp deletion (CCR5A32, as described in Ye et ah, PNAS, 111:9591-6, 2014, herein incorporated by reference).
- the disclosed methods reduce the symptoms of HIV-1 infection in the recipient subject (such as one or more of, fever, large tender lymph nodes, throat inflammation, a rash, headache, sores of the mouth, nausea, vomiting, diarrhea, peripheral neuropathy, Guillain-Barre syndrome, weight loss, viral load, decreased levels of CD4+ T cells, Pneumocystis pneumonia, cachexia in the form of HIV wasting syndrome and esophageal candidiasis) for example a reduction of at least 10%, at least 20%, at least 50%, at least 70%, or at least 90% (as compared to no administration of the CXCR4 knock down HSCs).
- the symptoms of HIV-1 infection in the recipient subject such as one or more of, fever, large tender lymph nodes, throat inflammation, a rash, headache, sores of the mouth, nausea, vomiting, diarrhea, peripheral neuropathy, Guillain-Barre syndrome, weight loss, viral load, decreased levels of CD4+ T cells, Pneumocystis pneumonia, cachexia in the form of
- the disclosed methods increase levels of CD4+ T cells in the HIV- infected recipient subject, for example an increase of CD4+ T cells of at least 10%, at least 20%, at least 50%, at least 70%, at least 90%, at least 100%, at least 200%, at least 500% or at least 1000% (as compared to no administration of the CXCR4 knock down HSCs).
- administration of CXCR4 knockdown HSCs can be used to treat or reduce the undesirable effects of a hematological malignancy in the recipient subject.
- the disclosed methods reduce the number of abnormal white blood cells (such as B cells) in the recipient subject (such as a subject with leukemia), for example a reduction of at least 10%, at least 20%, at least 50%, at least 70%, or at least 90% (as compared to no administration of the CXCR4 knock down HSCs).
- administration of CXCR4 knockdown HSCs can be used to treat or reduce the undesirable effects of a lymphoma, such as reduce the size of the lymphoma, volume of the lymphoma, rate of growth of the lymphoma, metastasis of the lymphoma, for example a reduction of at least 10%, at least 20%, at least 50%, at least 70%, or at least 90% (as compared to no administration of the CXCR4 knock down HSCs).
- administration of CXCR4 knockdown HSCs can be used to treat or reduce the undesirable effects of multiple myeloma, such as reduce the number of abnormal plasma cells in the recipient subject, for example a reduction of at least 10%, at least 20%, at least 50%, at least 70%, or at least 90% (as compared to no administration of the CXCR4 knock down HSCs).
- CXCR4 knockdown HSCs can be used to treat or reduce the undesirable effects of WHIM syndrome.
- the donor HSC includes a genetic modification to reduce expression of CXCRx, such as by disrupting one functional allele of CXCR4.
- the disclosed methods reduce the symptoms of WHIM syndrome in the recipient subject (such as one or more of, warts, bacterial infection, viral infection, reduction of lymphocytes, neutropenia, hypogammaglobulinemia, myelokathexis, cervical and vulval premalignant dysplasia, and human papillomavirus (HPV) infection) for example a reduction of at least 10%, at least 20%, at least 50%, at least 70%, or at least 90% (as compared to no
- the disclosed methods decrease the number of warts in the recipient subject, for example a decrease of at least 10%, at least 20%, at least 50%, at least 70%, at least 90%, or at least 95% (as compared to no administration of the CXCR4 knock down HSCs).
- the disclosed methods decrease the frequency of bacterial and/or viral infections in the recipient subject, for example a decrease of at least 10%, at least 20%, at least 50%, at least 70%, at least 90%, or at least 95% (as compared to no
- the disclosed methods increase white blood cell counts in the recipient subject, for example an increase of at least 10%, at least 20%, at least 50%, at least 70%, at least 90%, at least 100%, at least 200%, or at least 500% (as compared to no administration of the CXCR4 knock down HSCs).
- Cxcr4 targeted mice Strain 008767
- Strain 003724 mice mice were obtained from The Jackson Laboratory (Bar Harbor, ME) and bred together to generate Cxcr4 heterozygote knock out mice (Cxcr4 +/ ⁇ ).
- Creation of WHIM knockin mice bearing a heterozygous CXCR4 S338X mutation have been previously described and sperm from these mice were used for in vitro fertilization at NIH to impregnate female C57BL/6 mice from Taconic Farms (Hudson, NY) (Balabanian et al., 2012).
- mice were bred to backgrounds that expressed either CD45.1 or CD45.2 or both for purposes of tracking bone marrow engraftment in mixed bone marrow reconstitution assays where 5 million bone marrow cells were transferred intravenously into the recipient mouse via tail vein injection.
- recipient mice underwent lethal irradiation (900 rads) 6 to 8 hours prior to transplant.
- PBMC Peripheral blood mononuclear cells
- HPC hematopoietic progenitors
- PBMC peripheral blood mononuclear cells
- LCL lymphoblastoid cell lines
- EBV Epstein-Barr virus
- Fluorescence activated cell sorter made by Becton-Dickinson Biosciences (San Jose, CA) and equipped with 405nm, 488nm, 561nm, and 633nm lasers was used to sort cells.
- Purified monoclonal anti-human antibodies labeled with fluorochromes were obtained from BD Biosciences and for blood sorting included: CD 14- Fluorescein Isothiocyanate, CD 19- Phycoerythrin, CD4- AUophycocyanin, and CD8-Pacific Blue; while for bone marrow sorting included: CD14-Fluorescein Isothiocyanate, CD19-Phycoerythrin, CD34- AUophycocyanin, and CD3-Alexa Fluor 700.
- CD34 + cells were positively selected with Miltenyi Biotec (San Diego, CA) microbeads then cultured using the Arteriocyte (Cleveland, OH) NANEX HSC expansion system following manufacturer's directions.
- the CD34 + cells were cultured in HSC expansion serum free media (Stem Cell Technologies, Vancouver, Canada) supplemented with the cytokine cocktail (hSCF, hTPO, hflt3-L) obtained from Peprotech (Rocky Hill, NJ) and human LDL from Athens Research and Technology (Athens, GA).
- PCR-RFLP Polymerase chain reaction - restriction fragment length polymorphism
- a PCR assay was designed to detect the derivative chromosome by spanning one of the novel junctions created by the chromothripsis event such that the normal chromosome should not amplify.
- This assay used the following primers: 5 '-GG A ATCTC AC ATCC AG A ATC ATGC- 3 ' (SEQ ID NO: 3) and 5 '-TTGTTCTC ACCTTTGGCC AGTGG- 3 ' (SEQ ID NO: 4) and generates a 242 bp amplicon spanning the junction of pieces 16 and 13 in the derivative chromosome.
- Cytogenetics was performed on bone marrow aspirate samples, purified CD19 + B cells, and LCL cell lines by a clinical laboratory using standard techniques (Quest Diagnostics, Chantilly, VA).
- An Affymetrix Cytoscan HD array (Affymetrix, Santa Clara, CA) was used to identify chromosomal breakpoints using DNA from the same cells used in cytogenetic analysis, purified neutrophils and skin fibroblasts following the manufacturer recommended procedures.
- the Chromosome Analysis software suite (Affymetrix) was used to identify the approximate location of these breakpoints via loss of heterozygosity (LOH) determination using single nucleotide polymorphism (SNP), insertion/deletion (indel), and copy number variant (CNV) analysis.
- LH loss of heterozygosity
- SNP single nucleotide polymorphism
- indel insertion/deletion
- CNV copy number variant
- FFPE formalin fixed paraffin embedded
- Serum samples from the index patient, 5 WHIM patients and 5 healthy blood donors were obtained and immediately frozen at ⁇ -80°C until time of assay. Samples were then thawed and run at the same time. Assays for serum cytokine, interleukin, and chemokine concentrations were performed by RayBiotech, Inc. (Norcross, GA) using a multiplex quantitative enzyme-linked immunosorbent assay (ELISA) method with appropriate controls to insure signal linearity of signal to concentration in the reported measurement range.
- ELISA quantitative enzyme-linked immunosorbent assay
- DNA from fibroblasts obtained from a skin biopsy and blood neutrophils were used to prepare paired-end libraries using the TruSeq DNA protocol following the manufacturer's instructions (Illumina Inc., San Diego, CA). For each DNA sample, two different size libraries were generated, one of 200 to 400 bp and one of 300 to 500 bp. Each library was sequenced on 2 lanes of a HiSeq 2000 next generation sequencer (Illumina) and generated -380 million reads per library of 2 x 100 bp paired-end.
- T cell receptor (TRG locus) gene rearrangements DNA was extracted from peripheral blood cells using an automated DNA extraction system and tested for quality prior to PCR amplification for detection of T cell receptor (TRG locus) gene rearrangements.
- a single multiplexed PCR reaction was performed as described by Lawnicki et al. using primers that interrogate TRG rearrangements involving all of the known Vg family members, and the Jgl/2, JP1/2 and JP joining segments. (Lawnicki et al., 2003) To allow for fluorescence detection, each joining region primer was covalently linked to a unique fluorescent dye.
- TRG PCR is capable of detecting a clonal population comprising a minimum of 2-5% of the total T-cell population, and as performed at the NIH-CC, can identify > 90-95% of all TRG gene
- DNA from peripheral blood cells isolated as above was PCR amplified for detection of immunoglobulin (IGH and IGk loci) gene rearrangements.
- IGH and IGk loci immunoglobulin gene rearrangements.
- two separate reactions were performed, one using consensus primers to framework region III and the joining region of the immunoglobulin heavy chain gene (FRIII-IGH PCR) and a second using primers directed to the framework region II and the joining region of the immunoglobulin heavy chain gene (FRII-IGH PCR) as described by Ramasamy et al.(Ramasamy et al., 1992) Primers directed to the joining region were linked to the fluorescent marker FAM (carboxyfluorescein).
- FAM fluorescent marker
- the JAK2 V617F mutation was not detected on CLIA-88 approved testing developed by Ipsogen (Qiagen, Germantown, MD).
- a quantitative PCR assay was used to determine the relative levels of BCR-ABL and ABL using cDNA obtained by reverse transcribing RNA extracted from peripheral blood leukocytes. The levels of BCR-ABL and ABL were quantitated by comparison to plasmid reference standards using real time PCR. The ratio (BCR-ABL/ABL) was found in WHIM-09 to be 0.12%. In patients with newly diagnosed or relapsed chronic myeloid leukemia this typically varies between 50-150%. The coefficient of variation for replicate assays at the NIH- CC is 40-50%.
- the index patient and 2 of her 3 daughters self referred themselves to NIH for evaluation of their immunodeficiency.
- the index patient was the initial patient diagnosed with myelokathexis and had undergone bone marrow biopsy, splenectomy and extensive investigation of her congenital neutropenia at age 9 (Krill et al., 1964; Zuelzer, 1964).
- Her family's immunodeficiency syndrome was compatible with autosomal dominant transmission of WHIM syndrome and at least one of the daughters had previously been clinically diagnosed with this (FIG. 1A).
- genetic testing for a CXCR4 mutation had not been previously performed in this family.
- CD3 CD56 + NK 1270 32 51 126-729
- HSC niche in the absence of chemotherapy or radiation therapy as is commonly performed in bone marrow transplantation was explored.
- Bone marrow histology at time of examination did not reveal the characteristic findings of myelokathexis expected in WHIM syndrome (FIG. 4) in contrast to her previously reported bone marrow results and as noted above the patient's blood immunophenotype was abnormal and markedly different from her daughters (Table 2).
- Table 2 the patient's neutrophilia, monocytosis, CD4+ T cell lymphocytosis, and thrombocytosis, there was no evidence for CML, CMML, or myelodysplasia syndrome in the bone marrow pathology and specific testing for BCR-ABL and JAK mutations were negative.
- Cytogenetics was performed on the bone marrow aspirate and revealed that one copy of chromosome 2 was markedly abnormal but the other chromosomes exhibited a normal banding pattern (FIG. 5A). Fluorescent in situ hybridization (FISH) testing was performed and revealed that the anaplastic lymphoma receptor tyrosine kinase (ALK) gene and parts of the centromere were translocated in the abnormal chromosomal copy and the N-myc gene (MYCN) was absent on the abnormal chromosome (FIGS.5B and 5C). Almost all of the bone marrow cells with polymorphic nuclei had the abnormal chromosome, while the cells with round nuclei had a lower percentage of the abnormal chromosome. An immunohistochemical stain of ALK activity on a bone marrow core biopsy section did not reveal abnormal activation of the enzyme despite the translocation (FIG. 14).
- FISH Fluorescent in situ hybridization
- FIG.6A A clinical microarray was performed on the bone marrow cell DNA and compared with cultured fibroblast DNA. This revealed that the shortened chromosome 2 copy was due to 7 large deletions (FIG.6A). This was demonstrated by the loss of heterozygosity in these regions and by an abrupt change in the relative copy number from 2 to 1.
- One of these deletions involved the MYCN gene and the normal position of ALK, confirming the FISH results.
- one of the deletions included the position of the CXCR4 gene (FIG.6B). This had made the patient hemizygous for CXCR4 in cells from the myeloid lineage with loss of the CXCR4 R334X mutation as well as loss of one copy of multiple other genes (Table 3).
- Table 3 List of the orientation of the 18 pieces of the derivative chromosome of patient WHIM-09 and their nucleotide site of connections derived from whole genome sequencing of neutrophil DNA. Numbers are based on the chromosome 2 reference sequence of the hgl9 version of the human genome project. Note underlined numbers are uncertain because of repetitive sequences in the region of the connection that make assigning a specific nucleotide ambiguous.
- Microarray has limitations in resolution of chromosomal rearrangement boundaries caused by the variable spacing of the polymorphic markers on the array.
- the microarray technique does not easily reveal translocated DNA if it has been moved but not mutated or deleted; however, it was known that such existed by the abnormal cytogenetic banding pattern and FISH results described above.
- Whole genome sequencing (WGS) was performed on the patient's blood neutrophil DNA to identify these chromosomal rearrangement boundaries using as a comparison the patient's fibroblast DNA and the standard human genome sequence (version hgl9). An average of 40X coverage of both samples was obtained, and an analysis was performed to locate the stretches of DNA reads that had homology with multiple distinct areas of chromosome 2. This technique allowed precise basepair level identification of the translocations and deletions that had occurred on one copy of chromosome 2 (Table 4). Table 4. Alphabetical List of Genes deleted in the derivative chromosome of patient WHIM- 09 by whole genome sequencing
- apolipoprotein B (including Ag(x)
- DARS 1615 2q21.3 protein-coding aspartyl-tRNA synthetase
- E2F6 1876 2p25.1 protein-coding E2F transcription factor 6
- FK506 binding protein IB 12.6
- GCA 25801 2q24.2 protein-coding binding protein
- MGAT5 4249 2q21.3 protein-coding glucosaminyltransferase MI 128-1 406915 2q21.3 miscRNA microRNA 128-1
- NCKAP5 344148 2q21.2 protein-coding NCK-associated protein 5
- NOL10 79954 2p25.1 protein-coding nucleolar protein 10
- NT5C1B 93034 2p24.2 protein-coding 5'-nucleotidase, cytosolic IB
- ODC1 4953 2p25 protein-coding ornithine decarboxylase 1
- PQLC3 130814 2p25.1 protein-coding PQ loop repeat containing 3 proteasome (prosome, macropain) 26S subunit, non-
- solute carrier family 4 sodium bicarbonate transporter, member
- TATA box binding protein (TBP)- associated factor TATA box binding protein (TBP)- associated factor
- TP53I3 9540 2p23.3 protein-coding protein 3
- T IB2 28951 2p24.3 protein-coding tribbles homolog 2 (Drosophila) tetratricopeptide repeat domain
- the changes seen in the microarray were confirmed but were actually more complex than had been initially revealed.
- the derivative chromosome was composed of 18 remaining pieces arranged in random orientation. These remaining stretches of the normal chromosome 2 had been ligated back together in a random fashion characteristic of the newly described genetic
- FIG.7A A circular plot of the connections revealed by paired end whole genome sequencing of the neutrophil DNA is shown (FIG.7A).
- the abnormal derivative chromosome was modeled using the breakpoints and connections discovered (FIG.7B) and revealed a predicted structural banding pattern that was identical to what was observed using cytogenetics.
- microarray derived gene deletions were confirmed and the rearrangement breakpoints analyzed for the creation of novel fusion genes and two potential possibilities were identified (FIG. 15A); however, these genes are unlikely to be expressed or functional because they each lack a promoter and transcription initiation site, and major regions of the potentially fused genes are deleted. Thus, a novel driver mutation was not identified that would have given these cells a growth advantage other than loss of one copy (haploinsufficiency) of 164 genes on the shortened derivative chromosome that resulted when chromothripsis occurred.
- Example 7 Example 7
- Chromothripsis results when a chromosome or chromosomes are shattered into multiple pieces in a single event which is then repaired by the cellular DNA damage repair machinery. Thus it became apparent that the multiple genetic changes observed had occurred in a single HSC as an isolated event.
- FIG.8 A A scheme of hematopoietic differentiation is given in FIG.8 A.
- Knowledge of the exact breakpoints and orientations of the rearranged pieces allowed for the creation of four specific PCR amplification assays that confirmed the chromosomal rearrangement breakpoints predicted by the computer analysis of the WGS data and could detect DNA that had undergone chromothripsis.
- One of these PCR assays was used to investigate the hematopoietic system mosaicism further. Bone marrow aspirate was stained with fluorescent monoclonal antibodies and then underwent flow cytometric sorting to separate HSC, common lymphoid progenitors (CLP), common myeloid progenitors (CMP), and granulocyte macrophage progenitors (GMP).
- CLP common lymphoid progenitors
- CMP common myeloid progenitors
- GMP granulocyte macrophage progenitors
- index patient had neutrophilia, monocytosis and increased effector memory T cells, cytokine, interleukin, and chemokine levels in her blood were analyzed. Frozen serum samples from the index patient, 5 healthy blood donors, and 5 WHIM patients were used for determination of a variety of cytokine, interleukin, and chemokine levels (FIG. 9, Table 5). This revealed that the patient had increased levels of a variety of molecules known to stimulate neutrophils, monocytes and T cells.
- CXCL8 (aka Interleukin- 8), CXCL1 (aka Growth-regulated protein alpha) and Interleukin- 17 (IL-17) are known to stimulate and attract neutrophils; while Interleukins (IL) such as IL-2, IL-12, and IL-15 act to stimulate memory T cells.
- Interferon gamma (IFN- ⁇ ) and CXCL9 (aka monokine induced by gamma interferon or MIG) and IL-1 have broad effects on the immune system and stimulate all three cell types.
- G-CSF Granulocyte Colony-Stimulating Factor
- GM-CSF Granulocyte-Macrophage Co
- M-CSF Macrophage Colony-Stimulating Factor
- IFN Interferon
- IL Interferon
- CXCL CXC Chemokine Ligand
- CCL CC Chemokine Ligand
- TGF Transforming Growth Factor
- TNF Tumor Necrosis Factor
- HD Healthy Donor
- WHIM Warts
- Cxcr4 +/+ wild-type Cxcr4
- Cxcr4 +/o hemizygous Cxcr4
- WHIM syndrome Cxcr4 +/S338x mice
- Cxcr4 floxed mice (Strain 008767, B6.129P2- Cxcr4 tm2Yzo /J) and Ella promoter driven Cre recombinase transgenic mice (Strain 003724, B6.FVB-Tg(EIIa-cre)C5379Lmgd/J) were obtained from The Jackson Laboratory (Bar Harbor, ME) and bred together to generate Cxcr4 +/o mice on a homozygous CD45.2 background.
- Cxcr4 +/+ mice were obtained from Jackson Laboratory on the homozygous CD45.1 and homozygous CD45.2 backgrounds.
- WHIM knockin mice bearing a heterozygous Cxcr4 S338x mutation has been previously described (Balabanian et al., 2012) and sperm from these mice were used for in vitro fertilization to impregnate female C57BL/6 mice from Taconic Farms (Hudson, NY) to produce Cxcr4 +/S338x on a homozygous CD45.2 background.
- mice were fed with neomycin water for four weeks post irradiation. All animal experiments were performed using an NIAID Animal Care and Use Committee (ACUC) approved protocol in approved and certified facilities. In some experiments, ten million bone marrow cells were injected into non-irradiated mice. To isolate mouse hematopoietic stem cells (HSCs), the mixed bone marrow cells were lineage-depleted by negative selection with Lineage Cell Depletion Kit (Miltenyi Biotech Inc., San Diego, CA) and then HSCs (lineage Scal + c-Kit + CD48 " CD34 CD150 + ) were sorted using a sorting cytometer (FACS Aria II, BD Biosciences, San Jose, CA).
- HSCs mouse hematopoietic stem cells
- bone marrow cells from donors with a Cxcr4 +/o genotype on a homozygous CD45.2 background were mixed (47%:53%) with bone marrow cells from donors with a Cxcr4 +/+ genotype on a heterozygous CD45.1/CD45.2 background and then 5 million bone marrow cells were injected intravenously into each CD45.1 recipient mouse that had been lethally irradiated 8 hours prior.
- This patient represents the first example of a genetic reversion of the rare immunodeficiency WHIM syndrome.
- the data demonstrate that she is a somatic mosaic within the hematopoietic system (FIGS. 1C, 2A, and 2B).
- Her erythroid and myeloid lineages exhibited loss of the
- HPV is a chronic problem in WHIM patients once they become infected with this virus (Beaulich Cohen et al., 2012; Kawai and Malech, 2009; Tassone et al., 2009; Wetzler et al., 1990). Cutaneous and anogenital disease is typically recurrent despite surgical removal and other destructive methods being utilized, immunostimulants like imiquimod are ineffective, and chronic disease has led to lethal cancers in WHIM patients. HPV has evolved multiple ways to evade the immune system and can become a chronic infection even in normal individuals; however, patients with a wide variety of different immunodeficiencies are at increased risk of chronic HPV infection that progresses to cancer (Leiding and Holland, 2012).
- WHIM-09's reversal of HPV hand warts without treatment is unprecedented in WHIM syndrome and strongly indicates that the myeloid arm (monocytes and/or granulocytes) of the immune system plays an important and previously unsuspected role in successful viral clearance because the derivative chromosome was not found in the lymphoid arm (B, T, and NK cells) of the patient's immune system (FIG.2).
- the derivative chromosome was not found in the skin keratinocytes or fibroblasts, her case also indicates that mutation of CXCR4 in these cells is not the primary driver of HPV persistence (FIG.2).
- HSC are the only cells in the bone marrow that are both pluripotent and long lived (Seita and Weissman, 2010). These rare cells can be identified by a combination of characteristic cell surface markers and undergo a tightly controlled, hierarchical differentiation process into the mature elements of the blood (FIG. 8A).
- the data herein demonstrate that the HSC and myeloid compartments of the immune system were nearly completely or completely replaced by cells that bore the derivative chromosome (FIG.8B). This indicates that this genetic change created some type of survival or proliferative advantage for these mutated HSC versus the WHIM HSC that the patient was born with.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Pathology (AREA)
- Optics & Photonics (AREA)
- High Energy & Nuclear Physics (AREA)
- Surgery (AREA)
- Radiology & Medical Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Biophysics (AREA)
Abstract
Provided herein are methods of enhancing engraftment of hematopoietic stem cells (HSC) in recipient subjects by reducing expression (or activity) of CXC chemokine receptor 4 (CXCR4). Such methods can be used in gene therapy protocols and in HSC transplantation, for example allowing this to occur without radiation or chemotherapy conditioning as is typically done in non- myeloablative HSC transplant. In some examples, gene editing methods are used to delete one copy of the CXCR4 gene before HSC or bone marrow transplantation, enhancing the efficiency and durability of donor cell repopulation.
Description
REDUCING CXCR4 EXPRESSION AND/OR FUNCTION TO ENHANCE
ENGRAFTMENT OF HEMATOPOIETIC STEM CELLS
CROSS-REFERENCE TO RELATED APPLICATION
This application claims priority to U.S. Provisional Application No. 62/026,138, filed July 18, 2014, herein incorporated by reference.
FIELD
This application relates to methods of enhancing engraftment of donor hematopoietic stem cells (HSCs), for example increasing the efficiency and durability of donor HSC repopulation, by reducing expression or activity of CXCR4 in HSCs. In some examples such methods are used in combination with gene therapy.
BACKGROUND
WHIM syndrome (warts, hypogammaglobulinemia, infections, and myelokathexis syndrome) is an autosomal dominant immunodeficiency that can be caused by multiple
heterozygous mutations in the carboxy-terminus of the chemokine receptor, CXCR4. (Hernandez et al., 2003) These mutations disrupt negative regulatory elements and thus enhance function of the receptor (Haribabu et al., 1997; Signoret et al., 1998; Venkatesan et al., 2003). The syndrome name is an acronym for the four major clinical features that result from this: Warts,
Hypogammaglobulinemia, Infections, and Myelokathexis (Wetzler et al., 1990). Warts are the manifestation of chronic human papillomavirus (HPV) infection of the skin or oral or genital mucosa and are a severe and chronic problem in these patients (Beaussant Cohen et al., 2012; Dotta et al., 2011; Kawai and Malech, 2009). Hypogammaglobulinemia (low immunoglobulin G) is typically mild but variable and can predispose to frequent sinopulmonary infections and poor vaccine responses. The patients also suffer from oral, skin/soft tissue and bone and joint infections that arise because of severe blood neutropenia. This occurs in conjunction with an excess of neutrophils and myeloid precursors in the bone marrow that has been termed 'myelokathexis', from the Greek for marrow (myelo) and retention (kathexis) (Krill et al., 1964; Zuelzer, 1964). In fact the excessive CXCR4 function actually causes a panleukopenia in the blood with particularly severe reductions of neutrophils and B cells, and moderate reductions of T cells and monocytes.
CXCR4 is a chemokine receptor expressed on the surface of most leukocytes whose human ligand is CXCL12 (also known as stromal cell derived factor-1 or SDF-1) (Bachelerie et al., 2014). CXCR4 was originally discovered as a fusion co-factor (with CD4) for HIV viral entry and is
particularly important in late stage HIV disease (Berger et al., 1999; Feng et al., 1996); while CXCL12 is constitutively expressed in the bone marrow stroma and is known to play a vital role in hematopoietic stem cell (HSC) retention in the marrow (Bleul et al., 1996; Broxmeyer et al., 2005). A small molecule CXCR4 antagonist, plerixafor (formerly known as AMD3100), is FDA approved to facilitate the collection of HSC by apheresis for autologous bone marrow transplantation in certain malignancies. Plerixafor has also been successful at reversing the panleukopenia and treating WHIM syndrome in small studies (Dale et al., 2011; McDermott et al., 2011; McDermott et al., 2014).
Human hematopoiesis is a complex, hierarchical differentiation of a variety of progenitor cells that form all the terminally differentiated elements of the blood including red blood cells, platelets, lymphocytes, monocytes, and granulocytes (Seita and Weissman, 2010). All of these lineages can be traced back to a group of true pluripotent HSC that are capable of life-long self- renewal. These HSC undergo regulated differentiation to maintain homeostasis and markedly increased proliferation during injury or infection (emergency hematopoiesis) and have been identified by the expression of unique combinations of cell surface markers as well as in vitro and in vivo functional assays. In addition to playing an adhesive role for HSC in the bone marrow niche, CXCR4 signaling promotes HSC quiescence and homeostasis and can also play a role in HSC differentiation into committed myeloid progenitors such as the common myeloid progenitor (CMP) (Broxmeyer et al., 2003a; Broxmeyer et al., 2003b; Nie et al., 2008; Sugiyama et al., 2006).
Chromothripsis is derived from the Greek root for chromosome (chromo=' color', soma='body') and shattering to pieces (thripsis) (Stephens et al., 2011). The phenomenon was recently discovered when new genetic techniques of whole genome sequencing, single nucleotide polymorphism microarray, and bioinformatics analysis were applied to malignant tumor DNA. It represents a new paradigm for oncogenesis where a sudden catastrophic event can create multiple clustered genetic rearrangements and deletions rather than the sequential genetic changes that result in most tumorigenesis (Stephens et al., 2011). It is currently estimated that approximately 2% of all cancers exhibit somatic mutations compatible with chromothripsis (Jones and Jallepalli, 2012) and the same process has been identified in a patient with a severe congenital cognitive syndrome (Kloosterman et al., 2011). A very strong predisposition to chromothripsis has been demonstrated in a specific subtype of meduloloblastoma tumors that have defects in the TP53 gene which indicates that loss of this cell cycle checkpoint may allow cells with severe genetic damage resulting from chromothripsis to survive (Rausch et al., 2012). Criteria developed to allow the inference of chromothripsis include clustering of breakpoints in limited areas of one or several chromosomes with large intervening regions of normal sequence, copy number states that suddenly
oscillate between areas of normal heterozygosity and loss of heterozygosity, rearrangements affecting a single haplotype and with multiple fragments rearranged in random orientation and order (Korbel and Campbell, 2013). SUMMARY
Provided herein are methods enhancing engraftment of donor hematopoietic stem cells (HSCs), for example increasing the efficiency and durability of donor HSC repopulation in a recipient subject. In particular examples the methods include reducing expression or function of CXC chemokine receptor 4 (CXCR4) in a donor HSC, thereby generating a CXCR4 knockdown HSC. For example, expression and/or activity of CXCR4 can be reduced by at least 20%, at least 30%, at least 40%, at least 50% or at least 75% (but not 100%) in the CXCR4 knockdown HSC as compared to expression of CXCR4 in the donor HSC prior to reducing CXCR4 expression and/or activity. In some examples, this is done ex vivo, for example after obtaining HSCs from a donor. In some examples, donor HSCs are obtained from the recipient subject, while in other examples donor HSCs are obtained from a subject different from the recipient subject. Thus, the method can further include harvesting HSC from a donor subject. The disclosure is not limited to specific methods of editing gene expression or activity in a cell, but in some examples gene editing or RNA interference (RNAi) methods are used to manipulate a CXCR4 gene or other CXCR4 nucleic acid in the HSC. In other examples, the CXCR4 protein is targeted, for example with CXCR4 protein antagonists, such as small molecules, antibodies, or aptamers.
The resulting CXCR4 knockdown HSCs are then administered or transplanted into a recipient subject in therapeutically effective amounts, thereby increasing HSC engraftment in the recipient subject. In some examples at least 1 x 106, at least 1 x 107, or at least 1 x 108 CXCR4 knockdown HSCs are administered to the subject. Any method of administration can be used that allows proper function of the HSCs in vivo (for example allows the CXCR4 knockdown HSCs to reach the bone marrow), such as by injection of the CXCR4 knockdown HSCs into the subject, such as by intravenous administration. In some examples, the recipient subject has not received conditioning prior to administering the CXCR4 knockdown HSCs to the recipient subject, such as chemotherapy and/or total body irradiation.
In some examples, the methods further include manipulating one or more other genes (such as correcting a mutation and/or altering its expression) in the CXCR4 knockdown HSCs, which can then be used to treat a disease or disorder in the subject related to the gene that is manipulated. For example, manipulating one or more other genes in the donor HSC can include one or more of correcting a genetic defect in the HSC, wherein the genetic defect causes a disease in the recipient
subject; reducing expression of a first target gene in the HSC, wherein reducing expression of the first target gene treats a disease caused by upregulation of the first target gene in the recipient subject or treats a disease that benefits from reducing expression of the first target gene in the recipient subject; and increasing expression of a second target gene in the HSC, wherein increasing expression of the second target gene treats a disease caused by downregulation of the second target gene in the recipient subject or treats a disease that benefits from increasing expression of the second target gene in the recipient subject.
In some examples, manipulation of CXCR4 expression in the HSC and manipulation of one or more other genes is performed at the same time, such as by using gene editing methods or RNAi methods. In other examples, the donor HSC is first manipulated to decrease CXCR4
expression/activity, and then the donor HSC is manipulated to correct a mutation and/or alter expression of one or more other genes (or vice versa). Thus, a CXCR4 knockdown HSC can include other genetic alterations.
In some examples, the method is a method of treating a disease or disorder in the subject. For example, CXCR4 knockdown HSCs, which may include other genetic manipulations, can be used to treat a hematologic malignancy (such as chronic myelogenous leukemia wherein a BCR- ABL fusion gene is silenced or removed from the donor HSC), HIV-1 (wherein expression of the viral coreceptor and CC chemokine receptor CCR5 is reduced in the donor HSC), anemia, and a genetic disease of the blood, such as any of sickle cell anemia, hemophilia A, hemophilia B, alpha- thalassemia, beta-thalassemia, delta-thalassemia, von Willebrand Disease, pernicious anemia, Fanconi anemia, thrombocytopenic purpura, thrombophilia, and all primary immunodeficiency diseases.
The foregoing and other objects and features of the disclosure will become more apparent from the following detailed description, which proceeds with reference to the accompanying figures.
BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A-1C. DNA sequencing of a family with WHIM syndrome revealed genetic mosaicism of the index patient. (A) Family Pedigree, males (squares); females (circles); shaded (history of or current evidence of clinical WHIM); arrow (index patient); WT (wild- type CXCR4 genotype); R334X (CXCR4R334X heterozygous genotype). (B) DNA sequencing of the family. Shown are representative Sanger sequencing results from blood DNA for the 3 patients of the family at the site of the CXCR4R334X mutation (nucleotide position 1000). (C) DNA sequencing
from different tissues of the index patient at position 1000. Shown are the discrepant results from blood versus cheek versus skin fibroblast DNA.
FIGS. 2A-2B. Loss of the WHIM allele in myeloid derived cells from the index patient.
(A) blood, (B) bone marrow. Shown are representative results from a polymerase chain reaction- restriction fragment length polymorphism (PCR-RFLP) designed to detect the CXCR4R334X mutation performed on DNA from a variety of cell types purified from blood (using magnetic bead purification) or bone marrow aspirate (using flow cytometric sorting). PCR-, amplification in the absence of target DNA serving as a negative control; HD, healthy donor; PBMC, peripheral blood mononuclear cells; uncut, not subjected to restriction enzyme digestion; cut, cut with BstXJI restriction enzyme; LCL, lymphoblastoid cell line derived from PBMC; CD4+; purified CD4+ T cells; CD8+, purified CD8+ T cells; CD19+, purified CD19+ B cells; CD56+, purified CD56+ natural killer cells; CD14+, purified CD14+ monocytes; CD34+, purified CD34+ hematopoietic stem cells; CD3+, purified CD3+ T cells; CD15+, purified CD15+ neutrophils; cultured CD34+, purified CD34+ hematopoietic stem cells grown ex vivo.
FIG. 3. Blood counts by age in the index patient. WBC, white blood count; ANC, absolute neutrophil count; AMC, absolute monocyte count; ALC, absolute lymphocyte count. Arrow indicates age at splenectomy, horizontal lines indicate normal range of values. Note x axis is discontinuous to show pre/post splenectomy results more clearly.
FIGS. 4A-4C. Bone marrow pathology. A representative hematoxylin and eosin stain of the bone marrow is shown for an unrelated adult female WHIM patient (WHIM-03, A) and the index patient (WHIM-09) at age 9 (B, taken from Zuelzer, 1964) and at age 59 (C). Bone marrow characteristics of myelokathexis seen in WHIM-03 at age 30 and in WHIM-09 at age 9 such as an increased myeloid to erythroid ratio, increased late myeloid precursors, and hypersegmented, pyknotic appearing mature neutrophils with dense nuclear lobes connected by long, thin
intranuclear strands and intracytoplasmic vacuolization are no longer present in WHIM-09 at age 59.
FIGS. 5A-5C. Cytogenetics and Hybridization. Bone marrow aspirate was cultured and metaphase cells were lysed and stained with Giemsa. An analysis of the chromosomal banding pattern revealed that some of the patient cells were lacking part of one copy of chromosome 2 and that there was evidence of partial translocation of the centromere (A) while other chromosomes were normal. Fluorescence in situ hybridization (FISH) was performed on these cells for ALK (B), multicolor stain revealed translocation from 2p to 2q arm) and for MYCN (green) and the centromere (red) (C). The latter revealed a deletion of MYCN with a partial centromeric
translocation. When this FISH test was applied to cells with polymorphic nuclei nearly all were positive, but roughly 40% of the cells with round nuclei were negative (data not shown).
FIGS. 6A-6B. Microarray Results. Bone marrow cellular DNA was amplified and hybridized to a clinical microarray designed for investigation of chromosome abnormalities (Affymetrix Cytoscan HD array). Analysis of the copy number state and single nucleotide polymorphism variation using the Chromosome Analysis suite software revealed 7 distinct areas of chromosome 2 that were deleted (red boxes in screenshot (A)). A closer inspection of the 4th and 5th deleted regions reveals that CXCR4 is in the 5th deleted region (B).
FIGS. 7A-7B. Whole Genome Sequencing of the Index Patient. Purified neutrophil DNA was isolated and subjected to whole genome sequencing with paired end analysis. Depicted in (A) is a circular plot from the program Circos of chromosome 2 and its Giemsa cytogenetic banding pattern labeled from the p arm telomere (0) to the q arm telomere (-240) in megabases. Large pieces of chromosome 2 were missing (deletions marked by brackets) and 18 remaining pieces were arranged in random order. Connections between these pieces and their orientation are depicted by the colored lines. Note that 2 connections were poorly defined because of the involvement of repetitive centromeric sequence. The inner circular trace is the copy number variation data derived from the microarray. Note that the sites of connections derived from the paired end sequencing analysis closely matches the sites where copy number variation abruptly falls from 2 to 1. 8 larger piece locations are labeled in bold around the outside of the circle. The arrangement of these 8 larger pieces is given in cartoon form below the plot. (B, left side) shows a cartoon of the Giemsa cytogenetic banding pattern and the order and orientation of the 18 pieces with the deletions called by microarray shaded in yellow. The resultant remaining chromosome 2 banding pattern predicted by whole genome sequencing closely matches that seen by cytogenetic analysis (see Figure 5).
FIGS. 8A-8B. Hematopoietic Differentiation Precursor Markers and Chromothripsis
Analysis in Precursors. (A) shows a cartoon of the differentiation proceeding from the
hematopoietic stem cell (HSC) to final blood elements through the multipotent precursor (MPP) to the common myeloid precursor (CMP) to the megakaryocyte-erythroid precursor (MEP) and granulocyte-monocyte precursor (GMP). The MPP can also differentiate into the common lymphoid precursor (CLP). Cell surface markers used in flow cytometric sorting of these precursors is also shown. Red + symbol indicates precursors and final elements found to have evidence of chromothripsis and green - symbol indicates those that retain the CXCR4R334X allele. CD, cluster of differentiation. (B) shows the results of DNA from the purified bone marrow precursors after PCR- RFLP to detect the CXCR4R334X mutation (left side gel) and amplification using primers specific
for one of the 18 chromothripsis rearrangements (right side gel). Note CLP demonstrate continued presence of the CXCR4R334X heterozygous mutation and lack amplification for the derivative chromosome that resulted from chromothripsis. BM CD16+ indicate purified CD16+ neutrophils given as a positive control, HD PBMC indicates healthy donor peripheral blood mononuclear cell DNA as a negative control. PCR- indicates amplification in the absence of input DNA as a negative control.
FIG. 9. Serum Cytokines. Frozen serum from the index patient, 5 healthy donors and 5 WHIM patients was sent for measurement of 26 cytokines. Shown are selected results in picograms / milliliter (pg/ml) where each value for an individual is a dot with circles representing healthy donors (HD), squares representing WHIM patients, and W9 representing the index patient (WHIM-09). The lines represent the mean + the standard error of the mean. See Table 3 for a complete list.
FIGS. 10A-10B. Cxcr4 Haploinsufficiency Enhances Bone Marrow Engraftment in WHIM Syndrome Mouse Model. (A) Competitive bone marrow transplantation experiment in irradiated recipients: Cxcr4+/o versus Cxcr4+/S338X (mouse model of WHIM syndrome), (i)
Experimental design: Bone marrow cells from donors with a Cxcr4+/o genotype on a CD45.2 homozygous and Cxcr4+/S338x on a CD45.1/45.2 heterozygous background were mixed equally and then 5 million bone marrow cells were injected intravenously into each CD45.1 recipient mouse that had been lethally irradiated 8 hours prior. Serial blood draws every 2 weeks for flow cytometry were then performed to determine which mouse bone marrow could engraft more readily, (ii) Representative flow cytometry plots demonstrating the relative contributions of CD45 congenic markers in mixed donor bone marrow prior to transplantation (left panel) and in blood 298 days after bone marrow transplantation (right panel) in a single mouse, (iii) Cell frequency data for the leukocyte subsets indicated at the top of each panel (CD45+ hematopoietic cells, CD1 lb+ monocytes, Ly6G+ neutrophils, CD19+ B cells, and CD3+ T cells), presented as the mean + SEM percentage ( ) of total donor-derived cells for each subset (n =10 mice per data point). SEM was <5 of the mean in all cases and therefore is not visible for most data points (red circles = blood cells from Cxcr4+/o donors and black triangles = blood cells from Cxcr4+/S338x donors). Results were verified in two additional independent experiments. (B) Competitive bone marrow
transplantation experiments in non-irradiated Cxcr4+/S338X recipients: (i) Cxcr4+/+ versus
Cxcr4+/S338x and (ii) Cxcr4+/o versus Cxcr4+/+. Left panels: Experimental design. Bone marrow cells from donors with a Cxcr4+/S338x genotype (i) or a Cxcr4+/o genotype (ii) on a CD45.2 background were mixed equally with bone marrow cells from Cxcr4+/+ on a CD45.1 background and then 10 million bone marrow cells were injected intravenously into each non-irradiated
Cxcr4 recipient mouse on a CD45.1/45.2 heterozygous background. Serial blood draws every 2 weeks for flow cytometry were then performed to determine which mouse bone marrow could engraft more readily. Right panels: Donor-derived blood cell frequency data for the leukocyte subsets indicated at the top of each panel, presented as the mean + SEM percentage ( ) of total cells for each subset (n =5 mice per data point). Red circles = blood cells from Cxcr4+/o donors, blue triangles = blood cells from Cxcr4+/S338x donors, and black triangles = blood cells from
Cxcr4+/+ donors. Results were verified in one additional independent experiment.
FIGS. 11A-11B. Cxcr4 Haploinsufficiency Enhances Bone Marrow Engraftment. (A) Competitive bone marrow transplantation experiment in irradiated recipients: Cxcr4+/o versus Cxcr4+/+. (i) Experimental design: Bone marrow cells from donors with a Cxcr4+/o genotype on a CD45.2 homozygous and a Cxcr4+/+ genotype on a CD45.1/45.2 heterozygous background were mixed equally and then 5 million mixed bone marrow cells were injected intravenously into each CD45.1 recipient mouse that had been lethally irradiated 8 hours prior. Serial blood draws every 2 weeks for flow cytometry were then performed to determine which mouse bone marrow could engraft more readily, (ii) Representative flow cytometry plots demonstrating the relative contributions of CD45 congenic markers in mixed donor bone marrow prior to transplantation (left panel) and in blood 300 days after bone marrow transplantation (right panel) in a single mouse, (iii) Cell frequency data for the leukocyte subsets indicated at the top of each panel (CD45+ hematopoietic cells, CDl lb+ monocytes, Ly6G+ neutrophils, CD19+ B cells, and CD3+ T cells), presented as the mean + SEM percentage ( ) of total donor-derived cells for each subset (n =10 mice per data point). SEM was <5 of the mean in all cases and therefore is not visible for most data points (red circles = blood cells from Cxcr4+/o donors and black triangles = blood cells from Cxcr4+/+ donors). Results were verified in two additional independent
experiments. (B) Competitive bone marrow transplantation experiments in non-irradiated Cxcr4+/+ recipients: Cxcr4+/o versus Cxcr4+/+. Left panel: Experimental design. Bone marrow cells from donors with a Cxcr4+/o genotype on a CD45.2 background were mixed equally with bone marrow cells from donors with a Cxcr4+/+ genotype on a CD45.1 background, and then 10 million mixed bone marrow cells were injected intravenously into each non-irradiated Cxcr4+/+ recipient mouse on a CD45.1/45.2 heterozygous background. Serial blood draws every 2 weeks for flow cytometry were then performed to determine which mouse bone marrow could engraft more readily. Right panels: Donor-derived blood cell frequency data for the leukocyte subsets indicated at the top of each panel, presented as the mean + SEM percentage ( ) of total cells for each subset (n =5 mice per data point). Red circles = blood cells from Cxcr4+/o donors and black triangles = blood cells from Cxcr4+/+ donors. Results were verified in one additional independent experiment.
FIGS. 12A-12B. Cxcr4 Haploinsufficiency Enhances Bone Marrow Engraftment in mice in a Hematopoietic Stem Cell (HSC) Intrinsic Manner. (A) Competitive HSC
transplantation experiment in irradiated recipients: Cxcr4+/o versus Cxcr4+/S338X. (i)
Experimental design: Bone marrow cells from donors with a Cxcr4+/o genotype on a CD45.2 homozygous and from donors with a Cxcr4+/S338x genotype on a CD45.1/45.2 heterozygous background were mixed equally. The mixed BM cells were lineage-depleted by negative selection with Lineage Cell Depletion Kit (Miltenyi Biotech Inc) and then HSC cells (lineage"Scal+c- Kit+CD48"CD34"CD150+) were sorted with a flow cytometer. 2000 isolated HSC cells were injected intravenously into each CD45.1 recipient mouse that had been lethally irradiated 8 hours prior. Serial blood draws every 2 weeks for flow cytometry were then performed to determine which mouse bone marrow could engraft more readily, (ii) Representative flow cytometry plots demonstrating the relative contributions of CD45 congenic markers in mixed donor HSCs prior to transplantation (left panel) and in blood 16 days after HSC transplantation (right panel) in a single mouse, (iii) Cell frequency data for the leukocyte subsets indicated at the top of each panel, presented as the mean + SEM percentage (%) of total donor-derived cells for each subset (n =5 mice per data point). SEM was <5 of the mean in all cases and therefore is not visible for most data points. (B) Competitive HSC transplantation experiment in irradiated recipients:
Cxcr4+/o versus Cxcr4+/+. (i) Experimental design: Bone marrow cells from donors with a Cxcr4+/o genotype on a CD45.2 homozygous and from donors with a Cxcr4+/+ genotype on a CD45.1/45.2 heterozygous background were mixed equally. The mixed BM cells were lineage-depleted by negative selection with Lineage Cell Depletion Kit (Miltenyi Biotech Inc) and then HSC cells (lineage"Scal+c-Kit+CD48"CD34"CD150+) were sorted with flow cytometer. 2000 isolated HSCs were injected intravenously into each CD45.1 recipient mouse that had been lethally irradiated 8 hours prior. Serial blood draws every 2 weeks for flow cytometry were then performed to determine which mouse bone marrow could engraft more readily, (ii) Representative flow cytometry plots demonstrating the relative contributions of CD45 congenic markers in mixed donor HSCs prior to transplantation (left panel) and in blood 16 days after HSC transplantation (right panel) in a single mouse, (iii) Cell frequency data for the leukocyte subsets indicated at the top of each panel, presented as the mean + SEM percentage (%) of total donor-derived cells for each subset (n =5 mice per data point). SEM was <5 of the mean in all cases and therefore is not visible for most data points.
FIGS. 13A-13B. Cxcr4 haploinsufficiency enhances HSC engraftment in a mouse bone marrow transplantation model. (A) Haploinsufficiency of Cxcr4 promotes enhanced proliferation of HSCs. Bone marrow cells from donors with a Cxcr4+/o genotype on a CD45.2
homozygous and from donors with a Cxcr4 genotype on a CD45.1/45.2 heterozygous background were mixed (47:53) and then 5 million mixed bone marrow cells were injected intravenously into each CD45.1 recipient mouse that had been lethally irradiated 8 hours prior. 6 days after bone marrow transplantation, each mouse was given 1.25 mg of BrdU ip. 20 hours later, the mice were euthanized for HSC proliferation analysis, (i) Gating scheme for BrdU+ HSCs. Bone marrow cells were first gated with CD45.2 (Cxcr4+/o) and CD45.1/2 (Cxcr4+/+), then HSCs were gated as Flt3" Lin" Seal"1" c-Kit+ (Flt3"LSK) which includes long-term and short-term HSCs. The HSCs that proliferated in the last 20 hours were further gated as BrdU+. (ii) Percentage of BrdU+ HSCs in each donor. Data are expressed as mean + SEM from four mice, and the experiment was repeated once with similar results. (B) Selective advantage of Cxcr4+/o over Cxcr4+/+ donor hematopoietic progenitor cells for durable engraftment of normally differentiating cells. Bone marrow cells from donors with a Cxcr4+/o genotype on a CD45.2 background and from donors with a Cxcr4+/+ genotype on a CD45.1 background were mixed (42:58), and then 5 million mixed bone marrow cells were injected intravenously into each recipient mouse that had been lethally irradiated 8 hours prior. The mice were euthanized for hematopoietic progenitor population analysis 303 days after bone marrow transplantation. One experiment was performed with five CD45.1 and five CD45.2 male recipient mice and the results were combined in the figure because they were identical, (i) Gating scheme for the long term HSC (LT-HSC: CD34"Flt3" Lin" Scal+ c-Kit+), short term HSC (ST-HSC: CD34+Flt3" Lin" Scal+ c-Kit+ ), multipotent progenitors (MPP: CD34+Flt3+ Lin" Scal+ c-Kit+ ), and common lymphoid progenitors (CLP: IL7ra+ Lin" Scallow c-Kitlow ). (ii) The high proportion of Cxcr4+/o as compared to Cxcr4+/+ donor derived hematopoietic progenitor populations in bone marrow indicates a selective advantage of Cxcr4+/o cells for long term engraftment. (iii) The similar frequency of Cxcr4+/o and Cxcr4+/+ derived hematopoietic progenitor cells in corresponding CD45+ cell populations indicates that
differentiation was not affected by Cxcr4 haploinsufficiency.
FIG. 14. Bone marrow Testing for ALK activity. Two representative photomicrographs from a WHIM-09 bone marrow biopsy are shown. On the left is a typical hematoxylin and eosin stain and on the right is an immunohistochemical stain for anaplastic lymphoma receptor tyrosine kinase (ALK) activity. Lack of brown color indicates that although the ALK gene is translocated there is no detectable increased enzymatic activity.
FIGS. 15A and 15B. Bone Marrow Progenitor In vitro Culture Assay and PCR. (A) Representative example of the in vitro culture and differentiation of a healthy blood donor (HD) and WHIM-09's (W9) CD34+ HSC cultured to create burst forming unit-erythroid (BFU-E)
colonies. DNA isolated from these colonies was then used in the PCR-RFLP assay for the CXCR4R334X allele. (B) Demonstrates that BFU-E colonies lack the WHIM allele.
FIGS. 16A-16D. Complete TALEN system creates deletions in CXCR4 resulting in loss of CXCR4 expression. (A) Genomic DNA sequence of human CXCR4. TALEN sequences are underlined. (SEQ ID NO: 11 top, SEQ ID NO: 12 bottom) (B) FACS analysis of HeLa cells 2 days after transfection with maxGFP as a transfection control, CXCR4-copGFP-CXCR4 donor, incomplete TALEN (LI) with CXCR4-copGFP-CXCR4 donor, or complete TALEN (L1+R2) system with CXCR4-copGFP-CXCR4 donor; (C) HeLa cells that were transfected with the complete TALEN system were sorted by FACS (top), cultured for 7 days and analyzed by FACS analysis 7 days later (bottom); (D) Sequence analysis of the GFP negative cell population from (B). Sequences corresponding to LI and R2 TALENs are highlighted in green. Red box highlights sequences (sequences from top SEQ ID NOS: 13, 15, 13, 13, 16, 13, 13, 17, 13, 13, 13, and 13) from cells that express low levels of CXCR4 (CXCR4 Lo) population. SEQ ID NOS: 13, 13, 13, 14, 13, 13, 15, 13, 13, 16, 13, 13, 17, 13, 13, 13, 13 and 13 from top to bottom.
FIGS. 17A-17E. CRISPR-Cas9 system creates deletions in CXCR4 to generate cells with one copy of CXCR4. (A) Genomic DNA sequence of human CXCR4. CRISPR guide sequences are underlined, PAM motif is in italics; (SEQ ID NO: 18 top, SEQ ID NO: 19 bottom) (B) FACS analysis 6 days after HeLa cells were transfected with 2 μg maxGFP (transfection efficiency control), 2 μg CRISPR-cas9 D10A Nickase or 1 μg Nickase with 0.5 μg of each guide; (C) HeLa cells that were transfected with the complete Nickase system were sorted by FACS (top), after which surveyor assay was carried out to detect mutations in the sorted populations. CXCR4 Lo cells were cultured for 4 days and analyzed by FACS analysis (bottom); (D) Sequence analysis of populations of cells that expressed high (CXCR4 Hi; SEQ ID NOS: 20, 21, 20, 20, 20, 20, 20, 20, 20, 20, 22, 20, 20, 20 and 20 from top to bottom), medium (CXCR4 Mid SEQ ID NOS: 20, 20, 23, 24, 20, 20, 20, 25, and 20 from top to bottom), and low (CXCR4 Lo SEQ ID NOS: 26, 20, 20, 27, 20, 20, 20, 28, 20, 20, 20, 20, 20, 20, 20, 20, 29, 30, 31, 31, 31, 31, 20, 20, 20, 20, 20, 20, 32, 31, 31, 31, 31, and 31 from top to bottom) levels of CXCR4 and a consensus sequence is shown at the bottom (SEQ ID NO: 20); (E) Sequence analysis from 5 single cell clones. Each clone has at least 2 sequence reads. Sequences corresponding to guides are highlighted in green. SEQ ID NOS: 33, 33, 33, 34, 34, 34, 33, 34, 35, 34, 33, 33, and 33 from top to bottom.
SEQUENCE LISTING
The nucleic and amino acid sequences listed in the accompanying sequence listing are shown using standard letter abbreviations for nucleotide bases, and three letter code for amino
acids, as defined in 37 C.F.R. 1.822. Only one strand of each nucleic acid sequence is shown, but the complementary strand is understood as included by any reference to the displayed strand.
SEQ ID NOS: 1-4 are PCR primers for amplification of CXCR4.
SEQ ID NOS: 5 and 6 are exemplary human CXCR4 coding and protein sequences. In the nucleic acid sequence, nt 1-2643 is the promoter, 2603-2607 TATA signal, 2632-6409 the gene, with nt 2721..2735 joined to 4844..5911 to form the coding sequence.
SEQ ID NOS: 7-8 are PCR primers for genomic DNA amplification of CXCR4 for indel analysis.
SEQ ID NOS: 9-10 are PCR primers for genomic DNA amplification of CXCR4 for single cell clonal analysis.
SEQ ID NOS: 11-12 are human CXCR4 genomic DNA sequence targeted by TALENs.
SEQ ID NOS: 13-17 are resulting mutated human CXCR4 genomic DNA sequences using the TALEN system. A consensus sequence is shown in SEQ ID NO: 13.
SEQ ID NOS: 18-19 are human CXCR4 genomic DNA sequence containing CRISPR guide sequences and PAM sequences.
SEQ ID NOS: 20-32 are resulting mutated human CXCR4 genomic DNA sequences using the nickase system. SEQ ID NOS: 20 and 22 are sequences from cells that expressed high (CXCR4 Hi) levels of CXCR4; SEQ ID NOS: 20, 23, 24 and 25 are sequences from cells that expressed medium (CXCR4 Mid) levels of CXCR4, and SEQ ID NOS: 20, 26, 27, 28, 29, 30, 31 and 32 are sequences from cells that expressed low (CXCR4 Lo) levels of CXCR4.
SEQ ID NOS: 33-35 are normal (SEQ ID NO: 33) and resulting mutated human CXCR4 genomic DNA sequences (SEQ ID NOS: 34-35) using the nickase system from 5 single cell clones.
SEQ ID NOS: 36-50 are exemplary sequences that can be used to knock-down CXCR4 expression using CRISPR or TALEN.
DETAILED DESCRIPTION
Unless otherwise noted, technical terms are used according to conventional usage.
Definitions of common terms in molecular biology can be found in Benjamin Lewin, Genes VII, published by Oxford University Press, 1999; Kendrew et al. (eds.), The Encyclopedia of Molecular Biology, published by Blackwell Science Ltd., 1994; and Robert A. Meyers (ed.), Molecular
Biology and Biotechnology: a Comprehensive Desk Reference, published by VCH Publishers, Inc., 1995; and other similar references.
As used herein, the singular forms "a," "an," and "the," refer to both the singular as well as plural, unless the context clearly indicates otherwise. As used herein, the term "comprises" means
"includes." Thus, "comprising a nucleic acid molecule" means "including a nucleic acid molecule" without excluding other elements. It is further to be understood that any and all base sizes given for nucleic acids are approximate, and are provided for descriptive purposes, unless otherwise indicated. Although many methods and materials similar or equivalent to those described herein can be used, particular suitable methods and materials are described below. In case of conflict, the present specification, including explanations of terms, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting. All references, including patent applications and patents, and sequences associated with the GenBank® Accession Numbers listed (as of July 18, 2014) are herein incorporated by reference.
In order to facilitate review of the various embodiments of the disclosure, the following explanations of specific terms are provided:
Administration: To provide or give a subject an agent, such as a CXCR4 knock down HSC, by any effective route. Exemplary routes of administration include, but are not limited to, injection (such as subcutaneous, intramuscular, intradermal, intraperitoneal, and intravenous), transdermal, intranasal, and inhalation routes.
Antisense and Sense: Double- stranded DNA (dsDNA) has two strands, a 5' -> 3' strand, referred to as the plus strand, and a 3' -> 5' strand (the reverse complement), referred to as the minus strand. Because RNA polymerase adds nucleic acids in a 5' to 3' direction, the minus strand of the DNA serves as the template for the RNA during transcription. Thus, the RNA formed will have a sequence complementary to the minus strand and identical to the plus strand (except that U is substituted for T).
CD34: A cell surface antigen formerly known as hematopoietic progenitor cell antigen 1, and MY10, which is a marker of human hematopoietic stem cells. For example, CD34 is expressed selectively on human hematopoietic progenitor cells. CD34 is an adhesion molecule. The human CD34 gene, which maps to chromosome lq32, spans 26 kb and has 8 exons. CD34 is a 67 kDa transmembrane glycoprotein.
CD34 sequences are publically available, for example from the GenBank® sequence database (e.g., Accession Nos. NP_001020280.1 (precursor) and AAB25223.1 provide exemplary human CD34 protein sequences; while Accession Nos. M81104.1 and BC039146.1 provide exemplary human CD34 nucleic acid sequences). One of ordinary skill in the art can identify additional CD34 nucleic acid and protein sequences, including CD34 variants (e.g., sequences having at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98% or at least 99% sequence identity to the sequence of any Accession number listed).
Cell Culture: Cells grown under controlled conditions. A primary cell culture is a culture of cells, tissues or organs taken directly from an organism (such as a human or other mammal). Cells are expanded in culture when they are placed in a growth medium under conditions that facilitate cell growth and/or division, resulting in a larger population of the cells. When cells are expanded in culture, the rate of cell proliferation is typically measured by the amount of time required for the cells to double in number, otherwise known as the doubling time. In some examples, donor HSCs are grown in culture prior to introduction into a recipient. For example, HSCs grown in culture can be manipulated to downregulate CXCR4 expression or activity.
CXC chemokine receptor 4 (CXCR4): OMIM 162643. Also known as fusin, or CD 184, is a gene that encodes for the CXCR4 protein, an alpha-chemokine receptor found on most leukocytes that is specific for stromal cell-derived-factor- 1 (CXCL12), a molecule that has chemo tactic activity for both lymphocytes and phagocytes. In humans, the CXCR4 gene is found on chromosome 2 (2q22.1), and in mice it is found on chromosome 1.
CXCR4 sequences are publically available, for example from the GenBank® sequence database (e.g., Accession Nos. NP_001008540 and CAA12166.1 provide exemplary human
CXCR4 protein sequences; NP_034041.2 and AAH31665.1 provide exemplary mouse CXCR4 protein sequences, while Accession Nos. NG_011587.1 and AJ224869.1 provide exemplary human CXCR4 nucleic acid sequences and Accession Nos. NM_009911.3 and BC098322.1 provide exemplary mouse CXCR4 nucleic acid sequences). One of ordinary skill in the art can identify additional CXCR4 nucleic acid and protein sequences, including CXCR4 variants (e.g., sequences having at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98% or at least 99% sequence identity to the sequence of any Accession number listed, or to SEQ ID NO: 5 or 6).
Downregulated or knocked down: When used in reference to the expression of a molecule, such as a (e.g., CXCR4) gene or a protein, refers to any process which results in a decrease in production of a gene product, but in some examples not complete elimination of the gene product or gene function. A gene product can be RNA (such as mRNA, rRNA, tRNA, and structural RNA) or protein. Therefore, downregulation or knock down includes processes that decrease transcription of a gene or translation of mRNA and thus decrease the presence of proteins or nucleic acids, such as a CXCR4 protein or nucleic acid molecule.
Examples of processes that decrease transcription include those that facilitate degradation of a transcription initiation complex, those that decrease transcription initiation rate, those that decrease transcription elongation rate, those that decrease processivity of transcription and those that increase transcriptional repression. Gene downregulation can include reduction of expression above an existing level. Examples of processes that decrease translation include those that decrease
translational initiation, those that decrease translational elongation and those that decrease mRNA stability. In some examples, a gene editing method, inhibitory RNA, antibody, or other specific binding agent is used to decrease or knock down expression, such as expression or activity of CXCR4.
Downregulation or knock down includes any detectable decrease in the production of a gene product, such as a CXCR4 protein. In certain examples, detectable target protein or nucleic acid expression in a cell (such as a HSC cell) decreases by at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% (such as a decrease of 40% to 90%, 40% to 80% or 50% to 95%) as compared to a control (such an amount of protein or nucleic acid expression detected in a corresponding normal cell or sample). In one example, a control is a relative amount of expression in a normal HSC (e.g., a non-recombinant HSC or an HSC from a healthy or normal subject).
In one example, downregulation or knock down does not result in complete elimination of detectable expression or activity (such as expression or activity of CXCR4).
Expression: The process by which the coded information of a nucleic acid molecule, such as a CXCR4 nucleic acid molecule (e.g., Cxcr4 gene) is converted into an operational, non- operational, or structural part of a cell, such as the synthesis of a protein (e.g., CXCR4 protein). Expression of a gene can be regulated anywhere in the pathway from DNA to RNA to protein. Regulation can include controls on transcription, translation, RNA transport and processing, degradation of intermediary molecules such as mRNA, or through activation, inactivation, compartmentalization or degradation of specific protein molecules after they are produced.
The expression of a nucleic acid molecule or protein (such as CXCR4) can be altered relative to a normal (wild type) nucleic acid molecule or protein (such as in a normal non- recombinant HSC). Alterations in gene expression, such as differential expression, include but are not limited to: (1) overexpression (e.g., upregulation); (2) underexpression (e.g., downregulation); or (3) suppression of expression. Alternations in the expression of a nucleic acid molecule can be associated with, and in fact cause, a change in expression of the corresponding protein.
Protein expression can also be altered in some manner to be different from the expression of the protein in a normal (wild type) situation. This includes but is not necessarily limited to: (1) a mutation in the protein such that one or more of the amino acid residues is different; (2) a short deletion or addition of one or a few (such as no more than 10-20) amino acid residues to the sequence of the protein; (3) a longer deletion or addition of amino acid residues (such as at least 20 residues), such that an entire protein domain or sub-domain is removed or added; (4) expression of
an increased amount of the protein compared to a control or standard amount (e.g., upregulation); (5) expression of a decreased amount of the protein compared to a control or standard amount (e.g., downregulation); (6) alteration of the subcellular localization or targeting of the protein; (7) alteration of the temporally regulated expression of the protein (such that the protein is expressed when it normally would not be, or alternatively is not expressed when it normally would be); (8) alteration in stability of a protein through increased longevity in the time that the protein remains localized in a cell; and (9) alteration of the localized (such as organ or tissue specific or subcellular localization) expression of the protein (such that the protein is not expressed where it would normally be expressed or is expressed where it normally would not be expressed), each compared to a control or standard.
Controls or standards for comparison to a sample, for the determination of differential expression, include samples believed to be normal (in that they are not altered for the desired characteristic, for example a HSC from a normal subject) as well as laboratory values, even though possibly arbitrarily set, keeping in mind that such values can vary from laboratory to laboratory. Laboratory standards and values may be set based on a known or determined population value and can be supplied in the format of a graph or table that permits comparison of measured,
experimentally determined values.
Fokl nuclease: A nonspecific DNA nuclease that occurs naturally in Flavobacterium okeanokoites. The term includes fragments of the Fokl nuclease protein that retain nuclease activity that are, or may be, fused to a DNA-binding polypeptide. Also includes variants of a wild-type Fokl sequence.
Functional deletion: A mutation, partial or complete deletion, insertion, or other variation made to a gene sequence that reduces or can even inhibit production of the gene product or renders the gene product non-functional. For example, a functional deletion of a single CXCR4 allele in a HSC results in a cell that cannot produce CXCR4 protein from that allele (but can produce CXCR4 from the other allele), which results in the HSC having an increased engraftment and repopulation abilities.
Genomic insertion site: A site of the genome that is targeted for, or has undergone, insertion of an exogenous polynucleotide.
Hematopoietic stem cell (HSC): The stem cells that give rise to all blood cells. Thus,
HSCs have the ability to durably generate all blood lineages in vivo. They are present in the umbilical cord, blood, and bone marrow (BM). In some examples, HSCs express CD34. In some examples, HSCs express the following markers:
Mouse HSC: CD34lo/", SCA-1+, Flt-3+, C-kit+, lin-
Human HSC: CD34+, CD59+, Thyl/CD90+, CD38lo/", C-kit/CD117+, lin- A CXCR4 knock down HSC is a recombinant HSC having reduced, but not eliminated, CXCR4 expression and activity, such as a reduction of at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% (such as a decrease of 40% to 60%, 40% to 90%, 40% to 80%, 50% to 90%, or 50% to 95%) as compared to a control (such as a non-recombinant HSC with normal or wild- type CXCR4 expression).
Human Immunodeficiency Virus (HIV). A retrovirus that causes immunosuppression in humans and leads to a disease complex known as acquired immunodeficiency syndrome (AIDS). This immunosuppression results from a progressive depletion and functional impairment of T lymphocytes expressing the CD4 cell surface glycoprotein. The loss of CD4 helper/inducer T cell function may underlie the loss of cellular and humoral immunity leading to the opportunistic infections and malignancies seen in AIDS. HIV subtypes can be identified by particular number, such as HIV-1 and HIV-2.
Increase or Decrease: A statistically significant positive or negative change, respectively, in quantity from a control value. An increase is a positive change, such as an increase at least 50%, at least 100%, at least 200%, at least 300%, at least 400% or at least 500% as compared to the control value. A decrease is a negative change, such as a decrease of at least 20%, at least 25%, at least 50%, at least 75%, at least 80%, at least 90%, at least 95%, at least 98%, at least 99%, or at least 100% decrease as compared to a control value. In some examples the decrease is less than 100%, such as a decrease of no more than 90%, no more than 95% or no more than 99%.
Isolated: An "isolated" biological component (such as an HSC cell, nucleic acid or protein) has been substantially separated, produced apart from, or purified away from other biological components in the cell or tissue of the organism in which the component naturally occurs, such as other cells, chromosomal and extrachromosomal DNA and RNA, and proteins. Nucleic acids and proteins which have been "isolated" include nucleic acids and proteins purified by standard purification methods. The term also embraces nucleic acids and proteins prepared by recombinant expression in a host cell as well as chemically synthesized nucleic acids and proteins. Isolated HSCs in some examples are at least 50% pure, such as at least 75%, at least 80%, at least 90%, at least 95%, at least 98%, or at least 100% pure (that is free from other cell types in the blood or bone marrow).
Mammal: This term includes both human and non-human mammals. Similarly, the term "subject" includes both human and veterinary subjects.
Modulate: A change in the content of genomic DNA gene. Modulation can include, but is not limited to, gene activation (e.g., upregulation), gene repression (e.g., downregulation), gene deletion, polynucleotide insertion, and/or polynucleotide excision.
Operably linked: A first nucleic acid sequence is operably linked with a second nucleic acid sequence when the first nucleic acid sequence is placed in a functional relationship with the second nucleic acid sequence. For instance, a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence. Generally, operably linked DNA sequences are contiguous and, where necessary to join two protein-coding regions, in the same reading frame.
Pharmaceutically acceptable carriers: The pharmaceutically acceptable carriers useful in this invention are conventional. Remington's Pharmaceutical Sciences, by E. W. Martin, Mack Publishing Co., Easton, PA, 15th Edition (1975), describes compositions and formulations suitable for pharmaceutical delivery of a CXCR4 knock down HSC.
In general, the nature of the carrier will depend on the particular mode of administration being employed. For instance, parenteral formulations usually comprise injectable fluids that include pharmaceutically and physiologically acceptable fluids such as water, physiological saline, balanced salt solutions, aqueous dextrose, glycerol or the like as a vehicle. In addition to biologically-neutral carriers, pharmaceutical compositions to be administered can contain minor amounts of non-toxic auxiliary substances, such as wetting or emulsifying agents, preservatives, and pH buffering agents and the like, for example sodium acetate or sorbitan monolaurate.
Promoter: A promoter is an array of nucleic acid control sequences which direct transcription of a nucleic acid. A promoter includes necessary nucleic acid sequences near the start site of transcription. A promoter also optionally includes distal enhancer or repressor elements. A "constitutive promoter" is a promoter that is continuously active and is not subject to regulation by external signals or molecules. In contrast, the activity of an "inducible promoter" is regulated by an external signal or molecule (for example, a transcription factor). In one example, the promoter is a U6 promoter or a CMV promoter.
Recombinant or host cell: A cell that has been genetically altered, or is capable of being genetically altered by introduction of an exogenous polynucleotide, such as a recombinant plasmid or vector. Typically, a host cell is a cell in which a vector can be propagated and its DNA expressed. In one example the cell is an HSC. The term also includes any progeny of the subject host cell. It is understood that all progeny may not be identical to the parental cell since there may be mutations that occur during replication. However, such progeny are included when the term "host cell" is used.
RNA interference (RNAi): A post-transcriptional gene silencing mechanism mediated by RNA molecules. Introduction of short RNA molecules into cells (such as double stranded RNA), results in binding of the RNA molecules to other specific messenger RNA (mRNA) molecules and can either increase or decrease their activity, for example by preventing an mRNA from producing a protein. Examples of inhibitory RNA molecules include small interfering RNA (siRNA), micro RNA (miRNA), ribozymes (such as a hammerhead ribozyme, VS ribozyme, or hairpin ribozyme), and antisense molecules. In certain examples, an RNAi molecule is directed against a target gene, such as CXCR4 in an HSC, and is used to increase engraftment of the resulting recombinant
CXCR4 knockdown HSC following introduction into a recipient. In some examples, an RNAi molecule is at least about 19 nucleotides (nt), such as at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 26, or at least 27 nt in length.
Selectable marker: A gene introduced into a cell, such as HSCs in culture, which confers a trait suitable for artificial selection from HSCs that do not possess the gene.
Sequence identity/similarity: The similarity between amino acid (or nucleotide) sequences is expressed in terms of the similarity between the sequences, otherwise referred to as sequence identity. Sequence identity is frequently measured in terms of percentage identity (or similarity or homology); the higher the percentage, the more similar the two sequences are.
Methods of alignment of sequences for comparison are well known in the art. Various programs and alignment algorithms are described in: Smith and Waterman, Adv. Appl. Math. 2:482, 1981; Needleman and Wunsch, J. Mol. Biol. 48:443, 1970; Pearson and Lipman, Proc. Natl. Acad. Sci. U.S.A. 85:2444, 1988; Higgins and Sharp, Gene 73:237, 1988; Higgins and Sharp, CABIOS 5: 151, 1989; Corpet et al., Nucleic Acids Research 16: 10881, 1988; and Pearson and Lipman, Proc. Natl. Acad. Sci. U.S.A. 85:2444, 1988. Altschul et al., Nature Genet. 6: 119, 1994, presents a detailed consideration of sequence alignment methods and homology calculations.
The NCBI Basic Local Alignment Search Tool (BLAST) (Altschul et al., J. Mol. Biol.
215:403, 1990) is available from several sources, including the National Center for Biotechnology Information (NCBI, Bethesda, MD) and on the internet, for use in connection with the sequence analysis programs blastp, blastn, blastx, tblastn and tblastx. A description of how to determine sequence identity using this program is available on the NCBI website on the internet.
Homologs and variants of protein and nucleic acid sequences known in the art and disclosed herein are typically characterized by possession of at least about 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity counted over the full length alignment with the amino acid sequence using the NCBI Blast 2.0, gapped blastp set to default parameters. For comparisons of amino acid sequences of greater than about 30 amino acids, the Blast
2 sequences function is employed using the default BLOSUM62 matrix set to default parameters, (gap existence cost of 11, and a per residue gap cost of 1). When aligning short peptides (fewer than around 30 amino acids), the alignment should be performed using the Blast 2 sequences function, employing the PAM30 matrix set to default parameters (open gap 9, extension gap 1 penalties). Proteins with even greater similarity to the reference sequences will show increasing percentage identities when assessed by this method, such as at least 95%, at least 98%, or at least 99% sequence identity. When less than the entire sequence is being compared for sequence identity, homologs and variants will typically possess at least 80% sequence identity over short windows of 10-20 amino acids, and may possess sequence identities of at least 85% or at least 90% or at least 95% depending on their similarity to the reference sequence. Methods for determining sequence identity over such short windows are available at the NCBI website on the internet. One of skill in the art will appreciate that these sequence identity ranges are provided for guidance only; it is entirely possible that strongly significant homologs could be obtained that fall outside of the ranges provided.
Thus, a CXCR4 protein can have at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to any of GenBank® Accession Nos. NP_001008540, CAA12166.1, NP_034041.2 and AAH31665.1. Similarly, exemplary CXCR4 nucleic acid sequences in some examples have at least 70%, at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 98%, or at least 99% sequence identity to any of GenBank® Accession Nos. NG_011587.1, AJ224869.1, NM_009911.3 and BC098322.1.
Subject: Any subject that has a vascular system and has hematopoietic cells in the wild- type organism. In one embodiment, the subject is a non-human mammalian subject, such as a monkey or other primate, mouse, rat, rabbit, pig, goat, sheep, dog, cat, horse, or cow. In another embodiment, the subject is a human subject. In some examples, the subject has a genetic disease of the blood (e.g. sickle cell disease, primary immunodeficiency diseases), HIV (such as HIV-1), anemia, or a hematologic malignancy or cancer, such as one of those listed in Table 1.
Therapeutically effective amount: The amount of agent, such as CXCR4 knock down HSCs (which may include one or more other repaired genetic mutations as discussed herein), that is sufficient to prevent, treat, reduce and/or ameliorate the symptoms and/or underlying causes of a disorder or disease. For example, it can be an amount of CXCR4 knock down HSCs sufficient to reconstitute hematopoiesis in a subject receiving the CXCR4 knock down HSCs, such as a subject having genetic disease of the blood (e.g. sickle cell disease, primary immunodeficiency diseases), ΗΓ (such as HIV-1), or a hematologic malignancy or cancer, such as one of those listed in Table 1. An effective amount of CXCR4 knock down HSCs can be determined by various methods,
including generating an empirical dose-response curve, predicting potency and efficacy by using modeling, and other methods used in the art. In one embodiment, a therapeutically effective amount of CXCR4 knock down HSCs is at least 10,000, at least 20,000, at least 30,000, at least 40,000, at least 50,000, at least 100,000, at least 500,000, at least 1,000,000, at least 2,000,000, at least 3,000,000, at least 4,000,000, at least 5,000,000, at least 10,000,000, at least 20,000,000, at least 25,000,000, or at least 50,000,000 CXCR4 knockdown HSCs. Specific assays for
determining the therapeutically effective amount of CXCR4 knock down HSCs are provided herein. For example donor HSC engraftment (e.g., by measuring HSC repopulation) can be measured in the recipient subject.
In one embodiment, an "effective amount" of CXCR4 knockdown HSCs is an amount sufficient to reduce symptoms of a genetic disease of the blood, such as a primary
immunodeficiency disease, for example by at least 10%, at least 20%, at least 50%, at least 70%, or at least 90% (as compared to no administration of the CXCR4 knockdown HSCs).
In one embodiment, an "effective amount" of CXCR4 knockdown HSCs is an amount sufficient to reduce symptoms of anemia for example by at least 10%, at least 20%, at least 50%, at least 70%, or at least 90% (as compared to no administration of the CXCR4 knockdown HSCs). In one embodiment, a therapeutically effective amount of CXCR4 knockdown HSCs is an amount of CXCR4 knockdown HSCs sufficient to increase the number of red blood cells in an anemic recipient, wherein such cells are generated from the CXCR4 knockdown HSCs. In some examples the anemia is Fanconi anemia, and the CXCR4 HSCs include a repaired Fanconi anemia gene(s).
In one embodiment, an "effective amount" of CXCR4 knockdown HSCs is an amount sufficient to increase the number of CD4+ T cells in an HIV-infected subject. In one example, an "effective amount" of CXCR4 knockdown HSCs is an amount sufficient to reduce symptoms of HIV-l infection, for example by at least 10%, at least 20%, at least 50%, at least 70%, or at least 90% (as compared to no administration of the CXCR4 knockdown HSCs).
In one embodiment, an "effective amount" of CXCR4 knockdown HSCs is an amount sufficient to reduce the number of abnormal white blood cells in a subject with a hematological malignancy, such as a leukemia. In one embodiment, an "effective amount" of CXCR4 knockdown HSCs is an amount sufficient to reduce the number of abnormal plasma cells in a subject with multiple myeloma. In one example, an "effective amount" of CXCR4 knockdown HSCs is an amount used to treat or reduce the undesirable effects of a lymphoma, such as reduce the size of the lymphoma, volume of the lymphoma, rate of growth of the lymphoma, and/or metastasis of the lymphoma. Such reduction can be at least 10%, at least 20%, at least 50%, at least 70%, or at least 90% (as compared to no administration of the CXCR4 knock down HSCs). In one example, an
"effective amount" is an amount of CXCR4 knockdown HSCs sufficient to reduce symptoms of a hematological malignancy, for example by at least 10%, at least 20%, at least 50%, at least 70%, or at least 90% (as compared to no administration of the CXCR4 knockdown HSCs).
The therapeutically effective amount of cells can be dependent on the subject being treated (e.g., the species or size of the subject), the severity of the disease in the recipient subject. In one embodiment, a therapeutically effective amount of CXCR4 knockdown HSCs is an amount of CXCR4 knockdown HSCs sufficient to increase the number of B cells, T cells, monocytes and/or macrophages in the peripheral blood of a recipient, wherein such cells are generated from the CXCR4 knockdown HSCs.
Transduced, Transformed and Transfected: A virus or vector "transduces" a cell when it transfers nucleic acid molecules into a cell, such as an HSC. A cell is "transformed" or
"transfected" by a nucleic acid transduced into the cell (such as an HSC) when the nucleic acid becomes stably replicated by the cell, either by incorporation of the nucleic acid into the cellular genome, or by episomal replication.
These terms encompasses all techniques by which a nucleic acid molecule can be introduced into such a cell, including transfection with viral vectors, transformation with plasmid vectors, and introduction of naked DNA by electroporation, lipofection, particle gun acceleration and other methods in the art. In some example the method is a chemical method (e.g., calcium- phosphate transfection), physical method (e.g., electroporation, microinjection, particle
bombardment), fusion (e.g., liposomes), receptor-mediated endocytosis (e.g., DNA-protein complexes, viral envelope/capsid-DNA complexes) and biological infection by viruses such as recombinant viruses (Wolff, J. A., ed, Gene Therapeutics, Birkhauser, Boston, USA, 1994). In the case of infection by retroviruses, the infecting retrovirus particles are absorbed by the target cells, resulting in reverse transcription of the retroviral RNA genome and integration of the resulting pro virus into the cellular DNA. Methods for the introduction of genes into cells are known (e.g., see U.S. Patent No. 6,110,743). These methods can be used to transduce a HSC to manipulate its genome.
Genetic modification of the target cell is an indicium of successful transfection.
"Genetically modified cells" refers to cells whose genotypes have been altered as a result of cellular uptakes of exogenous nucleotide sequence by transfection, transduction, or transformation. A reference to a transfected cell or a genetically modified cell includes both the particular cell into which a vector or polynucleotide is introduced and progeny of that cell.
Transgene: An exogenous gene.
Transplantation: The transfer of a tissue or an organ, or cells (such as HSCs), from one body or part of the body to another body or part of the body. An "allogeneic transplantation" or a "heterologous transplantation" is transplantation from one individual to another, wherein the individuals have genes at one or more loci that are not identical in sequence in the two individuals. An allogeneic transplantation can occur between two individuals of the same species, who differ genetically, or between individuals of two different species. An "autologous transplantation" is a transplantation of a tissue or cells from one location to another in the same individual, or transplantation of a tissue or cells from one individual to another, wherein the two individuals are genetically identical.
Treating, Treatment, and Therapy: Any success or indicia of success in the attenuation or amelioration of an injury, pathology or condition, including any objective or subjective parameter such as abatement, remission, diminishing of symptoms or making the condition more tolerable to the patient, slowing in the rate of degeneration or decline, making the final point of degeneration less debilitating, improving a subject's physical or mental well-being, or prolonging the length of survival. The treatment may be assessed by objective or subjective parameters; including the results of a physical examination, blood and other clinical tests, and the like.
Upregulated: When used in reference to the expression of a molecule, such as a gene or a protein, refers to any process which results in an increase in production of a gene product. A gene product can be RNA (such as mRNA, rRNA, tRNA, and structural RNA) or protein. Therefore, upregulation includes processes that increase transcription of a gene or translation of mRNA and thus increase the presence of proteins or nucleic acids.
Examples of processes that increase transcription include those that increase transcription initiation rate, those that increase transcription elongation rate, those that increase processivity of transcription and those that decrease transcriptional repression. Gene upregulation can include increasing expression above an existing level. Examples of processes that increase translation include those that increase translational initiation, those that increase translational elongation and those that increase mRNA stability. In some examples, a gene editing method, antibody, or other specific binding agent is used to increase expression.
Upregulation includes any detectable increase in the production of a gene product. In certain examples, detectable target protein or nucleic acid expression in a cell (such as a HSC cell) increases by at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 90%, at least 95%, at least 100%, at least 200%, at least 400%, or at least 500% as compared to a control (such an amount of protein or nucleic acid expression detected in a corresponding normal cell or sample). In one example, a control is a relative amount
of expression in a normal HSC (e.g., a non-recombinant HSC or an HSC from a healthy or normal subject).
Under conditions sufficient for: A phrase that is used to describe any environment that permits a desired activity. In one example the desired activity is introduction of a nucleic acid molecule into an HSC, for example to reduce expression and activity of CXCR4 in the HSC.
Vector: A nucleic acid molecule into which a foreign nucleic acid molecule can be introduced without disrupting the ability of the vector to replicate and/or integrate in a host cell (such as an HSC). A vector can include nucleic acid sequences that permit it to replicate in a host cell, such as an origin of replication. A vector can also include one or more selectable marker genes and other genetic elements known in the art. An integrating vector is capable of integrating itself into a host nucleic acid. An expression vector is a vector that contains the necessary regulatory sequences to allow transcription and translation of inserted gene or genes. Vectors include plasmid vectors and viral vectors.
In one example the vector is a plasmid vector engineered to target CXCR4 by expressing single guide RNA (sgRNA) under the control of the U6 promoter and contain selection markers of puromycin resistance (e.g., from Genecopoeia, Rockville, MD). The sgRNA sequences target the Cas9 nuclease enzyme or the D10A mutant of the Cas9 nuclease enzyme known as 'nickase' encoded on a second plasmid to the wild-type or WHIM CXCR4 gene to create a double strand break (DSB) or single strand break (SSB) in the gene, respectively. Donor sequence encoding markers to interrupt CXCR4 can also be incorporated such that a fluorescent molecule such as GFP is inserted into the CXCR4 gene inactivating it or sequences designed to result in the repair of the targeted gene such as the mutant CXCR4WHIM allele or other genes listed in Table 1 can be accomplished at the same time.
In one example a TALEN encoding vector includes the promoter EF- 1 alpha and the selection marker puromycin (e.g., made by Sidansai Biotechnology, Shanghai, China). Methods to transfect HSC with plasmid DNA are available (e.g., Lonza nucleofector technology, WalkersviUe, MD). Other methods to transfect HSC include 3rd generation integration-deficient lenti viral vectors (for example Life Technologies, Gaithersburg, MD) and Adeno-Associated viral (AAV) vectors (for example Clontech, Moutain View, CA).
Overview
Chromothripsis is a recently discovered phenomenon of multiple clustered genetic abnormalities occurring simultaneously. It is estimated to occur in at least 2% of all cancers and occurs with varying frequency in a wide variety of malignancies. This disclosure describes a
patient who was born with a congenital immunodeficiency called WHIM syndrome due to a nonsense point mutation in the chemokine receptor CXCR4. As an adult she exhibits phenotypic and genetic evidence of reversion of her immunodeficiency syndrome and she is now a somatic mosaic within the hematopoietic system. Interestingly this appears to be due to a chromothriptic event in a hematopoietic stem cell involving only the chromosomal copy that carried her WHIM mutation allele. Her case demonstrates that chromothripsis may occasionally have beneficial effects and has implications for understanding hematopoietic stem cell development, bone marrow transplantation, and the immune system's control of human papillomavirus infection.
A patient with WHIM syndrome described herein was found to have all the above features of chromothripsis confined to a single copy of chromosome 2 (the location of CXCR4) and associated with loss of the disease allele (and 163 other genes on one copy of chromosome 2) and durable resolution of the clinical manifestations of her disease. The chromothriptic event most probably occurred in a single HSC that engrafted and acquired a selective advantage enabling it to repopulate her bone marrow with cells lacking the disease allele, thus affecting cure. To the inventors' knowledge this is the first chromothripsis event to be described that has a positive medical outcome.
In the course of studying gene(s) critical for the selective advantage in the patient, the inventors discovered that HSC engraftment can be durably enhanced by silencing one copy of CXCR4. In competitive repopulation experiments, deletion of one Cxcr4 allele was sufficient to confer a selective advantage on donor cells when transplanted into a mouse model of WHIM syndrome, phenocopying the patient. Further, Cxcr4 haploinsufficiency also enhanced engraftment of HSCs in wild-type mice.
It is shown herein that the patient in which one copy of CXCR4 had been deleted in a somatic mutation of an HSC, resulted in clonal repopulation of this cell in the bone marrow. In a bone marrow transplantation model in mice, donor cells with a single copy of the Cxcr4 gene repopulate recipient mice much faster and last much longer than donor cells having two copies of the Cxcr4 gene. Based on these observations, provided herein are methods to enhance HSC engraftment, for example in gene therapy protocols and in HSC transplantation. In some examples, this is done in non-conditioned recipients (e.g., subject does not receive radiation or chemotherapy conditioning prior to receiving HSCs as is typically done in a HSC transplant). Methods can be used to reduce CXCR4 expression and activity, for example by using gene editing to specifically delete one copy of the CXCR4 gene in the donor HSCs before HSC transplantation into a recipient (e.g., prior to bone marrow transplantation), enhancing the efficiency and durability of donor HSC
repopulation. This concept may also overcome a major hurdle limiting all gene therapy applications, namely that the corrected cell numbers wane with time.
One problem in gene therapy is the short-lived nature of gene-corrected cells. The discovery that hematopoietic stem cells with one copy of the CXCR4 gene have a durable selective advantage in bone marrow repopulation can solve this problem. For example, gene editing methods can be used to delete one copy of CXCR4 gene in gene-corrected cells (though other methods can be used to decrease CXCR4 expression, such as RNAi methods and use of agents that target CXCR4 proteins, such as antibodies or aptamers). As a result, these CXCR4 knocked down HSCs will out-grow the existing recipient cells bearing a disease-causing mutation, which have two copies of the CXCR4 gene putting them at a relative disadvantage.
The disclosed methods in some examples include (1) reducing expression or activity of CXCR4 in a donor HSC, for example by inactivating one copy of CXCR4 in the donor HSC, and (2) introducing (e.g., infusing, administering, transplanting) the CXCR4 knockdown HSCs into a recipient subject (e.g., if the HSC was manipulated ex vivo). Such methods can be used to treat diseases which benefit from improved HSC engraftment. For example, the disclosed methods can be used to improve bone marrow transplants (BMTs). In some examples, subjects need not undergo conditioning traditionally used in BMTs, but engraftment still occurs, thus reducing major side effects. In addition, these methods can be used in combination with manipulating one or more other genes in the donor HSC, for example using genome editing techniques, for controlling HIV and in treating diseases that benefit from gene therapy.
Methods of Enhancing HSC Engraftment
Provided herein are methods enhancing engraftment of donor hematopoietic stem cells (HSCs), for example increasing the efficiency and durability of donor HSC repopulation in a recipient subject. Subjects that can be treated with the disclosed methods include those with a hematopoietic system, such as a mammal, for example a non-human primate (such as an ape or monkey), veterinary subject (such as a cat, dog, mouse, rat, horse, cow, goat, sheep or pig), and humans.
In some examples, engraftment is increased by at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 90%, at least 95%, at least 100%, at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 10-fold, at least 20-fold, or at least 30-fold, for example at 30 days, 60 days, 90 days, 120 days, 1 year or 2 years following the HSC transplant. In some examples, enhanced engraftment is indicated by an increase in donor HSC repopulation in the recipient faster than donor HSC with normal CXCR4 expression or activity. For example, the
donor HSCs can repopulate at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 90%, at least 95%, at least 100%, at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 10-fold, at least 20-fold, or at least 30-fold, faster than donor HSCs with normal CXCR4 expression or activity (e.g., a wild-type HSC), for example at 30 days, 60 days, 90 days, 120 days, 1 year or 2 years following the HSC transplant. In some examples, enhanced engraftment is indicated by donor HSC lasting longer in the recipient than donor HSC with normal CXCR4 expression or activity. For example, the donor HSCs can survive at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 90%, at least 95%, at least 100%, at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 10-fold, at least 20-fold, or at least 30-fold longer than donor HSCs with normal CXCR4 expression or activity (e.g., a wild-type HSC), for example at 30 days, 60 days, 90 days, 120 days, 1 year or 2 years following the HSC transplant. In mouse models donor cells can be tracked by virtue of CD45.1 and CD45.2 variants. In humans that receive an allogeneic transplant, the donor chimerism can be tracked using specific common polymorphic genetic variations. In humans that receive an autologous transplant, correction of the genetic defect that is targeted can be determined (e.g., loss of the CXCR4 WHIM allele as occurred naturally in the patient).
In particular examples the methods include reducing expression of (e.g., downregulating) CXC chemokine receptor 4 (CXCR4) in a donor HSC, thereby generating a CXCR4 knockdown HSC. For example, expression and/or activity (e.g., function) of CXCR4 can be reduced in the donor HSC by at least 20%, at least 30%, at least 40%, at least 50%, at least 75%, at least 80%, at least 90%, at least 95% or at least 98% (but not 100%, such a reduction of 20% to 50%, 40% to 50%, 20 to 75%, 40% to 60%, or 20% to 90%) in the HSC as compared to expression of CXCR4 in the donor HSC prior to reducing CXCR4 expression and/or activity. In some examples, reducing expression of CXCR4 includes functionally deleting one copy of a CXCR4 allele in the donor HSC. HSCs having reduced CXCR4 activity are referred to herein as CXCR4 knockdown HSCs. In some examples, this downregulation of CXCR4 is done ex vivo, for example after obtaining HSCs from a donor. In other examples, this is done in vivo. The method can further include harvesting or obtaining HSC from a donor subject. For example, HSCs can be obtained from peripheral blood, bone marrow, and umbilical cord blood.
In some examples, donor HSCs are obtained from the recipient subject, and then reintroduced into the recipient subject after they are manipulated (e.g. , to downregulate CXCR4), while in other examples donor HSCs are obtained from a subject different from the recipient subject. The disclosure is not limited to specific methods of editing gene expression or activity in a cell, but in some examples gene editing or RNA interference (RNAi) methods are used to
manipulate a CXCR4 gene or other CXCR4 nucleic acid in the HSC. In other examples, the CXCR4 protein is targeted, for example with CXCR4 protein antagonists, such as small molecules, antibodies, or aptamers.
The resulting CXCR4 knockdown HSCs are administered or transplanted into a recipient subject in therapeutically effective amounts, thereby increasing HSC engraftment in the recipient subject. In some examples at least 1 x 106, at least 1 x 107, or at least 1 x 108 CXCR4 knockdown HSCs are administered to the subject. Any method of administration can be used that allows proper function of the HSCs in vivo (for example, allows the CXCR4 knockdown HSCs to reach the bone marrow), such as by injection of the CXCR4 knockdown HSCs into the subject, such as by intravenous administration. In some examples, the recipient subject has not received conditioning prior to administering the CXCR4 knockdown HSCs to the recipient subject, such as chemotherapy and/or total body irradiation which is typically used prior to bone marrow transplantation.
In some examples, the methods further include manipulating one or more other genes (such as correcting a mutation and/or altering its expression) in the CXCR4 knockdown HSCs, wherein the resulting HSCs are used to treat a disease or disorder in the subject related to the gene that is manipulated. For example, manipulating one or more other genes in the donor HSC can include one or more of correcting a genetic defect in the HSC, wherein the genetic defect causes a disease in the recipient subject; reducing expression of a first target gene in the HSC, wherein reducing expression of the first target gene treats a disease caused by upregulation of the first target gene in the recipient subject or treats a disease that benefits from reducing expression of the first target gene in the recipient subject; and increasing expression of a second target gene in the HSC, wherein increasing expression of the second target gene treats a disease caused by downregulation of the second target gene in the recipient subject or treats a disease that benefits from increasing expression of the second target gene in the recipient subject. Examples of genetic defects that can be fixed or corrected in the HSC include one or more of nucleotide point mutations, nucleotide deletions, nucleotide insertions, gene rearrangements, gene deletions, and gene insertions.
In some examples, manipulation of CXCR4 expression in the HSC and manipulation of one or more other genes is performed at the same time, such as by using gene editing methods or RNAi methods. In other examples, the donor HSC is first manipulated to decrease CXCR4
expression/activity, and then the donor HSC is manipulated to correct a mutation and/or alter expression of one or more other genes (or vice versa). Thus, a CXCR4 knockdown HSC can include other genetic alterations.
In some examples, the method is a method of treating a disease or disorder in the subject. In one example, CXCR4 knockdown HSCs (such as allogeneic HSCs) are administered to a subject
to treat a hematologic malignancy, such as a leukemia, lymphoma, or myeloma (including those listed in Table 1). In some examples, administration of CXCR4 knockdown HSCs not only enhances HSC engraftment, but results in a graft vs. tumor effect, thereby treating the hematologic malignancy.
In some examples, CXCR4 knockdown HSCs (such as autologous HSCs) include other genetic manipulations, which can be used to treat a disorder associated with a genetic mutation or a disorder that would benefit from upregulation a target gene or from downregulation of a target gene. The use of autologous HSCs can reduce or eliminate a graft vs. host disease effect.
For example, CXCR4 knockdown HSCs (such as autologous HSCs) that include other genetic manipulations can be used to treat a hematologic malignancy, such as one that results from a genetic mutation (e.g. , chronic myelogenous leukemia wherein a BCR-ABL fusion gene is repaired or silenced in the donor HSC), HIV- 1 (wherein expression of CCR5 is reduced in the donor HSC), anemia, and a genetic disease of the blood, such as any of sickle cell anemia, hemophilia A, hemophilia B, alpha-thalassemia, beta- thalassemia, delta-thalassemia, von
Willebrand Disease, pernicious anemia, Fanconi anemia, thrombocytopenic purpura,
thrombophilia, or a primary immunodeficiency disease. For example, if the subject has sickle cell anemia, the genetic defect that is repaired in the donor HSC is a Glu to Val mutation in amino acid 6 of a β-globin chain of hemoglobin. For example, if the subject has hemophilia A, the genetic defect that is repaired in the donor HSC can be a mutation in clotting factor VIII. For example, if the subject has hemophilia B, the genetic defect that is repaired in the donor HSC can be a mutation in clotting factor IX. For example, if the subject has thrombocytopenic purpura, the genetic defect that is repaired in the donor HSC can be a mutation in ADAMTS 13. For example, if the subject has thrombophilia, the genetic defect that is repaired in the donor HSC can be a mutation in factor V Leiden or prothrombin. Other exemplary diseases and mutations are provided in Table 1 below. However, the disclosure is not limited to particular diseases or mutations, as one skilled in the art will appreciate that based on the teaching provided herein, any genetic disease of the blood or any primary immunodeficiency disease that is due to a particular genetic mutation, can be treated with the disclosed methods. I. Obtaining HSCs
HSCs can be harvested from the umbilical cord, blood, and/or bone marrow. In some examples, the HSCs are obtained from the same subject to be treated (autologous, the donor and recipient are the same person). In other examples, the HSCs are obtained from a subject different from the one to be treated (allogeneic, the donor and recipient are different individuals, or
syngeneic, the donor and recipient are identical twins). Generally, hematopoietic progenitors present at a frequency of 0.05-0.2% among peripheral blood mononuclear cells (PBMCs), 0.1-0.5% among cord blood mononuclear cells (MNCs) or 0.5-3% among bone marrow MNCs.
The resulting HSCs are used to generate CXCR4 knock down HSCs (which can include further genetic manipulations to treat a disease). The population of HSCs used to generate the CXCR4 knock down HSCs, and the CXCR4 knock down HSCs administered to a subject, do not need to be 100% pure; lower amounts of purity are acceptable. For example, a population of cells that contains at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 99% HSCs or CXCR4 knock down HSCs can be used. In some exmaples, unpurified HSCs are used, such as by using the bone marrow (or PBMCs) directly from the donor, without isolating the HSCs from the bone marrow (or PBMCs).
A. Bone Marrow
For example, HSC can be obtained from the bone marrow (BM) of the pelvis or femur using a needle and syringe. In addition to HSCs, BM contains other cells including stromal cells, stromal stem cells, blood progenitor cells, and mature and maturing white and red blood cells. The resulting BM sample can then be used to isolate HSCs.
B. Peripheral Blood
To obtain stem cells from the circulating peripheral blood, donor subjects are injected with a cytokine, such as granulocyte colony- stimulating factor (G-CSF), to induce cells to leave the bone marrow and circulate in the blood vessels. For example, the donor can be injected with G-CSF alone or in combination with a CXCR4 inhibitor (e.g., plerixafor) before the cell harvest. In one example, G-CSF (e.g., 10 μg/kg) is administered subcutaneously to donor subjects daily for four days and on the fifth day in addition to G-CSF, a CXCR4 inhibitor (e.g., plerixafor) (e.g., 240 μg/kg) is administered subcutaneously. A mobilized peripheral blood stem cell (PBSC) concentrate can then be collected by leukapheresis on day 5 twelve hours after the administration of plerixafor and 2 hours after the last dose of G-CSF. In another example, G-CSF (e.g., 10 μg/kg) is administered subcutaneously to donor subjects daily for five days and a mobilized PBSC concentrate can then be collected by leukapheresis on day 5. The PBSCs express CD34 and/or CD 133. In one example, the method of Bloan et al. is used to obtain PBMCs (Br. J. Haematol. 120:801-7, 2003).
The resulting PBSC sample is used to isolate HSCs.
1. PBSCs collected by apheresis without CD34 selection
Donor stem cell mobilization with G-CSF can be performed as follows. After medical evaluation and clearance for suitability as an autologous or allogeneic donor, donors undergo mobilization with G-CSF (e.g., filgrastim, Neupogen, Amgen). The G-CSF can be administered in a dose of approximately 10- 12 ug/kg/day for 5-6 days, subcutaneously. The doses for days 1-4 may be given at any time of day, but the doses for day 5 and if necessary, day 6 is given early in the morning, at least one hour and preferably two hours prior to starting apheresis. Side effects of G- CSF, including headache, bone pain, and myalgia, can be treated with acetaminophen or ibuprofen. G-CSF can be administered according to a vial-based algorithm to reduce wastage and increase the G-CSF dose given to lighter weight donors to improve CD34 yields as shown below:
Donor Wt Total GCSF Dose (range)
38 - 60 kg 600 meg (10.0 to 15.8 mcg/kg)
61 - 78 kg 780 meg (10.0 to 12.8 mcg/kg)
79 - 90 kg 900 meg (10.0 to 11.4 mcg/kg)
91 - 96 kg 960 meg (10.0 to 10.5 mcg/kg)
97 - 108 kg 1080 meg (10.0 to 11.0 mcg/kg)
> 109 kg 1200 meg (<11.0 mcg/kg) Peripheral blood stem cell (PBSC) collection is then performed. An optimum CD34+ HSC dose to be collected by apheresis is >5 x 106/kg. The minimum CD34+ HSC dose that is recovered in order to proceed with further therapy is ~3 x 106/kg. Donors can receive prophylactic continuous intravenous calcium chloride infusions to prevent citrate toxicity during apheresis. The volume processed per apheresis procedure can be determined by medical staff on the day of apheresis, based on peak CD34+ HSC cell mobilization response to G-CSF, optimum and minimum CD34+ HSC cell dose needed, and kilogram weight of recipient. Volume of blood processed can range from 12 to 30 liters per procedure for 1 to 2 consecutive daily procedures, not to exceed a total of 60 liters over 2 days. In pediatric subjects, defined as less than 40 kg, a maximum of 8 blood volumes will be processed per procedure, for up to 2 consecutive daily procedures.
In children less than 18 kg undergoing autologous leukapheresis procedures, three additional considerations apply. A central venous double-lumen catheter can be used for apheresis. It may be necessary to "prime" the apheresis instrument with a unit of allogeneic red cells, due to the fact that the volume of blood in the device during apheresis will exceed the safe extracorporeal volume (SEV) allowed for the patient. The SEV is generally about 15% of circulating blood
volume or 10.5 ml/kg. In extremely small children (less than 16 kg), it may not be possible to citrate anticoagulant without risk of severe citrate toxicity, thus, systemic heparinization can be used during apheresis.
2. PBSCs collected by apheresis with CD34 selection
GCSF is administered as described above, except at the following dosage:
Donor Wt Total GCSF Dose (range)
38 - 48 kg 600 meg (12.5 to 15.8 mcg/kg)
49 - 56 kg 780 meg (13.9 to 15.9 mcg/kg)
57 - 60 kg 900 meg (15.0 to 15.8 mcg/kg)
61 - 67 kg 960 meg (14.3 to 15.7 mcg/kg)
68 - 108 kg 1080 meg (10.0 to 15.9 mcg/kg)
> 109 kg 1200 meg (<11.0 mcg/kg) PBMC donors can receive prophylactic continuous intravenous calcium chloride infusions.
The target (or "optimum") CD34+ HSC dose recovered after CD34 selection of the apheresis component is >5 x 106/kg. The minimum post-selection CD34+ HSC dose recovered in order to proceed with further therapy is ~3 x 106/kg. Since approximately 60% of the CD34+ HSC cells in the apheresis product are recovered following CD34+ HSC cell selection, the targeted CD34+ HSC dose to be collected by apheresis is 5 /0.6 = 8 x 106/kg. The volume processed per apheresis procedure will be determined by medical staff on the day of apheresis, based on peak CD34+ HSC cell mobilization response to G-CSF, optimum and minimum CD34+ HSC cell dose needed, and kilogram weight of recipient. Volume processed will range can 12 to 30 liters per procedure for 1 to 2 consecutive daily procedures, not to exceed a total of 60 liters over 2 days. In pediatric subjects (less than 40 kg), a maximum of 8 blood volumes will be processed per procedure, for up to 2 consecutive daily procedures. The same pediatric considerations discussed above apply.
3. Pediatric Apheresis in Subjects < 20 kg: Unstimulated Mononuclear Cell (MNC) and Stimulated Peripheral Blood Stem Cell (PBSC) Collection on the COBE® Spectra
Safe extracorporeal volume is defined as less than or equal to 15% of intravascular volume.
Intravascular volume is defined as: 80 mL/kg for children who weigh < 20 kg and 75 mL/kg for children who weigh > 20 to < 40 kg. Extracorporeal volume in the COBE® Spectra Apheresis System is 285 mL. This can vary further depending on the number of leukocytes targeted for collection and the subject's hemoglobin and WBC count. In general, safe extracorporeal volume is
exceeded with use of Spectra when the weight is less than 20 kg. Since it is not acceptable to administer a red blood cell prime for research purposes, the NIH Department of Transfusion Medicine (DTM) does not collect cells for research use in children less than 20 kg.
Citrate is the routine anticoagulant used in apheresis procedures. This method uses continuous intravenous calcium and magnesium replacement in all subjects less than 40 kg undergoing more than 2 blood volumes processed. No adverse events related to divalent cation replacement have occurred with use of the Alaris Guardrail Continuous IV Monitoring System. Citrate may safely be used as the sole anticoagulant in subjects as small as 18-20 kg; below this, the citrate mg/kg infusion rate exceeds a safe level. The acceptable range of citrate infusion rates in DTM is 1.2-3.5 mg/kg/min. Heparin is generally required in subjects less than 18-20 kg. For such patients, full systemic heparinization is used, in addition to a reduced amount of citrate. Since heparin causes systemic anticoagulation and carries additional risk, DTM does not collect cells for research in children less than 20 kg.
The inlet whole blood flow rate (WBFR) for Spectra is defined as the: AC Pump Rate (mL/min) x (Inlet:AC Ratio). In this calculation, for subjects < 20 kg, the default citrate infusion rate (CIR) is 2.5 mg/kg/min. The CIR may be increased up to 3.5 mg/kg/min. For subjects < 20 kg, the default Inlet:AC ratio is 25: 1. The Inlet:AC ratio may be set at 20: 1, 25: 1, or 30: 1.
Threshold CBC values are the same in children and in adults, and are based on worst case scenarios, such as machine malfunction with inability to return the blood in the machine to the donor. Minimum hematocrit is 28%, minimum platelet count 10,000/uL (50,000 for research procedures), and minimum WBC count 2000/uL.
When MNC is selected on the COBE® Spectra Apheresis System, the program will set up with a specific separation factor that is a measure of the centrifugal force to which the blood is exposed. Gambro BCT recommends a MNC separation factor of 500 g-minutes for MNC collection. This is the product of the centrifugal force and the length of time a blood element entering the channels is subjected to this force.
WBC Disposable Tubing Set Fluid Volumes
Disposable tubing set volume 285 mL
Total equivalent whole blood volume 285 mL
Total RBC volume 114 mL
Residual RBC volume 24 mL
Rinseback (total) 413 mL Normal Saline
Rinseback (net return to patient) 263 mL Normal saline
Prime Divert 150 mL Normal Saline
Preparation of the COBE® Spectra Apheresis System
1. Power the machine on.
2. Ensure that single-stage filler is in the centrifuge. Tube the Spectra following manufacturer's guidelines. See the COBE ©Spectra Apheresis System Operator's Manual
(Terumo BCT).
3. When the Set Selection screen appears on the operator interface screen, select 3=WBC. The WBC procedure section screen will then appear, select 1=MNC.
4. If performing blood prime, follow steps in Appendix (below), from this point.
If not performing blood prime, proceed with below procedural steps.
5. Prime the Spectra with 0.9 % normal Saline following manufacturer's guidelines.
6. Perform the alarm tests following manufacturer's guidelines.
7. Enter the patient/procedure data as prompted on the operator screen (gender, height, weight, patient's hematocrit).
8. Press YES to accept the target end results or NO to change the target end results (Inlet Volume, Inlet pump flow rate, Run time or Collect volume) as ordered by the physician and continue with "Connecting the Patient". See the COBE ©Spectra Apheresis System Operator's Manual (Terumo BCT). to change patient/procedure data.
9. After prime, the procedure is started within 4 hours or the disposable kit is discarded. Preparing the Patient/Donor for Procedure
1. Identify the patient/donor.
2. Check the patient/donor BP, pulse and temperature to ensure they are within the patient's normal limits.
3. Establish venous access.
4. Draw pre-lab samples if ordered by the DTM or primary care physician.
Labeling the Product Bag(s)
At the time of collection of blood (or components) and at the time of preparation of components, a label will be placed on each container.
To obtain the amount of AC in the collection bag for recording on transfusable product labels: press the MENU button on the operator interface screen; select l=Data Entry; select 4= AC Data; and record the number of mL in the Collect field on the product label.
Starting the Procedure
1. Anticoagulation with ACD-A
The inlet flow rate for Spectra is = AC Pump Rate (mL/min) x (Inlet: AC Ratio). For subjects < 20 kg, the default Inlet: AC Ratio is set at 25: 1. On Spectra, the true whole blood flow rate is the inlet flow rate minus the ACDA infusion rate
The citrate infusion rate (CIR) in subjects > 20 kg may range from 2.5 to 3.5 mg/kg/min, per MD order. The maximum allowable CIR will determine the AC pump rate. For subjects < 20 kg, the default citrate infusion rate is 2.5 mg/kg/min
2. Anticoagulation with heparin
Loading Dose: Heparin (50 U/kg) bolus IV push into return line, administer ordered dose immediately before attaching patient to the machine. If a red cell prime is used, the heparin should be given prior to the infusion of the red cell prime. Maintenance dose: Heparin (20 U/kg) IV push into draw/access line; administer ordered dose every 60 minutes, starting exactly one hour after administration of the loading dose.
3. If calcium chloride and magnesium sulfate intravenous replacement solutions are ordered, follow DTM SOP: 2401 Prophylactic Calcium Infusion and DTM SOP: 2402 Prophylactic Magnesium Sulfate Infusion for set up and dosing.
4. Return line: Attach a 4-way stop-cock to end of return line of Spectra tubing.
Connect the calcium IV line to a port of the 4-way stop-cock and prime. Connect the magnesium IV line to the remaining port of the 4-way stop-cock and prime. Attach a Braun Extension Set to the proximal port of the 4-way stopcock and prime.
5. Draw line: Attach a 3- way stop-cock to the end of the draw line. Attach a Braun Extension Set to the proximal port of the 3-way stopcock and prime.
6. Follow the guidelines for "Connecting the Patient" in the COBE ©Spectra Apheresis System Operator's Manual (Terumo BCT).
7. When prompted by Spectra, press Continue at the prompt for Diverting prime saline. (150 mL of NS will be diverted to the waste bag). The prime may be given at the direction of the DTM physician.
8. Spectra will prompt: Close return line saline. Press Clear.
9. Initiate calcium and magnesium infusions at the end of divert prime as the blood begins to return to the patient.
10. Monitor the patient/donor's temperature, BP and pulse at the beginning and end of the procedure and as needed.
11. Monitor and record fluid volumes for the Spectra' s operators screen with each change or approximately every 15 - 30 minutes.
Quick Start
Quick Start is an automated method to establish the interface in WBC procedures. The Plasma pump will automatically change to position the interface. An accurate patient/donor hematocrit is required to properly establish the interface. To exit Quick Start, change the plasma pump flow rate or press the Manual button twice. After Quick Start is complete, the collect valve moves to the open position. Quick Start is completed after the system processes 200 mL of RBC.
Interface Control
To maintain interface once it is established or to refine positioning at the end of Quick Start:
• Monitor the collect line hematocrit as it exits the centrifuge using the Colorgram™
• View the WBC collect tube (WBC out) through the port in the centrifuge door. If the WBC collect tube fills with RBC, the collection is too deep into the RBC or WBC layer→decrease the plasma pump flow rate in larger increments (1.0 - 3.0 mL/min) If the WBC collect tube is clear without RBC present, the collection is not deep enough into the RBC layer→increase the plasma pump flow rate in larger increments (1.0 - 3.0 mL/min)
• Make small incremental changes in the plasma pump flow rate (0.5-1.0 mL/min)
• Allow 3-5 minutes between changes in the plasma pump flow rate
• Interface is correct when the RBC layer is halfway up the channel, streaks of RBC are visible in the collect line, and the collect line exiting the centrifuge is at the desired hematocrit based on the Colorgram.
Colorgram™
The WBC Colorgram™ assists in determining the hematocrit of the product in the collect line. Insert the Colorgram™ under the smallest clear collect line where it exits the centrifuge. Compare the colored rectangles on the Colorgram™ to the color of the collect line. The hematocrit in the collect line, when compared against the Colorgram™ chart, should be maintained at 1-4% (such as 2-4%) for an MNC collection. Collecting light (1-2%) results in more platelets in the product. Collecting dark (4-5%) results in more granulocytes and RBC in the product. Adjust the plasma pump flow rate to adjust the hematocrit. See section 7.7 in the COBE ©Spectra Apheresis System Operator's Manual (Terumo BCT).for additional information.
Collect Pump Flow Rate
For MNC procedures, the Collect Flow Rate (CFR) defaults to 1.0 mL/min. The CFR generally varies between 0.8 and 1.5 mL/min which is the CFR recommended by the manufacturer to minimize cross cellular contamination. The CFR will be adjusted depending on the WBC count. The CFR cannot be changed during Quick Start (See above for information on Quick Start). CBC results may be obtained from Cell Processing Laboratory on the pre-apheresis tube.
Configuration of MNC InletrAC Ratio
The manufacturer's default Inlet: AC ratio for MNC procedures is 12: 1. The default AC infusion rate is 0.8 mL/min/L of TBV. The AC infusion rate may be increased to 1.2 mL/min/L of TBV without operator override. Change the Inlet: AC to 25: 1 if systemic heparinization is used. It is at physician discretion to order ratio's of 20: 1, 25: 1, or 30: 1. See the COBE ©Spectra Apheresis System Operator's Manual (Terumo BCT).for guidance though the operator interface screen. See SOP 2401 Prophylactic Calcium Infusion for calcium infusion guidelines.
The presence of cloudy, clumped light colored cells in the collect line and in the line entering the product bag may indicate platelet clumping and the need to decrease the AC ratio. The intermittent loss of a stable optimal interface during the procedure may indicate platelet clumping and that a clump has pushed through the collect line. This may require a decrease in the AC ratio.
Adding ACD-A to the Product
Using aseptic technique, add 15 ml of ACD-A to the collection bag after the first 150 mL of product has been collected. This is done to prevent clumping.
Plasma Collection during WBC Procedures
Plasma may be collected during a WBC procedure in the automatic mode. Plasma collection will not begin until Quick Start has completed. To enter the desired amount of plasma to be collected, use the Target Plasma key to enter the volume. The plasma will be collected at the rate the Plasma pump has been set to minimize disruption of the interface, however, the
manufacturer recommends collecting the plasma at the end of the procedure as plasma collection may cause temporary interface instability. The Plasma valve will automatically close when the desired amount has been collected. The plasma collection may be started at any time during the procedure. If no plasma is to be collected, close the plasma line of the WBC set before starting prime.
Configuration of MNC End Point
The manufacturer's default end point for MNC procedures is 2.0 X TBV. The endpoint maybe configured to: Specific run time, Specific volume of blood (inlet volume) to process, multiple of the donor/patient total blood volume. See COBE ©Spectra Apheresis System
Operator' s Manual (TerumoBCT) for guidance in setting these endpoints though the operator interface screen.
Pausing and Restarting the Procedure
If the procedure is paused, the centrifuge may not spin longer than 10 minutes. Allow the centrifuge to automatically stop after 10 minutes. While in Pause, if the centrifuge is allowed to continue to spin, there is potential for hemolysis to the cells. The centrifuge can remain off for a maximum of 60 minutes. If the centrifuge is restarted, drainage of the tubing is required as described below. Opening the normal saline from the draw and return lines drains only
approximately 3 inches of non-anticoagulated tubing between the apheresis kit and the donor connection. Complete drainage of the tubing is also required because there are no filters on the tubing below the return filter therefore, the pumps must be running to move blood sitting below the return filter out of the system. There is 1 mL of blood in every 6 inches of apheresis kit tubing. The operator will determine the amount of drainage required based on possible visible clots seen and whole blood flow rate speed while draining the tubing.
If the centrifuge is off less than 60 minutes and the procedure is able to be restarted, drain the draw and return line tubing as described below.
1. Clamp the donor's IV access.
2. Disconnect donor's draw line and open access NS roller-clamp.
3. Allow fluid to run into MPW bag until no visible clots are seen.
4. Close access NS roller-clamp.
5. Reconnect access tubing to donor's IV access, keeping the draw line clamped.
6. Clamp the return line.
7. Disconnect return line and open return NS roller-clamp.
8. Allow fluid to run into MPW bag until no visible clots are seen.
9. Close return NS roller-clamp.
10. Open draw line NS roller-clamp
11. Keeping return line over MPW box, restart procedure and allow fluid to drain until no visible clots are seen. (Rationale: The NS will serve as donor access fluid. The movement of the machine pumps will push the fluid below the return filter line out of the system for drainage. This will ensure that all possible clots are removed from the system.)
12. Close access NS roller-clamp.
13. Reconnect the donor return tubing and unclamp.
14. Unclamp donor's draw line.
15. Continue procedure. (Note: NS that was used as the donor access fluid during flushing may dilute the apheresis circuit. It may take a few more minutes to set the interface.)
If the centrifuge is off for greater than 60 minutes, drain the draw and return line tubing as described in Section above and then proceed below.
1. Begin Rinseback following manufacturer' s guidelines.
2. Remove the product from the apheresis set and add anticoagulant if indicated.
3. When Rinseback is complete, disconnect the donor from the apheresis kit.
4. If the procedure is to be restarted, keep venous access open with normal saline and set up and prime a new apheresis kit.
Ending the Procedure
The Run mode continues until the target end results are reached. To end the Run, press l=Rinseback and follow the prompts on the operator interface screen. If a red cell prime is used, DO NOT infuse the rinseback. To continue the Run, press 2=Continue run and increase the flashing target limits as directed on the operator interface screen. When a Functionally Closed WBC disposable set is in use and the inlet flow is >50 mL\min, change the inlet flow to 50 niLVmin to avoid ACCESS PRESSURE LOW alarms during Rinseback. Change the flow rate before starting Rinseback.
Disconnect the patient line from the patients' access using Nursing SOP / PRO: Venous
Access Devices, Care and Maintenance of Central or remove the antecubital IVs, apply direct pressure until bleeding has stopped then apply a pressure dressing. Repeat and document vital signs, including temperature, blood pressure and pulse in procedures where 5L or greater of volume is processed or as indicated. Record Final values from the operator interface screen on the
Apheresis Procedure Record. Complete the product label if the collection will be used for transfusion. Remove the procedural kit in the reverse order used to set it up. Dispose of all blood contaminated waste in the MPW container. Clean any spills.
Calculation of Net Fluid Balance
Subtract the fluid removed from the fluid infused.
Fluids IN: Rinseback + Prime (optional) + Calcium infusion (optional) + Magnesium infusion (optional) + Fluid Bolus + AC
Fluids OUT: Product Removed (cells + plasma) + pre-apheresis tube samples Appendix
1. Using the 600 mL transfer bag, sterile connect the needle adapter (from the Plasma transfer set with spike) to replace the spike adapter attached to the transfer bag
2. Verify that the patient's Typenex bracelet is in place. Verify that the patient's inpatient ID bracelet is in place or that patient has a outpatient ID card
3. Obtain patient's pre -procedure vital signs.
4. Pre-medicate if ordered by physician.
5. Establish IV access
6. Draw pre-lab samples if ordered.
7. Prime IV NS lines with 4-way stop-cock and extension tubing and attach to IV Access and Return lines
8. Administer NS at KVO infusion rate via Alaris pump to both lumens of CVAD or peripheral access
9. Prime the Spectra with 0.9 % Normal Saline following manufacturer's guidelines.
10. Attach a 3-way stop-cock to end of return and access line of Spectra tubing and prime. 11. Perform the alarm tests following manufacturer's guidelines.
12. Enter the patient/procedure data as prompted on the operator screen (gender, height, weight, and patient' s hematocrit)
13. Press YES to accept the target end results or NO to change the target end results (Inlet Volume, Inlet pump flow rate, Run time or Collect volume) as ordered by the DTM physician and continue with "Connecting the Patient". See the COBE® Spectra Apheresis System Cell Therapy Guide to change patient/procedure data.
14. Obtain PRBC unit from Transfusion Services Laboratory (TSL)
15. Perform blood administration clerical checks on all units to be infused per NIH CC
SOP: Blood Product Administration . In addition, visually compare the Typenex Barcode number
on blood component tag with the number embossed on the Typenex barcode band; visually compare ABO compatibility on unit; visually inspect expiration date has not exceeded on unit; visually inspect the interpretation of crossmatch is performed on unit; visually inspect appearance of unit to ensure they appear normal; and after the clerical checks are complete, the unit must be secured and may not leave the bedside.
16. Prime Blood Product IV Administration Set with Saline
17. When prompted by Spectra to Connect Access and Return Lines, Connect Blood Product IV Administration Set to Spectra Access Line via 3-way stop-cock
18. Attach Spectra return line to empty transfer bag via 3-way stopcock
19. Close roller clamps on Spectra access and return saline lines.
20. Open pinch clamps on the Spectra access and return lines.
21. Open roller clamp on the Blood Product IV Administration Set. Spectra Saline drip not necessary during blood prime as patient is not connected at this time.
22. Launch CareFusion Verification Application (Not Rapid Infusion)
23. Log in using valid User ID and Password
24. Scan patient ID and request patient to state first/last name and DOB to confirm identity. Scan product's donation ID number (upper left corner of the product's labeling system). Scan product Code (lower left corner of the product's labeling system).
25. Select the type of administration set to be used (gravity, infusion pump, apheresis) 26. Record vital signs (temperature, pulse, respirations, blood pressure)
27. Enter desired initial infusion rate. Per WBFR guidance on Pediatric Large- Volume Leukapheresis Worksheet, use the following calculation to enter Carefusion documentation of ml/hr. WBFR = 0; Note: Start of collection rate = 0 as transfusion is not yet running.
28. Complete the pre-transfusion checklist
29. Utilizing the unused spike, spike Blood Product IV Administration Set with PRBC
30. Press continue on Spectra machine. The Spectra draws blood from the PRBC unit into the extracorporeal circuit. The following information will display on the Spectra screen: Diverting Prime Saline.
a. To decrease processing time for the PRBC unit, increase AC ratio to 50: 1. This will increase your inlet flow rate.
31. Post Spectra Saline Prime Divert and Valve Position Check, Spectra display screen will advise to close return saline and press clear.
32. Continue to process the PRBC Unit. If PRBC undiluted, process entire unit. If PRBC diluted, process 300 mL to 500 mL. As volume processed increases, effects of dilution decreases
33. Continue performing the blood prime (in the run mode) until the leukoreduced PRBC unit begin entering the transfer pack from the return line and the inlet and return lines are approximately the same color.
34. When PRBC unit processed, Press pause on Spectra machine
35. Close pinch clamps to access and return lines
36. Using aseptic technique, disconnect PRBC Unit, transfer bag and 3-way stop-cocks from Spectra access and return lines. Cap the access and return lines with female leur adapter for safety and aseptic environment maintenance.
37. Record all values from the Spectra machine
38. Add inlet processed during blood prime to the target inlet volume
39. If the AC ratio was increased, change it back to desired AC ratio
40. In Data Entry, Change HCT back to patients HCT
41. Administer Heparin Loading Dose per order via bolus Γ push into return line.
42. Flush with approximately 10 mL NS from KVO - NS bag
43. Connect Spectra access and return lines to patient
44. Open pinch clamps on Spectra access and return lines
45. Press CONTINUE on Spectra machine
46. Begin the transfusion as soon as you receive a "Match confirmation" message
47. Select close
48. If calcium chloride and magnesium sulfate intravenous replacement solutions are ordered, attach medications to available 4-way stopcocks to return line and follow DTM SOP: 2401 Prophylactic Calcium Infusion and DTM SOP: 2402 Prophylactic Magnesium Sulfate Infusion for set up and dosing and per Pediatric Large- Volume Leukapheresis Worksheet orders.
49. (If applicable) After initial 15 minutes: Launch CareFusion Transfusion Verification application
50. Log in using valid User ID and Password
51. Scan patient ID
52. Click on the individual order of the transfusing product (showing blue) to show the transfusion activities hyperlink
53. Click transfusion activities
54. Select vitals menu and add, and enter vital signs as prompted
55. Enter new infusion rate: WBFR x 60 = mL/hr
56. Select close
57. When the Inlet Volume processed has doubled from the prime volume processed, COMPLETE the transfusion via Carefusion.
58. Launch TV application and login using valid User ID and Password
59. Scan patient ID
60. Select transfusing blood component (showing blue) to show transfusion activities
61. Click transfusion activities
62. Click on Complete button
63. Record vital signs as prompted
64. Enter ending infusion rate as ("0")
65. Enter total volume PRBC infused
66. Select close
67. Exit Carefusion system
68. Continue processing MNC procedure
Upon attempt to transfuse a red cell unit, the Carefusion system will issue an alert if the red cell units are not started within 30 minutes of issue. Select override reason, "Other / DTM
Physician Authorized" and proceed. Upon attempt to complete a red cell unit, the Carefusion system will issue an alert if the red cell unit is not completed within 4 hours of issue. If this time has been exceeded, you must stop the transfusion and seek DTM Physician approval to continue the transfusion. If approval via DTM Physician given, select override reason, "Other / DTM Physician Authorized" and proceed.
Carefusion: Stopping / Re-starting a Transfusion
For interruption of transfusion
1. Launch TV application and login as usual
2. Scan patient ID
3. Select transfusing blood component (showing blue)
4. Select STOP and document rationale
5. Select close
6. If and when ready to restart, launch TV as usual
7. Scan product donation ID number and Product code
8. Enter vital signs
9. Enter infusion rate
10. Select close
4. Mononuclear Cell (MNC) and Peripheral Blood Stem Cell (PBSC) Collection on the COBE® Spectra
When MNC is selected on the COBE® Spectra Apheresis System, the program will set up with a specific separation factor that is a measure of the centrifugal force to which the blood is exposed. Terumo BCT recommends a MNC separation factor of 500 g-minutes for MNC collection. This is the product of the centrifugal force and the length of time a blood element entering the channels is subjected to this force.
WBC Disposable Tubing Set Fluid Volumes are as in the section above.
Preparation of the COBE® Spectra Apheresis System.
1. Power the machine on.
2. Ensure that single-stage filler is in the centrifuge.
3. Tube the Spectra following manufacturer's guidelines (See the COBE® Spectra Apheresis Cell Therapy Guide).
4. When the Set Selection screen appears on the operator interface screen, select 3=WBC. The WBC procedure section screen will then appear, select 1=MNC.
5. Prime the Spectra with 0.9% Saline following manufacturer's guidelines.
6. Optional: Attach a 4-way stop-cock to end of draw line of Spectra tubing and prime. This step is at the nurses discretion for lab draws and line flushes, as needed.
7. Perform the alarm tests following manufacturer's guidelines.
8. Enter the patient/procedure data as prompted on the operator screen (gender, height, weight, patient's hematocrit).
9. Press "YES" to accept the target end results or "NO" to change the target end results (Inlet Volume, Inlet pump flow rate, Run time or Collect volume) as ordered by the physician and continue with "Connecting the Patient". See the COBE® Spectra Apheresis System Cell Therapy Guide to change patient/procedure data.
10. After prime, the procedure is started within 4 hours or the disposable kit is discarded.
Connecting the Patient/Donor
1. Identify the patient/donor following Clinical Center (CC) guidelines (name and date of birth).
2. Check the patient/donor BP, pulse and temperature to ensure they are within the patient's normal limits.
3. Establish venous access per BSS SOP- 2400 Dowling Apheresis Clinic Policies and Procedures
4. Draw specific pre-apheresis lab samples as ordered by the DTM or primary care physician
5. Draw standard pre-apheresis lab samples for transfusable products, per BSS SOP- 2400 Dowling Apheresis Policies and Procedures.
6. Follow the guidelines for "Connecting the Patient" in the COBE® Spectra Cell Therapy
Guide.
Starting the Procedure
1. When prompted by Spectra, press Continue at the prompt for Diverting prime saline. (150 mL of NS be diverted to the waste bag). The prime may be given at the direction of the DTM physician.
2. If calcium replacement is ordered, follow DTM SOP: 2401 Prophylactic Calcium Infusion for set up and dosing of calcium. Attach a 4-way stop-cock to end of return line of Spectra tubing. Attach a Braun Extension Set to the proximal port of the 4-way stopcock (on return line) and prime. Connect the calcium IV line to the medial port of the 4-way stop-cock. Initiate calcium infusion after prime has been diverted.
3. Spectra will prompt: Close return line saline. Press Clear.
4. Monitor and record fluid volumes for the Spectra's operators screen with each change or approximately every 15 - 30 minutes.
Quick Start
Quick Start is as in the section above Interface Control
Interface control is as in the section above. Colorgram™
The WBC Colorgram™ is as in the section above. Collect Pump Flow Rate
The Collect Flow Rate (CFR) is as in the section above, with this modification.
WBC CFR Colorgram™ Colorgram™ Colorgram™
HCT HCT HCT
Unstimulated Unstimulated Stimulated
Donor Donor Donor
Lymphocytes Monocytes
1,000- 0.8-1.0 2-3% 3-4 % 3-4 %
10,000
10,000 -
1.0-1.3 2-3% 3-4 % 3-4 %
25,000
>25,000 1.3-2 2-3% 3-4 % 3-4 %
Configuration of MNC InletrAC Ratio
The device defaults to an Inlet: AC ratio of 12: 1. If the pre-apheresis platelet count is greater than or equal to 250,000/uL, the initial Inlet:AC Ratio should be set at the device default of 12: 1, but should be changed to 13: 1 after the first 2-3 liters are processed. If the pre-apheresis platelet count is less than 250,000, the Inlet:AC ratio should be set at 13: 1 at the start of the procedure.
The default AC infusion rate is 0.8 mL/min/L of TBV. The AC infusion rate may be increased to 1.1 mL/min/L of TBV without operator override. Increases in the AC infusion rate exceeding these manufacturer' s recommendations must have physician approval and prophylactic calcium infusions ordered. See the COBE® Spectra Cell Therapy Guide for guidance though the operator interface screen. See SOP 2401 Prophylactic Calcium Infusion for calcium infusion guidelines.
The presence of cloudy, clumped light colored cells in the collect line and in the line entering the product bag may indicate platelet clumping and the need to decrease the AC ratio. The
intermittent loss of a stable interface during the procedure may indicate platelet clumping and that a clump has pushed through the collect line. This may require a decrease in the AC ratio.
Adding ACD-A to the Product
Post procedure using aseptic technique; add 15 ml of ACDA for every final product collected that contains 150 ml or greater. This is done to prevent clumping. If less than 150 ml product is collected, no ACDA is added to the product.
Plasma Collection during WBC Procedures
Plasma may be collected during a WBC procedure in the automatic mode. Plasma collection will not begin until Quick Start has completed. To enter the desired amount of plasma to be collected, use the Target Plasma key to enter the volume. The plasma will be collected at the rate the Plasma pump has been set to minimize disruption of the interface, however, the
manufacturer recommends collecting the plasma at the end of the procedure as plasma collection may cause temporary interface instability. The Plasma valve will automatically close when the desired amount has been collected. The plasma collection may be started at any time during the procedure.
Configuration of MNC End Point
The default end point for MNC procedures is 2.0 X TBV. The endpoint maybe configured to: specific run time, specific volume of blood (inlet volume) to process, multiple of the donor/patient total blood volume. See the COBE® Spectra Cell Therapy Guide for guidance in setting these endpoints though the operator interface screen.
Pausing and Restarting the Procedure, Ending the Procedure, and Calculation of Net Fluid Balance A blood prime may be done if ordered by the physician or if the system's extracorporeal blood volume exceeds 10-15% of the patient's TBV. See "Maintaining Hemodynamic Stability in Pediatric Apheresis Patients" in the COBE® Spectra Apheresis System Essentials Guide and see BSS SOP 2425 Pediatric Apheresis in Subjects less than 20 kg: MNC/PBSC on Spectra 5. Prophylactic Calcium Infusion during Large- Volume Apheresis
To avoid serious citrate toxicity while maintaining efficient whole blood processing rates, patients/donors who are scheduled for large volume leukapheresis procedures involving citrate
infusion rates of greater than 1.2 mg/kg/min should receive prophylactic calcium infusions.
Prophylactic infusion refers to administration of calcium at the beginning of apheresis, to prevent subsequent development of symptoms during the procedure. Prophylactic calcium infusions may also be administered during red blood cell exchanges and therapeutic plasma exchanges.
In general, donors/patients at risk for citrate toxicity include: donors/patients who have had a recent prior apheresis procedure as progressive depletion of calcium and albumin stores may occur; donors/patients with lighter body mass who are exposed to higher citrate infusion rates per kg of body weight; donors/patients who experience early onset of mild symptoms as mild symptoms are strongly predictive of the subsequent occurrence of more serious symptoms;
donors/patients who are unable to promptly and clearly describe the onset, nature and severity of their symptoms to the apheresis operator ( poor communication occurs when donors are not fluent in the language of the apheresis operator or do not communicate their symptoms due to personal or cultural reluctance); and women, due to lower body calcium stores, lower body weight, and smaller blood volumes than men.
Calcium infusions should not be administered to patients with known renal impairment unless they become symptomatic. Ceftriaxone and calcium solutions must not be administered simultaneously due to risk of ceftriaxone-calcium precipitation. Ceftriaxone should not be administered during an apheresis procedure.
Calcium Infusion Rate Calculation
The rate of calcium administration is based on the rate of ACD-A administration or replacement fluid administration (red cell or plasma exchange). The ACD-A rate is, in turn, related to the WBFR and the type of procedure being performed. Therefore, calcium infusions maybe be adjusted according to either the ACD-A flow rate or the WBFR.
IV calcium infusion rates are dosed to administer 0.6 calcium ion per 1 mL ACD-A. The initial dose of calcium may be increased by 10 to 15% in donors at high risk for citrate toxicity, and in all donors undergoing apheresis procedures at citrate infusion rates greater than 2.0 mg/kg/min. The maximum dose of calcium administration is set by the Alaris system, and will vary according to the weight of the donor. Changes in WBFR during the procedure are accompanied by changes in the calcium infusion rate.
Fenwal Amicus: The formula below starts with a WBFR that is measured in mL/min, and converts it to a calcium solution infusion rate that is measured in mL/hr.
[WBFR/(AC Ratio+1) X 18] = Calcium solution flow rate
For example, if the AC ratio is 12, then (AC ratio + 1) = 13, and the WBFR is multiplied by 18/13 = 1.38. So, for a WBFR of 70, and AC ratio of 12, the CaCl solution would be set for 70/13 x 18 (or 70 x 1.38) = 97 ml/hour.
COBE Spectra™: The Spectra is configured such that the ACD-A flow rate can be read directly from instrument's digital display panel. In addition to LVL, the Spectra may be used to perform plasma exchange and red cell exchange. The formulas below start with an ACD-A infusion rate that is measured in mL/min, and converts it to a calcium infusion rate that is measured in mL/hr.
Leukapheresis using the COBE Spectra™: For LVL collection with a 12: 1 WB:AC ratio, to achieve a calcium infusion rate of 0.6 mg Ca++/mL of ACD-A, the rate of Calcium 2 mg/mL solution is 18 times the ACD-A infusion rate.
(18) x (ACD-A flow rate in mL/min) = calcium IV rate (in mL/hr)
Plasma or Red Cell Exchange using the COBE Spectra™: These procedures may cause citrate-related symptoms due to infusion of replacement fluids containing citrate (plasma and red cells) or decreased levels of calcium (albumin). The dose of calcium replacement is further modified because a large part of the administered ACD-A is removed with the waste product. The rate of citrate administered to the patient depends on the rate of replacement fluid administration. Therefore, calcium replacement is based on the WBFR (as for the Amicus). Thawed Plasma: (1.7) x (whole blood flow rate in mL/min) = calcium solution IV rate (in mL/hr). Albumin/Saline replacement: (1.4) x (whole blood flow rate in mL/min) = calcium solution IV rate (in mL/hr). Red cell exchange: (1.1) x (whole blood flow rate in mL/min) = calcium solution Γ rate (in mL/hr). In general, maximum allowable administration of calcium solution will not exceed: 1.8 times the WBFR on the Amicus or 25 times the AC infusion rate on Spectra. Alaris Medley II Infusion Pump Set-Up
Obtain the correct medication for the correct patient from the refrigerator in Dowling designated for the storage of medications. Verify the expiration date. Verify the patient/donor ID following CC policies. Verify the medication against the physician order. Using aseptic technique, spike the IV calcium infusion bag with Alaris Medley/Gemini Infusion Set. Prime the tubing with IV fluid. Place the primed tubing in Pump Module following manufacturer's guidelines.
Alaris Medley II Infusion Pump Programming
Turn the Alaris Programming Module on by pressing Systems On. First Screen: Is this a new patient? Enter: Yes. Second Screen: Dept of Transfusion Med? Press: Yes. Third Screen: Select: Channel Select on Pump Module A or B Fourth Screen: Select: Guardrails Drug Library. Fifth Screen: Select: DTM calcium ion CL (544 mg/270 mL) or DTM calcium ion GLUC (588 mg/280 mL). Sixth Screen: Confirm by pressing: Yes. Seventh Screen: Enter the patient weight in kilograms. Press Next. Eighth Screen: Enter the Rate of calcium infusion in mL/hr (calculated from the WBFR or ACD-A infusion rate). Calcium infusion rates must be rounded to the nearest whole number (round up when the decimal is 0.5 or greater). Do not use decimal places. Enter the VTBI (volume to be infused). The Dose will be calculated and displayed on the LCD read-out on the front of the pump module. Press Start. Do not enter more than 280 mL. Do not hang more than one bag of calcium solution at a time. For further details regarding Alaris pump operation, see manufacturer's manual. Connecting the Infusion Set to the Apheresis Tubing Kit
Strict aseptic technique must be used in connecting the Γ pump tubing to the apheresis tubing kit.
Fenwal Amicus: Attach a 4 way stopcock to the end of the return line of the apheresis Attach the calcium solution IV tubing to the medial port of a 4 way stopcock. Divert the prime saline into the a waste bag (volume - 150 mL). Start the calcium solution IV drip at the end of the diversion of the saline prime (as the blood begins to return to the patient).
COBE Spectra™: Attach a 4 way stopcock to the end of the return line of the apheresis kit. Attach the calcium solution IV tubing to the medial port of a 4 way stopcock. The Spectra automatically diverts the prime to a waste bag unless the operator changes the default setting. Start the calcium solution IV drip at the end of the diversion of the saline prime (as the blood begins to return to the patient).
Calcium Infusion
Calcium infusions of 2 mg/mL are used. Calcium infusions are given via an Alaris Medley II IV pump. Calcium infusions are monitored continuously during the apheresis procedure. Rates of calcium infusion are recorded on the Apheresis Procedure Record (BSS form 2400) at 30 minute intervals or at the time of adjustments in WBFR or IV solution flow rate. At any cessation of blood flow, including PAUSE immediately PAUSE the calcium infusion. Failure to do so may cause clotting in the return line.
Discontinuation of Calcium Infusion
For the COBE Spectra™ discontinue the calcium infusion just before initiating Rinseback For the Fenwal Amicus, discontinue the calcium infusion at the end of the procedure prior to Rinseback.
Hypocalcemia, Citrate Induced, during Calcium Infusion
Both the duration of the apheresis procedure and the citrate infusion rate contribute to the risk of citrate toxicity. Mild symptoms, such as circumoral tingling, may occur even at relatively low citrate infusion rates of 1.2 mg/kg/min. These can be treated by methods known in the art.
C. Umbilical Cord
Blood is retrieved from the umbilical cord following birth. HSCs can be isolated from this blood sample, for example using CD34 and/or CD 133 antibodies as described herein.
D. Isolation Methods
Once cells are obtained from the BM, blood or umbilical cord, the HSCs in the sample can be optionally isolated or purified. Any methods of separating or isolating the HSCs from such samples can be used. Negative and positive selection methods can be used. Negative selection methods take advantage of cell surface markers which are not expressed on HSCs. Positive selection methods take advantage of cell surface markers, such as CD34 and CD133, which are expressed on HSCs.
In one example, methods are used that deplete non-HSCs from the sample, thereby permitting enrichment of the HSCs (that is, negative selection). For example, methods that substantially reduce the number of B cells, T cells, Natural Killer cells, dendritic cells, monocytes, granulocytes, and/or red blood cells can be used. In one example, labeled antibodies specific for the undesired cells can be incubated with the sample, allowing the labeled antibodies to bind to the undesired cells. Separation methods can then be used to remove those cells from the sample. For example, if the antibody label (such as biotin) is mixed with ferromagnetic particles coated with streptavidin, then passing the mixture through columns in the presence of a magnetic field can be used to remove the undesired cells. Thus, after incubation with the labeled antibodies, the sample is applied to the column, such that undesired cells bind to the column, while the HSCs pass through the column and can be collected. In some examples, the label is a fluorophore and flow cytometry can be used to remove the cells.
In addition, commercially available kits can be used to deplete non-HSCs from the sample, such as those from Miltenyi Biotec (San Diego, CA) and StemCell Technologies (Vancouver, Canada). For example, if mouse samples are used, the mouse lineage depletion kit (Miltenyi Biotec catalog number 130-090-858) or the EasyStep™ Mouse Hematopoietic Cell Isolation Kit
(StemCell Technologies catalog # 19856) can be used. The kit eliminates most
B/T/monocytes/Neutrophils/red cells using a cocktail of biotinylated antibodies followed by magnetic bead selection. The BM cells are magnetically labeled with a cocktail of biotinylated antibodies against a panel of lineage antigens (CD 5, CD45R (B220), CDl lb, Gr-1 (Ly-6G/C), 7-4, and Ter- 119) and Anti-Biotin MicroBeads. The labeling procedure leaves lineage-negative cells (e.g., HSCs) untouched, allowing further magnetic separation of lineage-negative cells according to expression of markers such as CD 117 or Sca- 1. For example, if human BM is used, the human lineage depletion kit (Miltenyi Biotec catalog number 130-092-211) can be used. Cells are labeled with a cocktail of biotin-conjugated antibodies against lineage- specific antigens (CD2, CD3, CDl lb, CD14, CD15, CD16, CD19, CD56, CD123, and CD235a (Glycophorin A)). These cells are subsequently magnetically labeled with anti-biotin beads. Lineage-negative stem and progenitor cells are obtained by depletion of the magnetically labeled cells.
In one example, methods are used that recover HSCs from the sample, thereby permitting enrichment of the HSCs (positive selection). In one example, labeled antibodies specific for HSCs can be incubated with the sample, allowing the labeled antibodies to bind to the HSCs, and subsequent recovery of the labeled HSCs. In one example, the sample is exposed or incubated with labeled CD34 or CD133 antibodies, thereby labeling the HSCs. The labeled HSCs can then be recovered, for example using flow cytometry (e.g., if the label is a fluorophore) or by use of a column (e.g., if the label is a magnetic label, such as magnetic beads containing CD34 and/or CD 133). In some examples, CD 133+ cells can be isolated from the sample by positive selection with anti-CD 133 and magnetic microparticles. In some examples, CD34+ cells can be isolated from the sample by positive selection with anti-CD34 and magnetic microparticles. In some examples, the antibodies are labeled with biotin, and the HSCs subsequently magnetically labeled with anti-biotin beads, thereby allowing selection of the magnetically labeled HSCs. Commercially available kits can be used to recover HSCs from the sample, such as those from Miltenyi Biotec (San Diego, CA). In some examples, the CD34 MicroBead Kit is used (e.g., Miltenyi Biotec catalog numbers 130-100-453 or 130-046-702) is used. In some examples, the human CD 133 MicroBead Kit is used (e.g., Miltenyi Biotec catalog number 130-050-801) is used.
The resulting HSCs can be used immediately to generate CXCR4 knock down HSCs, or frozen for future use (for example frozen in growth media containing DMSO).
E. Culturing HSCs
Isolated HSCs can be cultured ex vivo, for example to expand the HSC population prior to knocking down CXCR4 expression (and in some examples additional genetic manipulations). In some examples the HSCs are grown in Iscove' s modified Dulbecco' s Medium (IMDM), or RPMI- 1640, plus animal or human serum, or in serum free media designed for HSC culture such as mTesSR 1 medium (Stem Cell Technologies, catalog number 05850), DMEM:F12 (Lonza catalog number 12-719F, Walkersville, MD) supplemented with 20% serum replacement (Invitrogen, catalog number 10828-028) and in some examples also with cytokines, amino acids, and other growth supplements.
In some examples the grown medium includes one or more of stem cell factor (SCF), thrombopoietin (TPO), and FMS-like tyrosine kinase 3 ligand (Flt-3L). In one example the HSCs are grown in HPGM™ hematopoietic progenitor growth medium from Lonza (, Walkersville, MD catalog PT-3926), Stemline® II Hematopoietic Stem Cell Expansion Medium (Sigma-Aldrich, catalog # S0192, St. Louis, MO) for mouse cells or Stemline® Hematopoietic Stem Cell Expansion Medium (Sigma-Aldrich, catalog # SO 189) for human cells. II. Decreasing CXCR4 Expression and/or Activity in HSC and other Genetic
Manipulation
Any method that reduces CXCR4 signaling can be used to confer a selective advantage to donor HSCs relative to wild type recipient HSCs for engraftment in bone marrow. HSCs obtained from a donor can be manipulated to downregulate CXCR4. In some examples, such manipulation is done at the nucleic acid level, for example by mutating the genome (e.g., genetically inactivating one of the two CXCR4 alleles in the HSC), by mutating CXCR4 mRNA or cDNA (e.g., by using an RNAi molecule), or by interfering with the function of a produced CXCR4 protein (e.g. , by using a CXCR4 protein specific-binding agent). Thus, exemplary CXCR4 editing methods target the CXCR4 sequences shown in GenBank Accession No. NG_011587.1, AJ224869.1, NM_009911.3 or BC098322.1 (sequence available on July 18, 2014). In some examples, manipulating CXCR4 at the nucleic acid level in an HSC allows the HSC progeny to retain the manipulated (e.g., downregulated) CXCR4. Thus, in certain examples the disclosed methods include introducing an appropriate nucleic acid molecule (such as a marker designed to disrupt the gene) into an HSC that downregulates CXCR4 expression and/or activity.
In some examples, in addition to decreasing CXCR4 expression or activity in the HSCs, one or more other genes are manipulated, such as correction of a genetic mutation that results in disease, or increasing or decreasing expression of a target gene to treat a disease. The methods described herein for CXCR4 can be similarly used to manipulate any gene of interest, for example to upregulate the target, downregulate the target, or fix genetic mutations (e.g., point mutations, gene rearrangements, and the like). In some examples, manipulations to CXCR4 are made at the same time as a manipulation is made to another target gene (e.g., those in Table 1). In other examples, manipulations to CXCR4 are made before or after making a manipulation to another target gene (e.g., those in Table 1). Thus, in certain examples the disclosed methods include introducing an appropriate nucleic acid molecule (such as a vector encoding a transcription factor) into an HSC that upregulates or downregulates expression and/or activity of a target gene, or that corrects a genetic defect in a target gene associated with disease.
Although not necessary, detectable markers or selection markers can be introduced into the genome, to help permit the identification of cells with the desired target mutation. For example, such markers can be introduced into an allele of the target gene to be downregulated (e.g.,
CXCR4), such that the gene will be interrupted and nonfunctional and the markers help permit the identification of cells with the desired target mutation. In some examples introduced selection markers can be removed later (e.g., see Ye et al., Proc Natl Acad Sci U S A. l l l(26):9591-6, 2014). A. Gene/Genome Editing
Gene editing methods can be used to manipulate expression of CXCR4, for example in combination with altering a gene associated with disease, in HSCs. For example, gene editing can be used to reduce or silence gene expression, enhance gene expression or change specific genes, for example by correcting a gene carrying a harmful mutation (e.g., see those in Table 1). Such methods enable a specific area of a genome to be modified, thereby increasing the precision of the correction or insertion. Genome editing is based on the use of engineered nucleases composed of sequence-specific DNA-binding domains fused to a non-specific DNA cleavage module. These chimeric nucleases enable efficient and precise genetic modifications by inducing targeted DNA double-strand breaks (DSBs) that stimulate the cellular DNA repair mechanisms, including error- prone non-homologous end joining (NHEJ) and homology-directed repair (HDR). NHEJ is an error-prone process that is often accompanied by insertion or deletion of nucleotides (indels) at the targeted site, resulting in a genetic knockout of the targeted region of the genome due to frameshift mutations or the insertion of a premature stop codon. HDR relies on template DNA containing sequences homologous to the targeted site to repair the double stranded break.
Examples of such methods include multiplex automated genomic engineering (MAGE), zinc finger nuclease based engineering, transcription activator-like effector nucleases (TALENs), and clustered regularly interspaced short palindromic repeat (CRISPR). Prior to the discovery of CRISPR RNA-guided nucleases, most methods for genome editing involved protein engineering of zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), or homing meganucleases. CRISPR RNA-guided nucleases rely on simple Watson-Crick base pairing rules that abrogate the need for protein engineering.
(i) Zinc finger nucleases (ZFNs) and TALENs
Zinc-finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs) are chimeric nucleases composed of programmable, sequence- specific DNA-binding modules linked to a nonspecific DNA cleavage domain (such as Fokl nuclease). ZFNs and TALENs enable a broad range of genetic modifications by inducing DNA double- strand breaks that stimulate error- prone nonhomologous end joining or homology-directed repair at specific genomic locations (for review see Gaj et al., Trends Biotechnol. 31:397-405, 2013, herein incorporated by reference). Zinc-finger proteins and TALEs can be fused to enzymatic domains, such as site-specific nucleases, recombinases and transposases, that catalyze DNA integration, excision, and inversion. Because these enzymes can perform DNA cleavage and re-ligation autonomously, potentially toxic DNA double-strand breaks should not accumulate in the genome. Additionally, for applications that require targeted gene addition, recombinase and transposase activity is marked by the insertion of donor DNA into the genome, thereby enabling off-target effects to be monitored directly. Thus, zinc finger nuclease based engineering methods can edit a target sequence (such as CXCR4) by using zinc-finger nucleases to edit a target gene. Similarly, the TALEN method can be used to edit a target sequence (such as CXCR4) by using transcription activator-like effector nucleases to edit a target gene.
In some examples, a wild-type Fokl cleavage domain is used, but Fokl cleavage domain variants with mutations designed to improve cleavage specificity and/or cleavage activity can also be used (e.g., see Bitinaite et al. (1998) Proc. Natl. Acad. Set USA 95: 10570-5 and U.S. Published Patent Application No. 20110027235).
In zinc finger nuclease based engineering, a ZFN is used to cut genomic DNA at a desired location. Two ZFNs are used, with each containing two functional domains. The first is a DNA- binding domain comprised of a chain of at least two (such as 2, 3, 4, 5 or 6) zinc finger modules, each recognizing a unique hexamer (6 bp) sequence of DNA (such as a 6 bp sequence of CXCR4). Two-finger modules are stitched together to form a Zinc Finger Protein, each with specificity of > 24 bp. The second is a DNA-cleaving domain that includes a Fokl endonuclease (such as the
catalytic domain). When the DNA-binding and DNA-cleaving domains are fused together, a highly- specific pair of 'genomic scissors' are created. This permits editing of the HSC genome, for example downregulation of CXCR4. For example, following introduction of the two ZFNs into an HSC (e.g., using transfection, electroporation, or viral delivery), the ZFN pair recognizes and heterodimerizes around the target site (e.g., a CXCR4 allele). The ZFN pair makes a double strand break and then dissociates from the target DNA. If a corresponding repair template is co- transfected with the ZFN pair, this will result in repair of the target gene (e.g., repair a deletion, insertion, substitution, or other genetic alteration) by homologous recombination. Thus, the repair template can be designed to repair a mutated gene or upregulate gene expression or activity. If no corresponding repair template is co-transfected with the ZFN pair, this will result in disruption of the target gene (e.g., downregulation due to mutations introduced by nonhomologus end joining). Thus, such a method can be use to disrupt CXCR4.
Several approaches can be used to design specific zinc finger nucleases for the target sequence(s), such as CXCR4 or a gene listed in Table 1 (or other gene associated with the disorders provided herein). The most widespread involves combining zinc-finger units with known specificities (modular assembly). Various selection techniques, using bacteria, yeast or mammal cells have been developed to identify the combinations that offer the best specificity and the best cell tolerance. A zinc finger DNA binding domain is a protein domain that binds DNA in a sequence-specific manner through one or more zinc fingers, which are regions of amino acid sequence within the binding domain whose structure is stabilized through coordination of a zinc ion. Zinc finger binding domains, for example the recognition helix of a zinc finger, can be "engineered" to bind to a predetermined nucleotide sequence (e.g. , engineer it to bind to CXCR4 or other target). Rational criteria for design of zinc finger binding domains include application of substitution rules and computerized algorithms for processing information in a database storing information of existing ZFN pair designs and binding data, see for example U.S. Patent No.
5,789,538; U.S. Patent No. 5,925,523; U.S. Patent No. 6,007,988; U.S. Patent No. 6,013,453; U.S. Patent No. 6, 140,081 ; U.S. Patent No.6,200,759; U.S. Patent No. 6,453,242; and U.S. Patent No. 6,534,261 ; and PCT Publication Nos. WO 95/19431 ; WO 96/06166; WO 98/53057; WO
98/53058; WO 98/53059; WO 98/53060; WO 98/54311 ; WO 00/27878; WO 01/60970; WO 01/88197; WO 02/016536; WO 02/099084 and WO 03/016496.
In addition, commercially available kits can be used to design and develop vectors that include ZFNs specific for a target (e.g., CompoZR® targeted integration kits from Sigma- Aldrich).
In some examples, two different sets (pairs) of ZFNs are used, such that one set is specific for downregulating CXCR4, while the other set is specific for another genetic mutation that is to be
corrected in the HSC (such as one listed in Table 1). One skilled in the art will appreciate that more than two different sets of ZFNs can be used (e.g., at least 2, at least 3, at least 4, or at least 5 different sets, such as 2, 3, 4, 5, 6, 7, 8, 9, or 10 different sets), such that one set is specific for downregulating CXCR4, while another set is specific for a different genetic mutation that is to be corrected in the HSC. Such ZFN sets can be introduced into the HSC simultaneously, or at different times.
Methods for designing TALENs (e.g., see Bogdanove and Voytas, Science.
333(6051): 1843-6, 2011; Cermak et al, Nucleic Acids Res. 39:e82, 2011; Sander et al, Nat Biotechnol. 29(8):697-8, 2011) and performing TALEN-mediated gene targeting in human embryonic stem cells (hESCs) and iPSCs (e.g., see Hockenmeyer et al., Nat Biotechnol 29: 731— 734) are known and can be applied to the present disclosure. Genomic editing with TALENs and ZFNs capitalizes on the cell's ability to undergo homology directed repair (HDR), following an induced and targeted double-stranded DNA break (DSB). During this time a donor DNA template can be provided to the cell to insert new transgene or delete DNA sequences at the site of DSB (e.g., see Cheng et al., Genes Cells. 17(6):431-8, 2012). In addition, commercially available kits can be used to design and develop vectors that include TALENs specific for a target (e.g., Golden Gate TALEN and TAL Effector Kit from Addgene (Cambridge, MA), catalog #1000000024 and Joung Lab REAL Assembly TALEN kit, from Addgene, catalog #1000000017).
In the TALEN method, the TALE DNA binding domains, which can be designed to bind any desired DNA sequence (such as CXCR4 or those genes in Table 1), come from TAL effectors, DNA-binding proteins excreted by certain bacteria that infect plants (Xanthomonas). These are combined with a DNA cleavage domain. The DNA binding domain contains a repeated highly conserved 33-35 amino acid sequence with the exception of the 12th and 13th amino acids. These two locations are highly variable (Repeat Variable Diresidue, RVD) and have specific nucleotide recognition. This relationship between amino acid sequence and DNA recognition has allowed for the engineering of specific DNA binding domains by selecting a combination of repeat segments containing the appropriate RVDs. The non-specific DNA cleavage domain, for example from the end of a Fokl endonuclease, can be used to construct hybrid nucleases. The Fokl domain functions as a dimer, so that using two constructs with unique DNA binding domains for sites in the target genome with proper orientation and spacing allows excellent specificity. Both the number of amino acid residues between the TALE DNA binding domain and the Fokl cleavage domain and the number of bases between the two individual TALEN binding sites can be varied.
TALENs are used in a similar way to design zinc finger nucleases. TALE specificity is determined by two hypervariable amino acids known as the repeat-variable diresidues (RVDs).
Like zinc-fingers, modular TALE repeats are linked together to recognize contiguous DNA sequences. However in contrast to zinc finger proteins, there is no re-engineering of the linkage between repeats necessary to construct long arrays of TALEs with the ability to address single sites in the genome. In one example, TALENs are used to downregulate expression and/or activity of CXCR4 in a donor HSC. In some examples, in addition to downregulating CXCR4 expression in the donor HSC, other genetic defects are corrected using TALENs. For example, Park et al. (PNAS 111 :9253-8, 2014, herein incorporated by reference) describe the use of the TALEN method to correct a defect in a mutated coagulation factor VIII (which can be used to treat hemophilia A). Similar methods can be used to correct other genetic defects (such as those listed in Table 1).
Once the TALEN genes have been assembled they can be inserted into plasmids or other vectors; which are used to transfect the donor HSC where the gene products are expressed and enter the nucleus to access the genome. In one example, TALENs are delivered to the donor HSC as mRNA, which removes the possibility of genomic integration of the TALEN protein-encoding DNA. It can also increase the level of homology directed repair (HDR) and the success of integration during gene editing.
In some examples, two different sets (pairs) of TALENs are used, such that one set is specific for downregulating CXCR4, while the other set is specific for another genetic mutation that is to be corrected in the HSC (such as one listed in Table 1). One skilled in the art will appreciate that more than two different sets of TALENs can be used (e.g. , at least 2, at least 3, at least 4, or at least 5 different sets, such as 2, 3, 4, 5, 6, 7, 8, 9, or 10 different sets), such that one set is specific for downregulating CXCR4, while each other set is specific for a different genetic mutation that is to be corrected in the HSC. Such TALENs sets can be introduced into the HSC simultaneously, or at different times. (ii) Clustered regularly interspaced short palindromic repeat ( CRISPR)
Clustered regularly interspaced short palindromic repeat (CRISPR) RNA-guided adaptive immune systems that protect bacteria and archaea from infection by viruses have been repurposed for genome engineering in a wide variety of cell types and multicellular organisms. CRISPRs are DNA loci containing short repetitions of base sequences. Each repetition is followed by short segments of spacer DNA from previous exposures to a virus. CRISPRs are often associated with Cas genes. By introducing plasmids containing a Cas gene and specifically constructed CRISPRs into eukaryotic cells, the eukaryotic genome can be cut at any desired position. The Cas9 nuclease for targeted genome editing can include fused nuclear localization signals (NLSs) to a codon-
optimized version of the Cas9 gene. This Cas9 sequence can be co-expressed with plasmids expressing the tracrRNA and a crRNA-guide, or a single chimeric guide RNA (gRNA).
The CRISPR/Cas system can be used for gene editing in mammalian cells, for example of donor HSCs (see for example Le Cong et al., Science. 339:819-23, 2013; Mali et al., Science. 339:823-6, 2013; Wilkinson and Wiedenfeft FlOOOPrime Reports 6:3, 2014; Hsu et al, Cell
157: 1262-78, 2014, all herein incorporated by reference). In addition, commercially available kits can be used to design and develop vectors that include CRISPR/Cas9 genome editing materials for manipulating a specific target (e.g., those from Origene, Rockville, MD, from Addgene,
Cambridge, MA, such as the Church Lab CRISPR Plasmids, and from Life Technologies,
Gaithersburg, MD, such as the Gene Art® CRISPR Nuclease Vector Kit). In addition commercial services to engineer specific CRISPR/Cas9 genome editing materials are available from companies such as Genecopoeia, Rockville, MD.
The CRISPR/Cas system includes two components: (1) Cas9 protein (such as a wt or modified Cas9 gene, such as one that is codon optimized and/or mutated for specific nuclease activity), whose expression can be driven by a promoter, such as CMV and (2) single guide RNA (sgRNA) which is operably linked downstream of a target sequence (e.g., CXCR4) and upstream of a promoter (such as the U6 promoter). When introduced into cells (for example as part of a single vector or plasmid or divided into multiple vectors or plasmids), the gRNA guides the Cas9 nuclease to the locus and Cas9 will cut the target site. Cas9 unwinds the DNA duplex and cleaves one or both strands upon recognition of a target, sequence by the gRNA, but only if the correct
protospacer-adjacent motif (PAM) is present at the 3' end. Non-homologous end joining (NHEJ) repair of this cut will result in small insertions and deletions (indels), so the technique can be used to knockout genes. If short, homologous DNA is also included in the transfection, the technique can also be used to insert this DNA into the cut site through HDR. Using this system, DNA sequences within the endogenous genome and their functional outputs are easily edited or modulated, for example in a donor HSC. The sgRNA and Cas9 protein can also be delivered to the target cell in fixed amounts using encapsulation techniques such as gesicles (Clontech).
In some examples, a native or wild-type Cas9 sequence is used. In such examples, double strand (ds) breaks are introduced at sequences homologous to co-expressed gRNA. In another example, a mutated Cas9 sequence is used. In one example, the Cas9 sequence is codon optimized for mammalian or human cells. In one example a mutated "nickase" version of Cas9 is used, which generates a single-strand DNA break, instead of a ds break (for example to knock down CXCR4 expression). In one example a catalytically inactive Cas9 (dCas9) is used to knockdown gene expression by interfering with transcription (for example to knock down CXCR4 expression). The
dCas9 can be fused to an additional repressor peptide if desired, A catalytically inactive Cas9 (dCas9) fused to an activator peptide can activate or increase gene expression (for example to treat a genetic disorder in which upregulation of a target gene is desired).
In some examples, instead of using a Cas9 nuclease, CRISPR RNA-guided Fokl nucleases are used (e.g., for downregulation of CXCR4 and in some examples editing of one or more other target genes) (e.g., see Tsai et al., Nature Biotechnol. 32:569-76, 2014). Dimeric RNA-guided Fokl nucleases (RFNs) can recognize extended sequences and edit endogenous genes with high efficiencies in human cells. RFN cleavage activity depends on the binding of two guide RNAs (gRNAs) to DNA with a defined spacing and orientation. Such a method can be used to express multiple gRNAs bearing any 5' end nucleotide.
In one example, CRISPR is used to downregulate expression of CXCR4 in a donor HSC. In one example, multiple plasmids are used for the gene editing. The Cas9 or modified Cas9 (e.g., nickase) enzyme (or the Fokl nuclease) is provided, for example on one vector or plasmid, and the guide RNA (gRNA) on another plasmid. One or more other plasmids or vectors can supply a sequence for (1) downregulating CXCR4, (2) correction of a mutation using homologous recombination or an oligonucleotide template can be used, (3) downregulation of a target gene, or (4) upregulation of a target gene. Multiple plasmids can be mixed and transfected into HSCs at the same time, for example using Lonza nucleofector technology for the simultaneous transfection of multiple plasmids at this time. But one skilled in the art will appreciate that other methods can be used to introduce these sequences, such as viral transduction using lentiviral, adeno-associated virus (AAV), retrovirus, adenovirus, or alphavirus technology, or by using vesicles preloaded with sgRNA and Cas9 protein. Another method that can be used is to generate induced pluripotent stem cells and then edit them and test them using DNA sequencing to find correctly edited cell clones. Then these cells can be differentiated in vitro into HSC and infused into a recipient subject (e.g., see Suzuki, et al, Mol. Therapy 21(7): 1424-31, 2013).
In other examples, instead of using a plurality of plasmids or vectors, a single vector is used to both supply the Cas9 or modified Cas9 (e.g., nickase) enzyme (or the Fokl nuclease) and the guide RNA (gRNA) with the target sequence. In some examples a plurality of different gRNAs, one for each target, are present on a single plasmid. In one example for plasmid delivery to an HSC, the pCas-Guide vector from Origene can be used. In one example, for example for viral delivery to an HSC, the pLenti-Cas Guide vector from Origene (Rockville, MD) can be used. Thus, the method can include introducing an appropriate sequence. The CRISPR Nuclease OFP Reporter vector from Life Technologies can be similarly used. In some examples, in addition to downregulating CXCR4 expression in the donor HSC, other genes are manipulated, for example
using the pCas-Guide vector or the pLenti-Cas Guide vector from Origene but with an appropriate target sequence specific for the target gene and the modification desired.
B. Inhibitory RNA (RNAi) Methods
RNAi methods can be used to downregulate expression of CXCR4, for example in combination with altering a gene associated with disease, in HSC cells. For example, RNAi can be used to reduce or silence gene expression of an undesired gene, for example where upregulation of the gene causes or results in disease, or is undesirable (e.g., decreasing expression of CCR5 in a subject with HIV).
An RNAi molecule includes antisense molecules, siRNAs, miRNAs, and ribozymes specific for a target gene whose expression is to be downregulated (such as CXCR4 or CCR5), which reduce or prevent expression of the target, for example by at least 50%, at least 60%, at least 75%, or at least 90%. In some examples, RNAi molecules are at least 12 nt in length, at least 15 nt, or at least 19 nt in length, such as about 19 to 30 or 15 to 200 nucleotides in length, such as at least 21 nucleotides, for example at least 23 nucleotides (for example 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides). Once expressed in a cell, such as an HSC, the RNAi molecule interacts with the target nucleic acid and generates an RNAi response.
Targeted gene knockdown by RNA interference (RNAi) can be used to decrease expression of a target gene, such as CXCR4, in a donor HSC. For example, a single CXCR4 can be mutated by RNAi methods to decrease expression of CXCR4, which thus will decrease CXCR4 activity. In some examples, such methods decrease CXCR4 expression at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% (such as a decrease of 40% to 90%, 40% to 80% or 50% to 95%) as compared to a control (such as a non-recombinant HSC with normal or wild- type CXCR4 expression). Exemplary CXCR4 RNAi molecules target a CXCR4 sequence shown in GenBank Accession No. NG_011587.1, AJ224869.1, NM_009911.3 or BC098322.1. Examples of RNAis that can be used to interrupt or alter translation of a target nucleic acid molecule (such as CXCR4) include, but are not limited to, antisense RNA, miRNA, ribozymes, antisense molecules, or an siRNA, that bind specifically to the target nucleic acid molecule (such as CXCR4).
Methods of generating RNAi molecules, and introducing them into a cell, are known in the art. For example, nucleic acid molecules (such as a vector containing the RNAi molecule) can be introduced into HSCs by a variety of methods known to those of skill in the art, such as by transfection or transformation (e.g., by encapsulation in liposomes, by iontophoresis, by
incorporation into viruses or vectors which are introduced into the cell, or by incorporation into other delivery vehicles, such as hydrogels, cyclodextrins, biodegradable nanocapsules, and bioadhesive microspheres.). In some examples, RNAi molecules are expressed within an HSC from a eukaryotic promoter. In some examples, the RNAi molecules are administered directly to a subject, for example by injection (i.v., i.p., i.m.), topical administration, oral administration, by inhalation; or other routes.
In certain examples, expression vectors are used to express the RNAi molecule in an HSC. For example, an expression vector can include a nucleic acid sequence encoding at least one RNAi molecule that recognizes a target nucleic acid molecule (such as CXCR4 or CCR5). In a particular example, the vector contains a sequence encoding both strands of an RNAi molecule comprising a duplex. In another example, the vector also contains a sequence encoding a single nucleic acid molecule that is self-complementary and thus forms an RNAi molecule. Non-limiting examples of such expression vectors are described in Paul et al., Nature Biotech. 19:505, 2002; Miyagishi and Taira, Nature Biotech. 19:497, 2002.
In other examples, RNAi molecules can be expressed from transcription units (see for example, Couture et al., 1996, TIG 12:510) inserted into DNA or RNA vectors. The recombinant vectors can be DNA plasmids or viral vectors. RNAi expressing viral vectors can be constructed based on, for example, but not limited to, adeno-associated virus, retrovirus, adenovirus, lentivirus or alphavirus. In another example, pol III based constructs are used to express RNAi molecules (see for example, U.S. Pat. Nos. 5,902,880 and 6,146,886).
The recombinant vectors capable of expressing the RNAi molecules can be delivered as described above, and persist in target cells. Alternatively, viral vectors can be used that provide for transient expression of RNAi molecules.
In one example, an RNAi molecule is an siRNA. siRNAs are double- stranded RNAs that can induce sequence- specific post-transcriptional gene silencing, thereby decreasing or in some examples inhibiting gene expression. In one example, siRNA triggers the specific degradation of homologous RNA molecules, such as mRNAs, within the region of sequence identity between both the siRNA and the target RNA. In some examples, siRNA molecules are about 19-27 nucleotides (nt) in length, such as 20-25 nt, or 20 to 27 nt, for example 19, 20, 21, 22, 23, 24, 25, 26 or 27 nt in length.
One of ordinary skill in the art can readily generate siRNAs which specifically bind to a target nucleic acid sequence, such as CXCR4 or any gene whose expression needs to be decreased (such as CCR5 in an HIV-infected patient). Commercially available kits, such as siRNA synthesizing kits from Qiagen, Origene (Rockville, MD), Life Technologies (Grand Island, NY),
and SuperArray Bioscience Corporation (Hamburg, Germany) can be used to synthesize siRNA molecules. In addition, siRNAs can be obtained from commercial sources, such as from Life Technologies (Grand Island, NY) and GE Dharmacon (Lafayette, CO). Exemplary CXCR4 siRNA molecules target the CXCR4 sequences shown in GenBank Accession No. NG_011587.1,
AJ224869.1, NM_009911.3 or BC098322.1 (sequence available on July 18, 2014).
In one example, an RNAi molecule is an antisense oligonucleotide. Antisense RNA prevents protein translation of a target mRNA by binding to it. Thus, an antisense molecule can hybridize to a portion of a target (such as CXCR4 or CCR5). In some examples, antisense oligonucleotides are at least 19 nucleotides (nt) in length, such as at least 20, at least 30, at least 40, at least 50, at least 75, at least 100, or at least 200 nt in length. The antisense oligonucleotide can be modified at the base moiety, sugar moiety, or phosphate backbone, and can include other appending groups such as peptides, or agents facilitating transport across a cell membrane (e.g., see Letsinger et al, Proc. Natl Acad. Sci. USA 1989, 86:6553-6; Lemaifre et al, Proc. Natl. Acad. Sci. USA 1987, 84:648-52; WO 88/09810), hybridization triggered cleavage agents (Krol et al.,
BioTechniques 1988, 6:958-76) or intercalating agents (Zon, Pharm. Res. 5:539-49, 1988).
Antisense molecules can be synthesized by standard methods, for example by use of an automated DNA synthesizer. In a specific example, an antisense oligonucleotide includes catalytic RNA, or a ribozyme (see WO 90/11364, Sarver et al, Science 247: 1222-5, 1990).
The antisense oligonucleotides can include a sequence complementary to at least a portion of an RNA transcript of target gene, such as CXCR4 or CCR5. However, absolute
complementarity is not required. Exemplary CXCR4 antisense oligonucleotides target the CXCR4 sequences shown in GenBank Accession No. NG_011587.1, AJ224869.1, NM_009911.3 or BC098322.1 (sequence available on July 18, 2014).
In one example, an RNAi molecule is a ribozyme. Ribozymes are enzymatic RNA molecules capable of catalyzing the specific cleavage of RNA. Ribozymes can be synthesized and administered to the subject, or can be encoded on an expression vector, from which the ribozyme is synthesized in the targeted cell (e.g., see WO 9523225, and Beigelman et al., Nucl. Acids Res. 1995, 23:4434-42). Methods of using ribozymes to decrease or inhibit RNA expression are known in the art. For example, specific ribozyme cleavage sites within an RNA target can be identified by scanning the target molecule for ribozyme cleavage sites that include the following sequence: GUA, GUU and GUC. Once identified, short RNA sequences of about 15 ribonucleotides (such as 15 to 30 or 15 to 25 ribonucleotides) corresponding to the region of the target gene containing the cleavage site may be evaluated for predicted structural features, such as secondary structure, that may render the oligonucleotide sequence unsuitable. The suitability of candidate targets can also be
evaluated by testing their accessibility to hybridization with complementary oligonucleotides, using ribonuclease protection assays. An overview of ribozymes and methods of their use is provided in Kashani-Sabet (J. Imvestig. Dermatol Symp. Pwc, 7:76-78, 2002). Methods describing endogenous and exogenous delivery are known (e.g., see Marschall et ah, Cell Mol. Neurobiol 14:523-38, 1994). For example, a plasmid that contains a ribozyme directed against CXCR4, placed behind a promoter, can be transfected into donor HSCs. Expression of this plasmid in the HSC will decrease CXCR4 expression. Exemplary CXCR4 ribozymes target the CXCR4 sequences shown in
GenBank Accession No. NG_011587.1, AJ224869.1, NM_009911.3 or BC098322.1 (sequence available on July 18, 2014), and thus can include one or more sequences complementary to a CXCR4 mRNA and can include the well-known catalytic sequence responsible for mRNA cleavage (see U.S. Pat. No. 5,093,246).
C. Introduction of nucleic acids into the donor HSC
Nucleic acids encoding the necessary elements for the gene editing methods and RNAi methods can be introduced into a donor HSC using routine methods. In one example, such nucleic acids are cloned into a vector or plasmid, which is then used to transfect or transform a cell. In other examples, naked nucleic acid molecules are used.
Following isolation, donor HSCs can be incubated in a culturing medium in a culture apparatus for a period of time or until the cells reach confluency before passing the cells to another culture apparatus. The culturing apparatus can be of any culture apparatus commonly used for culturing cells in vitro. In one example, the level of confluency of the cells is greater than 70% before passing the cells to another culture apparatus. More preferably, the level of confluency of the cells is greater than 90%. A period of time can be any time suitable for the culture of cells in vitro. The culturing medium may be replaced during the culture of the HSCs. HSCs are then harvested from the culture apparatus. The HSCs can be used immediately or they can be cryopreserved and stored for use at a later time. For example the NANEX system (Arteriocyte Inc., Cleveland, OH) can be used to culture and expand HSC from blood and bone marrow.
The HSCs to be transformed or transfected can be grown in culture. Standard culture media typically contains a variety of essential components required for cell viability, including inorganic salts, carbohydrates, hormones, essential amino acids, vitamins, and the like. In some
embodiments, DMEM or F-12 is used as a culture medium. Additional additives can be used, such as glutamine, heparin, sodium bicarbonate and/or N2 supplement (Life Technologies, Gaithersburg, Md.). The pH of the culture medium is typically between 6-8, such as about 7, for example about
7.4. Cells are typically cultured at a temperature between 30-40°C, such as between 35-38°C, such as between 35-37°C, for example at 37°C.
Methods for introducing DNA into HSCs in culture include chemical and physical methods. Chemical methods include liposome-based gene transfer or lipofection, calcium phosphate- mediated gene transfer, DEAE-dextran transfection techniques, and polyethyleneimine (PEI)- mediated delivery. Physical methods include ballistic gene transfer (introduces particles coated with DNA into cells), microinjection, and nucleofection (e.g., from Lonzasuch as the Amaxa biosystem). In some embodiments, nucleofection can be used to introduce the nucleic acids disclosed herein into HSCs. In specific non-limiting examples, the nucleofection involves the use of a Nucleofector 4d apparatus.
D. CXCR4 Inhibitors
In one example, methods of decreasing CXCR4 activity occur at the protein level. That is, CXCR4 produced in an HSC can be contacted with agents that decrease its activity, such as a decrease of at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% (such as a decrease of 40% to 90%, 40% to 80% or 50% to 95%) as compared to a control (such as a non-recombinant HSC with normal or wild- type CXCR4 expression). Examples of such agents include small molecules and specific binding agents. Such agents can reduce CXCL12 binding to CXCR4.
In one example the agent that reduces CXCR4 protein activity is a CXCR4 antagonist, such as a small molecule (e.g., AMD3100 (plerixafor), AMD3465, T22 ([Tyr5'12, Lys7]-polyphemusin II), T134 (des-[Cys8>13, Tyr9'12]-[d-Lys10, Pro11, l-citrulline16]-T22 without C-terminal amide), T140 { [l-3-(2-naphthyl)alanine3]-T134}, and AMD070 (for review see Debnath et al., Theranostics, 2013; 3(l):47-75, herein incorporated by reference).
AMD3100
AMD3465
A specific binding agent is an agent that binds substantially only to a defined target, such as a CXCR4 protein. For example, a CXCR4 protein- specific binding agent binds substantially only to a CXCR4 protein (such as a protein provided in any of GenBank® Accession Nos.
NP_001008540, CAA12166.1, NP_034041.2 and AAH31665.1). Specific binding agents include CXCR4 antibodies (including polyclonal or monoclonal antibodies and functional fragments thereof, as well as humanized and chimeric antibodies), CXCR4 aptamers, and other agents that bind substantially only to the CXCR4 protein.
CXCR4 antibodies can be produced using standard procedures such as those described in
Harlow and Lane (Using Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press: Cold Spring Harbor, 1998). Antibodies can be polyclonal or monoclonal antibodies, humanized antibodies, Fab fragments, F(ab')2 fragments, single chain antibodies, or chimeric antibodies. In addition, CXCR4 antibodies are commercially available such as those from Abeam, Cambridge, MA (e.g., ab2074, ab58176, or abl617) and Novus Biologicals, Littleton, CO (e.g., NB100-74396 or NB 100-77835). In one example a CXCR4 antibody is a neutralizing antibody (such as one from a non-Hodgkin's lymphoma patient, or an antibody derived from such).
The determination that a particular agent binds substantially only to the target protein readily can be made by using or adapting routine procedures. For example, Western blotting can be used to determine that a given protein binding agent, such as a CXCR4 antibody or aptamer, binds substantially only to the CXCR4 protein. Other assays include, but are not limited to, competitive and non-competitive homogenous and heterogeneous enzyme-linked immunosorbent assays (ELISA) as symmetrical or asymmetrical direct or indirect detection formats; "sandwich" immunoassays; immunodiffusion assays; in situ immunoassays (for example, using colloidal gold, enzyme or radioisotope labels); agglutination assays; complement fixing assays; immunoelectrophoretic assays; enzyme-linked immunospot assays (ELISPOT); radioallergosorbent tests (RAST); fluorescent tests, such as used in fluorescent microscopy and flow cytometry; Western, grid, dot or tissue blots; dip-
stick assays; halogen assays; or antibody arrays (for example, see O'Meara and Tovey, Clin. Rev. Allergy Immunol., 18:341-95, 2000; Sambrook et al., 2001, Appendix 9; Simonnet and Guilloteau, in: Methods of Immunological Analysis, Masseyeff et al. (Eds.), VCH, New York, 1993, pp. 270- 388).
Thus, in some examples, an HSC is contacted in vivo or ex vivo (or both) with a
therapeutically effective amount of one or more agents that decrease CXCR4 activity, such as one or more of the agents listed above.
III. Introduction of CXCR4-Knockdown HSCs into a Subject
CXCR4 knockdown HSCs, which may include one or more other repaired genetic mutations as discussed herein, can be introduced, that is administered or transplanted, into a subject. Such subjects are referred to as recipient subjects. The CXCR4 knockdown HSCs can be generated from the recipient subject (autologous), or a different subject (allogeneic). In some examples, the subject has a hematologic malignancy and the CXCR4 knockdown HSCs used are allogeneic, for example to have graft vs. tumor effect. In some examples, the subject has a genetic hematologic disease and the CXCR4 knockdown HSCs used are autologous to reduce or eliminate risk of graft vs. host disease after transplant. Such methods can be used to enhance engraftment of HSCs. Thus, transplantation of the disclosed CXCR4 knockdown HSCs can be used to treat patients with hematological cancers and other disorders of the blood and immune systems.
In some examples, the CXCR4 knockdown HSCs include other undesirable mutations, such as those shown in Table 1. In such examples, one or more other undesirable mutations can be repaired, for example to treat a disease. Furthermore, if the donor HSCs include any gene that is undesirably up- or down-regulated, that too can be repaired in the HSC as described herein.
In some examples therapeutically effective amounts of CXCR4 knockdown HSCs, which may include one or more other repaired genetic mutations as discussed herein, include at least 1 x 106, at least 2 x 106, at least 3 x 106, at least 4 x 106, at least 5 x 106, at least 6 x 106, at least 7 x 106, at least 8 x 106, at least 9 x 106, at least 1 x 107, at least 2.5 x 107, at least 5 x 107, at least 1 x 108, at least 2.5 x 108, or at least 5 x 108 CXCR4 knockdown HSCs. Such amounts can be introduced into the recipient subject, for example by injection, such as intravenously.
In some examples, administration of the CXCR4 knockdown HSCs, which may include one or more other repaired genetic mutations as discussed herein, increases engraftment of the CXCR4 knockdown HSCs by at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 90%, at least 95%, at least 100%, at least 2-fold, at least 3- fold, at least 4-fold, at least 5-fold, at least 10-fold, at least 20-fold, or at least 30-fold, for example
at 30 days, 60 days, 90 days, 120 days, 1 year or 2 years following the HSC transplant, for example as compared to engraftment observed with HSCs without downregulated CXCR4. In some examples, enhanced engraftment is indicated by an increase in donor HSC repopulation in the recipient faster than donor HSC with normal CXCR4 expression. For example, the CXCR4 knockdown HSCs can repopulate at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 90%, at least 95%, at least 100%, at least 2- fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 10-fold, at least 20-fold, or at least 30- fold, faster than donor HSCs with normal CXCR4 expression (e.g., a wild-type HSC), for example at 30 days, 60 days, 90 days, 120 days, 1 year or 2 years following the HSC transplant. In some examples, enhanced engraftment is indicated by CXCR4 knockdown HSCs lasting longer in the recipient than donor HSC with normal CXCR4 expression. For example, the donor HSCs can survive at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 90%, at least 95%, at least 100%, at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 10-fold, at least 20-fold, or at least 30-fold, longer than donor HSCs with normal CXCR4 expression (e.g., a wild-type HSC), for example at 30 days, 60 days, 90 days, 120 days, 1 year or 2 years following the HSC transplant.
A. Subjects
In some examples, the subject receiving the CXCR4 knockdown HSCs (which may include one or more other repaired genetic mutations as discussed herein) does not receive a conditioning regimen prior to administration of the CXCR4 knockdown HSCs. For example, the subject does not receive chemotherapy or irradiation (such as total body irradiation) that is typically used to suppress the immune system and/or destroy the bone marrow. Thus, in some examples the subject to receive the CXCR4 knockdown HSCs does not previously receive a myeloablative regimen, such as chemotherapy agents given at maximally tolerated doses expected to eradicate the hematopoietic cells in the bone marrow and resulting in profound pancytopenia within one to three weeks from the time of administration. In some examples, the subject does not previously receive a non-myeloablative regimen, such as reduced doses of chemotherapy or whole body irradiation expected to partially ablate but not eliminate the recipient bone marrow. In some examples the recipient subject does not receive a therapy that will deplete or ablate the recipient's immune system, such as T cells, prior to receiving the CXCR4 knockdown HSCs.
Examples of chemotherapeutic agents that have been used in conditioning regimens for HSC transplantation include but are not limited to: carmustine, busulfan, carboplatin,
cyclophosphamide, Cytoxan, etoposide, fludarabine, melphalan, methotrexate, thiotepa, topotecan,
or combinations thereof. Thus, in some examples the recipient subject to receive the CXCR4 knockdown HSCs provided herein does not receive any of these chemotherapies prior to administration of the CXCR4 knockdown HSCs. In some examples the recipient subject does not receive an induction chemotherapy regimen which includes a therapeutically effective amount of etoposide, doxorubicin, vincristine, cyclophosphamide, and prednisone (EPOCH) or cytarabine with daunorubicin or idarubicin (7+3 regimen) prior to administration of the CXCR4 knockdown HSCs. In another example, the recipient subject does not receive fludarabine prior to
administration of the CXCR4 knockdown HSCs.
Thus, in some examples the subject to be treated with the methods provided herein does not receive irradiation, such as does not receive 1200 to 1300 centigray over three to four days, for example prior to receiving the CXCR4 knockdown HSCs.
B. Disorders
Diseases that can be treated with the disclosed methods include any genetic disease of the blood (e.g. sickle cell disease, primary immunodeficiency diseases), HIV (such as HIV-1), and hematologic malignancies or cancers, as well as WHIM syndome. Thus, in some examples, the subject who receives the CXCR4 knockdown HSCs has one of these diseases.
Primary immunodeficiency diseases weaken the immune system, allowing repeated infections and other health problems to occur more easily. Examples of primary immunodeficiency diseases and their corresponding mutations include those listed in Al-Herz et ah, Frontiers in Immunology, volume 5, article 162, April 22, 2014, herein incorporated by reference. Specific examples are provided in Table 1.
Hematologic malignancies or cancers are those tumors that affect blood, bone marrow, and lymph nodes. Examples include leukemia (e.g., acute lymphoblastic leukemia, acute myelogenous leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, acute monocytic leukemia), lymphoma (e.g., Hodgkin's lymphoma and non-Hodgkin's lymphoma), and myeloma. In some examples, a subject with a hematologic malignancy benefits from receiving CXCR4 knockdown HSCs (such as allogeneic HSCs) without the need for repair of other genetic mutations (e.g., the cancer is not caused by a genetic mutation). For example, receiving the CXCR4 knockdown HSCs can be used to induce a graft versus tumor effect in the subject with the hematologic malignancy. In other examples, a subject with a hematologic malignancy benefits from receiving CXCR4 knockdown HSCs (such as autologous HSCs) which further have a genetic mutation that causes the malignancy, which has been repaired prior to introduction of the donor HSCs into the recipient. For example, receiving the repaired CXCR4 knockdown HSCs can be
used to treat CML caused by a BCR-ABL fusion (which is repaired in the CXCR4 knockdown HSCs prior to administration to the recipient).
Table 1: Exemplary disorders and corresponding mutations
Disease Gene Mutation
Blood cell disorder sickle cell anemia β-globin chain of SNP (A to T) that gives rise
hemoglobin to point mutation (Glu->Val
at 6th aa)
hemophilia any of clotting factors I
through XIII
hemophilia A clotting factor VIII large deletions, insertions,
inversions, and point
mutations
hemophilia B clotting factor IX
Alpha-Thalassemia HBA1 or HBA2 Mutation or a deletion in
chromosome 16 p
Beta- Thalassemia HBB Mutations in chromosome 11
Delta-Thalas semia HBD mutation
von Willebrand Disease von Willebrand factor mutations or deletion
pernicious anemia MTHFR
Fanconi anemia FANCA, FANCC, FANCA: c.3788_3790del
FANCD2, FANCG, (p.Phel263del);
FANCJ c. l l l5_1118delTTGG
(p.Val372fs); Exon 12- 17del; Exon 12-31 del;
c.295C>T (p.Gln99X)
FANCC: c.711+4A>T
(originally reported as
IVS4+4A>T);
c.67delG (originally reported as 322delG)
FANCD2: c. l948- 16T>G
FANCG; c.313G>T
(p.Glul05X); c. l077-2A>G; c. l480+lG>C; c.307+lG>C; c. l794_1803del
(p.Trp599fs); c.637_643del (p.Tyr213fs)
FANCJ: c.2392C>T
(p.Arg798X)
Thrombocytopenic ADAMTS 13 Missense and nonsense purpura mutations
thrombophilia Factor V Leiden Mutation in the F5 gene at
Prothrombin position 1691
Prothrombin G20210A
Primary
Immunodeficiency
Diseases
T-B+ SCID IL-2RG, JAK3, defect in
gamma chain of receptors
for IL-2, -4,-7,-9, - 15 and - 21
T-B- SCID RAG1, RAG2
WHIM syndrome CXCR4 heterozygous mutations
(e.g., in the carboxy- terminus); carboxy- terminus truncation (e.g., 10-19 residues)
Other disorders
HIV C-C chemokine receptor Deletion of 32 bp in CCR5 type 5 (CCR5)
CML BCR-ABL fusion
AML Chromosome l lq23 or translocation
t(9;l l)
Administration of the CXCR4 knockdown HSCs can be used to treat any of these disorders. Treatment does not require 100% removal of all characteristics of the disorder, but can be a reduction in such. Although specific examples are provided below, based on this teaching one will understand that symptoms of other disorders can be similarly affected.
For example, administration of CXCR4 knockdown HSCs can be used to treat or reduce the undesirable effects of a genetic disease of the blood, such as a primary immunodeficiency disease.
For example, administration of CXCR4 knockdown HSCs (which can also include genetic alterations to correct a mutation in the β-globin chain of hemoglobin) can be used to treat or reduce the undesirable effects of sickle cell disease. In one example, the donor HSC includes a genetic modification to correct a mutation in the β-globin chain of hemoglobin that results in the sickle-cell disease. In one example the disclosed methods reduce the symptoms of sickle-cell disease in the recipient subject (such as one or more of, presence of sickle cells in the blood, pain, ischemia, necrosis, anemia, vaso-occlusive crisis, aplastic crisis, splenic sequestration crisis, and haemolytic crisis) for example a reduction of at least 10%, at least 20%, at least 50%, at least 70%, or at least 90% (as compared to no administration of the CXCR4 knock down HSCs). In one example the disclosed methods decrease the number of sickle cells in the recipient subject, for example a decrease of at least 10%, at least 20%, at least 50%, at least 70%, at least 90%, or at least 95% (as compared to no administration of the CXCR4 knock down HSCs).
For example, administration of CXCR4 knockdown HSCs (which can also include genetic alterations to correct a mutation in the factor V Leiden or prothrombin gene) can be used to treat or reduce the undesirable effects of thrombophilia. In one example, the donor HSC includes a genetic modification to correct a mutation in the factor V Leiden or prothrombin gene that results in the thrombophilia. In one example the disclosed methods reduce the symptoms of thrombophilia in the recipient subject (such as one or more of, thrombosis, such as deep vein thrombosis, pulmonary embolism, venous thromboembolism, swelling, chest pain, palpitations) for example a reduction of at least 10%, at least 20%, at least 50%, at least 70%, or at least 90% (as compared to no administration of the CXCR4 knock down HSCs). In one example the disclosed methods decrease the activity of coagulation factors in the recipient subject, for example a decrease of at least 10%, at least 20%, at least 50%, at least 70%, at least 90%, or at least 95% (as compared to no
administration of the CXCR4 knock down HSCs).
For example, administration of CXCR4 knockdown HSCs (which can also include genetic alterations to correct a mutation in the CD40 ligand gene) can be used to treat or reduce the undesirable effects of CD40 ligand deficiency. In one example, the donor HSC includes a genetic modification to correct a mutation in the CD40 ligand gene that results in the CD40 ligand deficiency. In one example the disclosed methods reduce the symptoms of CD40 ligand deficiency in the recipient subject (such as one or more of, elevate serum IgM, low serum levels of other immunoglobulins, opportunistic infections, autoimmunity and malignancies) for example a reduction of at least 10%, at least 20%, at least 50%, at least 70%, or at least 90% (as compared to no administration of the CXCR4 knock down HSCs). In one example the disclosed methods increase the amount or activity of CD40 ligand deficiency in the recipient subject, for example an increase of at least 10%, at least 20%, at least 50%, at least 70%, at least 90%, at least 100%, at least 200% or at least 500% (as compared to no administration of the CXCR4 knock down HSCs).
For example, administration of CXCR4 knockdown HSCs (which can also include genetic alterations to decrease CCR5 activity) can be used to treat or reduce the undesirable effects of HIV- 1 infection. In one example, the donor HSC includes a genetic modification to decrease CCR5 activity in the HSC, such as a decrease of at least 20%, at least 50%, at least 70% or at least 90%. In one example, the CCR5 is modified to include a 32-bp deletion (CCR5A32, as described in Ye et ah, PNAS, 111:9591-6, 2014, herein incorporated by reference). In one example the disclosed methods reduce the symptoms of HIV-1 infection in the recipient subject (such as one or more of, fever, large tender lymph nodes, throat inflammation, a rash, headache, sores of the mouth, nausea, vomiting, diarrhea, peripheral neuropathy, Guillain-Barre syndrome, weight loss, viral load, decreased levels of CD4+ T cells, Pneumocystis pneumonia, cachexia in the form of HIV wasting syndrome and esophageal candidiasis) for example a reduction of at least 10%, at least 20%, at least 50%, at least 70%, or at least 90% (as compared to no administration of the CXCR4 knock down HSCs). In one example the disclosed methods increase levels of CD4+ T cells in the HIV- infected recipient subject, for example an increase of CD4+ T cells of at least 10%, at least 20%, at least 50%, at least 70%, at least 90%, at least 100%, at least 200%, at least 500% or at least 1000% (as compared to no administration of the CXCR4 knock down HSCs).
For example, administration of CXCR4 knockdown HSCs can be used to treat or reduce the undesirable effects of a hematological malignancy in the recipient subject. In one example the disclosed methods reduce the number of abnormal white blood cells (such as B cells) in the recipient subject (such as a subject with leukemia), for example a reduction of at least 10%, at least 20%, at least 50%, at least 70%, or at least 90% (as compared to no administration of the CXCR4 knock down HSCs). In one example, administration of CXCR4 knockdown HSCs can be used to
treat or reduce the undesirable effects of a lymphoma, such as reduce the size of the lymphoma, volume of the lymphoma, rate of growth of the lymphoma, metastasis of the lymphoma, for example a reduction of at least 10%, at least 20%, at least 50%, at least 70%, or at least 90% (as compared to no administration of the CXCR4 knock down HSCs). In one example, administration of CXCR4 knockdown HSCs can be used to treat or reduce the undesirable effects of multiple myeloma, such as reduce the number of abnormal plasma cells in the recipient subject, for example a reduction of at least 10%, at least 20%, at least 50%, at least 70%, or at least 90% (as compared to no administration of the CXCR4 knock down HSCs).
For example, administration of CXCR4 knockdown HSCs can be used to treat or reduce the undesirable effects of WHIM syndrome. In one example, the donor HSC includes a genetic modification to reduce expression of CXCRx, such as by disrupting one functional allele of CXCR4. In one example the disclosed methods reduce the symptoms of WHIM syndrome in the recipient subject (such as one or more of, warts, bacterial infection, viral infection, reduction of lymphocytes, neutropenia, hypogammaglobulinemia, myelokathexis, cervical and vulval premalignant dysplasia, and human papillomavirus (HPV) infection) for example a reduction of at least 10%, at least 20%, at least 50%, at least 70%, or at least 90% (as compared to no
administration of the CXCR4 knock down HSCs). In one example the disclosed methods decrease the number of warts in the recipient subject, for example a decrease of at least 10%, at least 20%, at least 50%, at least 70%, at least 90%, or at least 95% (as compared to no administration of the CXCR4 knock down HSCs). In one example the disclosed methods decrease the frequency of bacterial and/or viral infections in the recipient subject, for example a decrease of at least 10%, at least 20%, at least 50%, at least 70%, at least 90%, or at least 95% (as compared to no
administration of the CXCR4 knock down HSCs). In one example the disclosed methods increase white blood cell counts in the recipient subject, for example an increase of at least 10%, at least 20%, at least 50%, at least 70%, at least 90%, at least 100%, at least 200%, or at least 500% (as compared to no administration of the CXCR4 knock down HSCs).
Example 1
Materials and Methods
This example describes the methods used to obtain the results described in Exampli
Patients
All patients and unaffected relatives signed informed consent consistent with the
Declaration of Helsinki under clinical protocols approved by the Institutional Review Board of the
National Institute of Allergy and Infectious Disease (NIAID) before taking part in research at the National Institutes of Health Clinical Center.
Animal Experiments
Cxcr4 targeted (Floxed mice = Strain 008767) and Ella promoter driven Cre recombinase transgenic mice (Strain 003724) mice were obtained from The Jackson Laboratory (Bar Harbor, ME) and bred together to generate Cxcr4 heterozygote knock out mice (Cxcr4 +/~). Creation of WHIM knockin mice bearing a heterozygous CXCR4S338X mutation have been previously described and sperm from these mice were used for in vitro fertilization at NIH to impregnate female C57BL/6 mice from Taconic Farms (Hudson, NY) (Balabanian et al., 2012). These mice were bred to backgrounds that expressed either CD45.1 or CD45.2 or both for purposes of tracking bone marrow engraftment in mixed bone marrow reconstitution assays where 5 million bone marrow cells were transferred intravenously into the recipient mouse via tail vein injection. In some experiments, recipient mice underwent lethal irradiation (900 rads) 6 to 8 hours prior to transplant.
Flow Cytometry, Cell Purification, and Culture
Patient cells were isolated from heparinized blood or bone marrow aspirate and purified by Ficoll-Hypaque centrifugation and stained as previously described (McDermott et al., 2014). Cell purification was performed either using magnetic bead selection (Miltenyi Biotec, Cambridge, MA) following manufacturer recommendations for blood samples or using a sorting cytometer (FACS Aria II, BD Biosciences, San Jose, CA) for bone marrow samples. Flow cytometric data was analyzed with FlowJo vlO (TreeStar Inc, Ashland, OR). Peripheral blood mononuclear cells (PBMC) and purified bone marrow cells were cultured to expand CD34+ hematopoietic progenitors (HPC) and PBMC were used to create lymphoblastoid cell lines (LCL) from Epstein-Barr virus (EBV) transformed B cells (detailed methods below).
100 μΐ of mouse blood was collected from the mandibular vein into EDTA anticoagulant tubes (Becton Dickinson, Franklin Lakes, NJ) then 2 μΐ Fc block (BioLegend, San Diego, CA) was added and incubated for 10 min prior to the addition of specific antibodies incubated on ice for 30 min. Red blood cells were then lysed with 1 ml of ACK lysis buffer (Quality Biologicals Inc., Gaithersburg, MD) for 1 min at room temperature before centrifugation and washing with flow cytometry buffer twice. Cells were then fixed with 1% paraformaldehyde, stored on ice, and run on a FACS LSRII instrument (BD Biosciences). A similar procedure was followed for staining bone marrow cells isolated from sacrificed animals from the femurs.
Flow Cytometric Sorting and HSC selection and culture
A Fluorescence activated cell sorter (FACS Aria II (SORP)) made by Becton-Dickinson Biosciences (San Jose, CA) and equipped with 405nm, 488nm, 561nm, and 633nm lasers was used to sort cells. For sorting of bone marrow hematopoietic progenitors, Enrich mode (Purity mask=0; Yield mask=8) to select CD34+ cells was performed first followed by Purity mode sorting for HSC, CLP, CMP, and GMP populations. Purified monoclonal anti-human antibodies labeled with fluorochromes were obtained from BD Biosciences and for blood sorting included: CD 14- Fluorescein Isothiocyanate, CD 19- Phycoerythrin, CD4- AUophycocyanin, and CD8-Pacific Blue; while for bone marrow sorting included: CD14-Fluorescein Isothiocyanate, CD19-Phycoerythrin, CD34- AUophycocyanin, and CD3-Alexa Fluor 700. In other experiments, blood and bone marrow derived CD34+ cells were positively selected with Miltenyi Biotec (San Diego, CA) microbeads then cultured using the Arteriocyte (Cleveland, OH) NANEX HSC expansion system following manufacturer's directions. In some experiments, the CD34+ cells were cultured in HSC expansion serum free media (Stem Cell Technologies, Vancouver, Canada) supplemented with the cytokine cocktail (hSCF, hTPO, hflt3-L) obtained from Peprotech (Rocky Hill, NJ) and human LDL from Athens Research and Technology (Athens, GA).
Mutation Detection and Sanger DNA Sequencing
Polymerase chain reaction - restriction fragment length polymorphism (PCR-RFLP) analysis was performed as previously described (Hernandez et al., 2003) using genomic DNA isolated from purified cell populations or whole blood. Amplification utilized the following primers: 5'-ATCCTCTATGCTTTCCTTGGAGCC-3' (SEQ ID NO: 1) and 5'- GTGGAAACAGATGAATGTCCACCGC-3' (SEQ ID NO: 2). The CXCR4R334X mutation (lOOOC— >T) destroys a naturally present BstXJI restriction enzyme site such that the mutant allele is uncut (126 bp amplicon versus 104 and 22 bp digested pieces). In addition the same DNA was subjected to traditional Sanger method DNA sequencing at a Clinical Laboratory Improvement Amendment of 1988 (CLIA-88) certified core facility.
A PCR assay was designed to detect the derivative chromosome by spanning one of the novel junctions created by the chromothripsis event such that the normal chromosome should not amplify. This assay used the following primers: 5 '-GG A ATCTC AC ATCC AG A ATC ATGC- 3 ' (SEQ ID NO: 3) and 5 '-TTGTTCTC ACCTTTGGCC AGTGG- 3 ' (SEQ ID NO: 4) and generates a 242 bp amplicon spanning the junction of pieces 16 and 13 in the derivative chromosome.
Amplicons for 3 other junctions yielded similar results.
Cytogenetics
Cytogenetics was performed on bone marrow aspirate samples, purified CD19+ B cells, and LCL cell lines by a clinical laboratory using standard techniques (Quest Diagnostics, Chantilly, VA).
Microarray and Analysis
An Affymetrix Cytoscan HD array (Affymetrix, Santa Clara, CA) was used to identify chromosomal breakpoints using DNA from the same cells used in cytogenetic analysis, purified neutrophils and skin fibroblasts following the manufacturer recommended procedures. The Chromosome Analysis software suite (Affymetrix) was used to identify the approximate location of these breakpoints via loss of heterozygosity (LOH) determination using single nucleotide polymorphism (SNP), insertion/deletion (indel), and copy number variant (CNV) analysis. Molecular Pathology Testing and Cytokine Analysis
A formalin fixed paraffin embedded (FFPE) block was obtained from the patient's splenectomy in 1963. This was examined histologically and DNA was extracted using the methods described below. This DNA was then used in the PCR-RFLP analysis. A variety of short tandem repeat (STR) loci were compared between the patient's neutrophil and buccal DNA using an STR chimerism assay developed for the tracking of bone marrow transplant engraftment at the
Hematology Service, Division of Laboratory Medicine, NIH Clinical Center. This assay is capable of detecting 5-95% donor chimerism and has a standard deviation of +5%. Purified CD3+ and CD19+ DNA was checked for T and B cell clonality using previously published methods. (Lawnicki et al., 2003; Ramasamy et al., 1992; van Dongen et al., 2003) Finally, a specific mutation (V617F) in the JAK2 oncogene and presence of the BCR-ABL gene fusion were excluded using DNA sequencing and a specific real time PCR assay respectively (see below). Serum samples from the index patient, 5 WHIM patients and 5 healthy blood donors were obtained and immediately frozen at < -80°C until time of assay. Samples were then thawed and run at the same time. Assays for serum cytokine, interleukin, and chemokine concentrations were performed by RayBiotech, Inc. (Norcross, GA) using a multiplex quantitative enzyme-linked immunosorbent assay (ELISA) method with appropriate controls to insure signal linearity of signal to concentration in the reported measurement range.
Whole Genome Sequencing and Analysis
DNA from fibroblasts obtained from a skin biopsy and blood neutrophils were used to prepare paired-end libraries using the TruSeq DNA protocol following the manufacturer's instructions (Illumina Inc., San Diego, CA). For each DNA sample, two different size libraries were generated, one of 200 to 400 bp and one of 300 to 500 bp. Each library was sequenced on 2 lanes of a HiSeq 2000 next generation sequencer (Illumina) and generated -380 million reads per library of 2 x 100 bp paired-end. Reads were trimmed for adaptor and poor quality sequence and mapped to build hgl9 of the human genome using publically available Tophat2 software from the McKusick-Nathans Institute of Genetic Medicine (Kim et al., 2013) using the fusion search option. The output from this software (fusion. out file) was used to identify candidate fusion junctions that were present in the neutrophil but not the fibroblast samples. All fusion junctions were verified by visual inspection using publically available software from the Broad Institute: Integrative Genomics Viewer (IGV version 2.3). (Robinson et al., 2011) Rearrangements were visualized using publically available software from the Canadian Michael Smith Genome Centre: Circos.(Krzywinski et al., 2009)
T cell clonality testing
DNA was extracted from peripheral blood cells using an automated DNA extraction system and tested for quality prior to PCR amplification for detection of T cell receptor (TRG locus) gene rearrangements. A single multiplexed PCR reaction was performed as described by Lawnicki et al. using primers that interrogate TRG rearrangements involving all of the known Vg family members, and the Jgl/2, JP1/2 and JP joining segments. (Lawnicki et al., 2003) To allow for fluorescence detection, each joining region primer was covalently linked to a unique fluorescent dye. The products were analyzed by capillary electrophoresis on an ABI 3130x1 Genetic Analyzer, and electrophero grams were analyzed using GeneMapper software version 4.) (Applied Biosystems, Life Technologies, Grand Island, NY). A polyclonal rearrangement pattern was detected and there was no evidence of a clonal T-cell process, within the detection limits of the assay. TRG PCR is capable of detecting a clonal population comprising a minimum of 2-5% of the total T-cell population, and as performed at the NIH-CC, can identify > 90-95% of all TRG gene
rearrangements occurring in clonal T-cell proliferations.
B cell clonality testing
DNA from peripheral blood cells isolated as above was PCR amplified for detection of immunoglobulin (IGH and IGk loci) gene rearrangements. For the IGH locus, two separate
reactions were performed, one using consensus primers to framework region III and the joining region of the immunoglobulin heavy chain gene (FRIII-IGH PCR) and a second using primers directed to the framework region II and the joining region of the immunoglobulin heavy chain gene (FRII-IGH PCR) as described by Ramasamy et al.(Ramasamy et al., 1992) Primers directed to the joining region were linked to the fluorescent marker FAM (carboxyfluorescein). Two additional reactions were performed for the IGk locus using the Biomed II primer set described by van Dongen et al and supplied by InVivoScribe Technologies (San Diego, CA) using the IGK Gene clonality assay and ABI Fluorescence Detection). (van Dongen et al., 2003) These reactions interrogate rearrangements involving the Vk loci and Jk, the Vk locus and the kDE locus, and the k intron RSS locus and the kDE locus. Products were run on an ABI 3130x1 Genetic Analyzer and electrophero grams were analyzed using GeneMapper software version 4 (ABI). Polyclonal rearrangement patterns were detected in all reactions and there was no evidence of clonal B cell proliferation within the limits of the assay. These assays performed at the NIH-CC are capable of detecting a clonal population comprising 2-10% of the total B cell population and can identify about 85-90% of all clonal B cell proliferations.
JAK2 and BCR-ABL Mutation Analysis
The JAK2 V617F mutation was not detected on CLIA-88 approved testing developed by Ipsogen (Qiagen, Germantown, MD). A quantitative PCR assay was used to determine the relative levels of BCR-ABL and ABL using cDNA obtained by reverse transcribing RNA extracted from peripheral blood leukocytes. The levels of BCR-ABL and ABL were quantitated by comparison to plasmid reference standards using real time PCR. The ratio (BCR-ABL/ABL) was found in WHIM-09 to be 0.12%. In patients with newly diagnosed or relapsed chronic myeloid leukemia this typically varies between 50-150%. The coefficient of variation for replicate assays at the NIH- CC is 40-50%.
Example 2
Index patient is a genetic mosaic for the CXCR4R334X mutation
The index patient and 2 of her 3 daughters self referred themselves to NIH for evaluation of their immunodeficiency. The index patient was the initial patient diagnosed with myelokathexis and had undergone bone marrow biopsy, splenectomy and extensive investigation of her congenital neutropenia at age 9 (Krill et al., 1964; Zuelzer, 1964). Her family's immunodeficiency syndrome was compatible with autosomal dominant transmission of WHIM syndrome and at least one of the daughters had previously been clinically diagnosed with this (FIG. 1A). However, to our
knowledge genetic testing for a CXCR4 mutation had not been previously performed in this family. Since mutations in this gene account for more than 95% of the known WHIM cases, most individuals would be expected to have one of the eight currently described carboxy terminal mutations. Therefore, the index patient, her husband, and all 3 daughters were genotyped. Two of the three daughters (WHIM- 10 and WHIM- 11) who had neutropenia and severe human
papillomavirus disease (warts) tested positive for the most common truncation mutation causing WHIM, CXCR4R334X, while the husband and third daughter without these symptoms tested negative (FIG. IB). However, unexpectedly a blood sample from the index patient (WHIM-09), tested negative for the same mutation and her immunophenotype was markedly different from her 2 daughters (Table 2) and other WHIM patients studied.
This prompted a repeat blood sample to be tested and it confirmed the initial negative result followed by a cheek swab and skin biopsy both of which demonstrated that the patient was in fact heterozygous for the CXCR4R334X mutation in non-hematologic tissues (FIG. 1C). A WHIM pedigree with germ-line/somatic genetic mosaicism where the mother of 2 affected children was hematologically normal had been previously described (Hernandez et al., 2003) but this was deemed unlikely in this case because the index patient had been markedly symptomatic with severe neutropenia as a child.(Krill et al., 1964; Zuelzer, 1964) Therefore, it was suspected that a genetic reversion had occurred and whether this was the case and when this had happened was determined. Table 2. Immunophenotype of 3 WHIM patients
cell
CD19+ B cell 18 5 10 61-329
CD19+ CD27+ 2 1 1 12-68
memory B cell
CD19+ CD27 B 16 4 9 90-176
cell
CD19+ CD27- 12 3 4 42-85
IgD+ IgM+
transitional/naive
B cell
CD19+ CD27- 4 1 1 2-10
IgD" IgM+
immature B cell
CD14+ CD 16" 1344 35 117 371-539
Classical
Monocyte
CD14+ CD16+ 235 5 23 14-30
Inflammatory
Monocyte
Low patient values are underlined and high patient values are in bold font. ND, not defined.
†Based on the values of 11-40 healthy blood donors seen at the NIH Clinical Center.
Example 3
Index patient exhibits a genetic myeloid/lymphoid dichotomy
Testing of multiple purified leukocyte lineages from blood revealed that the CXCR4R334X mutation was present in lymphocytic lineages (CD56+ NK, CD19+ B and CD3+ T cells) but was absent from myeloid lineages (CD14+ monocytes and neutrophils) and CD34+ hematopoietic stem cells. These results were initially demonstrated using PCR-RFLP (FIG. 2A) and confirmed by Sanger DNA sequencing. A pathological specimen was obtained from the splenectomy performed at age 9 and DNA extracted for testing and this revealed the presence of the CXCR4R334X mutation.
In order to test whether the myeloid components expressing the CXCR4R334X mutation might be differentially retained in bone marrow and thus absent from the blood, a bone marrow biopsy and aspirate were performed. An identical myeloid / lymphoid dichotomous result was
obtained from cells purified by flow cytometric sorting from the bone marrow aspirate (FIG. 2B) and in CD34+ hematopoietic stem cells obtained both by flow cytometric sorting and ex vivo culture from blood and bone marrow. Thus the combined evidence suggested that an early myeloid progenitor or HSC had undergone genetic reversion of the CXCR4R334X mutation.
Example 4
Neutropenia and other symptoms of WHIM resolved at about age 30
A careful analysis of blood cell counts and symptoms of the index patient with time revealed that the patient's neutropenia had resolved around the age of 30 years (FIG. 3). This was accompanied by increased monocytes with similar kinetics. In addition, the patient reported that her last serious infection requiring hospitalization occurred at about this age and for the past 30 years she had been largely infection free except for some recurrent episodes of sinusitis and bronchitis treated as an outpatient. WHIM-09 also noted that while she had previously had many confluent warts on her left hand, these had resolved at about the same time without surgery, cytotoxic treatment, or residual scars. Since the patient reported she had undergone several surgeries and blood transfusions at about the same time as her neutrophil counts normalized, we tested her blood for any evidence of allogeneic chimerism and found none. Taken together this evidence indicated that the patient had undergone a clinical and genetic reversion of the
CXCR4R334X mutation at about age 30. Surprisingly this reversion had apparently occurred in a hematopoietic stem cell that then developed a proliferative advantage and fully repopulated the
HSC niche in the absence of chemotherapy or radiation therapy as is commonly performed in bone marrow transplantation. The mechanism of this phenomenon was explored.
Example 5
Bone Marrow Pathology, Cytogenetics, Microarray
Bone marrow histology at time of examination did not reveal the characteristic findings of myelokathexis expected in WHIM syndrome (FIG. 4) in contrast to her previously reported bone marrow results and as noted above the patient's blood immunophenotype was abnormal and markedly different from her daughters (Table 2). Despite the patient's neutrophilia, monocytosis, CD4+ T cell lymphocytosis, and thrombocytosis, there was no evidence for CML, CMML, or myelodysplasia syndrome in the bone marrow pathology and specific testing for BCR-ABL and JAK mutations were negative. Cytogenetics was performed on the bone marrow aspirate and revealed that one copy of chromosome 2 was markedly abnormal but the other chromosomes exhibited a normal banding pattern (FIG. 5A). Fluorescent in situ hybridization (FISH) testing was
performed and revealed that the anaplastic lymphoma receptor tyrosine kinase (ALK) gene and parts of the centromere were translocated in the abnormal chromosomal copy and the N-myc gene (MYCN) was absent on the abnormal chromosome (FIGS.5B and 5C). Almost all of the bone marrow cells with polymorphic nuclei had the abnormal chromosome, while the cells with round nuclei had a lower percentage of the abnormal chromosome. An immunohistochemical stain of ALK activity on a bone marrow core biopsy section did not reveal abnormal activation of the enzyme despite the translocation (FIG. 14).
A clinical microarray was performed on the bone marrow cell DNA and compared with cultured fibroblast DNA. This revealed that the shortened chromosome 2 copy was due to 7 large deletions (FIG.6A). This was demonstrated by the loss of heterozygosity in these regions and by an abrupt change in the relative copy number from 2 to 1. One of these deletions involved the MYCN gene and the normal position of ALK, confirming the FISH results. In addition, one of the deletions included the position of the CXCR4 gene (FIG.6B). This had made the patient hemizygous for CXCR4 in cells from the myeloid lineage with loss of the CXCR4R334X mutation as well as loss of one copy of multiple other genes (Table 3).
Table 3. List of the orientation of the 18 pieces of the derivative chromosome of patient WHIM-09 and their nucleotide site of connections derived from whole genome sequencing of neutrophil DNA. Numbers are based on the chromosome 2 reference sequence of the hgl9 version of the human genome project. Note underlined numbers are uncertain because of repetitive sequences in the region of the connection that make assigning a specific nucleotide ambiguous.
15 16 Tail to Head 137402471 155186295
16 13 Tail to Tail 137413696 134383068
13 10 Head to Head 134208472
10 8 Tail to Head 133712996 132361705
8 4 Tail to Head 106220579 24238501
4 14 Tail to Tail 22647206 137344145
14 7 Head to Tail 137350425 92314297
7 2 Head to Head 102176282 13364053
2 9 Tail to Tail 13332820 133689046
9 11 Head to Head 133712975 134248797
11 18 Tail to Tail 134208529 164835205
This hemizygosity at CXCR4 with only the wild-type copy remaining thus provided an explanation for why the CXCR4R334X mutation in myeloid cell DNA was not detected by either DNA sequencing or PCR-RFLP. Thus, the genetic reversion had apparently been caused by multiple large deletions of the copy of chromosome 2 that bore the WHIM immunodeficiency causing mutation.
Example 6
Whole Genome Sequencing revealed evidence for chromothripsis
Microarray has limitations in resolution of chromosomal rearrangement boundaries caused by the variable spacing of the polymorphic markers on the array. In addition, the microarray technique does not easily reveal translocated DNA if it has been moved but not mutated or deleted; however, it was known that such existed by the abnormal cytogenetic banding pattern and FISH results described above. Whole genome sequencing (WGS) was performed on the patient's blood neutrophil DNA to identify these chromosomal rearrangement boundaries using as a comparison the patient's fibroblast DNA and the standard human genome sequence (version hgl9). An average of 40X coverage of both samples was obtained, and an analysis was performed to locate the stretches of DNA reads that had homology with multiple distinct areas of chromosome 2. This technique allowed precise basepair level identification of the translocations and deletions that had occurred on one copy of chromosome 2 (Table 4). Table 4. Alphabetical List of Genes deleted in the derivative chromosome of patient WHIM- 09 by whole genome sequencing
Entrez Map
Gene symbol gene id location Type of gene Full name
aminocarboxymuconate
ACMSD 130013 2q21.3 i protein-coding semialdehyde decarboxylase
ACV 1 90 2q23-q24 1 protein-coding activin A receptor, type 1
ACVR1C 130399 2q24.1 protein-coding activin A receptor, type IC
ADAM metallopeptidase domain
ADAM17 6868 2p25 1 protein-coding 17
ADCY3 109 2p23.3 protein-coding adenylate cyclase 3
AN KRD30BL 554226 2q21.2 i pseudo ankyrin repeat domain 30B-like
apolipoprotein B (including Ag(x)
APOB 338 2p24-p23 protein-coding antigen)
additional sex combs like 2
ASXL2 55252 2p24.1 protein-coding (Drosophila)
ATPase, H+ transporting,
ATP6V1C2 245973 - i protein-coding lysosomal 42kDa, VI subunit C2
bromodomain adjacent to zinc
BAZ2B 29994 2q24.2 i protein-coding finger domain, 2B
chromosome 2 open reading
C2orf27A 29798 2q21.2 protein-coding frame 27A
chromosome 2 open reading
C2orf27B 408029 2q21 protein-coding frame 27B
chromosome 2 open reading
C2orf43 60526 2p24.1 protein-coding frame 43
chromosome 2 open reading
C2orf44 80304 2p23.3 protein-coding frame 44
chromosome 2 open reading
C2orf48 348738 2p25.1 protein-coding frame 48
chromosome 2 open reading
C2orf49 79074 2ql2.1 protein-coding frame 49
chromosome 2 open reading
C2orf50 130813 2p25.1 protein-coding frame 50
chromosome 2 open reading
C2orf84 653140 2p23.3 protein-coding frame 84
CCDC148 130940 2q24.1 protein-coding coiled-coil domain containing 148
CCNT2 905 2q21.3 protein-coding cyclin T2
CD302 9936 2q24.2 protein-coding CD302 molecule
CENPO 79172 2p23.3 protein-coding centromere protein O
chemokine (C-X-C motif) receptor
CXC 4 7852 2q21 protein-coding 4
CYS1 192668 2p25.1 protein-coding cystin 1
CYTIP 9595 2qll.2 protein-coding cytohesin 1 interacting protein
DAPL1 92196 2q24.1 protein-coding death associated protein-like 1
DARS 1615 2q21.3 protein-coding aspartyl-tRNA synthetase
DEAD (Asp-Glu-Ala-Asp) box
DDX1 1653 2p24 protein-coding polypeptide 1
DnaJ (Hsp40) homolog, subfamily
DNAJC27 51277 2p23.3 protein-coding C, member 27
DNAJC27 antisense RNA 1 (non-
DNAJC27-AS1 729723 2p23.3 miscRNA protein coding)
DNA (cytosine-5-)-
DNMT3A 1788 2p23 protein-coding methyltransferase 3 alpha
DPP4 1803 2q24.3 protein-coding dipeptidyl-peptidase 4
DTNB 1838 2p24 protein-coding dystrobrevin, beta
E2F6 1876 2p25.1 protein-coding E2F transcription factor 6
EF 3B 22979 2p23.3 protein-coding EFR3 homolog B (S. cerevisiae)
ERMN 57471 2q24.1 protein-coding ermin, ERM-like protein
family with sequence similarity
FAM49A 81553 2p24.2 protein-coding 49, member A
family with sequence similarity
FAM84A 151354 2p24.3 protein-coding 84, member A
fibroblast activation protein,
FAP 2191 2q23 protein-coding alpha
FHL2 2274 2ql2.2 protein-coding four and a half LIM domains 2
FIGN 55137 2q24.3 protein-coding fidgetin
FK506 binding protein IB, 12.6
FKBP1B 2281 2p23.3 protein-coding kDa
FLJ 12334 400946 2p24.1 miscRNA
FLJ33534 285150 2p25.1 miscRNA
UDP-N-acetyl-alpha-D- galactosamine:polypeptide N- acetylgalactosaminyltransferase
GALNT13 114805 2q24.1 protein-coding 13 (GalNAc-T13)
UDP-N-acetyl-alpha-D- galactosamine:polypeptide N- acetylgalactosaminyltransferase
GALNT5 11227 2q24.1 protein-coding 5 (GalNAc-T5)
grancalcin, EF-hand calcium
GCA 25801 2q24.2 protein-coding binding protein
GCG 2641 2q36-q37 protein-coding glucagon
GDF7 151449 2p24.1 protein-coding growth differentiation factor 7
Gen endonuclease homolog 1
GEN1 348654 2p24.2 protein-coding (Drosophila)
GPR39 2863 2q21-q22 protein-coding G protein-coupled receptor 39
GPR45 11250 2qll.l-ql2 protein-coding G protein-coupled receptor 45
GREB1 9687 2p25.1 protein-coding growth regulation by estrogen in
breast cancer 1
LOC1002870 1002870
10 10 2ql2.1 miscRNA
LOC1005064 1005064
21 21 2ql2 miscRNA
LOC1005064 1005064
74 74 2p24 miscRNA
LOC1005076 1005076
00 00 - miscRNA
LOC150568 150568 2ql2.1 miscRNA
LOC284998 284998 2ql2.1 miscRNA
LOC285000 285000 2ql2.2 miscRNA
LOC375190 375190 2p23.3 protein-coding
LOC554201 554201 2q24.1 miscRNA
LOC645949 645949 2p24.1 miscRNA
LPIN1 23175 2p25.1 protein-coding lipin 1
LY75 4065 2q24 protein-coding lymphocyte antigen 75
1005266
LY75-CD302 64 2q protein-coding LY75-CD302 readthrough
LYPD1 116372 2q21.2 protein-coding LY6/PLAUR domain containing 1 mitogen-activated protein kinase
MAP4K4 9448 2qll.2-ql2 protein-coding 4
membrane-associated ring finger
MARCH7 64844 2q24.2 protein-coding (C3HC4) 7
MATN3 4148 2p24-p23 protein-coding matrilin 3
minichromosome maintenance
MCM6 4175 2q21 protein-coding complex component 6
major facilitator superfamily
MFSD2B 388931 2p23.3 protein-coding domain containing 2B
major facilitator superfamily
MFSD9 84804 2ql2.1 protein-coding domain containing 9
mannosyl (alpha-1,6-)- glycoprotein beta-l,6-N-acetyl-
MGAT5 4249 2q21.3 protein-coding glucosaminyltransferase
MI 128-1 406915 2q21.3 miscRNA microRNA 128-1
1003022
MIR1301 46 - miscRNA microRNA 1301
1004229
MIR3125 86 - miscRNA microRNA 3125
1005008
MIR3679 78 - miscRNA microRNA 3679
1004229
MIR4261 29 - miscRNA microRNA 4261
1004229
MIR4262 96 - miscRNA microRNA 4262
1006164
MIR4429 69 - miscRNA microRNA 4429
1006163
MIR4757 07 - miscRNA microRNA 4757
1006161
MIR4772 57 - miscRNA microRNA 4772
1006163
MIR4785 64 - miscRNA microRNA 4785
1003138
MIR663B 24 - miscRNA microRNA 663b
mitochondrial ribosomal protein
MRPS9 64965 2ql2.1 protein-coding S9
MSGN1 343930 2p24.2 protein-coding mesogenin 1
v-myc myelocytomatosis viral related oncogene,
MYCN 4613 2p24.3 protein-coding neuroblastoma derived (avian)
MYCN opposite strand/antisense
MYCNOS 10408 2p24.1 miscRNA RNA (non-protein coding)
neuroblastoma amplified
NBAS 51594 2p24 protein-coding sequence
NCKAP5 344148 2q21.2 protein-coding NCK-associated protein 5
NCOA1 8648 2p23 protein-coding nuclear receptor coactivator 1
NOL10 79954 2p25.1 protein-coding nucleolar protein 10
NT5C1B 93034 2p24.2 protein-coding 5'-nucleotidase, cytosolic IB
NT5C1B- 1005267
RDH14 94 2p protein-coding NT5C1B-RDH14 readthrough
NTSR2 23620 2p25.1 protein-coding neurotensin receptor 2
ODC1 4953 2p25 protein-coding ornithine decarboxylase 1
odd-skipped related 1
OSR1 130497 2p24.1 protein-coding (Drosophila)
protein disulfide isomerase
PDIA6 10130 2p25.1 protein-coding family A, member 6
PFN4 375189 2p23.3 protein-coding profilin family, member 4
PKP4 8502 2q24.1 protein-coding plakophilin 4
phospholipase A2 receptor 1,
PLA2R1 22925 2q23-q24 protein-coding 180kDa
POMC 5443 2p23.3 protein-coding proopiomelanocortin
POTE ankyrin domain family,
POTEKP 440915 2q21.1 pseudo member K, pseudogene
POU3F3 5455 2ql2.1 protein-coding POU class 3 homeobox 3
PQLC3 130814 2p25.1 protein-coding PQ loop repeat containing 3 proteasome (prosome, macropain) 26S subunit, non-
PSMD14 10213 2q24.2 protein-coding ATPase, 14
peptidyl-tRNA hydrolase domain
PTRHD1 391356 2p23.3 protein-coding containing 1
PUM2 23369 2p22-p21 protein-coding pumilio homolog 2 (Drosophila)
R3HDM1 23518 2q21.3 protein-coding R3H domain containing 1
RAB3 GTPase activating protein
RAB3GAP1 22930 2q21.3 protein-coding subunit 1 (catalytic)
RAD51AP2 729475 2p24.2 protein-coding RAD51 associated protein 2
RNA binding motif, single
RBMS1 5937 2q24.2 protein-coding stranded interacting protein 1 retinol dehydrogenase 14 (all-
RDH14 57665 2p24.2 protein-coding trans/9-cis/ll-cis)
ras homolog gene family,
RHOB 388 2p24 protein-coding member B
Rho-associated, coiled-coil OCK2 9475 2p24 protein-coding containing protein kinase 2
RRM2 6241 2p25-p24 protein-coding ribonucleotide reductase M2
SDC1 6382 2p24.1 protein-coding syndecan 1
2pter-
SF3B14 51639 p25.1 protein-coding
solute carrier family 4, sodium bicarbonate transporter, member
SLC4A10 57282 2q23-q24 protein-coding 10
solute carrier family 9
(sodium/hydrogen exchanger),
SLC9A2 6549 2qll.2 protein-coding member 2
solute carrier family 9
(sodium/hydrogen exchanger),
SLC9A4 389015 2ql2.1 protein-coding member 4
structural maintenance of
SMC6 79677 2p24.2 protein-coding chromosomes 6
1003027 small nucleolar RNA, H/ACA box
SNORA80B 43 2p25.1 snoRNA 80B
TATA box binding protein (TBP)- associated factor, RNA
TAF1B 9014 2p25 protein-coding polymerase 1, B, 63kDa
tetratricopeptide repeat, ankyrin repeat and coiled-coil containing
TANC1 85461 2q24.2 protein-coding 1
TRAF family member-associated
TANK 10010 2q24-q31 protein-coding NFKB activator
TBR1 10716 2q24 protein-coding T-box, brain, 1
transforming growth factor, beta
TGFBRAP1 9392 2ql2.1 protein-coding receptor associated protein 1
TMEM163 81615 2q21.3 protein-coding transmembrane protein 163
TMEM182 130827 2ql2.1 protein-coding transmembrane protein 182 tumor protein p53 inducible
TP53I3 9540 2p23.3 protein-coding protein 3
T IB2 28951 2p24.3 protein-coding tribbles homolog 2 (Drosophila) tetratricopeptide repeat domain
TTC32 130502 2p24.1 protein-coding 32
UBXN4 23190 2q21.3 protein-coding UBX domain protein 4
UPP2 151531 2q24.1 protein-coding uridine phosphorylase 2
VSNL1 7447 2p24.3 protein-coding visinin-like 1
WDR35 57539 2p24.1 protein-coding WD repeat domain 35
WD repeat, sterile alpha motif
WDSUB1 151525 2q24.2 protein-coding and U-box domain containing 1
YSK4 Spsl/Ste20-related kinase
YSK4 80122 2q21.3 protein-coding homolog (S. cerevisiae)
tyrosine 3- monooxygenase/tryptophan 5- monooxygenase activation
YWHAQ 10971 2p25.1 protein-coding protein, theta polypeptide
zinc finger, RAN-binding domain
ZRANB3 84083 2q21.3 protein-coding containing 3
The changes seen in the microarray were confirmed but were actually more complex than had been initially revealed. The derivative chromosome was composed of 18 remaining pieces arranged in random orientation. These remaining stretches of the normal chromosome 2 had been ligated back together in a random fashion characteristic of the newly described genetic
phenomenon called chromothripsis. A circular plot of the connections revealed by paired end whole genome sequencing of the neutrophil DNA is shown (FIG.7A). The abnormal derivative chromosome was modeled using the breakpoints and connections discovered (FIG.7B) and revealed a predicted structural banding pattern that was identical to what was observed using cytogenetics.
The microarray derived gene deletions were confirmed and the rearrangement breakpoints analyzed for the creation of novel fusion genes and two potential possibilities were identified (FIG. 15A); however, these genes are unlikely to be expressed or functional because they each lack a promoter and transcription initiation site, and major regions of the potentially fused genes are deleted. Thus, a novel driver mutation was not identified that would have given these cells a growth advantage other than loss of one copy (haploinsufficiency) of 164 genes on the shortened derivative chromosome that resulted when chromothripsis occurred.
Example 7
Purification and in vitro culture of HSC and Hematopoietic Progenitors
Chromothripsis results when a chromosome or chromosomes are shattered into multiple pieces in a single event which is then repaired by the cellular DNA damage repair machinery. Thus it became apparent that the multiple genetic changes observed had occurred in a single HSC as an isolated event.
A scheme of hematopoietic differentiation is given in FIG.8 A. Knowledge of the exact breakpoints and orientations of the rearranged pieces allowed for the creation of four specific PCR amplification assays that confirmed the chromosomal rearrangement breakpoints predicted by the computer analysis of the WGS data and could detect DNA that had undergone chromothripsis. One of these PCR assays was used to investigate the hematopoietic system mosaicism further. Bone marrow aspirate was stained with fluorescent monoclonal antibodies and then underwent flow cytometric sorting to separate HSC, common lymphoid progenitors (CLP), common myeloid progenitors (CMP), and granulocyte macrophage progenitors (GMP). DNA isolated from these cell groups and subjected to the chromosomal rearrangement PCR described above revealed that three of the four hematopoietic progenitor types had evidence of chromothripsis (FIG.8B). CLP was the only progenitor type that did not show chromothripsis consistent with the patient's CD19+ B and CD3+ T cells lacking evidence of chromothripsis and retaining the CXCR4R334X mutation. In vitro cultures of purified CD34+ progenitor cells were performed under conditions that allowed development of progenitor colonies and PCR of DNA from these revealed a similar dichotomy (FIGS. 15A and 15B).
Example 8
Cytokine Abnormalities
To further understand why the index patient had neutrophilia, monocytosis and increased effector memory T cells, cytokine, interleukin, and chemokine levels in her blood were analyzed. Frozen serum samples from the index patient, 5 healthy blood donors, and 5 WHIM patients were used for determination of a variety of cytokine, interleukin, and chemokine levels (FIG. 9, Table 5). This revealed that the patient had increased levels of a variety of molecules known to stimulate neutrophils, monocytes and T cells. In particular, CXCL8 (aka Interleukin- 8), CXCL1 (aka Growth-regulated protein alpha) and Interleukin- 17 (IL-17) are known to stimulate and attract neutrophils; while Interleukins (IL) such as IL-2, IL-12, and IL-15 act to stimulate memory T cells.
Interferon gamma (IFN-γ) and CXCL9 (aka monokine induced by gamma interferon or MIG) and IL-1 have broad effects on the immune system and stimulate all three cell types.
Table 5. Serum cytokine concentrations of the index patient compared to 5 other WHIM patients and 5 Healthy Donors
G-CSF, Granulocyte Colony-Stimulating Factor; GM-CSF, Granulocyte-Macrophage Co
Stimulating Factor; M-CSF, Macrophage Colony-Stimulating Factor; IFN, Interferon; IL,
Interleukin; CXCL, CXC Chemokine Ligand; CCL, CC Chemokine Ligand, TGF, Transforming Growth Factor; TNF, Tumor Necrosis Factor; HD, Healthy Donor; WHIM, Warts,
Hypogammaglobulinemia, Infections, Myelokathexis Syndrome Patient; WHIM-09, index patient of this report
Example 9
Loss of one copy of CXCR4 causes a transplantation advantage for CD34+ HSC
To model the effects of loss of CXCR4 haploinsufficiency on HSC engraftment in transplantation, wild-type Cxcr4 (Cxcr4+/+), hemizygous Cxcr4 (Cxcr4+/o), and WHIM syndrome (Cxcr4+/S338x) mice were used to perform competitive repopulation experiments. Leukocytes from these strains were specifically marked with either CD45.1 or CD45.2 or both, allowing tracking of transplanted donor cell fate in vivo by FACS.
Cxcr4 floxed mice (Strain 008767, B6.129P2- Cxcr4tm2Yzo/J) and Ella promoter driven Cre recombinase transgenic mice (Strain 003724, B6.FVB-Tg(EIIa-cre)C5379Lmgd/J) were obtained from The Jackson Laboratory (Bar Harbor, ME) and bred together to generate Cxcr4+/o mice on a homozygous CD45.2 background. Cxcr4+/+ mice were obtained from Jackson Laboratory on the homozygous CD45.1 and homozygous CD45.2 backgrounds. Creation of WHIM knockin mice bearing a heterozygous Cxcr4S338x mutation has been previously described (Balabanian et al., 2012) and sperm from these mice were used for in vitro fertilization to impregnate female C57BL/6 mice from Taconic Farms (Hudson, NY) to produce Cxcr4+/S338x on a homozygous CD45.2 background. Both Cxcr4+/o and Cxcr4+,S338X mice on the homozygous CD45.2 background were bred to Cxcr4+/+ mice on a homozygous CD45.1 background to produce Cxcr4+/o and Cxcr4+,S338X mice on a heterozygous CD45.1/CD45.2 background. In this way, differentially marked donor bone marrow cells could be tracked in vivo during competitive transplantation experiments. Five million bone marrow cells, or 2000 HSCs, (-50% from each donor) were transferred via tail vein injection into recipient mice that had undergone lethal irradiation (900 rads) 8 hours prior to transplant. The mice were fed with neomycin water for four weeks post irradiation. All animal experiments were performed using an NIAID Animal Care and Use Committee (ACUC) approved protocol in approved and certified facilities. In some experiments, ten million bone marrow cells were injected into non-irradiated mice. To isolate mouse hematopoietic stem cells (HSCs), the mixed bone marrow cells were lineage-depleted by negative selection with Lineage Cell Depletion Kit
(Miltenyi Biotech Inc., San Diego, CA) and then HSCs (lineage Scal+c-Kit+CD48"CD34 CD150+) were sorted using a sorting cytometer (FACS Aria II, BD Biosciences, San Jose, CA).
To study the proliferation of HSCs, bone marrow cells from donors with a Cxcr4+/o genotype on a homozygous CD45.2 background were mixed (47%:53%) with bone marrow cells from donors with a Cxcr4+/+ genotype on a heterozygous CD45.1/CD45.2 background and then 5 million bone marrow cells were injected intravenously into each CD45.1 recipient mouse that had been lethally irradiated 8 hours prior. Six days after bone marrow transplantation, each mouse was given 1.25 mg of BrdU ip. Twenty hours later, the mice were euthanized for HSC proliferation analysis with FITC BrdU Flow Kit (BD Biosciences, San Jose, CA).
When donor bone marrow cells from two different Cxcr4 genotype mice were mixed together in equal proportions (~50 :50 ) and transplanted into lethally irradiated or non-irradiated Cxcr4+/+ recipients, the results showed that in both irradiated and non-irradiated recipient mice there was much more rapid and complete engraftment of the donor bone marrow from the Cxcr4+/o mice than from either the Cxcr4+/S338x mice (FIGS. 10A and 10B) or the Cxcr4+/+ mice (FIGS. 11A and 11B). The same effect was observed with HSC transplantation (FIGS. 12A and 12B), indicating that the enhanced engraftment attributable to Cxcr4 haploinsufficiency is HSC intrinsic.
To investigate the mechanism for the apparent competitive advantage of Cxcr4+/o over Cxcr4+/+ bone marrow cells for reconstituting the blood, the proliferative status of the
corresponding HSCs in vivo by BrdU incorporation early after transplantation (day 7) was measured (FIG. 13A). The results indicated -20% greater frequency of BrdU+ Cxcr4+/o HSCs as compared to Cxcr4+/+ HSCs, indicating a proliferative advantage of Cxcr4+/o HSCs in the bone marrow. To test whether differential retention of leukocytes in the bone marrow might also contribute to the skewed distribution of mature leukocytes in the blood, mice were sacrificed at day 298 after competitive transplantation with Cxcr4+/o and Cxcr4+/+ bone marrow cells (the same combination of donor bone marrow cells as were analyzed in the proliferation experiments). The results showed that Cxcr4+/o HSCs, HPCs (hematopoietic progenitor cells) and total CD45+ cells (mostly mature leukocytes) predominated in the bone marrow by the same 4: 1 ratio over the corresponding Cxcr4+/+ cells as was found for mature leukocytes in the blood. Thus, the predominance of mature Cxcr4+/o over Cxcr4+/+ leukocytes in the blood of competitively transplanted mice cannot be simply explained by low retention of mature Cxcr4+/o leukocytes relative to the retention of mature Cxcr4+/+ leukocytes in the bone marrow. Moreover, the results at this very late time point clarify that enhanced Cxcr4+/o HSC proliferation does not result in long term depletion of HSCs. The frequency distribution of stem and progenitor subtypes was the same for each genotype, indicating no block to progenitor cell differentiation (FIG. 13B).
Example 10
Discussion
This patient represents the first example of a genetic reversion of the rare immunodeficiency WHIM syndrome. The data demonstrate that she is a somatic mosaic within the hematopoietic system (FIGS. 1C, 2A, and 2B). Her erythroid and myeloid lineages exhibited loss of the
CXCR4WHIM allele and presence of a derivative chromosome while lymphoid lineages exhibit retention of the CXCR4WHIM allele and lack of the derivative chromosome (FIG. 2). Multiple lines of evidence point to this genetic reversion occurring in a single primitive hematopoietic stem cell in early adulthood which then resulted in reversal of neutropenia, monocytopenia, bacterial infections and severe cutaneous HPV disease (FIGS. 3 and 4). Unexpectedly this reversion is the
consequence of a complex chromosomal rearrangement of only the chromosomal copy where the mutant CXCR4WHM allele was located (FIGS. 5 and 6). Whole genome sequencing and microarray demonstrated that this rearrangement bears all the hallmarks of the recently defined chromothripsis phenomenon (FIG. 7) (Korbel and Campbell, 2013). Chromothripsis has been identified to date as a source of complex chromosomal rearrangements present in various cancers (Jones and Jallepalli, 2012). Thus, this is the first example of chromothripsis resulting in a positive outcome and fully understanding this patient will have important implications to understanding the biology of the immune response to human papillomavirus (HPV) infection, hematopoietic stem cells (HSC) and bone marrow transplantation (BMT) and gene therapy of HSC.
Implications for HPV disease
HPV is a chronic problem in WHIM patients once they become infected with this virus (Beaussant Cohen et al., 2012; Kawai and Malech, 2009; Tassone et al., 2009; Wetzler et al., 1990). Cutaneous and anogenital disease is typically recurrent despite surgical removal and other destructive methods being utilized, immunostimulants like imiquimod are ineffective, and chronic disease has led to lethal cancers in WHIM patients. HPV has evolved multiple ways to evade the immune system and can become a chronic infection even in normal individuals; however, patients with a wide variety of different immunodeficiencies are at increased risk of chronic HPV infection that progresses to cancer (Leiding and Holland, 2012). WHIM-09's reversal of HPV hand warts without treatment is unprecedented in WHIM syndrome and strongly indicates that the myeloid arm (monocytes and/or granulocytes) of the immune system plays an important and previously unsuspected role in successful viral clearance because the derivative chromosome was not found in the lymphoid arm (B, T, and NK cells) of the patient's immune system (FIG.2). In addition since
the derivative chromosome was not found in the skin keratinocytes or fibroblasts, her case also indicates that mutation of CXCR4 in these cells is not the primary driver of HPV persistence (FIG.2). These findings reinforce the importance of the immune response in clearing the virus once infection develops and provide further hope that correcting the immune system defects either through drug therapy with CXCR4 antagonists like plerixafor, directed gene therapy to remove the mutant CXCR4 allele, or BMT with allogeneic HSC could ameliorate this problem.
Implications for HSC Biology
HSC are the only cells in the bone marrow that are both pluripotent and long lived (Seita and Weissman, 2010). These rare cells can be identified by a combination of characteristic cell surface markers and undergo a tightly controlled, hierarchical differentiation process into the mature elements of the blood (FIG. 8A). The data herein demonstrate that the HSC and myeloid compartments of the immune system were nearly completely or completely replaced by cells that bore the derivative chromosome (FIG.8B). This indicates that this genetic change created some type of survival or proliferative advantage for these mutated HSC versus the WHIM HSC that the patient was born with. This advantage was capable of repopulating the HSC compartment without the application of any standard methods used to clear the stem cell niche in BMT such as radiation therapy or chemotherapy. Therefore, it is likely that the chromothripsis induced genetic change enhanced the ability of the HSC to populate, proliferate or survive in the niche. This idea is consistent with prior knowledge that CXCL12 abundant reticular (CAR) cells that contact HSC in the bone marrow niche enhance their quiescence by stimulating CXCR4 signaling (Sugiyama et al., 2006). However, in previously published mouse models using HSC transfected with CXCR4+/+ or CXCR4WHIM, it was demonstrated that constructs containing the WHIM mutation can enhance trafficking of infused HSC to the bone marrow (Kawai et al., 2007). Therefore prior to
understanding more about this patient, it would have been believed that increased rather than reduced CXCR4 signaling would be beneficial to engraftment.
Implications for BMT and HSC Gene Therapy
BMT using HSC is an increasingly common medical therapy for severe hematologic cancers and primary hematologic immunodeficiencies (Copelan, 2006). However, for significant engraftment to occur there must usually be pre-transplant conditioning with either irradiation or chemotherapy or both. The purpose of this conditioning is to kill the rapidly growing cancer cells and clear bone marrow niches for the infused HSC in the case of hematologic malignancy.
However, reduced intensity conditioning is needed for BMT even in the case of most
immunodeficiencies to create marrow space for the infused HSC. This pre-transplant conditioning causes cellular and immune system damage that is directly or indirectly responsible for most of the morbidity and mortality associated with BMT.
The patient described herein however was able to replace her HSC clonally without the need for either pre-transplant conditioning regimen (FIG. 8B). This indicates that her
chromothripsis induced derivative chromosome had a genetic change that created a marked proliferative or survival advantage for the resultant mutated HSC. Since no evidence was found for creation of a novel fusion gene in the derivative chromosome, the data supported that the loss of one copy of a gene (haploinsufficiency) on chromosome 2 had created the advantage. Inspection of the list of genes (Table 4) that she was haploinsufficient for indicates that CXCR4 is a logical candidate gene as previous studies had indicated that CXCR4 signaling resulting from CXCL12 secretion by CAR cells in the bone marrow niche played a role in HSC quiescence (Sugiyama et al., 2006).
The CXCL12 / CXCR4 system is highly conserved in the mouse and functions quite similarly to the human system (Bachelerie et al., 2014). A WHIM mouse model (Cxcr4+ WHIM) was previously generated by creating a truncation mutation in a single copy of the mouse gene with a human disease causing mutation (S338X) (Balabanian et al., 2012). This enabled the use of a competitive bone marrow repopulation assay in a mouse model of bone marrow transplantation to confirm that loss of one copy of CXCR4 was creating an engraftment advantage. When the recipient mouse was lethally irradiated prior to the infusion of donor marrow (FIG. 10A), the bone marrow cells lacking one copy of CXCR4 (Cxcr4+/0) were rapidly able to take over the bone marrow production of granulocytes (Ly6G+), monocytes (CDl lb+) and B cells (CD19+) and nearly completely effaced the Cxcr4+ WHIM bone marrow within the first 30 days of BMT. These results were stable for up to 10 months when the experiment was terminated. Results with T cells (CD3+) were less impressive but this is probably inherent in this model because adult mice were
transplanted who likely lacked a functional thymus necessary for full T cell development. In addition memory T cells are radioresistant (allowing continued presence of these cells in the recipient (CD45.1 mice) and capable of self -proliferation in the periphery. When experiments were performed without irradiating the recipient mice (FIG. 10B), markedly enhanced engraftment of the Cxcr4+/" derived bone marrow was observed as compared to Cxcr4+ WHIM derived bone marrow. This latter model is most comparable to the patient's likely mechanism of bone marrow
repopulation and provides significant support of the conclusion that CXCR4 is the major factor producing her outcome. The selective advantage in Cxcr4+/" derived bone marrow was also evident
in competition experiments with Cxcr4 derived bone marrow in both irradiated and non- irradiated recipient mice (FIGS. 11A and 11B).
Example 11
Methods to Knock-Out One Allele of CXCR4
This example describes methods used to knock-out one allele of CXCR4 using gene editing tools.
Materials and Methods
Guides: Wild-type CRISPR-Cas9, Cas9-D10A nickase, guides and CXCR4-copGFP-
CXCR4 donor were purchased from GeneCopoeia (Rockville, MD). TALEN vectors were generated using the FastTALE system from Sidansai Biotechnology (Shanghai, China) according to manufacturer's instruction.
Cell culture: HeLa cells were grown in EMEM media (Quality Biological, Gaithersburg, MD) supplemented with 10% fetal bovine serum (Quality Biological, Gaithersburg, MD), minimum non-essential amino acids (Corning, Corning, NY), sodium pyruvate (Corning, Corning, NY) and penicillin-streptomycin antibiotics (Life Technologies, Carlsbad, CA). Cells were maintained at 37°C with 5% C02.
Transfection: 1 million HeLa cells were transfected with 2 μg of maxGFP (Lonza,
Walkersville, MD), 2 μg CXCR4-copGFP-CXCR4 donor, 6 μg CXCR4-copGFP-CXCR4 donor and 6 μg TALEN LI, 6 μ CXCR4-copGFP-CXCR4 donor along with 3 μg TALEN LI and 3 μg TALEN R2, 1 μg of wild-type Cas9 and 1 μg of each guide or 1 μg of Cas9-nickase and 0.5 μg of each guide using 4D-Nucleofector (Lonza) according to manufacturer' s instructions with the following additions. Prior to plating, 0.5 mis of media was added to cells in nucleocuvettes and the cells were incubated at 37°C in for 30 minutes.
FACS analysis: Unless otherwise noted, cells were harvested 6 days after nucleofection and stained with CXCR4-PE (BD Pharmingen, San Jose, CA) or isotype control antibodies according to the manufacturer's instructions. Cells were sorted using the FACS Ariall system.
Indel analysis from bulk populations of cells: Edited cells were harvested and indel analysis was carried out using the Clontech Indel Identification kit (Mountain View, CA) according to the manufacturer's instructions. Briefly, lysate was made from harvested cells after which PCR amplification of genomic DNA was carried out using the primers:
CXCR4-indel forward; 5 ' -CGGTACCCGGGGATCTTGTGCCCTTAGCCCACTAC-3 ' (SEQ ID NO: 7)
CXCR4-indel reverse; 5 ' -CGACTCTAGAGGATCCC ACCTTTTCAGCCAACAGC-3 ' (SEQ ID NO: 8)
The PCR products were sub-cloned into vectors followed by transformation into bacteria. CXCR4 sequences were PCR amplified from bacteria and sequenced.
Single cell clonal analysis: Cells were serially diluted to produce single cells in 96 well plates. Single cell cultures were grown for 4 weeks and genomic DNA was extracted using Wizard Genomic DNA extraction kit (Promega, Madison, WI) according to the manufacturer's instructions with the modification that the DNA was resuspended into a volume of 25 μΐ. 5 μΐ DNA was CXCR4 amplified in 25 μΐ volumes using PCR master mix (Life Technologies) according to the manufacturer's instructions and using the following primers and cycling conditions:
CXCR4 forward; 5 ' - AGCGTCTCAGTGCCCTTTTG-3 ' (SEQ ID NO: 9)
CXCR4 reverse; 5 ' - ATCTGCCTCACTGACGTTGG-3 ' (SEQ ID NO: 10)
Cycling conditions: 95°C, 3 minutes; 95°C, 40 seconds; 55°C, 40 seconds; 72°C, 40 seconds; 72°C, 7 minutes for a total of 40 cycles.
The PCR products were TA cloned into vectors using the TOPO-TA cloning kit (Life
Technologies, Grand Island, NY) according to the manufacturer's instructions. PCR products in TA vectors were sequenced.
Surveyor assay: Genomic DNA was extracted using Wizard Genomic DNA extraction kit (Promega, Madison, WI) according to the manufacturer's instructions with the modification that the DNA was resuspended into a volume of 25 μΐ. CXCR4 DNA was PCR amplified as above, mixed with nuclease free water and NEB buffer 2 in a final volume of 18 μΐ, after which the PCR products were denatured and re-annealed using the cycling conditions: 95°C, 10 minutes for denaturation; decrease at 0.1 sec to 85°C; hold at 85°C for 2 minutes; decrease at 0.1 sec to 75°C; hold at 75°C for 3 minutes; decrease at 0.1 sec to 65°C; hold at 65°C for 3 minutes; decrease at 0.1 sec to 65°C; hold at 65°C for 3 minutes; decrease at 0.17sec to 55°C; hold at 55°C for 3 minutes; decrease at 0.1 sec to 45°C; hold at 45°C for 3 minutes; decrease at 0.17sec to 45°C; hold at 45°C for 3 minutes; decrease at 0.17sec to 35°C; hold at 35°C for 3 minutes; decrease at 0.17sec to 25°C; hold at 25°C for 3 minutes; then hold at 4°C. Each reaction was split into two, 0.5 μΐ per reaction of Surveyor enzyme (Transgenomics (Omaha, NE) was added to one set of reactions along with nuclease free water and NEB Buffer 2 in final volumes of 20 μΐ volumes while the other set of reactions only received nuclease-free water and NEB Buffer 2. The samples were incubated at 37°C for 40 minutes. 45 mM EDTA was used to stop the reaction after which the samples were mixed with DNA loading dye and run on 2% ethidium bromide stained gels.
Results
Single allele editing of CXCR4
Transfection of the complete TALEN system (LI + R2) into HeLa cells generated mutations in CXCR4 as demonstrated by a reduction in CXCR4 protein expression by FACS analysis (FIGS. 16B and 16C) and by sequence analysis (FIG. 16D). 25% of the TALEN sequences sorted from the CXCR4 low cells (CXCR4 lo) carried deletions varying from one (SEQ ID NO: 17) to several nucleotides (FIG. 16D, and SEQ ID NOS: 15 and 16). On the contrary, transfection of the incomplete system did not affect CXCR4 expression (FIG. 16B) or sequence (FIG. 16D) indicating that the effect is specific to TALEN-mediated gene editing. Interestingly, cells that were sorted initially as CXCR4 Lo expressed significant amounts of the protein when cultured (FIGS. 16C, 17C).
The CRISPR-Cas9 system was also used to create deletions in human CXCR4 (FIG. 17A). Transfection of only Cas9-D10A nickase into HeLa cells did not affect the expression of CXCR4 whereas the combination of nickase and guides down-regulated CXCR4 expression indicating that the effect was specific (FIG. 17B). Surveyor assay confirmed the presence of mutations in the population of cells that expressed little or no CXCR4 (CXCR4 Lo) (as indicated by the presence of 2 additional bands upon Surveyor treatment, (FIG. 17C) whereas no mutations were detected by Surveyor for the population of cells that expressed high levels of CXCR4 (CXCR4 Hi) (FIG. 17C). The presence of a remaining band of the original 800 base pair size after Surveyor treatment indicated the presence of wild-type CXCR4 in the cells and suggested that the cells are
hemizygous, containing one wild-type and one null allele of CXCR4. Sequencing confirmed the presence of mutations in the populations of cells that expressed medium (CXCR4 Mid) and low (CXCR4 Lo) levels of CXCR4 (FIG. 17C). Interestingly, approximately 60% of the mutations obtained were an identical 40 base pair deletion (FIG. 17D). When examined at the single cell clone level, sequencing analysis confirmed that only one copy of CXCR4 had been mutated in 60% of the clones (FIG. 17E).
Example 12
Treatment of Sickle Cell Anemia in Mice
Commercially available humanized sickle cell mice (Jackson Laboratories strain #013071) can be used. These mice develop infarcted organs, enlarged spleens, anemia, and sickled red cells as they age because the mouse hemoglobin genes have been replaced by human versions and the hemoglobin B gene (HBB) has the exact same mutation as is found in human sickle cell patients.
HSCs obtained from CXCR4+/- mice as described above will be introduced into the sickle cell mice as described above. It will then be determined if these donor HSCs will engraft and cure the disease symptoms in these mice without a requirement for bone marrow conditioning.
In some examples, donor HSCs from Cxcr4+/+ congenic as well as from sickle cell mice will be manipulated ex vivo to downregulate CXCR4 and correct the mutated HBB using CRISPR-Cas9 to cure the sickle cell disease. The Crispr/Cas system will be used to target CXCR4 for disruption by NHEJ. A second plasmid will encode a single guide RNA to create a DSB or 2 SSB near the HBB mutation that will then be repaired by homologous recombination using a donor sequence on either a third plasmid carrying wt HBB or a specifically designed oligonucleotide sequence designed to repair the mutation. This will be done in sickle cell mice obtained commercially from The Jackson Laboratory (Bar Harbor, ME). Similar experiments can be done using the TALEN system. Exemplary sequences that can be used are shown in Table 6.
Table 6: Exemplary Crisper and TALEN sequences to knock-down CXCR4
TALEN Rl 5'-ACTTGTCCGTCATGC-3' (44) 5'-WT mCXCR4 Exon 2
TALEN R2 5'-ACTTGTCCGTCATG-3' (45) 5'-WT mCXCR4 Exon 2 sgRNA6 5'-TCl CT(:K3TAACCCATGACC-3' (46) 5'-WT hCXCR4 Exon 2 sgRNA7 5 -GAAGCATGACGGACAAGTAC-3' 5'-WT hCXCR4 Exon 2
(47) sgRNA8 5'-GCTGGACCCTCTGCTCACAG-3' 3'-WT hCXCR4 Exon 2
(48) sgRNA9 5 '-CTCTCC A A AGG A A AGCG AGG- 3 ' 3'-WT hCXCR4 Exon 2
(49) sgRNAlO 5'-CTCTCCAAAGGAAAG7GAGG-3' 3'-M hCXCR4 Exon 2
CXCR4-R334X mutant specific (50)
WT=wild type, M=mutant, bold/italic letters indicate deliberate mismatch to WT sequence
References
Bachelerie, F., Ben-Baruch, A., Burkhardt, A.M., Combadiere, C, Farber, J.M., Graham, G.J., Horuk, R., Sparre-Ulrich, A.H., Locati, M., Luster, A.D., et al. (2014). International Union of Pharmacology. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors. Pharmacological reviews 66, 1-79.
Balabanian et al, Blood 119, 5722-5730, 2012.
Beaussant et al., Orphanet journal of rare diseases 7, 71, 2012.
Berger et al., (1999). Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annual review of immunology 17, 657-700.
Bleul et al, (1996). J. Exp. Med. 184, 1101-1109.
Broxmeyer et al., (2003a). J Immunol 776», 421-429.
Broxmeyer et al., (2003b). Journal of leukocyte biology 73, 630-638.
Broxmeyer et al. (2005). J. Exp. Med. 201, 1307-1318.
Copelan, E.A. (2006). The New England J. Med. 354, 1813-1826.
Dale et al, (2011). The CXCR4 antagonist plerixafor is a potential therapy for myelokathexis, WHIM syndrome. Blood. 118:4963-6.
Dotta et al, (2011). Current molecular medicine 11, 317-325.
Feng et al, (1996). Science 272, 872-877.
Haribabu et al, (1997). The J. Biol. Chem. 272, 28726-28731.
Hernandez et al, (2003). Nat Genet 34, 70-74.
Jones, M.J., and Jallepalli, P.V. (2012). Developmental cell 23, 908-917.
Kawai et al, (2007). Blood 109, 78-84.
Kawai, T., and Malech, H.L. (2009). Curr Opin Hematol 16, 20-26.
Kim et al, (2013). Genome biology 14, R36.
Kloosterman et al. (2011). Human molecular genetics 20, 1916-1924.
Korbel, J.O., and Campbell, P.J. (2013). Criteria for inference of chromothripsis in cancer genomes. Cell 152, 1226-1236.
Krill et al, (1964). The New England journal of medicine 276», 973-979.
Krzywinski et al., . (2009). Genome research 19, 1639-1645.
Lawnicki et al, (2003). JMD 5, 82-87.
Leiding, J.W., and Holland, S.M. (2012).. The Journal of allergy and clinical immunology 130, 1030-1048.
McDermott et al. (2011). Blood. 118:4957-62.
McDermottei al. (2014). Blood 123, 2308-2316.
Nie et al, (2008). J. Exp. Med. 205, 777-783.
Ramasamy et al, (1992). Journal of clinical pathology 45, 770-775.
Rausch et al. (2012). Cell 148, 59-71.
Robinson et al, (2011). Nature biotechnology 29, 24-26.
Seita, J., and Weissman, I.L. (2010). Hematopoietic stem cell: self-renewal versus differentiation. Wiley interdisciplinary reviews Systems biology and medicine 2, 640-653.
Signoret et al, (1998). J Cell Sci 111 ( Pt 18), 2819-2830.
Stephens et al. (2011). Cell 144, 27-40.
Sugiyama et al, (2006). Immunity 25, 977-988.
Tassone et al, (2009). The Journal of allergy and clinical immunology 123, 1170-1173, 1173 el l71-1173.
van Dongen, et al. (2003). Leukemia 17, 2257-2317.
Venkatesan et al, (2003). Mol. Biol. Cell 14, 3305-3324.
Wetzler et al.,. (1990). Am J Med 89, 663-672.
Zuelzer, W.W. (1964). New England J. Med 270, 699-704.
In view of the many possible embodiments to which the principles of the disclosure may be applied, it should be recognized that the illustrated embodiments are only examples of the invention and should not be taken as limiting the scope of the invention. Rather, the scope of the disclosure is defined by the following claims. We therefore claim as our invention all that comes within the scope and spirit of these claims.
Claims
1. A method of increasing hematopoietic stem cell (HSC) engraftment in a recipient subject, comprising
reducing expression or activity of CXC chemokine receptor 4 (CXCR4) in a donor HSC, thereby generating a CXCR4 knockdown HSC; and
administering a therapeutically effective amount of the CXCR4 knockdown HSC to the recipient subject, thereby increasing HSC engraftment in the recipient subject.
2. The method of claim 1, further comprising:
correcting a genetic defect in the HSC, wherein the genetic defect causes a disease in the recipient subject;
reducing expression of a first target gene in the HSC, wherein reducing expression of the first target gene treats a disease caused by upregulation of the first target gene in the recipient subject or treats a disease that benefits from reducing expression of the first target gene in the recipient subject; or
increasing expression of a second target gene in the HSC, wherein increasing expression of the second target gene treats a disease caused by downregulation of the second target gene in the recipient subject or treats a disease that benefits from increasing expression of the second target gene in the recipient subject.
3. The method of claim 2, wherein the genetic defect comprises a point mutation, gene rearrangement, gene deletion, gene insertion, or combinations thereof.
4. The method of any of claims 1 to 3, wherein the subject has a hematologic malignancy.
5. The method of claim 4, wherein the hematologic malignancy is a leukemia, lymphoma, or myeloma.
6. The method of claim 4, wherein the hematologic malignancy is chronic myelogenous leukemia (CML) and the genetic defect in the HSC is a BCR-ABL fusion gene.
7. The method of claim 2, wherein the subject has HIV-1, and the first target gene is C-C chemokine receptor type 5 (CCR5).
8. The method of any of claims 1, 2, 3 or 7, wherein the subject has a genetic disease of the blood.
9. The method of claim 8, wherein the genetic disease of the blood is sickle cell anemia, hemophilia A, hemophilia B, alpha-thalassemia, beta- thalassemia, delta-thalassemia, von
Willebrand Disease, pernicious anemia, Fanconi anemia, thrombocytopenic purpura, thrombophilia or WHIM syndrome.
10. The method of claim 8, wherein the genetic disease of the blood is a primary
immunodeficiency disease.
11. The method of any of claims 2 to 9, wherein the subject has;
sickle cell anemia and the genetic defect in the HSC is a Glu to Val mutation in amino acid 6 of a β-globin chain of hemoglobin;
hemophilia A and the genetic defect in the HSC comprises a mutation in clotting factor
VIII;
hemophilia B and the genetic defect in the HSC comprises a mutation in clotting factor IX; thrombocytopenic purpura and the genetic defect in the HSC comprises a mutation in ADAMTS13; or
thrombophilia and the genetic defect in the HSC comprises a mutation in factor V Leiden or prothrombin.
12. The method of any of claims 1 to 11, wherein the donor HSC and the CXCR4 knockdown HSC express CD34.
13. The method of any of claims 1 to 12, wherein expression of CXCR4 is reduced by at least 20% in the CXCR4 knockdown HSC as compared to expression of CXCR4 in the donor HSC prior to reducing CXCR4 expression.
14. The method of any of claims 1 to 12, wherein expression of CXCR4 is reduced by at least 50% in the CXCR4 knockdown HSC as compared to expression of CXCR4 in the donor HSC prior to reducing CXCR4 expression.
15. The method of any of claims 1 to 14, wherein reducing expression of CXCR4 comprises functionally deleting one copy of a CXCR4 allele in the donor HSC.
16. The method of any of claims 1 to 15, wherein expression of CXCR4 is reduced by a gene editing method, an RNA interference method, or a CXCR4- specific binding agent.
17. The method of any of claims 2 to 16, wherein
correcting the genetic defect in the HSC, reducing expression of a first target gene in the HSC, or increasing expression of a second target gene in the HSC, is achieved by a gene editing method or an RNA interference method.
18. The method of any of claims 1 to 17, wherein the donor HSCs are obtained from the recipient subject.
19. The method of any of claims 1 to 17, wherein the donor HSCs are obtained from a subject different from the recipient subject.
20. The method of any of claims 1 to 19, wherein the method further comprises harvesting HSC from a donor subject.
21. The method of any of claims 1 to 20, wherein the recipient subject has not received conditioning prior to administering the CXCR4 knockdown HSCs to the recipient subject.
22. The method of claim 21, wherein the conditioning comprises chemotherapy and/or total body irradiation.
23. The method of any of claims 1 to 22, wherein the recipient subject is a human subject.
24. The method of any of claims 15 to 23, wherein functionally deleting one copy of a CXCR4 allele in the donor HSC comprises expressing one or more of SEQ ID NOS: 11, 12, 18, 19, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, and 50 in the donor HSC.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/324,219 US11278572B2 (en) | 2014-07-18 | 2015-07-17 | Reducing CXCR4 expression and/or function to enhance engraftment of hematopoietic stem cells |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462026138P | 2014-07-18 | 2014-07-18 | |
US62/026,138 | 2014-07-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016011381A1 true WO2016011381A1 (en) | 2016-01-21 |
Family
ID=53783970
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2015/040954 WO2016011381A1 (en) | 2014-07-18 | 2015-07-17 | Reducing cxcr4 expression and/or function to enhance engraftment of hematopoietic stem cells |
Country Status (2)
Country | Link |
---|---|
US (1) | US11278572B2 (en) |
WO (1) | WO2016011381A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016183236A1 (en) * | 2015-05-11 | 2016-11-17 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for treating hiv infection and aids |
EP3500671A4 (en) * | 2016-08-17 | 2020-07-29 | The Broad Institute, Inc. | Novel crispr enzymes and systems |
EP3500670A4 (en) * | 2016-08-17 | 2020-08-19 | The Broad Institute, Inc. | Novel crispr enzymes and systems |
US10973852B2 (en) | 2016-01-25 | 2021-04-13 | Nantcell, Inc. | NK cells with altered CXCL12/CXCR4 signaling |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20220220472A1 (en) * | 2019-05-06 | 2022-07-14 | The Regents Of The University Of Michigan | Targeted therapy |
CN110577952B (en) * | 2019-09-26 | 2022-11-25 | 江苏省人民医院(南京医科大学第一附属医院) | Application of siRNA interfering long non-coding RNA in preparation of medicine for treating breast cancer |
Citations (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1988009810A1 (en) | 1987-06-11 | 1988-12-15 | Synthetic Genetics | Novel amphiphilic nucleic acid conjugates |
WO1990011364A1 (en) | 1989-03-24 | 1990-10-04 | University Patents, Inc. | Rna ribozyme restriction endoribonucleases and methods |
US5093246A (en) | 1986-12-03 | 1992-03-03 | University Patents, Inc. | Rna ribozyme polymerases, dephosphorylases, restriction endoribo-nucleases and methods |
WO1995019431A1 (en) | 1994-01-18 | 1995-07-20 | The Scripps Research Institute | Zinc finger protein derivatives and methods therefor |
WO1995023225A2 (en) | 1994-02-23 | 1995-08-31 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for inhibiting the expression of disease related genes |
WO1996006166A1 (en) | 1994-08-20 | 1996-02-29 | Medical Research Council | Improvements in or relating to binding proteins for recognition of dna |
US5716827A (en) * | 1990-03-30 | 1998-02-10 | Systemix, Inc. | Human hematopoietic stem cell |
US5789538A (en) | 1995-02-03 | 1998-08-04 | Massachusetts Institute Of Technology | Zinc finger proteins with high affinity new DNA binding specificities |
WO1998053058A1 (en) | 1997-05-23 | 1998-11-26 | Gendaq Limited | Nucleic acid binding proteins |
WO1998053059A1 (en) | 1997-05-23 | 1998-11-26 | Medical Research Council | Nucleic acid binding proteins |
WO1998054311A1 (en) | 1997-05-27 | 1998-12-03 | The Scripps Research Institute | Zinc finger protein derivatives and methods therefor |
US5902880A (en) | 1994-08-19 | 1999-05-11 | Ribozyme Pharmaceuticals, Inc. | RNA polymerase III-based expression of therapeutic RNAs |
US5925523A (en) | 1996-08-23 | 1999-07-20 | President & Fellows Of Harvard College | Intraction trap assay, reagents and uses thereof |
WO2000027878A1 (en) | 1998-11-09 | 2000-05-18 | Gendaq Limited | Screening system for zinc finger polypeptides for a desired binding ability |
US6110743A (en) | 1995-02-10 | 2000-08-29 | The Regents Of The University Of California | Development and use of human pancreatic cell lines |
US6140081A (en) | 1998-10-16 | 2000-10-31 | The Scripps Research Institute | Zinc finger binding domains for GNN |
US6146886A (en) | 1994-08-19 | 2000-11-14 | Ribozyme Pharmaceuticals, Inc. | RNA polymerase III-based expression of therapeutic RNAs |
WO2001060970A2 (en) | 2000-02-18 | 2001-08-23 | Toolgen, Inc. | Zinc finger domains and methods of identifying same |
WO2001088197A2 (en) | 2000-05-16 | 2001-11-22 | Massachusetts Institute Of Technology | Methods and compositions for interaction trap assays |
WO2002016536A1 (en) | 2000-08-23 | 2002-02-28 | Kao Corporation | Bactericidal antifouling detergent for hard surface |
US6453242B1 (en) | 1999-01-12 | 2002-09-17 | Sangamo Biosciences, Inc. | Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites |
WO2002099084A2 (en) | 2001-04-04 | 2002-12-12 | Gendaq Limited | Composite binding polypeptides |
WO2003016496A2 (en) | 2001-08-20 | 2003-02-27 | The Scripps Research Institute | Zinc finger binding domains for cnn |
US6534261B1 (en) | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
WO2008136656A1 (en) * | 2007-05-02 | 2008-11-13 | Erasmus University Medical Center Rotterdam | Improved methods and means for lentiviral gene delivery |
US20110027235A1 (en) | 2009-04-09 | 2011-02-03 | Sangamo Biosciences, Inc. | Targeted integration into stem cells |
US20120177616A1 (en) * | 2010-12-22 | 2012-07-12 | Plasalus LLC | Methods for augmentation collection of placental hematopoietic stem cells and uses thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2305787A1 (en) * | 2000-05-09 | 2001-11-09 | The University Of British Columbia | Cxcr4 antagonist treatment of hematopoietic cells |
AU2010226313B2 (en) * | 2009-03-20 | 2014-10-09 | Sangamo Therapeutics, Inc. | Modification of CXCR4 using engineered zinc finger proteins |
BR112013003366A2 (en) | 2010-08-12 | 2020-08-04 | Fate Therapeutics, Inc. | improved hematopoietic and progenitor stem cell therapy |
EP2931899A1 (en) * | 2012-12-12 | 2015-10-21 | The Broad Institute, Inc. | Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof |
JP2016522679A (en) * | 2013-04-04 | 2016-08-04 | プレジデント アンド フェローズ オブ ハーバード カレッジ | Therapeutic use of genome editing with the CRISPR / Cas system |
US20180141992A1 (en) * | 2014-11-06 | 2018-05-24 | President And Fellows Of Harvard College | Cells lacking b2m surface expression and methods for allogeneic administration of such cells |
-
2015
- 2015-07-17 WO PCT/US2015/040954 patent/WO2016011381A1/en active Application Filing
- 2015-07-17 US US15/324,219 patent/US11278572B2/en active Active
Patent Citations (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5093246A (en) | 1986-12-03 | 1992-03-03 | University Patents, Inc. | Rna ribozyme polymerases, dephosphorylases, restriction endoribo-nucleases and methods |
WO1988009810A1 (en) | 1987-06-11 | 1988-12-15 | Synthetic Genetics | Novel amphiphilic nucleic acid conjugates |
WO1990011364A1 (en) | 1989-03-24 | 1990-10-04 | University Patents, Inc. | Rna ribozyme restriction endoribonucleases and methods |
US5716827A (en) * | 1990-03-30 | 1998-02-10 | Systemix, Inc. | Human hematopoietic stem cell |
WO1995019431A1 (en) | 1994-01-18 | 1995-07-20 | The Scripps Research Institute | Zinc finger protein derivatives and methods therefor |
WO1995023225A2 (en) | 1994-02-23 | 1995-08-31 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for inhibiting the expression of disease related genes |
US6146886A (en) | 1994-08-19 | 2000-11-14 | Ribozyme Pharmaceuticals, Inc. | RNA polymerase III-based expression of therapeutic RNAs |
US5902880A (en) | 1994-08-19 | 1999-05-11 | Ribozyme Pharmaceuticals, Inc. | RNA polymerase III-based expression of therapeutic RNAs |
WO1996006166A1 (en) | 1994-08-20 | 1996-02-29 | Medical Research Council | Improvements in or relating to binding proteins for recognition of dna |
US6007988A (en) | 1994-08-20 | 1999-12-28 | Medical Research Council | Binding proteins for recognition of DNA |
US6013453A (en) | 1994-08-20 | 2000-01-11 | Medical Research Council | Binding proteins for recognition of DNA |
US5789538A (en) | 1995-02-03 | 1998-08-04 | Massachusetts Institute Of Technology | Zinc finger proteins with high affinity new DNA binding specificities |
US6110743A (en) | 1995-02-10 | 2000-08-29 | The Regents Of The University Of California | Development and use of human pancreatic cell lines |
US6200759B1 (en) | 1996-08-23 | 2001-03-13 | President And Fellows Of Harvard College | Interaction trap assay, reagents and uses thereof |
US5925523A (en) | 1996-08-23 | 1999-07-20 | President & Fellows Of Harvard College | Intraction trap assay, reagents and uses thereof |
WO1998053058A1 (en) | 1997-05-23 | 1998-11-26 | Gendaq Limited | Nucleic acid binding proteins |
WO1998053057A1 (en) | 1997-05-23 | 1998-11-26 | Gendaq Limited | Nucleic acid binding polypeptide library |
WO1998053059A1 (en) | 1997-05-23 | 1998-11-26 | Medical Research Council | Nucleic acid binding proteins |
WO1998053060A1 (en) | 1997-05-23 | 1998-11-26 | Gendaq Limited | Nucleic acid binding proteins |
WO1998054311A1 (en) | 1997-05-27 | 1998-12-03 | The Scripps Research Institute | Zinc finger protein derivatives and methods therefor |
US6140081A (en) | 1998-10-16 | 2000-10-31 | The Scripps Research Institute | Zinc finger binding domains for GNN |
WO2000027878A1 (en) | 1998-11-09 | 2000-05-18 | Gendaq Limited | Screening system for zinc finger polypeptides for a desired binding ability |
US6534261B1 (en) | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
US6453242B1 (en) | 1999-01-12 | 2002-09-17 | Sangamo Biosciences, Inc. | Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites |
WO2001060970A2 (en) | 2000-02-18 | 2001-08-23 | Toolgen, Inc. | Zinc finger domains and methods of identifying same |
WO2001088197A2 (en) | 2000-05-16 | 2001-11-22 | Massachusetts Institute Of Technology | Methods and compositions for interaction trap assays |
WO2002016536A1 (en) | 2000-08-23 | 2002-02-28 | Kao Corporation | Bactericidal antifouling detergent for hard surface |
WO2002099084A2 (en) | 2001-04-04 | 2002-12-12 | Gendaq Limited | Composite binding polypeptides |
WO2003016496A2 (en) | 2001-08-20 | 2003-02-27 | The Scripps Research Institute | Zinc finger binding domains for cnn |
WO2008136656A1 (en) * | 2007-05-02 | 2008-11-13 | Erasmus University Medical Center Rotterdam | Improved methods and means for lentiviral gene delivery |
US20110027235A1 (en) | 2009-04-09 | 2011-02-03 | Sangamo Biosciences, Inc. | Targeted integration into stem cells |
US20120177616A1 (en) * | 2010-12-22 | 2012-07-12 | Plasalus LLC | Methods for augmentation collection of placental hematopoietic stem cells and uses thereof |
Non-Patent Citations (100)
Title |
---|
AL-HERZ ET AL., FRONTIERS IN IMMUNOLOGY, vol. 5, 22 April 2014 (2014-04-22) |
ALTSCHUL ET AL., J. MOL. BIOL., vol. 215, 1990, pages 403 |
ALTSCHUL ET AL., NATURE GENET., vol. 6, 1994, pages 119 |
AMANDA F CASHEN: "Plerixafor hydrochloride: a novel agent for the mobilization of peripheral blood stem cells", DRUGS OF TODAY, vol. 45, no. 7, July 2009 (2009-07-01), ES, pages 497 - 505, XP055215844, ISSN: 1699-3993, DOI: 10.1358/dot.2009.45.7.1395292 * |
BACHELERIE, F.; BEN-BARUCH, A.; BURKHARDT, A.M.; COMBADIERE, C.; FARBER, J.M.; GRAHAM, G.J.; HORUK, R.; SPARRE-ULRICH, A.H.; LOCAT: "International Union of Pharmacology. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors", PHARMACOLOGICAL REVIEWS, vol. 66, 2014, pages 1 - 79 |
BALABANIAN ET AL., BLOOD, vol. 119, 2012, pages 5722 - 5730 |
BEAUSSANT ET AL., ORPHANET JOURNAL OF RARE DISEASES, vol. 7, 2012, pages 71 |
BEIGELMAN ET AL., NUCL. ACIDS RES., vol. 23, 1995, pages 4434 - 42 |
BENJAMIN LEWIN: "Genes", vol. VII, 1999, OXFORD UNIVERSITY PRESS |
BERGER ET AL.: "Chemokine receptors as HIV- coreceptors: roles in viral entry, tropism, and disease", ANNUAL REVIEW OF IMMUNOLOGY, vol. 17, 1999, pages 657 - 700, XP000999878, DOI: doi:10.1146/annurev.immunol.17.1.657 |
BITINAITE ET AL., PROC. NATL. ACAD. SCI. USA, vol. 95, 1998, pages 10570 - 5 |
BLEUL ET AL., J. EXP. MED., vol. 184, 1996, pages 1101 - 1109 |
BLOOD, vol. 104, no. 11, Part 1, November 2004 (2004-11-01), 46TH ANNUAL MEETING OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY; SAN DIEGO, CA, USA; DECEMBER 04 -07, 2004, pages 38A, ISSN: 0006-4971 * |
BOGDANOVE; VOYTAS, SCIENCE, vol. 333, no. 6051, 2011, pages 1843 - 6 |
BR. J. HAEMATOL., vol. 120, 2003, pages 801 - 7 |
BROXMEYER ET AL., J IMMUNOL, vol. 170, 2003, pages 421 - 429 |
BROXMEYER ET AL., J. EXP. MED., vol. 201, 2005, pages 1307 - 1318 |
BROXMEYER ET AL., JOURNAL OF LEUKOCYTE BIOLOGY, vol. 73, 2003, pages 630 - 638 |
CERMAK ET AL., NUCLEIC ACIDS RES., vol. 39, 2011, pages E82 |
CHENG ET AL., GENES CELLS, vol. 17, no. 6, 2012, pages 431 - 8 |
COPELAN, E.A., THE NEW ENGLAND J. MED., vol. 354, 2006, pages 1813 - 1826 |
CORPET ET AL., NUCLEIC ACIDS RESEARCH, vol. 16, 1988, pages 10881 |
COUTURE ET AL., TIG, vol. 12, 1996, pages 510 |
DALE ET AL.: "The CXCR4 antagonist plerixafor is a potential therapy for myelokathexis, WHIM syndrome", BLOOD, vol. 118, 2011, pages 4963 - 6 |
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; November 2004 (2004-11-01), FOUDI ADLEN ET AL: "The hematopoietic reconstitution defect of mice lacking CXCR4 is related to an altered retention of hematopoietic cells in the bone marrow.", XP002745250, Database accession no. PREV200510268093 * |
DEBNATH ET AL., THERANOSTICS, vol. 3, no. 1, 2013, pages 47 - 75 |
DOTTA ET AL., CURRENT MOLECULAR MEDICINE, vol. 11, 2011, pages 317 - 325 |
E. W. MARTIN: "Remington's Pharmaceutical Sciences, 15th ed.", 1975, MACK PUBLISHING CO. |
FENG ET AL., SCIENCE, vol. 272, 1996, pages 872 - 877 |
FLOMENBERG N ET AL: "Plerixafor (Mozobil<(>R)) Alone to Mobilize Hematopoietic Stem Cells from Multiple Myeloma Patients for Autologous Transplantation", BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, KLUGE CARDEN JENNINGS PUBLISHING, CHARLOTTESVILLE, VA, US, vol. 16, no. 5, May 2010 (2010-05-01), pages 695 - 700, XP027017568, ISSN: 1083-8791, [retrieved on 20100420] * |
FRUEHAUF STEFAN: "Current clinical indications for plerixafor.", TRANSFUSION MEDICINE AND HEMOTHERAPY : OFFIZIELLES ORGAN DER DEUTSCHEN GESELLSCHAFT FUR" TRANSFUSIONSMEDIZIN UND IMMUNHAM"ATOLOGIE AUG 2013, vol. 40, no. 4, August 2013 (2013-08-01), pages 246 - 250, XP002745249, ISSN: 1660-3796 * |
GAJ ET AL., TRENDS BIOTECHNOL., vol. 31, 2013, pages 397 - 405 |
GRZEGORZ WLADYSLAW BASAK ET AL: "Hematopoietic stem cell mobilization with the reversible CXCR4 receptor inhibitor plerixafor (AMD3100)-Polish compassionate use experience", ANNALS OF HEMATOLOGY, SPRINGER, BERLIN, DE, vol. 90, no. 5, 12 October 2010 (2010-10-12), pages 557 - 568, XP019893245, ISSN: 1432-0584, DOI: 10.1007/S00277-010-1098-7 * |
HARIBABU ET AL., J. BIOL. CHEM., vol. 272, 1997, pages 28726 - 28731 |
HARLOW; LANE: "Using Antibodies: A Laboratory Manual", 1998, COLD SPRING HARBOR LABORATORY PRESS |
HERNANDEZ ET AL., NAT GENET, vol. 34, 2003, pages 70 - 74 |
HIGGINS; SHARP, CABIOS, vol. 5, 1989, pages 151 |
HIGGINS; SHARP, GENE, vol. 73, 1988, pages 237 |
HOCKENMEYER ET AL., NAT BIOTECHNOL, vol. 29, pages 731 - 734 |
HSU ET AL., CELL, vol. 157, 2014, pages 1262 - 78 |
J. FOGUENNE ET AL: "Ex vivo expansion of hematopoietic progenitor cells is associated with downregulation of 4 integrin- and CXCR4-mediated engraftment in NOD/SCID 2-microglobulin-null mice", HAEMATOLOGICA, THE HEMATOLOGY JOURNAL : OFFICIAL ORGAN OF THE EUROPEAN HEMATOLOGY ASSOCIATION, vol. 94, no. 2, 14 January 2009 (2009-01-14), Pavia, pages 185 - 194, XP055215887, ISSN: 0390-6078, DOI: 10.3324/haematol.13206 * |
JONES, M.J.; JALLEPALLI, P.V., DEVELOPMENTAL CELL, vol. 23, 2012, pages 908 - 917 |
K. KAWABATA ET AL: "A cell-autonomous requirement for CXCR4 in long-term lymphoid and myeloid reconstitution", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 96, no. 10, 11 May 1999 (1999-05-11), pages 5663 - 5667, XP055215940, ISSN: 0027-8424, DOI: 10.1073/pnas.96.10.5663 * |
KASHANI-SABET, J. IMVESTIG. DERMATOL SYMP. PROC, vol. 7, 2002, pages 76 - 78 |
KAWAI ET AL., BLOOD, vol. 109, 2007, pages 78 - 84 |
KAWAI, T.; MALECH, H.L., CURR OPIN HEMATOL, vol. 16, 2009, pages 20 - 26 |
KENDREW ET AL.: "The Encyclopedia of Molecular Biology", 1994, BLACKWELL SCIENCE LTD. |
KIM ET AL., GENOME BIOLOGY, vol. 14, 2013, pages R36 |
KLOOSTERMAN ET AL., HUMAN MOLECULAR GENETICS, vol. 20, 2011, pages 1916 - 1924 |
KORBEL, J.O.; CAMPBELL, P.J.: "Criteria for inference of chromothripsis in cancer genomes", CELL, vol. 152, 2013, pages 1226 - 1236, XP029001379, DOI: doi:10.1016/j.cell.2013.02.023 |
KRILL ET AL., THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 270, 1964, pages 973 - 979 |
KROL ET AL., BIOTECHNIQUES, vol. 6, 1988, pages 958 - 76 |
KRZYWINSKI ET AL., GENOME RESEARCH, vol. 19, 2009, pages 1639 - 1645 |
LAPIDOT T ET AL: "How do stem cells find their way home?", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 106, no. 6, 15 September 2005 (2005-09-15), pages 1901 - 1910, XP003011680, ISSN: 0006-4971, DOI: 10.1182/BLOOD-2005-04-1417 * |
LAWNICKI ET AL., JMD, vol. 5, 2003, pages 82 - 87 |
LE CONG ET AL., SCIENCE, vol. 339, 2013, pages 819 - 23 |
LEIDING, J.W.; HOLLAND, S.M., THE JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, vol. 130, 2012, pages 1030 - 1048 |
LEMAIFRE ET AL., PROC. NATL. ACAD. SCI. USA, vol. 84, 1987, pages 648 - 52 |
LETSINGER ET AL., PROC. NATL ACAD. SCI. USA, vol. 86, 1989, pages 6553 - 6 |
M P RETTIG ET AL: "Mobilization of hematopoietic stem and progenitor cells using inhibitors of CXCR4 and VLA-4", LEUKEMIA., vol. 26, no. 1, 2 September 2011 (2011-09-02), US, pages 34 - 53, XP055215851, ISSN: 0887-6924, DOI: 10.1038/leu.2011.197 * |
MALI ET AL., SCIENCE, vol. 339, 2013, pages 823 - 6 |
MARSCHALL ET AL., CELL MOL. NEUROBIOL, vol. 14, 1994, pages 523 - 38 |
MCDERMOTT ET AL., BLOOD, vol. 118, 2011, pages 4957 - 62 |
MCDERMOTT ET AL., BLOOD, vol. 123, 2014, pages 2308 - 2316 |
MIYAGISHI; TAIRA, NATURE BIOTECH., vol. 19, 2002, pages 497 |
NEEDLEMAN; WUNSCH, J. MOL. BIOL., vol. 48, 1970, pages 443 |
NIE ET AL., J. EXP. MED., vol. 205, 2008, pages 777 - 783 |
O'MEARA; TOVEY, CLIN. REV. ALLERGY IMMUNOL., vol. 18, 2000, pages 341 - 95 |
PARK ET AL., PNAS, vol. 111, 2014, pages 9253 - 8 |
PAUL ET AL., NATURE BIOTECH., vol. 19, 2002, pages 505 |
PEARSON; LIPMAN, PROC. NATL. ACAD. SCI. U.S.A., vol. 85, 1988, pages 2444 |
QING MA ET AL: "The chemokine receptor CXCR4 is required for the retention of B lineage and granulocytic precursors within the bone marrow microenvironment", IMMUNITY, CELL PRESS, US, vol. 10, no. 4, January 1999 (1999-01-01), pages 463 - 471, XP002453198, ISSN: 1074-7613, DOI: 10.1016/S1074-7613(00)80046-1 * |
RAMASAMY ET AL., JOURNAL OF CLINICAL PATHOLOGY, vol. 45, 1992, pages 770 - 775 |
RAUSCH ET AL., CELL, vol. 148, 2012, pages 59 - 71 |
ROBERT A. MEYERS: "Molecular Biology and Biotechnology: a Comprehensive Desk Reference", 1995, VCH PUBLISHERS, INC. |
ROBINSON ET AL., NATURE BIOTECHNOLOGY, vol. 29, 2011, pages 24 - 26 |
SAMBROOK ET AL., APPENDIX, 2001, pages 9 |
SANDER ET AL., NAT BIOTECHNOL., vol. 29, no. 8, 2011, pages 697 - 8 |
SARVER ET AL., SCIENCE, vol. 247, 1990, pages 1222 - 5 |
SEITA, J.; WEISSMAN, I.L.: "Hematopoietic stem cell: self-renewal versus differentiation", WILEY INTERDISCIPLINARY REVIEWS SYSTEMS BIOLOGY AND MEDICINE, vol. 2, 2010, pages 640 - 653 |
SIGNORET ET AL., J CELL SCI, vol. 111, 1998, pages 2819 - 2830 |
SIMON P FRICKER: "A novel CXCR4 antagonist for hematopoietic stem cell mobilization", EXPERT OPINION ON INVESTIGATIONAL DRUGS, vol. 17, no. 11, 15 October 2008 (2008-10-15), UK, pages 1749 - 1760, XP055215855, ISSN: 1354-3784, DOI: 10.1517/13543784.17.11.1749 * |
SIMON P. FRICKER: "Physiology and pharmacology of plerixafor", TRANSFUSION MEDICINE AND HEMOTHERAPY, vol. 40, no. 4, 19 July 2013 (2013-07-19), CH, pages 237 - 245, XP055215876, ISSN: 1660-3796, DOI: 10.1159/000354132 * |
SIMONNET; GUILLOTEAU ET AL.: "Methods of Immunological Analysis", 1993, VCH, pages: 270 - 388 |
SMITH; WATERMAN, ADV. APPL. MATH., vol. 2, 1981, pages 482 |
STEPHENS ET AL., CELL, vol. 144, 2011, pages 27 - 40 |
SUGIYAMA ET AL., IMMUNITY, vol. 25, 2006, pages 977 - 988 |
SUZUKI ET AL., MOL. THERAPY, vol. 21, no. 7, 2013, pages 1424 - 31 |
TASSONE ET AL., THE JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, vol. 123, 2009, pages 1170 - 1173 |
TOSHINAO KAWAI ET AL: "39: ENHANCED ENGRAFTMENT OF HUMAN HEMATOPOIETIC STEM CELLS INFECTED WITH INTEGRATION DEFECTIVE LENTIVIRUS VECTOR ENCODING WHIM-TYPE MUTANT CXCR4 IN NOD/SCID MOUSE XENOGRAFT MODEL", JOURNAL OF GENE MEDICINE, vol. 11, no. 12, December 2009 (2009-12-01) - 14 June 2008 (2008-06-14), US, pages 1167, XP055215846, ISSN: 1099-498X, DOI: 10.1002/jgm.1400 * |
TSAI ET AL., NATURE BIOTECHNOL., vol. 32, 2014, pages 569 - 76 |
VAN DONGEN ET AL., LEUKEMIA, vol. 17, 2003, pages 2257 - 2317 |
VENKATESAN ET AL., MOL. BIOL. CELL, vol. 14, 2003, pages 3305 - 3324 |
WETZLER ET AL., AM J MED, vol. 89, 1990, pages 663 - 672 |
WILKINSON; WIEDENFEFT, FL000PRIME REPORTS, vol. 6, 2014, pages 3 |
WOLFF, J. A.: "Gene Therapeutics", 1994, BIRKHAUSER |
YE ET AL., PNAS, vol. 111, 2014, pages 9591 - 6 |
YE ET AL., PROC NATL ACAD SCI U S A., vol. 111, no. 26, 2014, pages 9591 - 6 |
ZON, PHARM. RES., vol. 5, 1988, pages 539 - 49 |
ZUELZER, W.W., NEW ENGLAND J. MED, vol. 270, 1964, pages 699 - 704 |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016183236A1 (en) * | 2015-05-11 | 2016-11-17 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for treating hiv infection and aids |
US10973852B2 (en) | 2016-01-25 | 2021-04-13 | Nantcell, Inc. | NK cells with altered CXCL12/CXCR4 signaling |
EP3500671A4 (en) * | 2016-08-17 | 2020-07-29 | The Broad Institute, Inc. | Novel crispr enzymes and systems |
EP3500670A4 (en) * | 2016-08-17 | 2020-08-19 | The Broad Institute, Inc. | Novel crispr enzymes and systems |
US11352647B2 (en) | 2016-08-17 | 2022-06-07 | The Broad Institute, Inc. | Crispr enzymes and systems |
Also Published As
Publication number | Publication date |
---|---|
US11278572B2 (en) | 2022-03-22 |
US20170196911A1 (en) | 2017-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kim et al. | Genetic inactivation of CD33 in hematopoietic stem cells to enable CAR T cell immunotherapy for acute myeloid leukemia | |
US11278572B2 (en) | Reducing CXCR4 expression and/or function to enhance engraftment of hematopoietic stem cells | |
Kuo et al. | Site-specific gene editing of human hematopoietic stem cells for X-linked hyper-IgM syndrome | |
Avery et al. | Germline-activating mutations in PIK3CD compromise B cell development and function | |
JP6734283B2 (en) | Point of care and/or portable platform for gene therapy | |
US20200339979A1 (en) | Method for improving fetal hemoglobin expression | |
CN108026545A (en) | For the CRISPR/CAS9 compounds introducing functional polypeptide in blood cell lineages cell | |
EP4176048A1 (en) | Genetically engineered t cells with regnase-1 and/or tgfbrii disruption have improved functionality and persistence | |
McAuley et al. | Human T cell generation is restored in CD3δ severe combined immunodeficiency through adenine base editing | |
US20230081343A1 (en) | Crispr-based foxp3 gene engineered t cells and hematopoietic stem cell precursors to treat ipex syndrome patients | |
US20230346836A1 (en) | Genetically engineered t cells with disrupted casitas b-lineage lymphoma proto-oncogene-b (cblb) and uses thereof | |
Cardoso et al. | Interleukin-10 induces interferon-γ-dependent emergency myelopoiesis | |
Doerfler et al. | Genetic therapies for the first molecular disease | |
Weber et al. | Editing a g-globin repressor binding site restores fetal hemoglobin synthesis and corrects the sickle cell disease phenotype | |
EP3390432B1 (en) | Treatment | |
US20210015866A1 (en) | Tissue resident memory cell profiles, and uses thereof | |
Becker et al. | Controlling genetic heterogeneity in gene-edited hematopoietic stem cells by single-cell expansion | |
US20200199534A1 (en) | Therapeutic formulations containing cd34+ stem cells derived from negative selection | |
Chen et al. | Co-transplantation with mesenchymal stem cells expressing a SDF-1/HOXB4 fusion protein markedly improves hematopoietic stem cell engraftment and hematogenesis in irradiated mice | |
Watts et al. | Hematopoietic stem cell expansion facilitates multilineage engraftment in a nonhuman primate cord blood transplantation model | |
Lee et al. | Impact of CRISPR/HDR-editing versus lentiviral transduction on long-term engraftment and clonal dynamics of HSPCs in rhesus macaques | |
Rezvani et al. | Using allogeneic stem cell/T-cell grafts to cure hematologic malignancies | |
Zhang et al. | Restoring T and B cell generation in X-linked severe combined immunodeficiency mice through hematopoietic stem cells adenine base editing | |
Shen | A Study of Immune Dynamics in Experimental Arthritis Using CRISPR and PET Techniques | |
Schejtman Borisonik | Lentiviral gene therapy for p47-deficient Chronic Granulomatous disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15747667 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15324219 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 15747667 Country of ref document: EP Kind code of ref document: A1 |